Top Banner
The Application of Pericyclic, Photolytic, Chemoenzymatic and Cross-coupling Techniques to the Synthesis of Biologically Active Natural Products and Related Structures A thesis submitted for the Degree of Doctor of Philosophy of The Australian National University by Qiao Yan Research School of Chemistry Canberra, Australia April, 2017 © Copyright by Qiao Yan 2017 All Rights Reserved
500

The Application of Pericyclic, Photolytic, Chemoenzymatic

Feb 09, 2023

Download

Documents

Khang Minh
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: The Application of Pericyclic, Photolytic, Chemoenzymatic

The Application of Pericyclic, Photolytic, Chemoenzymatic

and Cross-coupling Techniques to the Synthesis of

Biologically Active Natural Products and Related Structures

A thesis submitted for the Degree of Doctor of Philosophy of

The Australian National University

by

Qiao Yan

Research School of Chemistry

Canberra, Australia

April, 2017

© Copyright by Qiao Yan 2017

All Rights Reserved

Page 2: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 3: The Application of Pericyclic, Photolytic, Chemoenzymatic

i

Declaration I declare that, to the best of my knowledge, the material presented in this thesis

represents the result of original work carried out by the author during the period 2012-

2017 and has not been presented for examination for any other degree. This thesis by

publication is comprised of four journal articles. Established methodologies have been

acknowledged, wherever possible, by citation of the original publications from which

they derive.

Qiao Yan

April, 2017

Page 4: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 5: The Application of Pericyclic, Photolytic, Chemoenzymatic

iii

Acknowledgements During my four and a half years of PhD life, I have been changed a lot by the

experience. In this long journey, I am lucky to have received plenty of help from a range

of people. Without them I would not have got to this point in a long but nevertheless

rewarding experience.

First, I would like to thank Professor Martin Banwell for his supervision,

encouragement and guidance. He gave me the opportunity to study in Banwell Group

and made me grow up in the past few years. His encouragement gave me the energy to

overcome the difficulties encountered in many of my experiments. In addition, when I

saw how diligent he is, working late almost every day, I told myself that I too must

work hard to become a successful scientist. All in all, both the Banwell chemistry and

habits have contributed so much to the entirety of my PhD studies. There is so much I

could say but put simply….many thanks Martin!

I am indebted to Dr Xinghua Ma. Although invariably busy working on his own

projects, Xinghua has always been so enthusiastic in discussions and provided many

effective solutions to the problems I encountered in my experiments. His careful

analysis and down-to-earth advice gave me the confidence to complete complex tasks.

Many thanks Xinghua and I wish you all the very best for your future.

I would also like to thank all the members of the Banwell Group, especially Nadia, Ping,

Shuxin and Benoit. In addition, I want to express my sincere thanks to my lab mates in

3.27, namely Xiang, Jeremy and Josh. I have spent almost every working day of the last

four and a half years with the three of you and am so grateful for your companionship

and advice.

I should also acknowledge the technical staff in Research School of Chemistry, in

particular Dr Anthony Wills, Dr Paul Carr, Mr Chris Blake and Ms Anithahini

Jeyasingham. Their patience and professionalism helped me acquire all the high quality

X-ray diffraction, nuclear magnetic resonance and mass spectrometric data sets required

for the completion of my research.

Page 6: The Application of Pericyclic, Photolytic, Chemoenzymatic

iv

Finally, I must give deep thanks to my parents, my husband and my sister. Although I

could not stay nearby my parents, they always understood me and supported my beliefs

and goals. Deepest thanks must also go to my husband Hao Zhang. He has always been

a patient listener and the provider of perfect advice. He is also my best friend with

whom I share both the happiness and sadness that comes with life. All my achievements

belong to both of us. I also feel exceptionally lucky to have an older sister who has

always taken care of me, as she has the rest of the family. All of them are the great

blessings of my life and I cherish our precious times together.

Page 7: The Application of Pericyclic, Photolytic, Chemoenzymatic

v

Publications and Presentations The following list details the publications and presentations that have resulted from the

author’s research work performed during her candidature for the Degree of Doctor of

Philosophy.

Publications:

1. Establishing the True Structure of the Sorbicillinoid-derived Isolate

Rezishanone C by Total Synthesis

Qiao Yan, Martin G. Banwell, Michelle L. Coote, Richmond Lee and Anthony C.

Willis

Chem. Asian J., 2017, 12, 1480.

2. Studies on the Photochemical Rearrangements of Enantiomerically Pure,

Polysubstituted and Variously Annulated Bicyclo[2.2.2]octenones

Qiao Yan, Benoit Bolte, Yuhua Bai, Martin G. Banwell, Anthony C. Willis and Paul

D. Carr

J. Org. Chem., 2017, 82, 8008.

3. A Palladium-Catalyzed Ullmann Cross-Coupling/Reductive Cyclization Route

to the Carbazole Natural Products 3-Methyl-9H-carbazole, Glycoborine,

Glycozoline, Clausazoline K, Mukonine and Karapinchamine A

Qiao Yan, Emma Gin, Malgorzata Wasinska-Kalwa, Martin G. Banwell and Paul D.

Carr

J. Org. Chem., 2017, 82, 4148.

4. A Unified Approach to the Isomeric α-, β-, γ- and δ-Carbolines via their

6,7,8,9-Tetrahydro Counterparts

Qiao Yan, Emma Gin, Martin G. Banwell, Anthony C. Willis and Paul D. Carr

J. Org. Chem., 2017, 82, 4328.

Page 8: The Application of Pericyclic, Photolytic, Chemoenzymatic

vi

Presentations:

1. Establishing the True Structure of a Sorbicillinoid-derived Isolate by

Chemoenzymatic Synthesis

Qiao Yan, Martin G. Banwell and Anthony C. Willis

Poster Presentation at The Royal Australian Chemical Institute Organic One-Day

Symposium, November 30th, 2016, Sydney, Australia.

Page 9: The Application of Pericyclic, Photolytic, Chemoenzymatic

vii

Commentary on the Contributions of Ms Qiao Yan to

the Four Papers Included in this PhD Thesis by

Publications

Publication 1

This is a communication detailing the author’s extensive experimental efforts directed

towards the total synthesis of ent-rezishanone C. The author carried out, single-

handedly, the entirety of the synthetic chemistry-based laboratory work reported in this

communication. Except for the reported computational chemistry studies, she wrote the

whole of the experimental section and conducted relevant literature surveys. In addition,

the author collated and formatted all of the reported spectral data presented in the

associated supporting information document. Dr Anthony C. Wills conducted the X-ray

crystallographic studies reported in this paper. Professor Martin Banwell wrote the body

of the paper.

Publication 2

This is a full paper detailing extensive experimental work concerned with the

photochemical rearrangements of bicyclo[2.2.2]octenones. The author carried out 90%

of the synthetic chemistry-based laboratory work reported in this article. She also wrote

95% of the experimental section and conducted relevant literature surveys. In addition,

the author collated and formatted all of the reported spectral data presented in the

supporting information document. Drs Anthony C. Wills and Paul D. Carr conducted

the X-ray crystallographic studies reported in this paper while Professor Martin Banwell

wrote the body of the paper.

Publication 3

This is a full paper detailing extensive experimental work directed towards the synthesis

of carbazole natural products 3-methyl-9H-carbazole, glycoborine, glycozoline,

clausazoline K, mukonine and karapinchamine A. The author carried out 70% of the

synthetic chemistry-based laboratory work reported in this article and also wrote the

whole of the experimental section as well as conducting relevant literature surveys. In

Page 10: The Application of Pericyclic, Photolytic, Chemoenzymatic

viii

addition, the author collated and formatted all the reported spectral data presented in the

supporting information document. Dr Paul D. Carr conducted the X-ray crystallographic

studies reported in this paper while Professor Martin Banwell wrote the body of the

paper.

Publication 4

This is a full paper detailing extensive experimental work directed towards a unified

approach to the isomeric α-, β-, γ- and δ-carbolines. The author carried out the entirety

of the synthetic chemistry-based laboratory work reported in this article, wrote the

whole of the experimental section and conducted relevant literature surveys. In addition,

she collated and formatted all of the reported spectral data presented in the supporting

information document. Drs Anthony C. Wills and Paul D. Carr conducted the X-ray

crystallographic studies reported in this paper. Professor Martin Banwell wrote the body

of the paper.

Page 11: The Application of Pericyclic, Photolytic, Chemoenzymatic

ix

Table of Contents

Declaration…………………………………………………………….i

Acknowledgements……………...…………………………………...iii

Publications and Presentations……..………………………………..v

Relative Contributions to Publications……..………………………vii

Table of Contents………...…………………………………………...ix

Abstract…………………...…………………………………………...1

Thesis Overview……………..…………………..…………………….3

Publication 1 ……………….……………………..………………….10

Publication 2 ….…………………………………….………………168

Publication 3 …………………………………………..……..……..301

Publication 4 ………………………………………………………..382

Appendices…….…………………………………………………….437

Page 12: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 13: The Application of Pericyclic, Photolytic, Chemoenzymatic

1

Abstract

The body of this thesis is comprised of four scientific articles and is preceded by an

overview that contextualises all of this submitted/published work.

The first major part of this thesis is comprised of Publication 1. This details work

concerned with establishing the true structure of the sorbicillinoid-derived isolate

rezishanone C by total synthesis. Specifically, the enantiomer, B, of what proved to be

the true structure, C, of the sorbicillinoid rezishanone C (sorbivinetone) was synthesized

from the homochiral cis-1,2-dihydrocatechol A that is itself generated through the

whole-cell biotransformation of toluene. These studies and dispersion-corrected DFT

calculations support the proposal that rezishanone C is an artefact of the isolation

process and arises through a Diels-Alder cycloaddition reaction between ethyl vinyl

ether and sorbicillinol (D).

The second major part of the thesis is comprised of Publication 2. This is concerned

with the synthesis and photochemical rearrangements of enantiomerically pure,

polysubstituted and, in some cases, variously annulated bicyclo[2.2.2]octenones.

Specifically, then, a series of bicyclo[2.2.2]octenones has been prepared by engaging

the enzymatically-derived and enantiomerically pure cis-1,2-dihydrocatechol A in either

inter- or intra-molecular Diels-Alder cycloaddition reactions with various dienophiles.

These polycyclic adducts or simple derivatives thereof were shown to readily participate

in both photochemically promoted 1,3-acyl migration and oxa-di-π-methane

rearrangement processes to give products such as E and F, respectively.

OH

OH

A

O

O

O

OOH

H

HO

O

OOH

O

O OH

O

OH

B C D

O

H

OO

HO

O

O

E F

Page 14: The Application of Pericyclic, Photolytic, Chemoenzymatic

2

The third major part of the thesis is comprised of Publication 3. This details the

establishment of a palladium-catalyzed Ullmann cross-coupling/reductive cyclization

route to the carbazole natural products 3-methyl-9H-carbazole, glycoborine,

glycozoline, clausazoline K, mukonine and karapinchamine A. These were prepared by

reductive cyclisation of the relevant 2-arylcyclohex-2-en-1-one (e.g. G) to the

corresponding tetrahydrocarbazole (e.g. H) and dehydrogenation of this to give the

target carbazole (e.g. I). Compounds such as G were themselves prepared using a

palladium-catalyzed Ullmann cross-coupling reaction that served to link the appropriate

2-iodocyclohex-2-en-1-one and o-halonitrobenzene.

The fourth and final part of the thesis is comprised of Publication 4. This details a

unified approach to the isomeric α-, β-, γ- and δ-carbolines via their 6,7,8,9-tetrahydro

counterparts. Specifically, then, a cross-coupling/reductive cyclisation protocol has been

employed in preparing all four carbolines. So, for example, the 2-nitropyridine (L),

which is readily generated through an efficient palladium-catalyzed Ullmann cross-

coupling reaction, is reductively cyclized under conventional conditions to give 6,7,8,9-

tetrahydro-α-carboline (M) that is itself readily aromatized to give α-carboline (N).

OO2N

NH N

H

OMe OMe OMe

G IH

O NO2NNN

H NNH

L M N

Page 15: The Application of Pericyclic, Photolytic, Chemoenzymatic

3

Thesis Overview

Publication 1: Establishing the True Structure of the Sorbicillinoid-derived Isolate

Rezishanone C by Total Synthesis

The sorbicillins are an ever-expanding class of polyketide-derived fungal metabolite1

that display significant structural diversity and (sometimes) unusual biological

activities.2 Rezishanone C3 is a representative member of the sub-type2c of sorbicillins

that arise through a Diels-Alder reaction between sorbicillinol and various non-

sorbicillinoid-derived compounds containing a dienophilic residue. In particular,

rezishanone C is thought to arise through reaction between ethyl vinyl ether (a common

contaminant in ethyl acetate, the solvent used to isolate this material) but precisely

which one of eight possible adducts represents the true structure of this artefact remains

unclear. Given the uncertainty regarding the structure of rezishanone C and informed by

theoretical calculations, the author developed a total synthesis of what proved to be ent-

rezishanone C.

Figure 1. Structures of rezishanone C, ent-rezishanone C and sorbicillinol

Thus, this publication details a twenty-three step total synthesis of ent-rezishanone C

(Scheme 1). Starting from cis-1,2-dihydrocatechol 1, and through the application of

intermolecular Diels-Alder and retro-aldol/aldol sequences, trans-diol 2 was formed.

Over nine steps this last compound was converted into ethyl ether 3 that was itself

subjected to cis-dihydroxylation under conditions defined by Bäckvall4 and so affording

diol 4. A Barton-McCombie deoxygenation reaction5 then a DMP (Dess-Martin

periodinane)-mediated oxidation followed and compound 4 was thereby transformed

into ketone 5. When the potassium enolate derived from compound 5 was treated with

(3E,5E)-2-oxo-3,5-heptadienenitrile6,7 then the desired C-acylated product 6 was formed.

Hydrolysis of the acetonide residue within compound 6 and oxidation of the resulting

sorbicillinol

7

O

O

O

OHO

H

ent-rezishanone C

O

O OH

O

OH

H

OHO

O

O

O

rezishanone C

HO

O OOH

Page 16: The Application of Pericyclic, Photolytic, Chemoenzymatic

4

diol then gave ent-rezishanone C. All the spectral data derived from this material

matched those reported for the isolate. Furthermore, the specific rotation of the

synthetic material was of the same magnitude but opposite sign to that reported for the

isolate and so definitively establishing the structure of rezishanone C as that shown in

Figure 1.

Scheme 1. Key steps involved in the synthesis of ent-rezishanone C

Publication 2: Studies on the Photochemical Rearrangements of Enantiomerically

Pure, Polysubstituted and Variously Annulated Bicyclo[2.2.2]octenones

Bicyclo[2.2.2]octenones including the parent system 7 (Scheme 2) are excellent

substrates for certain photochemically promoted rearrangement reactions.8 Specifically,

on irradiation in the presence of photosensitizers such as acetophenone they participate

in oxa-di-π-methane rearrangements and so affording, via a triplet pathway,

cyclopropannulated diquinanes such as 8. In contrast, on direct irradiation they engage,

now via a singlet pathway, in a 1,3-acyl migration reaction (Givens rearrangement) to

give bicyclo[4.2.0]oct-4-en-7-ones such as 9. Upon sustained irradiation photoproduct 9

and many of its derivatives can undergo decarbonylation to give the corresponding Δ2-

norcarene, e.g. 10.

OH

OH

1

OH

OOH O

OO

2 3

OO

O

4HOOH

6

O O

O

OH

O OO

O

5

O

4 steps 9 steps

KHMDS thenE,E-CH3(CH=CH)2COCN

THF–78 °C, 3 h

55% or 81% brsm

5% K2OsO4•H2Ocitric acid, NMO

CH3CN/H2O22 °C, 14 h

68%

6 steps

2 steps

O

O OH

O

OH

ent-rezishanone C

Page 17: The Application of Pericyclic, Photolytic, Chemoenzymatic

5

Scheme 2. Photochemical rearrangement reactions of bicyclo[2.2.2]octenone (7)

By way of example, then, Publication 2 describes methods for the synthesis of

enantiomerically pure bicyclo[2.2.2]octenones such as 11-14 (Figure 2)9 and the

engagement of these systems in the above-mentioned photochemical processes. As a

result a suite of novel diquinanes, bicyclo[4.2.0]octenones and/or bicyclo[4.1.0]octenes

was produced. A number of these photoproducts are potential precursors to a range of

terpenoid-type natural products.

Figure 2. Examples of enantiomerically pure bicyclo[2.2.2]octenones

Publication 3: A Palladium-Catalyzed Ullmann Cross-Coupling/Reductive

Cyclization Route to the Carbazole Natural Products 3-Methyl-9H-carbazole,

Glycoborine, Glycozoline, Clausazoline K, Mukonine and Karapinchamine A

9H-Carbazole and its various derivatives continue to fascinate organic chemists because

of their value in both medicine and materials science.10 Many biologically active natural

products embodying this framework have also been isolated, particularly from higher

plants.10d,10e,11 Accordingly, this publication details the development of a two-step

process leading to 1,2,3,4-tetrahydro-9H-carbazoles (formally 2,3,4,9-tetrahydro-1H-

carbazoles)12 that can then be oxidized (directly) to the corresponding carbazoles.13 A

relevant example leading to the natural product glycozoline is shown in Scheme 3.

O

H

H

O

7 8

9 10

oxa-di-π-methanerearrangement

1,3-acylmigration

decarbonylation

hνsens

hν(direct)

hν(direct)

H

HH

H

O

OOOHOO OOTBS

OOH OAcO

OAc

11 12 13 14

Page 18: The Application of Pericyclic, Photolytic, Chemoenzymatic

6

Scheme 3. The synthesis of glycozoline

By such means the author has been able to realize syntheses of the parent carbazole as

well as the natural products 3-methyl-9H-carbazole,14 glycoborine (a.k.a.

glycrophylamine),11a,15 glycozoline,11a,16 clauszoline K,17 mukonine18 and

karapinchamine A19 together with their mono-methoxylated congener 2-methoxy-9H-

carbazole (Figure 3).

Figure 3. Structures of certain carbazole-based natural products and a mono-

methoxylated congener

Publication 4: A Unified Approach to the Isomeric α-, β-, γ- and δ-Carbolines via

their 6,7,8,9-Tetrahydro Counterparts

The isomeric α-, β-, γ- and δ-carbolines (Figure 4) are important heterocyclic ring

systems20 encountered, albeit to varying extents, as key structural motifs in various

biologically active natural products.

Figure 4. The isomeric α-, β-, γ- and δ-carbolines (17-20, respectively)

OO2N

NH N

H15 16 glycozoline

OMe OMe OMeH2

Raney-Nickel 10 wt. % Pd/C

Ph2O, 210 °C0.33 h, 89%

MeOH, 22 °C16 h, 72%

Pd[0]-catalyzedUllmann cross-coupling

3-methyl-9H-carbazole glycozolineglycoborine

clauszoline K karapinchamine A

NH

NH

NH

OMe

NH

OHC

OMe

N OH

OMe

NH

OMe

CO2Me

mukonine

NH OMe

2-methoxy-9H-carbazole

17

NNH

18

NNH

19

N

NH

20

N

NH

Page 19: The Application of Pericyclic, Photolytic, Chemoenzymatic

7

This publication reports on the development of a unified approach (perhaps the first to

have been developed) to the carbolines involving palladium-catalyzed Ullmann cross-

coupling,21 reductive cyclization and dehydrogenation reactions as key steps, the last

being employed to convert tetrahydro-carbolines into their fully aromatic counterparts

(viz. the carbolines). The synthesis of α-carboline, as shown in Scheme 4, is illustrative

of the reaction sequence used.

Scheme 4. The synthesis of α-carboline

O N

H210 wt. % Pd/C 10 wt. % Pd/C

O2NNN

H NNH

Ph2O, 210 °C0.66 h, 97%

MeOH, 22 °C16 h, 75%

palladium-catalyzedUllmann cross-coupling

21 22 α-carboline

Page 20: The Application of Pericyclic, Photolytic, Chemoenzymatic

8

References

1. For examples of recently reported sorbicillins see: (a) El-Elimat, T.; Raja, H. A.;

Figueroa, M.; Swanson, S. M.; Falkinham III, J. O.; Lucas, D. M.; Grever, M. R.;

Wani, M. C.; Pearce, C. J.; Oberlies, N. H. J. Antibiot., 2015, 68, 191; (b) Zhai, M.-

M.; Qi, F.-M.; Li, J.; Jiang, C.-X.; Hou, Y.; Shi, Y.-P.; Di, D.-L.; Zhang, J.-W.; Wu,

Q.-X. J. Agric. Food Chem., 2016, 64, 2298.

2. For useful points-of entry into the literature on sorbicillinoids see: (a) Harned, A.

M.; Volp, K. A. Nat. Prod. Rep., 2011, 28, 1790; (b) Meng, J.; Wang, X.; Xu, D.;

Fu, X.; Zhang, X.; Lai, D.; Zhou, L.; Zhang, G. Molecules, 2016, 21, 715.

3. (a) Bringmann, G.; Lang, G.; Gulder, T. A. M.; Tsuruta, H.; Mühlbacher, J.;

Maksimenja, K.; Steffens, S.; Schaumann, K.; Stöhr, R.; Wiese, J.; Imhoff, J. F.;

Perovíc-Ottstadt, S.; Boreiko, O.; Müller, W. E. G. Tetrahedron, 2005, 61, 7252; (b)

Lee, D.; Lee, J. H.; Cai, X. F.; Shin, J. C.; Lee, K.; Hong, Y.-S.; Lee, J. J. J.

Antibiot., 2005, 58, 615; (c) Maskey, R. P.; Grün-Wollny, I.; Laatsch, H. J. Nat.

Prod., 2005, 68, 865; (d) Neumann, K.; Abdel-Lateff, A.; Wright, A. D.; Kehraus,

S.; Krick, A.; König, G. M. Eur. J. Org. Chem., 2007, 2268.

4. Ell, A.; Closson, A.; Adolfsson, H.; Bäckvall, J.-E. Adv. Synth. Catal., 2003, 345,

1012.

5. Barton, D. H. R.; McCombie, S. W. J. Chem. Soc., Perkin Trans. 1, 1975, 16, 1574.

6. Volp, K. A.; Johnson, D. M.; Harned, A. M. Org. Lett., 2011, 13, 4486.

7. For a related conversion see Franck, G.; Brödner, K.; Helmchen, G. Org. Lett.,

2010, 12, 3886.

8. For a relevant and recent review see Banwell, M. G.; Bon, D. J.-Y. D. Applications

of the Di-π-Methane and Related Rearrangement Reactions in Chemical Synthesis.

In Molecular Rearrangements in Organic Synthesis: Rojas, C. M., Ed.; Wiley,

Hobokjen, NJ, 2015; Chapter 9, pp 261-288.

9. Juo, S.-Y.; Jang, Y.-J.; Liu, J.-Y.; Chu, C.-S.; Liao, C.-C.; Hung, S.-C. Angew.

Chem. Int. Ed. 2008, 47, 8082 and references cited therein.

10. Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. Synthesis, 1994, 639.

11. See, for example, (a) Cheenpracha, S.; Laphookhieo, S. Phytochem. Lett. 2011, 4,

187; (b) Miller, C. M.; McCarthy, F. O. RSC Advances, 2012, 2, 8883; (c) Pieroni,

M.; Girmay, S.; Sun, D.; Sahu, R.; Tekwani, B. L.; Tan, G. T. Chem. Med. Chem.

2012, 7, 1895; (d) Russell, F.; Harmody, D.; McCarthy, P. J.; Pomponi, S. A.;

Page 21: The Application of Pericyclic, Photolytic, Chemoenzymatic

9

Wright, A. E. J. Nat. Prod. 2013, 76, 1989; (e) Kim, S.-H.; Ha, T.-K.-Q.; Oh, W.

K.; Shin, J.; Oh, D.-C. J. Nat. Prod. 2016, 79, 51; (f) Patel, O. P. S.; Mishra, A.;

Maurya, R.; Saini, D.; Pandey, J.; Taneja, I.; Raju, K. S. R.; Kanojiya, S.; Shukla,

S. K.; Srivastava, M. N.; Wahajuddin, M.; Tamrakar, A. K.; Srivastava, A. K.;

Yadav, P. P. J. Nat. Prod. 2016, 79, 1276.

12. Banwell, M. G.; Kelly, B. D.; Kokas, O. J.; Lupton, D. W. Org. Lett. 2003, 5, 2497.

13. Campaigne, E.; Lake, R. D. J. Org. Chem. 1959, 24, 478.

14. (a) Chakrabarty, M.; Nath, A. c.; Khasnobis, S.; Chakrabarty, M.; Konda, Y.;

Harigaya, Y.; Komiyama, K. Phytochem. 1997, 46, 751; (b) Cui, C.-B.; Yan, S.-Y.;

Cai, B.; Yao, X.-S. J. Asian. Nat. Prod. Res. 2002, 4, 233.

15. Chakravarty, A. K.; Sarkar, T.; Masuda, K.; Takey, T.; Doi, H.; Kotani, E.;

Shiojima, K. Indian J. Chem. Sec. B 2001, 40, 484.

16. (a) Chakraborty, D. P. Phytochem. 1969, 8, 769; (b) Li, W. S.; McChesney, J. D.;

El-Feraly, F. S. Phytochem. 1991, 30, 343.

17. (a) Birari, R.; Roy, S. K.; Singh, A.; Bhutani, K. Nat. Prod. Commun. 2009, 4,

1089; (b) Lin, W.; Wang, Y.; Lin, S.; Li, C.; Zhou, C.; Wang, S.; Huang, H.; Liu,

P.; Ye, G.; Shen, X. Eur. J. Med. Chem. 2012, 47, 214.

18. (a) Brenna, E.; Fuganti, C.; Serra, S. Tetrahedron, 1998, 54, 1585; (b)

Laphookhieo, S.; Sripisut, T.; Prawat, U.; Karalai, C. Heterocycles, 2009, 78, 2115.

19. Nakamura, S.; Nakashima, S.; Oda, Y.; Yokota, N.; Fujimoto, K.; Matsumoto, T.;

Ohta, T.; Ogawa, K.; Maeda, S.; Nishida, S.; Matsuda, H.; Yoshikawa, M. Bioorg.

Med. Chem. 2013, 21, 1043.

20. For useful points-of-entry into the substantial body of literature on these

compounds see (a) Smirnova, O. B.; Golovko, T. V.; Granik, V. G. Pharm. Chem.

J., 2011, 44, 654; (b) Hung, T. Q.; Dang, T. T.; Janke, J.; Villinger, A. Langer, P.

Org. Biomol. Chem., 2015, 13, 1375 and references cited therein.

21. Banwell, M. G.; Jones, M. T.; Reekie, T. A. Chem. New Zealand, 2011, 75, 122.

Page 22: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 23: The Application of Pericyclic, Photolytic, Chemoenzymatic

Publication One

Establishing the True Structure of the Sorbicillinoid-

derived Isolate Rezishanone C by Total Synthesis

Qiao Yan, Martin G. Banwell, Michelle L. Coote,

Richmond Lee and Anthony C. Willis

Chem. Asian J., 2017, 12, 1480.

Page 24: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 25: The Application of Pericyclic, Photolytic, Chemoenzymatic

Natural Product Synthesis

Establishing the True Structure of the Sorbicillinoid-DerivedIsolate Rezishanone C by Total Synthesis

Qiao Yan,[a] Martin G. Banwell,*[a] Michelle L. Coote,[a, b] Richmond Lee,[a, b] andAnthony C. Willis[a]

Abstract: The enantiomer, ent-4, of the true structure, 4,

of the sorbicillinoid rezishanone C (sorbivinetone) hasbeen synthesized from a homochiral cis-1,2-dihydrocate-chol that is itself generated through the whole-cell bio-transformation of toluene. These studies together withdispersion-corrected DFT calculations support the propos-

al that rezishanone C is an artefact of the isolation processand arises through a Diels–Alder reaction between ethyl

vinyl ether and sorbicillinol (3).

The sorbicillins are an ever-expanding class of polyketide-de-rived fungal metabolite[1] that display significant structural di-

versity and (sometimes) unusual biological activities.[2] Rezisha-

none C (sorbivinetone, Figure 1),[3] for which both structures1 and 2 have been suggested, can be classified as a member

of the so-called hybrid sub-type[2a] of sorbicillins that arisethrough a Diels–Alder reaction between sorbicillinol (3) and

various non-sorbicillinoid-derived compounds containing a di-enophilic residue. In the case of rezishanone C, it has been

suggested[3a] that ethyl vinyl ether is the dienophile involved.

Since this ether is a contaminant often found in ethyl acetate,the solvent used in extracting rezishanone C from various

fungal sources, it is quite possible that this compound is an ar-tefact of the isolation process rather than a true natural prod-

uct. Some support for this argument follows from the report[3a]

that the acetate of the racemic modification of compound 3(i.e. (:)-sorbicillinol acetate) reacts with ethyl vinyl ether under

ambient conditions to give a Diels–Alder adduct designated O-acetylrezishanone C. On this basis, Bringmann proposed[3a]

structure 1 for rezishanone C (a compound that would arisethrough a-face addition of ethyl vinyl ether to diene 3).

Others who have isolated what we now confirm to be thesame material have suggested that it may be one or other of

the C7 epimeric forms of compound 2 (that would arise if thesame dienophile added, depending on the C7 stereochemistry,

in either an exo or endo mode to the b face of diene 3).[3b–d] It

should be noted that each of the four research groups whohave reported isolating rezishanone C used a different solvent

to acquire their 1H and 13C NMR spectral data sets and thuspreventing direct comparisons between them.3

Rezishanone C, in any of its structurally proposed or plausi-ble alternate forms,[4] embodies a polyfunctionalized and ho-mochiral bicyclo[2.2.2]octane core bearing a bridgehead

methyl group, a structural motif that we have been able to as-semble by chemoenzymatic means during the course of ourstudies on the total synthesis of various terpenoids.[5] Accord-ingly, and given the absence of any prior studies[6] as well as

the ambiguities associated with its structure, we were attract-ed to rezishanone C as a synthetic target. As a prelude to un-

dertaking synthetic studies, we carried out dispersion-correct-ed DFT calculations to determine the transition state energiesassociated with the various possible modes of Diels–Alder cy-cloaddition that could take place between sorbicillinol (2) andethyl vinyl ether. These suggested that the reaction pathway

leading to compound 4 (rather than congener 1 or the 7R epi-meric form of 2) is the most energetically favorable one (see

the Supporting Information). As such, and given the nature ofthe homochiral starting material available to us, we pursuedthe total synthesis of ent-rezishanone C (ent-4, Figure 2), and

thereby established that the illustrated structure 4 is the cor-rect one for rezishanone C.

The opening stages of the synthesis are shown in Scheme 1and involved converting, under standard conditions, the readi-

Figure 1. The two possible structures, 1 and 2, originally proposed for re-zishanone C (sorbivinetone) and its likely biogenetic precursor sorbicillinol(3).

[a] Q. Yan, Prof. M. G. Banwell, Prof. M. L. Coote, Dr. R. Lee, Dr. A. C. WillisResearch School of ChemistryInstitute of Advanced StudiesThe Australian National UniversityCanberra, ACT 2601 (Australia)E-mail : [email protected]

[b] Prof. M. L. Coote, Dr. R. LeeARC Centre of Excellence for Electromaterials Science

Supporting information and the ORCID identification number(s) for the au-thor(s) of this article can be found under https ://doi.org/10.1002/asia.201700456.

This manuscript is part of a special issue celebrating the 100th anniversaryof the Royal Australian Chemical Institute (RACI). Click here to see the Tableof Contents of the special issue.

Chem. Asian J. 2017, 12, 1480 – 1484 T 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim1480

CommunicationDOI: 10.1002/asia.201700456

Page 26: The Application of Pericyclic, Photolytic, Chemoenzymatic

ly available, enzymatically derived and homochiral cis-1,2-dihy-drocatechol 5[7] into the corresponding and previously report-

ed acetonide 6.[5, 8] Compound 6 was itself engaged in a ther-mally induced Diels–Alder cycloaddition reaction with a-chlor-

oacrylonitrile,[9] and the epimeric mixture of ortho adducts thusobtained were hydrolyzed using potassium hydroxide in tert-

butanol to give the known[5, 10] bicyclo[2.2.2]octenone 7 (53 %from 5). Cleavage of the acetonide moiety within the last com-pound was achieved using acidified AG-50W-X8 resin in hot

aqueous methanol, but this process was accompanied bya retro-aldol/aldol sequence that led to the production of the

trans-diol 8 (86 %). The structure of compound 8 was con-firmed via single-crystal X-ray analysis (see the Supporting In-

formation). The propensity for retro-aldol reactions to take

place within this framework was further emphasized on at-tempting to convert the ketone moiety within compound 8into the corresponding ethylene ketal. Thus, on treating thissubstrate with ethylene glycol in benzene under reflux, the un-

expected, ring-cleaved and crystalline cyclohexenone 9[10]

(48 %) was obtained.

Progress towards the bicyclo[2.2.2]octane core of target ent-4 could be made (Scheme 2) by selectively converting the hy-droxyl residue remote from the bridgehead methyl groupwithin compound 8 into the corresponding TBS ether 10(88 %). Reduction of the ketone moiety associated with com-pound 10 was achieved stereoselectively using DIBAL-H, and

so affording a chromatographically separable mixture of epi-mers 11[10] (15 %) and 12 (83 %). Two-fold acetylation of diol 12under standard conditions gave the diester 13 (98 %), and

treatment of the latter with tetra-n-butylammonium fluoride(TBAF) then gave alcohol 14[10] (91 %) that could be oxidized to

the corresponding ketone 15 (95 %) using Dess–Martin periodi-nane (DMP).[11] Reaction of compound 15 with methyl magne-

sium bromide at 0 8C for a brief period gave the cis diol 16[10]

(85 %) through selective si-face addition of the nucleophile to

the ketone carbonyl and as a result of the a-acetoxy group

hindering the corresponding re face. After saponification of theremaining acetate residue within compound 16, the triol 17[10]

(79 %) was converted, by standard methods, into the acetonide

Figure 2. The theoretically favored Diels–Alder adduct, 4, arising from the re-action of sorbicillinol (3) with ethyl vinyl ether and the structure of its enan-tiomer (ent-4) targeted for synthesis in the present study.

Scheme 1. Assembling the bicyclo[2.2.2]octane core of ent-rezishanone C(ent-4).

Scheme 2. Elaborating the bicyclo[2.2.2]octane core of ent-rezishanone C(ent-4).

Chem. Asian J. 2017, 12, 1480 – 1484 www.chemasianj.org T 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim1481

Communication

Page 27: The Application of Pericyclic, Photolytic, Chemoenzymatic

18 (91 %). Finally, compound 18 was treated with sodium hy-dride and ethyl iodide and so generating the ethyl ether 19(86 %) that embodies a number of the key structural featuresof the core of ent-rezishanone C.

Our proposed conversion of compound 19 into target 1 re-quired that the double bond within the former compound be

manipulated such that a ketone carbonyl group is introducedadjacent to (rather than remote from) the bridgehead methyl

group. In one of a number of attempts to achieve such an out-

come alkene 19 (Scheme 3) was treated with meta-chloroper-

benzoic acid (mCPBA) and a single epoxide 20 (86 %) was ob-

tained. The high degree of selectivity associated with this elec-trophilic addition reaction may be the result of hydrogen

bonding between the epoxidizing agent and the oxygen ofthe pendant ethoxy group. Disappointingly, all efforts to effect

the reductive cleavage of this compound with the desired re-gioselectivity failed. So, for example, on reaction of com-

pound 20 with lithium triethylborohydride the undesired alco-

hol 21 (84 %) was obtained, perhaps as a result of electronic ef-fects exerted by the pendant ethoxy group and/or steric ones

arising from the methyl group at the junction between dioxo-lane and bicyclo[2.2.2]octane frameworks. The structure of

compound 21 (and, therefore, the precursor epoxide 20) fol-lowed from a single-crystal X-ray analysis of the crystalline triol

22[10] (59 % or 84 %, based on recovered starting material) pro-duced through hydrolysis of the acetonide group using acidi-fied AG-50W-X8 resin.

The above-mentioned difficulties were overcome by themeans outlined in Scheme 4. Thus, alkene 19 was subjected to

dihydroxylation under conditions defined by B-ckvall,[12] afford-ing a chromatographically separable mixture of products 23(22 %) and 24 (68 %). Presumably, the facial selectivity of this

oxidation process, which is essentially opposite to that ob-served in the conversion 19!20, is now dictated, to some

extent at least, by the steric demands of the pendant ethoxygroup. Treatment of the latter with para-methoxybenzalde-

hyde dimethylacetal (PMBDMA) in the presence of para-tolue-nesulfonic acid monohydrate (pTsOH·H2O) afforded the epimer-

ically pure acetal 25 (89 %) that was reductively cleaved with

diisobutylaluminum hydride (DIBAL-H) in CH2Cl2 and so givingthe diol mono-ether 26[10] in 95 % yield.[13] As a prelude to con-ducting a Barton–McCombie deoxygenation reaction,[14] com-

pound 26 was converted into the corresponding xanthate 27(96 %) under standard conditions and on treatment of this

with tris(trimethylsilyl)silane (TTMSS)[15] and azobisisobutyroni-trile (AIBN) reduction took place to give the anticipated ether

28 (79 %). 2,3-Dichloro-5,6-dicyanobenzoquinone (DDQ)[16] was

used to effect the oxidative cleavage of compound 28, afford-ing alcohol 29 (89 %) that was converted into the target

ketone 30[10, 17] (79 %) using DMP in pyridine. Disappointingly,when the enolate anion derived from ketone 30 [obtained by

treating it with potassium hexamethyl disilazide (KHMDS)] wasquenched with sorbyl chloride in THF at @78 8C, O-acylation

Scheme 3. An unwanted regiochemical outcome associated with manipulat-ing the olefinic residue in compound 19.

Scheme 4. Regiocontrolled manipulation of the olefinic residue within com-pound 19 and an O-acylation reaction.

Chem. Asian J. 2017, 12, 1480 – 1484 www.chemasianj.org T 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim1482

Communication

Page 28: The Application of Pericyclic, Photolytic, Chemoenzymatic

rather than C-acylation took place, leading to the unstableenol ester 31 (84 %) as the exclusive product of reaction.

The difficulties detailed immediately above were overcomein the same manner as used by Harned and co-workers[6a]

during the course of their synthesis of sorbicillactone A. Thus,the potassium enolate derived from deprotonation of ketone

30 (Scheme 5) was treated with (3E,5E)-2-oxo-3,5-heptadieneni-

trile[6a, 18] in THF at @78 8C, and now the desired C-acylated

product 32 (55 %) was obtained as a crystalline solid, the struc-

ture of which was confirmed by single-crystal X-ray analysis.The completion of the target compound ent-4 from this point

involved hydrolysis[19] of the acetonide residue within com-pound 32 using acidified AG-50W-X8 resin then pyridinium

para-toluenesulfonate (PPTS).[20] Oxidation of the resulting diol33 (63 % or 82 %, based on recovered starting material) withthe Ley–Griffith reagent[21] then gave compound ent-4 (52 %).

All the spectral data acquired on compound ent-4 were incomplete accord with the assigned structure. In addition, thespecific rotation of this material was of similar magnitude butopposite sign to that reported for rezishanone C[22] while the1H and 13C NMR data recorded on the synthetic materialmatched those reported by Bringmann,[3a] Lee,[3b] Laatsch,[3c]

and Kçnig[3d] for the title isolate (see the Supporting Informa-tion for tabulated comparisons). The studies detailed aboveclearly indicate that rezishanone C has the illustrated structure

and not that originally depicted by Bringmann (structure 1).[3a]

Furthermore, the materials subsequently isolated by others are

one and the same compound (and not, for example, the 7R-epimeric form of 2). This outcome, when considered in con-

junction with the theoretical calculations described above,

adds weight to the hypothesis that rezishanone C is an artefactof the isolation process and arises as detailed above.[3a] The

present work also emphasizes the unique capacity of total syn-thesis to definitively establish/re-assign the structures of com-

pounds isolated from natural sources.[23]

Experimental Section

All computational methods, the derived data and the ensuing anal-yses are provided in the Supporting Information, as are the proce-dures for the preparation of all new compounds and the associat-ed spectroscopic and analytical data. Copies of the NMR spectra ofnew compounds, and X-ray plots and data for compounds 7, 8, 9,11, 14, 16, 17, 22, 26, 30 and 32 are also included in the SI.

Acknowledgements

We thank the Australian Research Council for financial support

through grants DP150101947 and CE140100012. QY is thegrateful recipient of PhD Scholarship provided by the CSC of

the People’s Republic of China. We are grateful to ProfessorBringmann (University of Werzburg) for kindly providing

copies of the various spectra recorded on sorbivinetone (re-zishanone C).

Conflict of interest

The authors declare no conflict of interest.

Keywords: density functional calculations · Diels–Alder ·natural products · sorbicillins · total synthesis

[1] For examples of recently reported sorbicillins see: a) T. El-Elimat, H. A.Raja, M. Figueroa, S. M. Swanson, J. O. Falkinham, III, D. M. Lucas, M. R.Grever, M. C. Wani, C. J. Pearce, N. H. Oberlies, J. Antibiot. 2015, 68, 191,b) M.-M. Zhai, F.-M. Qi, J. Li, C.-X. Jiang, Y. Hou, Y.-P. Shi, D.-L. Di, J.-W.Zhang, Q.-X. Wu, J. Agric. Food Chem. 2016, 64, 2298.

[2] For useful points-of entry into the literature on sorbicillinoids see:a) A. M. Harned, K. A. Volp, Nat. Prod. Rep. 2011, 28, 1790, b) J. Meng, X.Wang, D. Xu, X. Fu, X. Zhang, D. Lai, L. Zhou, G. Zhang, Molecules 2016,21, 715.

[3] a) G. Bringmann, G. Lang, T. A. M. Gulder, H. Tsuruta, J. Mehlbacher, K.Maksimenja, S. Steffens, K. Schaumann, R. Stçhr, J. Wiese, J. F. Imhoff, S.Perov&c-Ottstadt, O. Boreiko, W. E. G. Meller, Tetrahedron 2005, 61, 7252,b) D. Lee, J. H. Lee, X. F. Cai, J. C. Shin, K. Lee, Y.-S. Hong, J. J. Lee, J. Anti-biot. 2005, 58, 615, c) R. P. Maskey, I. Gren-Wollny, H. Laatsch, J. Nat.Prod. 2005, 68, 865, d) K. Neumann, A. Abdel-Lateff, A. D. Wright, S. Keh-raus, A. Krick, G. M. Kçnig, Eur. J. Org. Chem. 2007, 2268.

[4] In principle the dienophile ethyl vinyl ether could add to either the a-or b-face of the diene 3, in either an exo- or endo-mode and in eitheran ortho- or para-like manner.

[5] See D. J.-Y. D. Bon, M. G. Banwell, J. S. Ward, A. C. Willis, Tetrahedron2013, 69, 1363and references therein.

[6] For representative recent examples of studies on the synthesis of sorbi-cillinoids see: a) K. A. Volp, D. M. Johnson, A. M. Harned, Org. Lett. 2011,13, 4486, b) C. Qi, T. Qin, D. Suzuki, J. A. Porco, Jr. , J. Am. Chem. Soc.2014, 136, 3374.

[7] For reviews on cis-1,2-dihydrocatechols see: a) R. A. Johnson, Org. React.2004, 63, 117, b) T. Hudlicky, J. W. Reed, Synlett 2009, 685, c) S. E. Lewis,Chem. Commun. 2014, 50, 2821.

[8] T. Hudlicky, H. Luna, G. Barbieri, L. D. Kwart, J. Am. Chem. Soc. 1988, 110,4735.

[9] E. G. Mackay, C. G. Newton, Aust. J. Chem. 2016, 69, 1365.[10] X-ray analysis data for this compound are provided in the SI.[11] R. E. Ireland, L. Liu, J. Org. Chem. 1993, 58, 2899.[12] A. Pll, A. Closson, H. Adolfsson, J.-E. B-ckvall, Adv. Synth. Catal. 2003,

345, 1012.[13] For a related sequence see: M. G. Banwell, P. Darmos, M. D. McLeod,

D. C. R. Hockless, Synlett 1998, 897.

Scheme 5. A successful C-acylation reaction and completion of the synthesisof ent-rezishanone C (ent-4). [a] Based on recovered starting material.

Chem. Asian J. 2017, 12, 1480 – 1484 www.chemasianj.org T 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim1483

Communication

Page 29: The Application of Pericyclic, Photolytic, Chemoenzymatic

[14] D. H. R. Barton, S. W. McCombie, J. Chem. Soc. Perkin Trans. 1 1975,1574.

[15] C. Chatgilialoglu, D. Griller, M. Lesage, J. Org. Chem. 1988, 53, 3641.[16] K. Horita, T. Yoshioka, T. Tanaka, Y. Oikawa, O. Yonemitsu, Tetrahedron

1986, 42, 3021.[17] Compound 23 can be converted into ketone 30 using a three-step re-

action sequence. See the Supporting Information for details.[18] For a related conversion see G. Franck, K. Brçdner, G. Helmchen, Org.

Lett. 2010, 12, 3886.[19] Only this two-stage hydrolysis process produced good yields of diol 33.[20] M. Miyashita, A. Yoshokoshi, P. A. Grieco, J. Org. Chem. 1977, 42, 3772.[21] S. V. Ley, J. Norman, W. P. Griffith, S. P. Marsden, Synthesis 1994, 639.

[22] The CD spectrum of compound ent-4 is provided in the Supporting In-formation and is essentially a “mirror image” to that of rezishanone C,kindly provided to us by Professor Bringmann.

[23] a) K. C. Nicolaou, S. A. Snyder, Angew. Chem. Int. Ed. 2005, 44, 1012;Angew. Chem. 2005, 117, 1036, b) M. E. Maier, Nat. Prod. Rep. 2009, 26,1105.

Manuscript received: March 26, 2017Revised manuscript received: April 28, 2017

Accepted manuscript online: April 28, 2017

Version of record online: June 5, 2017

Chem. Asian J. 2017, 12, 1480 – 1484 www.chemasianj.org T 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim1484

Communication

Page 30: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 31: The Application of Pericyclic, Photolytic, Chemoenzymatic

Supporting Information

Establishing the True Structure of the Sorbicillinoid-DerivedIsolate Rezishanone C by Total Synthesis

Qiao Yan,[a] Martin G. Banwell,*[a] Michelle L. Coote,[a, b] Richmond Lee,[a, b] andAnthony C. Willis[a]

asia_201700456_sm_miscellaneous_information.pdf

Page 32: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S1!

SUPPORTING INFORMATION FOR:

Establishing the True Structure of the Sorbicillinoid-derived Isolate Rezishanone C by Total Synthesis

Qiao Yan,a Martin G. Banwell,*, a Michelle L. Coote,a,b Richmond Lee a,b and Anthony C. Willis a

a Research School of Chemistry, Institute of Advanced Studies The Australian National University, Canberra, ACT 2601, Australia

b ARC Centre of Excellence for Electromaterials Science

Part A: Computational Studies S2

1. General Approach and Outcomes

2. Total Energies of Species

3. Gaussian Archive Entries for All Species

!Part B: Experimental Studies S8

4. General Experimental Procedures

5. Specific Chemical Transformations

6. Comparison of the 13C NMR Data Derived From Rezishanone C with

those Recorded on ent-Rezishanone C

7. CD Spectrum of Compound ent-4

8. Data Associated with Single-crystal X-ray Analyses of Compounds

7, 8, 9, 11, 14, 16, 17, 22, 26, 30 and 32

9. References

10. ORTEPs Derived from Single-crystal X-ray Analyses of Compounds

7, 8, 9, 11, 14, 16, 17, 22, 26, 30 and 32

11. 1H and 13C NMR Spectra of Compounds ent-4 and 7-35

Page 33: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S2!

Part A: Computational Studies

1. General Approach and OutcomesAll quantum chemical calculations were carried out with Gaussian 09.1 The activationfree energy barriers in solution (ΔG‡) are reported relative to the individual freestarting materials: the diene and dienophile. The [4+2]-cycloaddition transition state(TS) electronic structures were optimized with the meta-hybrid functional M06-2X2

in conjunction with Grimme’s empirical dispersion correction D3 (zero damping),3herein termed M06-2X(D3), using Pople’s4 6-31G(d,p) basis set and the SMD5

polarizable continuum solvent model under ethyl acetate (EA) parameters. Theultrafine integral grid was selected during the optimization calculations to ensureaccuracy in the computed vibrational frequencies. Frequency calculations at 298Kbased on harmonic oscillator approximation were performed at the same level oftheory to verify that all TSs had one imaginary frequency and to compute thevibrational contributions to the entropies.Figure S1 shows the various possible transition structures for the [4+2]-cycloadditionreaction between sorbicillinol (3) and ethyl vinyl ether. We also endeavored to searchfor a step-wise [4+2] pathway but only the concerted one was found. From Figure S1it is seen that the lowest energy transition structure (designated here as TScDA-1aS)is that leading to ent-rezishanone C (ent-4). The next lowest transition structure issome 2.5 kcal mol–1 higher in energy and would thus not contribute significantly tothe reaction. As shown in Figure S1, the reason for this preference is predominantlysteric.

Page 34: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S3!

Figure S1. Structures and computed Gibbs free energy barriers for possible transition states associated with the addition of ethyl vinyl ether to sorbicillinol (3).

Page 35: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S4!

2. Total Energies of Species

Table S1. Energies and correctionsSpecies Ee Gcorrection Hcorrection ZPE G H Ee + ZPE Diene + dienophile -1075.98901 0.31310 0.41684 0.39008 -1075.67592 -1075.57217 -1075.59894

TScDA-1aS -1075.99632 0.33880 0.41802 0.39268 -1075.65751 -1075.57829 -1075.60363

TScDA-1aR -1075.99202 0.33845 0.41780 0.39233 -1075.65357 -1075.57422 -1075.59969

TScDA-2aS -1075.96614 0.33732 0.41765 0.39216 -1075.62882 -1075.54848 -1075.57398

TScDA-2aR -1075.97559 0.33967 0.41762 0.39249 -1075.63592 -1075.55797 -1075.58310

TScDA-1bS -1075.97955 0.33837 0.41799 0.39237 -1075.64118 -1075.56156 -1075.58718

TScDA-1bR -1075.98234 0.33910 0.41848 0.39305 -1075.64324 -1075.56386 -1075.58929All energy values are in hatrees. Ee is the electronic energy of the species. The energy corrections Gcorrection and Hcorrection and Zero Point Energy (ZPE) are added to Ee to constitute Gibb’s free energy (G), enthalpy (H) and the Ee + ZPE respectively.

3. Gaussian Archive Entries for All Speciesdiene 1\1\GINC-CA139\FOpt\RM062X\6-31G(d,p)\C14H16O4\ROOT\25-Nov-2015\0\\# m 062x/6-31G** opt=(maxcyc=200) scf=maxcyc=200 int=ultrafine freq # empi ricaldispersion=gd3 scrf=(smd,solvent=EthylEthanoate)\\Diene\\0,1\H,0. 9118471652,0.7607602863,1.7283129434\C,0.1551268325,0.1116187999,1.298 5048231\C,0.4098413776,-0.7043179035,0.2609841291\C,-0.6843127873,-1.5 701009665,-0.2593218829\C,-1.8943788889,-1.6900160766,0.362866934\C,1. 7561279323,-0.7650692082,-0.3825210329\C,2.905566831,-0.1254867215,0.2 649600274\H,2.7976888363,0.3088998433,1.2514618313\C,4.1004276879,-0.1 013309942,-0.3578786624\H,4.1782986604,-0.5525737361,-1.3464052082\C,5 .2976098793,0.4889509388,0.2007347235\H,5.229474379,0.9362420702,1.191 5679964\C,6.4637859718,0.4956193515,-0.4638072003\H,6.498005103,0.0395 895755,-1.4535924069\O,1.8887362015,-1.3599686844,-1.4605970159\C,-1.2 191827129,0.2671202915,1.86026615\C,-2.134988324,-0.9245279383,1.56506 37885\O,-3.0760467599,-1.1068489135,2.3323034454\O,-1.1434422387,0.476 8534779,3.2488645514\H,-1.9821446651,0.1243791629,3.5914649959\C,-1.86 69261517,1.4924337158,1.1722677981\H,-1.9374648635,1.3558912191,0.0902 926179\H,-2.871920573,1.621884268,1.5846551066\H,-1.2744295152,2.38401 02505,1.3903003518\O,-0.4522564725,-2.2990532726,-1.3471090501\H,0.467 6303633,-2.0846847507,-1.6565792445\C,-2.9195900933,-2.6763413524,-0.1 148552616\H,-3.8697935749,-2.49169118,0.3888882417\H,-3.065313454,-2.5 956258926,-1.1954655369\H,-2.6185656121,-3.7083702328,0.0950921827\C,7 .733296543,1.0848245403,0.0507555614\H,8.0961179432,1.8667433365,-0.62 55489385\H,7.6030492583,1.5154443712,1.0461209855\H,8.5191257616,0.322 7423047,0.0969522558\\Version=AS64L-G09RevD.01\State=1-A\HF=-843.66271 3\RMSD=4.198e-09\RMSF=2.771e-06\Dipole=2.8977284,1.4239484,-0.4058954\ Quadrupole=10.8581703,-2.6167901,-8.2413802,0.8479145,2.6773196,-0.781 7147\PG=C01 [X(C14H16O4)]\\@

dienophile 1\1\GINC-CA138\FOpt\RM062X\6-31G(d,p)\C4H8O1\ROOT\25-Nov-2015\0\\# m06 2x/6-31G** opt=(maxcyc=200) scf=maxcyc=200 int=ultrafine freq # empiri caldispersion=gd3 scrf=(smd,solvent=EthylEthanoate)\\Dienophile\\0,1\C ,-1.403718679,1.3926371956,-1.4945288669\C,-0.3521507403,1.6984085923, -0.7397477275\O,-1.3479173941,0.4578558643,-2.4731676641\C,-2.5684537044,0.2581938115,-3.1845290428\H,-3.3561482552,-0.0500943017,-2.4846590767\H,-2.8799109149,1.2010179362,-3.6529290445\C,-2.3302387688,-0.8078496772,-4.2290837283\H,-3.2476550637,-0.9873588261,-4.7954533259\H,-1.5478534861,-0.4953426323,-4.925270607\H,-2.0237957624,-1.7452903641,-3.7581671996\H,-0.4453472634,2.4529434227,0.0308176543\H,0.603549061,1.205139319,-0.8799616079\H,-2.3703590188,1.8807396697,-1.3643197731\\Version=AS64L-G09RevD.01\State=1-A\HF=-232.3263002\RMSD=5.907e-09\RMSF=4.863e-06\Dipole=-0.8227371,0.0521043,-0.2791994\Quadrupole=0.4241394,-0.363871,-0.0602684,-0.2959503,0.5605454,1.3506336\PG=C01 [X(C4H8O1)]\\@

TScDA-1aS 1\1\GINC-CA043\FTS\RM062X\6-31G(d,p)\C18H24O5\ROOT\24-Nov-2015\0\\# m0 62x/6-31G** opt=(ts,calcfc,noeigen,maxcyc=200) scf=maxcyc=200 int=ultr afine freq # empiricaldispersion=gd3 scrf=(smd,solvent=EthylEthanoate)

Page 36: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S5!

\\TS Diels-Alder concerted to product regio 1a (top) - S isomer\\0,1\H ,-0.3360018093,0.8635709343,1.0759069627\C,0.3938925775,0.2155934066,0 .5985407536\C,-0.0302969441,-1.0181731854,0.0757697514\C,0.9988445727, -1.9403480819,-0.3773111648\C,2.3525674673,-1.6506332187,-0.30483666\C ,-1.4138960889,-1.3000677958,-0.2562124002\C,-2.4535020226,-0.27950286 17,-0.029928811\H,-2.1789082757,0.6896542077,0.3720740718\C,-3.7386000 503,-0.5364427277,-0.3336660389\H,-3.9853950902,-1.5181452884,-0.73591 82707\C,-4.8233184446,0.4100083431,-0.1607059355\H,-4.577119261,1.3932 385886,0.2398286956\C,-6.0932857188,0.1139683683,-0.4741801392\H,-6.31 07825326,-0.877337855,-0.8728796928\O,-1.7465676254,-2.4062449777,-0.7 482651432\C,1.7499303742,0.2550906319,1.2606334497\C,2.7849324833,-0.4 873395465,0.4144272336\O,3.9499276272,-0.0799709649,0.462343303\O,2.19 09793816,1.5695963025,1.4857945363\H,3.1520872146,1.5183398354,1.33196 12769\C,1.6414725157,-0.4687950078,2.6207392488\H,1.31961288,-1.505997 9784,2.5097698247\H,0.9311303507,0.0654526961,3.2571071766\H,2.6251905 501,-0.4460030627,3.0982863918\O,0.6226342871,-3.0722984239,-0.9693841 267\H,-0.3899407908,-3.055988901,-0.9682497922\C,3.4015376009,-2.52430 18452,-0.9316563425\H,4.0188434557,-3.0137160319,-0.1696728965\H,4.081 5649454,-1.9272542069,-1.5478671207\H,2.9493113419,-3.2993322879,-1.55 20671276\C,-7.2492185457,1.0454423795,-0.3187862649\H,-7.7441581538,1. 2113575223,-1.2821760798\H,-6.9354354221,2.0118206408,0.0830407281\H,- 8.0039301011,0.6174711349,0.3504318918\C,1.2353286636,0.7503347251,-1. 9263227994\H,2.3083574265,0.6917451197,-2.1077327896\C,0.6597459832,1. 5533288143,-0.9758682852\O,0.4523494839,-0.064879729,-2.6032150334\C,1 .0817363568,-1.0116392029,-3.4920610542\H,1.7964137338,-1.6047701963,- 2.9120832566\H,1.6206483805,-0.4548574138,-4.2653637952\C,-0.014409887 2,-1.8714911824,-4.0707156754\H,0.4210562706,-2.6381152325,-4.71585566 23\H,-0.7097691065,-1.2700838291,-4.6611719414\H,-0.5664258695,-2.3630 492839,-3.2661015286\H,1.2661312121,2.305271334,-0.4886372151\H,-0.408 2653969,1.730495334,-1.061762253\\Version=AS64L-G09RevD.01\State=1-A\H F=-1075.9963159\RMSD=6.982e-09\RMSF=2.996e-06\Dipole=-1.8882506,1.2712 682,-1.1050708\Quadrupole=3.3414481,-6.9803872,3.6389391,-5.527101,-7. 4171643,-0.2596998\PG=C01 [X(C18H24O5)]\\@ TScDA-1aR 1\1\GINC-CA075\FTS\RM062X\6-31G(d,p)\C18H24O5\ROOT\24-Nov-2015\0\\# m0 62x/6-31G** opt=(ts,calcfc,noeigen,maxcyc=200) scf=maxcyc=200 int=ultr afine freq # empiricaldispersion=gd3 scrf=(smd,solvent=EthylEthanoate) \\TS Diels-Alder concerted to product regio 1a (top) - R isomer\\0,1\H ,-0.2808218816,0.8374100752,0.7161396023\C,0.3629562437,0.0518649679,0 .3299677469\C,-0.1661440944,-1.2353008761,0.1515860946\C,0.7650918749, -2.2875177723,-0.2051919477\C,2.132700073,-2.0830851502,-0.3348617485\ C,-1.5921883209,-1.5034036526,0.0834644974\C,-2.5633616348,-0.40482929 6,0.2380700857\H,-2.2136868132,0.6042260823,0.4264809322\C,-3.88360922 24,-0.6435438637,0.1346435052\H,-4.2090702284,-1.6653847484,-0.0564565 338\C,-4.9090022107,0.3731204319,0.2634742715\H,-4.5865010347,1.395376 9065,0.4602248406\C,-6.2158433915,0.0919435032,0.1536531602\H,-6.50840 26487,-0.9400206716,-0.0426851032\O,-2.0149226526,-2.6655880801,-0.120 1286165\C,1.7899481358,0.1640155324,0.8032240334\C,2.7032452102,-0.841 1004296,0.0924966945\O,3.8956796206,-0.5283229877,-0.0112956045\O,2.28 97202989,1.463300294,0.6289455461\H,3.192358417,1.3296259233,0.2887736 006\C,1.814356583,-0.1802669627,2.3092648361\H,1.4424582254,-1.1875938 018,2.5079077284\H,1.2085048245,0.5454840458,2.8581833293\H,2.84982711 83,-0.104059475,2.6520878896\O,0.2943572623,-3.4972155654,-0.488335685 9\H,-0.7071510333,-3.4324578576,-0.3824197428\C,3.0176249211,-3.187075 0138,-0.840886778\H,4.0543731655,-2.8450869077,-0.8532723121\H,2.73846 00094,-3.5045033044,-1.8511335719\H,2.9522512998,-4.0738124709,-0.2013 591944\C,-7.317194298,1.0906908614,0.2824848953\H,-7.9163063488,1.1264 797116,-0.6342725816\H,-6.9299831593,2.0920804841,0.4851209509\H,-8.00 07502954,0.8097215858,1.0913599749\C,1.4364324964,0.3877920328,-2.2308 100552\C,0.4475393615,1.0262397564,-1.5269095603\O,2.6712568123,0.8553 901418,-2.2743281685\C,3.6296393969,0.0224989552,-2.9593464361\H,3.314 8714589,-0.071011439,-4.0047430794\H,3.6232836737,-0.9665153267,-2.489 7711368\C,4.9803788662,0.6812685738,-2.8372391453\H,5.7289906779,0.077 6707991,-3.3562879375\H,5.2598008612,0.7591360097,-1.784676422\H,4.967 6106593,1.6782597053,-3.2847079468\H,0.6574894312,2.0163438988,-1.1387 795272\H,-0.5764666662,0.7747136602,-1.7743612085\H,1.2421989559,-0.52 99582853,-2.7872941712\\Version=AS64L-G09RevD.01\State=1-A\HF=-1075.99 20184\RMSD=7.657e-09\RMSF=1.702e-06\Dipole=-1.65978,1.4327332,-1.07215 62\Quadrupole=10.922113,-12.7958623,1.8737493,-7.4666513,-8.841663,0.4 559919\PG=C01 [X(C18H24O5)]\\@ TScDA-2aS 1\1\GINC-CA043\FTS\RM062X\6-31G(d,p)\C18H24O5\ROOT\24-Nov-2015\0\\# m0 62x/6-31G** opt=(ts,calcfc,noeigen,maxcyc=200) scf=maxcyc=200 int=ultr afine freq # empiricaldispersion=gd3 scrf=(smd,solvent=EthylEthanoate) \\TS Diels-Alder concerted to product regio 2a (top) - R isomer\\0,1\H

Page 37: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S6!

,-0.2334157103,0.984924462,0.9043012491\C,0.4617064942,0.2140744917,0. 5836421072\C,-0.0237956745,-1.0603561504,0.256765379\C,0.9513705982,-2 .0163415054,-0.1500611421\C,2.2946418905,-1.6430314449,-0.2913488788\C ,-1.4449709658,-1.3666993089,0.0573863635\C,-2.4563781931,-0.309229151 ,0.2193882952\H,-2.1471283642,0.693266668,0.4927604145\C,-3.7605361133 ,-0.579852946,0.0249531255\H,-4.0404863313,-1.5969398597,-0.2472674486 \C,-4.8249603005,0.3936995115,0.1596881191\H,-4.5499864824,1.410906895 4,0.4372553821\C,-6.113407585,0.0775990238,-0.0395567645\H,-6.35794903 ,-0.948515975,-0.3158699645\O,-1.7982740502,-2.519559097,-0.2564522708 \C,1.8076410291,0.2914755529,1.2775913548\C,2.8376584666,-0.5323045893 ,0.5031129324\O,4.026930742,-0.2699600356,0.5737712011\O,2.2440106931, 1.6059661505,1.5051138394\H,2.5692902531,1.9445704665,0.6580757112\C,1 .6805890131,-0.3425213551,2.6774987344\H,1.3701430259,-1.387044887,2.6 294482273\H,0.9506091682,0.2243635089,3.2608181359\H,2.6557603494,-0.2 726933582,3.1656820331\O,0.5964548791,-3.221163262,-0.6067327839\H,-0. 3979106636,-3.2497957958,-0.5425318801\C,3.2564302843,-2.5684717373,-0 .9721970097\H,4.2287028812,-2.0831955028,-1.0683577055\H,2.8919597365, -2.8570124023,-1.9623716985\H,3.3873596396,-3.4901836394,-0.3948170609 \C,-7.2543513399,1.0298763453,0.0913279926\H,-7.8008775108,1.110854010 1,-0.8549315914\H,-6.9151149899,2.0260487239,0.3849013215\H,-7.9726582 998,0.6707150982,0.8366173075\H,2.8873572777,0.1717019714,-2.067858516 4\C,1.8312132541,0.0096936124,-1.8757463856\H,1.3431592576,-0.78491151 09,-2.4243688178\C,1.0690155919,1.043233894,-1.3589254951\H,0.01855610 88,1.1482023892,-1.6214774957\O,1.7244507577,2.2240381248,-1.082364266 3\C,0.8681924524,3.3012930383,-0.6999317985\H,0.3073454364,3.023988349 5,0.2011037351\H,0.1515757817,3.4909595323,-1.509393998\C,1.7328741804 ,4.5141253271,-0.4418950185\H,1.1038684593,5.3711833628,-0.1890844363\ H,2.3213034466,4.7624721966,-1.3283797674\H,2.4157124558,4.3342248069, 0.3933622333\\Version=AS64L-G09RevD.01\State=1-A\HF=-1075.9661372\RMSD =6.439e-09\RMSF=7.305e-07\Dipole=-3.1134839,1.7603694,-0.6959952\Quadr upole=3.1253256,-1.1532915,-1.9720342,-5.6372889,-4.5842957,-2.613618\ PG=C01 [X(C18H24O5)]\\@ TScDA-2aR 1\1\GINC-CA137\FTS\RM062X\6-31G(d,p)\C18H24O5\ROOT\25-Nov-2015\0\\# m0 62x/6-31G** opt=(ts,calcfc,noeigen,maxcyc=200) scf=(novaracc,maxcyc=20 0) int=ultrafine freq # empiricaldispersion=gd3 scrf=(smd,solvent=Ethy lEthanoate) iop(1/8=1)\\TS Diels-Alder concerted to product regio 2a ( top) - R isomer\\0,1\H,-0.0180103034,-1.5682696255,0.564218462\C,0.778 0838345,-0.9332659451,0.1835552758\C,0.4685524271,0.0558675286,-0.7629 918252\C,1.5441448639,0.8957167772,-1.1758998934\C,2.8512051615,0.6654 349331,-0.7256978845\C,-0.9070874712,0.4477426406,-1.093546517\C,-2.03 13190961,-0.4280717448,-0.7174307424\H,-1.8275099462,-1.4273754948,-0. 3479185352\C,-3.3004414421,0.0062687658,-0.8291709962\H,-3.4690911787, 1.013464643,-1.2094381019\C,-4.4642846376,-0.7733984945,-0.4572436682\ H,-4.2971794632,-1.7830934807,-0.0830067768\C,-5.7122239374,-0.2900971 896,-0.5509094579\H,-5.8478908027,0.7236679927,-0.9286954238\O,-1.1309 77351,1.5013832054,-1.7198106878\C,2.0972685434,-1.6401992659,0.053742 547\C,3.2234812779,-0.659419549,-0.2640621421\O,4.3798904086,-1.036051 3916,-0.0889662642\O,2.409517802,-2.302326085,1.261689286\H,3.37181420 44,-2.4315282289,1.2299877623\C,2.0200428532,-2.6563317827,-1.09954498 86\H,1.8036023705,-2.1646279376,-2.0514700744\H,1.2416953873,-3.394226 0437,-0.8895913164\H,2.9845936731,-3.1668296321,-1.1776310047\O,1.3233 72414,1.9971003136,-1.8952288212\H,0.3304151036,2.0669257621,-1.980564 1925\C,3.9422397938,1.6530584377,-1.0043494189\H,4.3392819473,1.525946 9583,-2.0180976504\H,4.7674993411,1.5001402909,-0.3057190349\H,3.57336 46719,2.6771389724,-0.9193815518\C,-6.946799277,-1.0381877637,-0.17300 81827\H,-7.5021824247,-0.4975260643,0.6014334492\H,-6.7139199226,-2.03 87519193,0.1987567056\H,-7.6206855954,-1.132052987,-1.0317589386\H,2.4 690243224,1.8624639471,1.4918273068\C,2.3616235413,0.7953848817,1.6514 27164\H,3.2401646869,0.2363705924,1.9478127073\C,1.1067199935,0.259428 9233,1.8793619793\O,0.0623441918,1.1447307193,1.8642393377\C,-1.164030 8669,0.630426579,2.3706064223\H,-1.0445533031,0.3804807166,3.433822967 \H,-1.4325856451,-0.2917290732,1.8379644963\C,-2.2262277772,1.68789014 15,2.1733299993\H,-3.1990273622,1.3113245893,2.5002679909\H,-2.2951498 303,1.9606647489,1.116556026\H,-1.9871105178,2.5867617495,2.7471146332 \H,1.0057113368,-0.6263721111,2.5055675737\\Version=AS64L-G09RevD.01\S tate=1-A\HF=-1075.9755891\RMSD=9.470e-09\RMSF=2.574e-06\Dipole=-2.6951 235,-0.9435248,1.0622776\Quadrupole=7.7660361,-4.0201536,-3.7458825,4. 5393899,-0.174139,3.2361566\PG=C01 [X(C18H24O5)]\\@ TScDA-1bS 1\1\GINC-CA040\FTS\RM062X\6-31G(d,p)\C18H24O5\ROOT\24-Nov-2015\0\\# m0 62x/6-31G** opt=(ts,calcfc,noeigen,maxcyc=200) scf=maxcyc=200 int=ultr afine freq # empiricaldispersion=gd3 scrf=(smd,solvent=EthylEthanoate) \\TS Diels-Alder concerted to product regio 1b (bottom) - S isomer\\0, 1\H,-0.3078639866,0.9212968229,-0.6614787015\C,0.346327319,0.129665527

Page 38: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S7!

8,-0.3068050617\C,-0.1667809998,-1.1662038922,-0.179004716\C,0.7822571 492,-2.2197921041,0.146271712\C,2.1428342735,-2.0032191959,0.272067407 2\C,-1.5908352518,-1.4559943421,-0.1335403755\C,-2.5755158501,-0.36838 13315,-0.2799838837\H,-2.2390271304,0.6429325154,-0.4788120119\C,-3.89 2095816,-0.6200857982,-0.1614546254\H,-4.2056000855,-1.643923471,0.038 7719098\C,-4.9282655554,0.3862528834,-0.2850178562\H,-4.6171505354,1.4 101533764,-0.4913308099\C,-6.2313340251,0.094117881,-0.1601776528\H,-6 .5126585838,-0.9391941033,0.0452683836\O,-1.9997765032,-2.6271405933,0 .040749567\C,1.7794612898,0.2790415889,-0.799453148\C,2.7190383003,-0. 7341351494,-0.115990555\O,3.9145217434,-0.4681053299,-0.0123994427\O,1 .7369777076,-0.0380556199,-2.1965840837\H,1.4001214317,-0.9423564126,- 2.2824330102\C,2.3312880523,1.6887560741,-0.7267563719\H,2.5819050933, 1.9693034578,0.2958541803\H,3.2450130398,1.727120327,-1.3208678944\H,1 .6069484127,2.3957259506,-1.1417668994\O,0.323743201,-3.4455679812,0.3 894179514\H,-0.6764548547,-3.3897012087,0.2876353667\C,3.0412961135,-3 .1244485497,0.7133883517\H,4.0720394769,-2.7679282799,0.7556076849\H,2 .7578252221,-3.5101785409,1.6983676243\H,2.995387401,-3.9705760393,0.0 189788962\C,-7.3428042518,1.0822507333,-0.2842019741\H,-7.9332041825,1 .118373204,0.6381783833\H,-6.966582747,2.0857891165,-0.4967347502\H,-8 .0316139683,0.7902779777,-1.0846653462\C,1.4018607191,0.3160062581,2.2 894913703\C,0.4010543782,0.986820406,1.6317885072\O,2.6131679321,0.827 5330258,2.4088620558\C,3.6135730474,-0.0336608,2.9945546946\H,3.342666 7688,-0.2031916854,4.0424064808\H,3.603672339,-0.9876111238,2.45775450 17\C,4.945191205,0.6603784208,2.8587852385\H,5.7281085507,0.0376624046 ,3.2986751924\H,5.169605698,0.8165267009,1.8017691994\H,4.9355475738,1 .6230841456,3.3759934378\H,0.5598354566,2.027733703,1.3684201019\H,-0. 6171055261,0.677059521,1.8290744046\H,1.2371197578,-0.6636164103,2.738 6785169\\Version=AS64L-G09RevD.01\State=1-A\HF=-1075.9795462\RMSD=6.42 0e-09\RMSF=7.828e-06\Dipole=-2.1053653,1.6209969,1.5705496\Quadrupole= 8.2193915,-7.5404825,-0.6789089,-7.3337323,10.9378237,0.1989229\PG=C01 [X(C18H24O5)]\\@ TScDA-1bR 1\1\GINC-CA134\FTS\RM062X\6-31G(d,p)\C18H24O5\ROOT\25-Nov-2015\0\\# m0 62x/6-31G** opt=(ts,calcfc,noeigen,maxcyc=200) scf=maxcyc=200 int=ultr afine freq # empiricaldispersion=gd3 scrf=(smd,solvent=EthylEthanoate) \\TS Diels-Alder concerted to product regio 1b (bottom) - R isomer\\0, 1\H,0.648741236,0.9206698462,1.4398249904\C,-0.1227036707,0.3654075069 ,0.9127535266\C,0.246031723,-0.7823900162,0.2002493568\C,-0.8207376588 ,-1.673083453,-0.2412368707\C,-2.1591893075,-1.4476564118,0.012528868\ C,1.6064225369,-1.0348099093,-0.2403276845\C,2.6784819885,-0.069112784 1,0.067607522\H,2.4575165342,0.8152205469,0.6554994789\C,3.9277863214, -0.2710362697,-0.3892739531\H,4.1208742986,-1.1657189228,-0.9798240368 \C,5.040549773,0.6273951995,-0.150994881\H,4.8511204859,1.5214212801,0 .4427582557\C,6.269610412,0.3917206434,-0.6334495888\H,6.4291940197,-0 .5109414537,-1.2239606381\O,1.8893391324,-2.0645588213,-0.8967164803\C ,-1.4439230073,0.3385703645,1.6749836996\C,-2.5625631954,-0.3560315485 ,0.8682600844\O,-3.7325731761,-0.0339170681,1.0640176287\O,-1.18876925 99,-0.4549287528,2.8404929838\H,-0.9385331112,-1.3414612845,2.54021990 61\C,-1.905845668,1.6827008765,2.2036437851\H,-2.3247368131,2.30828222 77,1.4140637987\H,-2.692088494,1.5058930541,2.9379985775\H,-1.07571619 43,2.2068396816,2.6860748954\O,-0.4921393248,-2.7510123225,-0.95272221 76\H,0.5106146836,-2.7071292895,-1.0700425263\C,-3.2061501579,-2.35208 81419,-0.5746825774\H,-4.1813507729,-1.8651985264,-0.5113892264\H,-2.9 895317705,-2.5911360035,-1.6207194314\H,-3.2709639727,-3.3056079571,-0 .037350349\C,7.4522195496,1.2782745345,-0.4262046548\H,7.8563307482,1. 6146982944,-1.387478721\H,7.1960497283,2.1568485046,0.1707493697\H,8.2 587248625,0.7355768502,0.0792997611\C,-1.2887971706,1.4403472798,-1.26 44221993\C,-0.3153778657,1.9480525362,-0.4468198474\O,-0.9484935791,0. 6320533017,-2.2463998591\C,-2.036094532,0.0566459815,-3.003783507\H,-2 .8065607109,-0.275065665,-2.2998326527\H,-2.449422039,0.8416841198,-3. 645013324\C,-1.4844635054,-1.0941471397,-3.8081972453\H,-2.2901216279, -1.54443046,-4.3939518863\H,-0.7083222533,-0.749298436,-4.4960343522\H ,-1.0635495611,-1.8543233509,-3.1456622\H,-0.5712175715,2.7558274146,0 .2263330179\H,0.7141797497,1.8859123524,-0.7845953505\H,-2.3528518116, 1.6240415913,-1.108273245\\Version=AS64L-G09RevD.01\State=1-A\HF=-1075 .9823391\RMSD=7.808e-09\RMSF=2.441e-06\Dipole=2.0783348,2.2219918,-1.3 505933\Quadrupole=3.7475697,-0.4740664,-3.2735033,2.4713957,12.1393436 ,-0.610344\PG=C01 [X(C18H24O5)]\\@

Page 39: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S8!

Part B: Experimental Studies

4. General Experimental Procedures

Unless otherwise specified, proton (1H) and carbon (13C) NMR spectra were recorded

at 18 °C in base-filtered CDCl3 on a spectrometer operating at 400 MHz for proton

and 100 MHz for carbon nuclei. 1H NMR data are recorded as follows: chemical shift

(δ) [multiplicity, coupling constant(s) J (Hz), relative integral] where multiplicity is

defined as s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet or

combinations of the above. In relevant cases, the signal due to residual CHCl3

appearing at δH 7.26 and the central resonance of the CDCl3 “triplet” appearing at δC

77.0 were used to reference 1H and 13C NMR spectra, respectively. Samples were

analyzed by infrared spectroscopy (νmax) as thin films on KBr plates. Optical rotations

were recorded using the sodium D-line (589 nm) in a cell with a path length of 1 dm,

at the concentrations indicated and in the specified solvent at 22 °C. Specific rotations

were then calculated in the usual manner. Low- and high-resolution electron impact

(EI) mass spectra were recorded on a double focusing, triple sector machine. Low-

and high-resolution ESI mass spectra were recorded on a triple-quadrupole mass

spectrometer operating in positive ion mode. Melting points are uncorrected.

Analytical thin layer chromatography (TLC) was performed on aluminum-backed 0.2

mm thick silica gel 60 F254 plates. Eluted plates were visualized using a 254 nm UV

lamp and/or by treatment with a suitable dip followed by heating. These dips included

phosphomolybdic acid/ceric sulfate/sulfuric acid (conc.)/water (37.5 g : 7.5 g : 37.5 g

: 720 mL), potassium permanganate/potassium carbonate/5% sodium hydroxide

aqueous solution/water (3 g : 20 g : 5 mL : 300 mL), and p-anisaldehyde or

vanillin/sulfuric acid (conc.)/ethanol (15 g : 2.5 mL : 250 mL). Flash chromatographic

separations were carried out following protocols defined by Still et al.6 with silica gel

60 (40-63 µm) as the stationary phase and using the AR- or HPLC-grade solvents

indicated. The melting points of solids purified by such means were recorded directly

(ie after they had crystallized from the concentrated chromatographic fractions).

Starting materials, reagents, drying agents, and other inorganic salts were generally

commercially available and were used as supplied. Tetrahydrofuran (THF), methanol

and dichloromethane were dried using a solvent purification system that is based upon

a technology originally described by Grubbs et al.7 Where necessary, reactions were

performed under a nitrogen atmosphere.

Page 40: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S9!

5. Specific Chemical Transformations

(3aR,7aS)-2,2,4-Trimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole (6)

A magnetically stirred solution of commercially available diol 5 (10.00 g, 79.3 mmol)

in 2,2-dimethoxypropane (320 mL) was cooled to −10 °C then treated with p-

toluenesulfonic acid monohydrate (1.60 g, 8.0 mmol). The ensuing mixture was

stirred at −10 °C for 0.40 h then treated with triethylamine (4.0 mL, 28.6 mmol)

before being concentrated under reduced pressure (no heating) to provide a brown oil.

This oil was dissolved in diethyl ether (400 mL) and the resulting solution washed

with NaOH (1 × 200 mL of a 1 M aqueous solution). The separated aqueous phase

was extracted with diethyl ether (1 × 200 mL) and the combined organic extracts

washed with water (2 × 200 mL) before being dried (MgSO4), filtered then

concentrated under reduced pressure to afford diene 6 (10.60 g, 80%) as a pale-yellow

oil. This material, the spectral data for which matched these reported previously,8 was

used immediately in the next step of the reaction sequence.

(3aS,4R,7S)-2,2,7-Trimethyl-3a,4,7,7a-tetrahydro-4,7-ethanobenzo[d][1,3]dioxol-

8-one (7)

Step i: A magnetically stirred solution of diene 6 (5.29 g, 31.8 mmol) and α-

chloroacrylonitrile (7.62 mL, 95.4 mmol) in benzene (62 mL) maintained under a

nitrogen atmosphere was heated under reflux for 18 h then cooled and concentrated

under reduced pressure. The residue thus obtained was subjected to flash column

chromatography (silica, 0:1 → 1:24 v/v ethyl acetate/40-60 petroleum ether gradient

O

O

6

OO

O

7

Page 41: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S10!

elution) to give a 4:1 mixture of epimeric and previously reported Diels-Alder

adducts.9

Step ii: A magnetically stirred solution of the mixture of adducts (3.98 g, 15.7 mmol)

obtained from Step i in t-BuOH (120 mL) was treated with potassium hydroxide (3.52

g of pellets, 62.7 mmol) and the resulting mixture heated under reflux for 15 h before

being cooled then concentrated under reduced pressure. The residue thus obtained

was diluted with ethyl acetate (200 mL) and the ensuing mixture washed with water

(1 × 200 mL). The separated aqueous phase was treated with potassium carbonate

(1.47 g, 10.6 mmol) and extracted with ethyl acetate (2 × 100 mL) then the combined

organic phases were dried (MgSO4), filtered, and concentrated under reduced

pressure. The orange oil thus obtained was subjected to flash chromatography (silica,

0:1 → 1:9 v/v ethyl acetate/40-60 petroleum ether gradient elution) to afford, after

concentration of the appropriate fractions (Rf = 0.5 in 1:4 v/v ethyl acetate/40-60

petroleum ether), ketone 79 (2.91 g, 89%) as a colorless, crystalline solid, mp = 79-80

°C (lit.9 mp = 81-82 °C). 1H NMR (400 MHz, CDCl3) δ 6.34 (t, J = 7.1 Hz, 1H), 5.72 (d, J = 8.0 Hz, 1H), 4.49

(m, 1H), 4.05 (d, J = 7.1 Hz, 1H), 3.17 (m, 1H), 2.12 (dd, J = 18.7 and 3.9 Hz, 1H),

1.88 (d, J = 18.7 Hz, 1H), 1.37 (s, 3H), 1.30 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 210.5, 133.7, 131.6, 110.9, 79.9, 79.3, 54.8, 35.6,

35.3, 25.5, 25.1, 14.5.

IR (KBr) νmax 2977, 2935, 2887, 1731, 1374, 1208, 1093, 1070 cm–1.

MS (EI, 70 eV) m/z 208 (M+•, 30%), 193 [(M−CH3•)+, 40], 150 (60), 121 (70), 108

(100), 105 (72), 100 (70).

HRMS M+• calcd for C12H16O3 208.1099, found 208.1095.

Specific rotation [α]D = +313.5 (c = 0.8, CHCl3).

(1S,4R,7S,8S)-7,8-Dihydroxy-1-methylbicyclo[2.2.2]oct-5-en-2-one (8)

A magnetically stirred solution of compound 7 (2.40 g, 11.5 mmol) in methanol/water

(126 mL of a 105:21 v/v mixture) was treated with AG-50W-X8 resin (2.86 g of H+

OH

O

OH

8

Page 42: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S11!

form). The ensuing mixture was heated at 65 °C for 16 h then cooled and filtered. The

retained solids were washed with methanol (40 mL) and the combined filtrates

concentrated under reduced pressure. The residue thus obtained was diluted with ethyl

acetate (40 mL) and the separated aqueous phase extracted with ethyl acetate (2 × 40

mL). The combined organic extracts were dried (MgSO4), filtered and concentrated

under reduced pressure and the residue thus obtained subjected to flash column

chromatography (silica, 1:1 → 1:0 v/v ethyl acetate/40-60 petroleum ether gradient

elution) to give, after concentration of the appropriate fractions (Rf = 0.2 in ethyl

acetate), diol 8 (1.67 g, 86%) as a colorless, crystalline solid, mp = 122-125 °C. 1H NMR (400 MHz, CD3OD) δ 6.45 (m, 1H), 5.82 (dd, J = 7.8 and 1.1 Hz, 1H), 3.91

(s, 1H), 3.45 (s, 1H), 2.93 (broad s, 1H), 2.07 (m, 2H), 1.23 (s, 3H) (signals due to

hydroxyl group protons not observed). 13C NMR (100 MHz, CD3OD) δ 213.1, 136.9, 132.6, 82.8, 80.0, 57.2, 40.5, 36.9,

14.8.

IR (KBr) νmax 3388, 1714, 1366, 1097, 1033, 744 cm–1.

MS (ESI, +ve) m/z 191 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C9H12NaO3 191.0684, found 191.0687.

Specific rotation [α]D = +487.8 (c = 0.6, CH3OH).

(5S)-5-((1,3-Dioxolan-2-yl)(hydroxy)methyl)-2-methylcyclohex-2-en-1-one (9)

A magnetically stirred solution of diol 8 (60 mg, 0.36 mmol) in benzene (5 mL) was

treated with ethylene glycol (240 µL, 4.30 mmol) and p-toluenesulfonic acid

monohydrate (12 mg, 0.06 mmol). The ensuing mixture was heated under reflux for

1.5 h then cooled and concentrated under reduced pressure to give a pale-yellow oil.

This oil was dissolved in ethyl acetate (50 mL) and the solution thus obtained washed

with NaHCO3 (1 × 50 mL of a saturated aqueous solution). The separated aqueous

phase was extracted with ethyl acetate (1 × 50 mL) and the combined organic phases

were then dried (MgSO4), filtered, and concentrated under reduced pressure. The

O

HO

O

O

H

9

Page 43: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S12!

residue thus obtained was subjected to flash column chromatography (silica, 2:3 →

1:1 v/v ethyl acetate/40-60 petroleum ether elution) to give, after concentration of the

appropriate fractions (Rf = 0.5 in ethyl acetate), compound 9 (37 mg, 48%) as a

colorless, crystalline solid, mp = 112-114 °C. 1H NMR (400 MHz, CDCl3) δ 6.72 (m, 1H), 4.86 (d, J = 4.0 Hz, 1H), 4.10-3.85

(complex m, 4H), 3.53 (broad s, 1H), 2.70 (m, 1H), 2.45-2.32 (complex m, 4H), 1.93

(broad s, 1H), 1.77 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 199.8, 144.4, 135.7, 103.6, 73.9, 65.6, 65.4, 39.2,

37.7, 29.1, 15.9.

IR (KBr) νmax 3452, 2966, 2923, 2891, 1668, 1152, 1090, 1074, 963 cm–1.

MS (ESI, +ve) m/z 235 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C11H16NaO4 235.0946, found 235.0939.

Specific rotation [α]D = +34.0 (c = 0.5, CHCl3).

(1S,4R,7S,8S)-8-((tert-Butyldimethylsilyl)oxy)-7-hydroxy-1-methylbicyclo[2.2.2]-

oct-5-en-2-one (10)

A magnetically stirred solution of diol 8 (700 mg, 4.16 mmol) in dry dichloromethane

(45 mL) maintained under an atmosphere of nitrogen was treated with imidazole (1.13

g, 16.6 mmol), DMAP (51 mg, 0.42 mmol) and then TBSCl (1.88 g, 12.5 mmol). The

ensuing mixture was heated under reflux for 16 h then cooled to room temperature

before bring poured into NH4Cl (100 mL, a saturated aqueous solution) and extracted

with dichloromethane (3 × 100 mL). The combined organic phases were then dried

(MgSO4) filtered, and concentrated under reduced pressure. The residue thus obtained

was subjected to flash column chromatography (silica, 0:1 → 1:4 v/v ethyl acetate/40-

60 petroleum ether elution) to give, after concentration of the appropriate fractions (Rf

= 0.7 in ethyl acetate), compound 10 (1.04 g, 88%) as a colorless, crystalline solid,

mp = 71-73 °C.

OTBS

O

OH

10

Page 44: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S13!

1H NMR (400 MHz, CDCl3) δ 6.42 (dd, J = 7.7 and 6.3 Hz, 1H), 5.77 (dd, J = 7.7 and

1.7 Hz, 1H), 3.96 (d, J = 3.2 Hz, 1H), 3.52 (d, J = 3.8 Hz, 1H), 2.86 (broad s, 1H)

2.14-2.03 (complex m, 2H), 1.96 (m, 1H), 1.27 (s, 3H), 0.89 (s, 9H), 0.11 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 210.3, 136.0, 130.6, 83.3, 79.8, 55.7, 39.8, 35.9, 25.9,

18.2, 14.4, −4.5(7), −4.6(1).

IR (KBr) νmax 3458, 2955, 2930, 2858, 1720, 1256, 1116, 1087, 838, 777 cm–1.

MS (ESI, +ve) m/z 305 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C15H26NaO3Si 305.1549, found 305.1549.

Specific rotation [α]D = +331.2 (c = 0.8, CHCl3).

(1R,2S,3S,4R,6S)-3-((tert-Butyldimethylsilyl)oxy)-1-methylbicyclo[2.2.2]oct-7-en-

e-2,6-diol (11) and (1R,2S,3S,4R,6R)-3-((tert-Butyldimethylsilyl)oxy)-1-

methylbicyclo[2.2.2]oct-7-ene-2,6-diol (12)

A magnetically stirred solution of ketone 10 (2.82 g, 10.0 mmol) in dry THF (140

mL) maintained under an atmosphere of nitrogen was cooled to −78 °C then treated,

dropwise over 1 h, with DIBAL-H (60 mL of a 1 M solution in THF, 60.0 mmol). The

ensuing mixture was stirred at −78 °C for 1 h before being warmed to 0 °C and

quenched by the slow addition of ice (CAUTION! EXOTHERMIC REACTION).

The ensuing mixture was poured into HCl (40 mL of a 1 M aqueous solution) and

extracted with ethyl acetate (3 × 200 mL). The combined organic phases were then

dried (MgSO4), filtered and concentrated under reduced pressure. The residue thus

obtained was subjected to flash column chromatography (silica, 1:19 → 3:7 v/v ethyl

acetate/40-60 petroleum ether gradient elution) to give two fractions, A and B.

Concentration of fraction A (Rf = 0.5 in 1:4 v/v ethyl acetate/40-60 petroleum

ether) afforded compound 11 (470 mg, 15%) as a colorless, crystalline solid, mp =

83-85 °C. 1H NMR (400 MHz, CDCl3) δ 6.14 (dd, J = 8.0 and 6.2 Hz, 1H), 5.75 (dd, J = 8.0 and

1.2 Hz, 1H), 3.85 (m, 1H), 3.63 (m, 1H), 3.32 (m, 1H), 3.06 (m, 1H), 2.62 (t, J = 6.8

OTBS

OH

OH

OTBS

OH

HO

11 12

+

Page 45: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S14!

Hz, 1H), 2.48 (broads s, 1H), 2.10 (m, 1H), 1.55 (s, 1H), 1.39 (s, 3H), 0.88 (s, 9H),

0.10 (s, 3H), 0.09 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 134.3, 134.2, 85.8, 80.6, 74.2, 43.3, 38.3, 35.2, 26.0,

18.5, 18.3, −4.4(9), −4.5(4).

IR (KBr) νmax 3325, 2953, 2929, 2857, 1463, 1257, 1112, 1083, 1060, 836, 776 cm–1.

MS (ESI, +ve) m/z 307 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C15H28NaO3Si 307.1705, found 307.1705.

Specific rotation [α]D = +89.2 (c = 1.3, CHCl3).

Concentration of fraction B (Rf = 0.1 in 1:4 v/v ethyl acetate/40-60 petroleum

ether) afforded compound 12 (2.31 g, 83%) as a clear, colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.33 (m, 1H), 5.76 (d, J = 8.1 Hz, 1H), 3.93 (d, J = 7.2

Hz, 1H), 3.54 (s, 1H), 3.25 (s, 1H), 2.49 (broad s, 1H), 2.15-2.03 (complex m, 1H),

1.30 (s, 3H), 1.22 (m, 1H), 0.86 (s, 9H), 0.05 (s, 6H) (signals due to hydroxyl group

protons not observed). 13C NMR (100 MHz, CDCl3) δ 134.8, 132.4, 83.2, 79.8, 68.4, 45.5, 39.2, 36.8, 26.0,

18.2, 18.0, −4.5, −4.6.

IR (KBr) νmax 3413, 2955, 2929, 2857, 1252, 1111, 1092, 1055, 934, 859, 836, 775,

718 cm–1.

MS (EI, 70 eV) m/z 284 (M+•, 3%), 227 (35), 165 (56), 135 (55), 117 (82), 75 (100).

HRMS M+• calcd for C15H28O3Si 284.1808, found 284.1807.

Specific rotation [α]D = +80.3 (c = 0.6, CHCl3).

(1R,2S,3S,4R,6R)-3-((tert-Butyldimethylsilyl)oxy)-1-methylbicyclo[2.2.2]oct-7-

ene-2,6-diyl Diacetate (13)

A magnetically stirred solution of compound 12 (1.70 g, 6.0 mmol) in dry

dichloromethane (212 mL) maintained at 0 °C under an atmosphere of nitrogen was

treated with DMAP (58 mg, 0.5 mmol), pyridine (10 mL, 123.6 mmol) and acetic

anhydride (5.5 mL, 58.6 mmol). After a further 1 h at 0 °C the reaction mixture was

warmed to 22 °C and then allowed to stir at this temperature for 16 h before being

OTBS

OAc

AcO

13

Page 46: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S15!

poured into water (200 mL) and extracted with dichloromethane (3 × 200 mL). The

combined organic phases were dried (MgSO4), filtered and concentrated under

reduced pressure. The residue thus obtained was subjected to flash column

chromatography (silica, 0:1 → 1:9 v/v ethyl acetate/40-60 petroleum ether gradient

elution) to give, after concentration of the appropriate fractions (Rf = 0.5 in 3:7 v/v

ethyl acetate/40-60 petroleum ether), compound 13 (2.16 g, 98%) as a clear, colorless

oil. 1H NMR (400 MHz, CDCl3) δ 6.33 (m, 1H), 5.83 (d, J = 8.2 Hz, 1H), 4.97 (dd, J =

8.2 and 2.6 Hz, 1H), 4.60 (d, J = 1.6 Hz, 1H), 3.60 (m, 1H), 2.52 (m, 1H), 2.21 (m,

1H), 2.08 (s, 3H), 2.00 (s, 3H), 1.24 (m, 1H), 1.09 (s, 3H), 0.84 (s, 9H), 0.00 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 171.3, 170.3, 133.6, 132.2, 82.9, 77.3, 71.8, 42.6,

38.8, 34.4, 25.8, 21.3, 21.1, 18.1, 17.7, −4.8, −4.9.

IR (KBr) νmax 2955, 2858, 1743, 1372, 1228, 1114, 1096, 1061, 858, 838, 777 cm–1.

MS (EI, 70 eV) m/z 368 (M+•, <1%), 311 (16), 269 (22), 251 (24), 209 (30), 174 (33),

159 (32), 135 (65), 117 (100), 93 (60), 75 (53), 73 (45).

HRMS M+• calcd for C19H32O5Si 368.2019, found 368.2026.

Specific rotation [α]D = +22.1 (c = 0.4, CHCl3).

(1R,2S,3S,4R,6R)-3-Hydroxy-1-methylbicyclo[2.2.2]oct-7-ene-2,6-diyl Diacetate

(14)

A magnetically stirred solution of compound 13 (2.13 g, 5.8 mmol) in dry THF (187

mL) maintained at 0 °C under an atmosphere of nitrogen was treated, dropwise over

0.33 h, with TBAF (14.4 mL of a 1 M solution in THF, 14.4 mmol). After a further

0.66 h at 0 °C the reaction mixture was warmed to 22 °C and allowed to stir at this

temperature for 1 h then re-cooled to 0 °C and treated with NaHCO3 (200 mL of a

saturated aqueous solution). The ensuing mixture was extracted with ethyl acetate (3

× 200 mL) and the combined organic phases dried (MgSO4), filtered, and

concentrated under reduced pressure. The residue thus obtained was subjected to flash

column chromatography (silica, 3:7 v/v ethyl acetate/40-60 petroleum ether elution)

OH

OAc

AcO

14

Page 47: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S16!

to give, after concentration of the appropriate fractions (Rf = 0.5 in ethyl acetate),

compound 14 (1.34 g, 91%) as a colorless, crystalline solid, mp = 82-86 °C. 1H NMR (400 MHz, CDCl3) δ 6.37 (m, 1H), 5.81 (d, J = 8.2 Hz, 1H), 4.98 (dd, J =

8.2 and 2.9 Hz, 1H), 3.90 (s, 1H), 3.48 (s, 1H), 3.18 (s, 1H), 2.66 (broad s, 1H), 2.18

(m, 1H), 2.09 (s, 3H), 1.98 (s, 3H), 1.23 (d, J = 14.2 Hz, 1H), 1.17 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 172.8, 171.1, 133.5, 132.3, 85.6, 76.9, 71.2, 41.4,

36.5, 34.5, 21.2, 21.0, 17.7.

IR (KBr) νmax 3493, 2975, 1733, 1374, 1249, 1055, 1028, 728 cm–1.

MS (EI, 70 eV) m/z 254 (M+•, 5%), 134 (32), 108 (100), 93 (60), 92 (43).

HRMS M+• calcd for C13H18O5 254.1154, found 254.1155.

Specific rotation [α]D = −99.2 (c = 0.3, CHCl3).

(1R,2S,4R,6R)-1-Methyl-3-oxobicyclo[2.2.2]oct-7-ene-2,6-diyl Diacetate (15)

A magnetically stirred solution of alcohol 14 (2.00 g, 7.9 mmol) in dry

dichloromethane (200 mL) maintained at 0 °C under an atmosphere of nitrogen was

treated with pyridine (4 mL, 49.5 mmol) then the Dess-Martin periodinane (6.00 g,

14.1 mmol). After a further 0.66 h at 0 °C the reaction mixture was warmed to 22 °C,

stirred at this temperature for 3 h then poured into water (200 mL) and extracted with

dichloromethane (3 × 200 mL). The combined organic phases were washed with

NaOH (100 mL of a 1 M aqueous solution) and HCl (100 mL of a 1 M aqueous

solution) before being dried (MgSO4), filtered, and concentrated under reduced

pressure. The residue thus obtained was subjected to flash column chromatography

(silica, 3:17 v/v ethyl acetate/40-60 petroleum ether elution) to give, after

concentration of the appropriate fractions (Rf = 0.3 in 3:7 v/v ethyl acetate/40-60

petroleum ether), ketone 15 (1.89 g, 95%) as a colorless, crystalline solid, mp = 101-

104 °C. 1H NMR (400 MHz, CDCl3) δ 6.38 (m, 1H), 6.07 (dd, J = 8.2 and 0.7 Hz, 1H), 5.15

(dd, J = 8.2 and 3.0 Hz, 1H), 4.90 (s, 1H), 3.14 (broad s, 1H), 2.52 (m, 1H), 2.13 (s,

3H), 2.02 (s, 3H), 1.59 (m, 1H), 1.20 (s, 3H).

OAc

AcOO

15

Page 48: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S17!

13C NMR (100 MHz, CDCl3) δ 204.0, 170.8, 170.1, 136.6, 129.6, 72.1, 71.4, 46.8,

45.4, 35.5, 21.1, 20.7, 17.2.

IR (KBr) νmax 2917, 1737, 1372, 1223, 1037, 744 cm–1.

MS (ESI, +ve) m/z 275 [(M+Na)+, 45%], 249 (100), 231 (98), 133 (20).

HRMS m/z (M+Na)+ calcd for C13H16NaO5 275.0895, found 275.0895.

Specific rotation [α]D = +0.9 (c = 0.9, CHCl3).

(1S,2R,4R,7S,8R)-7,8-Dihydroxy-1,8-dimethylbicyclo[2.2.2]oct-5-en-2-yl Acetate

(16)

A magnetically stirred solution of ketone 15 (2.50 g, 9.9 mmol) in dry THF (200 mL)

maintained at 0 °C under an atmosphere of nitrogen was treated, in one portion, with

methylmagnesium bromide solution (10.7 mL of a 3 M solution in diethyl ether, 32.2

mmol). The ensuing mixture was stirred at 0 °C for 0.33 h then quenched by the slow

addition of ice (CAUTION! EXOTHERMIC REACTION). The ensuing mixture was

poured into NH4Cl (200 mL of a saturated aqueous solution) and extracted with ethyl

acetate (3 × 200 mL). The combined organic phases were then dried (MgSO4), filtered,

and concentrated under reduced pressure. The residue thus obtained was subjected to

flash column chromatography (silica, 1:4 v/v ethyl acetate/40-60 petroleum ether

elution) to give, after concentration of the appropriate fractions (Rf = 0.3 in 1:1 v/v

ethyl acetate/40-60 petroleum ether), compound 16 (1.90 mg, 85%) as a colorless,

crystalline solid, mp = 124-126 °C. 1H NMR (400 MHz, CDCl3) δ 6.32 (dd, J = 8.2 and 6.7 Hz, 1H), 5.74 (d, J = 8.2 Hz,

1H), 5.07 (dd, J = 8.2 and 3.5 Hz, 1H), 3.05 (s, 1H), 2.71 (m, 1H), 2.48 (m, 1H), 2.31

(broad s, 2H), 2.00 (s, 3H), 1.24 (s, 6H), 1.00 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 171.4, 134.5, 134.2, 77.4, 71.7, 69.7, 44.1, 43.0, 32.2,

30.6, 21.3, 18.0.

IR (KBr) νmax 3418, 2967, 1735, 1712, 1369, 1248, 1146, 1051, 1033, 937, 730 cm–1.

MS (ESI, +ve) m/z 475 [(2M+Na)+, 30%], 249 [(M+Na)+, 100].

HRMS (M+Na)+ calcd for C12H18NaO4 249.1103, found 249.1105.

OH

AcOOH

16

Page 49: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S18!

Specific rotation [α]D = −60.3 (c = 0.6, CHCl3).

(1R,2R,3S,4R,5R)-2,4-Dimethylbicyclo[2.2.2]oct-7-ene-2,3,5-triol (17)

A magnetically stirred solution of diol 16 (960 mg, 4.2 mmol) in methanol (97 mL)

was treated with potassium carbonate (586 mg, 4.2 mmol). The ensuing mixture was

heated under reflux for 16 h then cooled and concentrated under reduced pressure.

The residue thus obtained was treated with water (30 mL) and extracted with ethyl

acetate (3 × 100 mL). The combined organic phases were then dried (MgSO4), filtered

and concentrated under reduced pressure and the residue thus obtained was subjected

to flash column chromatography (silica, 7:3 v/v ethyl acetate/40-60 petroleum ether

elution). Concentration of the appropriate fractions (Rf = 0.4 in ethyl acetate) then

gave triol 17 (620 mg, 79%) as a white, crystalline solid, mp = 180-183 °C. 1H NMR (400 MHz, CD3OD) δ 6.30 (m, 1H), 5.67 (d, J = 8.2 Hz, 1H), 3.91 (m, 1H),

2.94 (s, 1H), 2.58 (m, 1H), 2.38 (m, 1H), 1.26 (s, 3H), 1.15 (s, 3H), 0.96 (dt, J = 13.2

and 3.2 Hz, 1H) (signals due to hydroxyl group protons not observed). 13C NMR (100 MHz, CD3OD) δ 135.6, 135.4, 78.6, 70.3, 68.2, 46.7, 44.6, 34.9, 30.7,

18.6.

IR (KBr) νmax 3362, 3246, 2955, 1372, 1286, 1140, 1064, 1030, 967, 919, 729 cm–1.

MS (ESI, +ve) m/z 265 (100%), 207 [(M+Na)+, 95].

HRMS (M+Na)+ calcd for C10H16NaO3 207.0997, found 207.0996.

Specific rotation [α]D = −10.8 (c = 0.1, CHCl3).

(3aS,4R,7R,9R)-2,2,4,7a-Tetramethyl-3a,4,7,7a-tetrahydro-4,7-ethanobenzo[d]-

[1,3]dioxol-9-ol (18)

OH

HOOH

17

O

HOO

18

Page 50: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S19!

A magnetically stirred solution of triol 17 (1.40 g, 7.6 mmol) and p-toluenesulfonic

acid monohydrate (217 mg, 1.1 mmol) in dichloromethane (370 mL) maintained at 0

°C was treated with 2,2-dimethoxypropane (4.7 mL, 38.0 mmol). The ensuing

mixture was stirred at 0 °C for 2 h then warmed to 22 °C, stirred at this temperature

for 1 h then quenched with triethylamine (57 µL, 4.1 mmol). The ensuing mixture

was concentrated under reduced pressure and the residue thus obtained poured into

water (100 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic

phases were then dried (MgSO4), filtered, and concentrated under reduced pressure.

The residue thus obtained was subjected to flash column chromatography (silica, 1:4

v/v ethyl acetate/40-60 petroleum ether elution) to give, after concentration of the

appropriate fractions (Rf = 0.4 in 1:1 v/v ethyl acetate/40-60 petroleum ether), alcohol

18 (1.55 g, 91%) as a white, crystalline solid, mp = 122-124 °C. 1H NMR (400 MHz, CDCl3) δ 6.42 (t, J = 8.0 Hz, 1H), 5.68 (d, J = 8.0 Hz, 1H), 4.05

(d, J = 8.0 Hz, 1H), 3.60 (s, 1H), 2.63 (dd, J = 14.0 and 8.1 Hz, 1H), 2.51 (broad s,

1H), 1.45 (s, 3H), 1.39 (s, 3H), 1.38 (s, 3H), 1.35 (s, 3H), 1.26 (broad s, 1H), 1.01 (d,

J = 14.1 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 136.6, 133.2, 111.3, 87.3, 83.9, 69.6, 45.5, 42.8, 34.0,

28.9, 27.2(8), 27.2(5), 19.1.

IR (KBr) νmax 3388, 2967, 2945, 1368, 1207, 1121, 1040, 730 cm–1.

MS (EI) m/z 224 (M+•, <1%), 209 [(M−CH3•)+, 10], 166 (38), 123 (77), 114 (100),

107 (53), 95 (51).

HRMS (M−CH3•)+ calcd for C12H17O3 209.1178, found 209.1180.

Specific rotation [α]D = −3.4 (c = 0.4, CHCl3).

(3aS,4R,7R,9R)-9-Ethoxy-2,2,4,7a-tetramethyl-3a,4,7,7a-tetrahydro-4,7-ethano-

benzo[d][1,3]dioxole (19)

Sodium hydride (936 mg of a 60% dispersion in mineral oil, 23.4 mmol) was added to

a magnetically stirred solution of alcohol 18 (350 mg, 1.6 mmol) in THF (18 mL)

O

OO

19

Page 51: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S20!

maintained at room temperature under an atmosphere of nitrogen. The resulting

mixture was treated with iodoethane (753 µL, 9.4 mmol) then stirred at 22 °C for 18 h

before being cooled to 0 °C then quenched by the slow addition of ice (CAUTION!

EXOTHERMIC REACTION AND POSSIBILITY OF HYDROGEN EVOLUTION).

The ensuing mixture was poured into water (100 mL) and extracted with ethyl acetate

(3 × 100 mL). The combined organic phases were then dried (MgSO4), filtered, and

concentrated under reduced pressure. The residue thus obtained was subjected to flash

column chromatography (silica, 1:19 v/v ethyl acetate/40-60 petroleum ether elution)

to give, after concentration of the appropriate fractions (Rf = 0.6 in 3:7 v/v ethyl

acetate/40-60 petroleum ether), alcohol 19 (358 mg, 91%) as a clear, colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.32 (m, 1H), 5.70 (d, J = 8.1 Hz, 1H), 3.72 (m, 1H),

3.54 (m, 2H), 3.34 (m, 1H), 2.51 (m, 1H), 2.44 (m, 1H), 1.46 (s, 3H), 1.39 (s, 3H),

1.34 (s, 3H), 1.33 (s, 3H), 1.17-1.10 (complex m, 4H). 13C NMR (100 MHz, CDCl3) δ 134.6, 134.1, 111.1, 87.5, 83.8, 77.0, 64.9, 44.7, 42.7,

31.1, 29.0, 27.5, 27.4, 19.1, 15.6.

IR (KBr) νmax 2975, 2933, 2874, 1372, 1243, 1207, 1120, 1095, 1054, 872, 715 cm–1.

MS (ESI, +ve) m/z 275 [(M+Na)+, 85%], 209 (100).

HRMS (M+Na)+ calcd for C15H24NaO3 275.1623, found 275.1624.

Specific rotation [α]D = −35.4 (c = 0.3, CHCl3).

(1aR,2S,2aS,6R,6aS,8R)-8-Ethoxy-2,4,4,5a-tetramethylhexahydro-2,6-ethano-

oxireno[2',3':4,5]benzo[1,2-d][1,3]dioxole (20)

A magnetically stirred solution of compound 19 (1.06 g, 4.2 mmol) in

dichloromethane (289 mL) maintained at 22 °C was treated with m-chloroperbenzoic

acid (6.20 g of approx. 77% - technical grade - material, 25.2 mmol). The resulting

mixture was stirred at 22 °C for 16 h then poured into water (200 mL) and extracted

with ethyl acetate (3 × 200 mL). The combined organic phases were washed with

NaOH (1 × 50 mL of a 1 M aqueous solution) before being dried (MgSO4), filtered

O

OOO

20

Page 52: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S21!

and concentrated under reduced pressure. The residue thus obtained was subjected to

flash column chromatography (silica, 3:17 v/v ethyl acetate/40-60 petroleum ether

elution) to give, after concentration of the appropriate fractions (Rf = 0.3 in 3:7 v/v

ethyl acetate/40-60 petroleum ether), epoxide 20 (970 mg, 86%) as a white,

crystalline solid, mp = 57-59 °C. 1H NMR (400 MHz, CDCl3) δ 3.81 (s, 1H), 3.57 (m, 1H), 3.41 (m, 2H), 3.25 (m, 1H),

2.83 (m, 1H), 2.30 (m, 1H), 2.09 (m, 1H), 1.54 (m, 1H), 1.50 (s, 3H), 1.44 (s, 6H),

1.29 (s, 3H), 1.18 (t, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 111.1, 86.6, 82.6, 74.8, 66.2, 54.6, 53.2, 42.7, 40.7,

28.2, 28.1, 27.3, 26.6, 19.2, 15.7.

IR (KBr) νmax 2977, 2936, 2871, 1375, 1208, 1121, 1100, 1069, 1019, 869 cm–1.

MS (ESI, +ve) m/z 559 [(2M+Na)+, 40%], 291 [(M+Na)+, 100].

HRMS (M+Na)+ calcd for C15H24NaO4 291.1572, found 291.1572.

Specific rotation [α]D = −76.7 (c = 0.6, CHCl3).

(3aS,4R,6R,7R,9R)-9-Ethoxy-2,2,4,7a-tetramethylhexahydro-4,7-ethanobenzo-

[d][1,3]dioxol-6-ol (21)

A magnetically stirred solution of epoxide 20 (1.00 g, 3.7 mmol) in THF (48 mL)

maintained under nitrogen was cooled to 0 °C then treated, dropwise over 0.25 h, with

LiEt3BH (37 mL of a 1 M solution in THF, 37 mmol). The ensuing mixture was

stirred at 0 °C for 0.5 h before being warmed to 22 °C and stirred at this temperature

for 16 h. The resulting mixture was re-cooled to 0 °C then quenched by the slow

addition of ice (CAUTION! EXOTHERMIC REACTION AND POSSIBILITY OF

HYDROGEN EVOLUTION) before being diluted with ethyl acetate (20 mL). The

ensuing mixture was poured into water (200 mL) and extracted with ethyl acetate (3 ×

200 mL). The combined organic phases were then dried (MgSO4), filtered and

concentrated under reduced pressure and the ensuing light-yellow oil subjected to

flash chromatography (silica, 1:9 → 3:17 v/v ethyl acetate/40-60 petroleum ether

OOHOO

21

Page 53: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S22!

gradient elution). Concentration of the appropriate fractions (Rf = 0.6 in 3:7 v/v ethyl

acetate/40-60 petroleum ether) then gave alcohol 21 (840 mg, 84%) as a clear,

colorless oil. 1H NMR (400 MHz, CDCl3) δ 3.84 (m, 1H), 3.69 (m, 1H), 3.51 (s, 1H), 3.43-3.34

(complex m, 2H), 2.14 (m, 1H), 1.95 (m, 1H), 1.75 (dd, J = 15.0 and 4.3 Hz, 1H),

1.61-1.57 (complex m, 2H), 1.48-1.42 (complex m, 4H), 1.39 (s, 3H), 1.37 (s, 3H),

1.20 (t, J = 7.0 Hz, 3H), 1.07 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 108.5, 86.8, 80.7, 75.6, 65.7, 64.9, 43.0, 38.1, 35.4,

26.8, 26.5, 26.3, 23.1, 22.0, 15.6.

IR (KBr) νmax 3501, 2975, 2871, 1378, 1206, 1056, 1011, 1081, 870 cm–1.

MS (ESI, +ve) m/z 293 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C15H26NaO4 293.1729, found 293.1725.

Specific rotation [α]D = +4.6 (c = 0.7, CHCl3).

(1S,2S,3R,4R,5R,7R)-7-Ethoxy-1,3-dimethylbicyclo[2.2.2]octane-2,3,5-triol (22)

A magnetically stirred solution of compound 21 (250 mg, 0.9 mmol) in

methanol/water (9.5 mL of an 4:1 v/v mixture) maintained at 22 °C was treated with

AG-50W-X8 resin (212 mg of H+ form) and the ensuing mixture heated at 65 °C for

40 h then cooled and filtered. The solids thus retained were washed with methanol (20

mL) and the combined filtrates concentrated under reduced pressure to give a light-

yellow oil. This material was subjected to flash column chromatography (silica,

1:1→1:0 v/v ethyl acetate/40-60 petroleum ether gradient elution) and thus affording

two fractions, A and B.

Concentration of the fraction A (Rf = 0.7 in 1:1 v/v ethyl acetate/40-60

petroleum ether) gave compound 21 (75 mg, 30% recovery) as a clear, colorless oil

that was identical, in all respects, with an authentic sample.

Concentration of the fraction B (Rf = 0.1 in 1:1 v/v ethyl acetate/40-60

petroleum ether) gave compound 22 (126 mg, 59% or 84% brsm) as a colorless,

OHOHHOO

22

Page 54: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S23!

crystalline solid, mp = 87-90 °C. 1H NMR (400 MHz, CDCl3) δ 3.89 (broad s, 1H), 3.68 (m, 1H), 3.40 (m, 2H), 3.10

(m, 1H), 3.06 (s, 1H), 2.89 (d, J = 4.1 Hz, 1H), 2.57 (s, 1H), 2.14 (m, 1H), 1.81 (m,

2H), 1.63-1.50 (complex m, 2H), 1.31 (s, 3H), 1.19 (t, J = 7.0 Hz, 3H), 1.03 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 79.4, 74.9, 69.9, 65.6, 65.0, 44.6, 39.6, 36.3, 28.9,

23.0, 21.1, 15.6.

IR (KBr) νmax 3351, 2969, 2929, 1455, 1371, 1068, 1047, 1007, 973 cm–1.

MS (ESI, +ve) m/z 253 [(M+Na)+, 100%], 167 (20).

HRMS (M+Na)+ calcd for C12H22NaO4 253.1416, found 253.1412.

Specific rotation [α]D = −123.3 (c = 1.1, MeOH).

(3aS,4R,5R,6S,7R,9R)-9-Ethoxy-2,2,4,7a-tetramethylhexahydro-4,7-ethanobenzo-

[d][1,3]dioxole-5,6-diol (23) and (3aS,4R,5S,6R,7R,9R)-9-Ethoxy-2,2,4,7a-tetra

methylhexahydro-4,7-ethanobenzo[d][1,3]dioxole-5,6-diol (24)

A magnetically stirred solution of compound 19 (1.10 g, 4.4 mmol) in

acetonitrile/water (44 mL of a 4:1 v/v mixture) maintained at 22 °C was treated with

4-methylmorpholine N-oxide (1.02 g, 8.7 mmol), citric acid (2.50 g, 13.0 mmol) and

potassium osmate dihydrate (77 mg, 0.2 mmol). The ensuing mixture was stirred at 22

°C for 14 h then quenched with Na2SO3 (10 mL of a saturated aqueous solution)

before being poured into water (50 mL) and extracted with ethyl acetate (3 × 50 mL).

The combined organic phases were then dried (MgSO4) filtered, and concentrated

under reduced pressure. The residue thus obtained was subjected to flash column

chromatography (silica, 1:9→3:7 v/v ethyl acetate/40-60 petroleum ether gradient

elution) to give two fractions, A and B.

Concentration of fraction A (Rf = 0.4 in 3:7 v/v ethyl acetate/petroleum ether)

afforded diol 24 (849 mg, 68%) as a white, crystalline solid, mp = 98-101 °C. 1H NMR (400 MHz, CDCl3) δ 4.20 (m, 1H), 4.06-4.02 (complex m, 2H), 3.54 (m,

1H), 3.38 (d, J = 8.3 Hz, 1H), 3.26 (m, 1H), 2.52 (m, 1H), 2.35 (complex m, 1H), 2.25

OOHOO

23

HO OO

O

24HOOH

+

Page 55: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S24!

(m, 1H), 1.87 (s, 1H), 1.58 (s, 3H), 1.43 (s, 3H), 1.41 (s, 3H), 1.28 (s, 3H), 1.25 (m,

1H), 1.12 (t, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 107.4, 82.5, 80.0, 75.3, 70.1, 68.6, 64.7, 44.2, 42.2,

29.6, 27.9, 26.8, 26.7, 18.8, 15.6.

IR (KBr) νmax 3406, 2975, 2936, 1379, 1206, 1183, 1097, 1051 cm–1.

MS (ESI, +ve) m/z 309 [(M+Na)+, 100%], 307 (60).

HRMS (M+Na)+ calcd for C15H26NaO5 309.1678, found 309.1679.

Specific rotation [α]D = −58.1 (c = 0.2, CHCl3).

Concentration of fraction B (Rf = 0.2 in 3:7 v/v ethyl acetate/petroleum ether)

afforded diol 23 (270 mg, 22%) as a clear, pale-yellow oil. 1H NMR (400 MHz, CDCl3) δ 3.98 (m, 1H), 3.66 (m, 1H), 3.52 (d, J = 8.7 Hz, 1H),

3.48 (s, 1H), 3.33-3.26 (complex m, 2H), 2.14-2.02 (complex m, 2H), 1.87 (broad d, J

= 14.2 Hz, 1H), 1.42 (s, 3H), 1.38 (s, 6H), 1.20 (s, 3H), 1.16 (t, J = 7.0 Hz, 3H)

(signals due to hydroxyl group protons not observed). 13C NMR (100 MHz, CDCl3) δ 109.1, 85.9, 79.5, 76.9, 69.9, 65.3, 65.1, 42.2, 41.1,

26.8, 26.7, 26.6, 22.0, 18.3, 15.5.

IR (KBr) νmax 3471, 2980, 1451, 1378, 1244, 1209, 1177, 1075, 1044, 874 cm–1.

MS (ESI, +ve) m/z 309 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C15H26NaO5 309.1678, found 309.1678.

Specific rotation [α]D = −42.9 (c = 0.1, CHCl3).

(3aS,4S,4aS,6S,7aR,8R,10R)-10-Ethoxy-6-(4-methoxyphenyl)-2,2,4,8a-tetra-

methylhexahydro-4,8-ethanobenzo[1,2-d:4,5-d']bis([1,3]dioxole) (25)

A magnetically stirred solution of diol 24 (560 mg, 2.0 mmol) and p-

methoxybenzaldehyde dimethyl acetal (400 µL, 2.1 mmol) in THF (18 mL)

maintained under a nitrogen atmosphere was cooled to 0 °C then treated with p-

toluenesulfonic acid monohydrate (14 mg, 0.08 mmol). The ensuing mixture was

OO

O

OO

PMP

25

Page 56: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S25!

stirred at 0 °C for 4 h then quenched with triethylamine (40 µL) before being

concentrated under reduced pressure. The residue thus obtained was dissolved in ethyl

acetate (50 mL) and the resulting solution washed with water (1 × 50 mL). The

separated aqueous phase was extracted with ethyl acetate (3 × 50 mL) and the

combined organic phases were then dried (MgSO4), filtered and concentrated under

reduced pressure to afford a light-yellow oil. Subjection of this material to flash

chromatography (silica, 1:19→1:9 v/v ethyl acetate/40-60 petroleum ether gradient

elution) and concentration of the appropriate fractions (Rf = 0.6 in 3:7 v/v ethyl

acetate/40-60 petroleum ether) gave compound 25 (704 mg, 89%) as a clear, colorless

oil. 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.7 Hz, 2H), 5.60

(s, 1H), 4.37-4.30 (complex m, 2H), 4.07 (s, 1H), 3.81 (s, 3H), 3.61-3.49 (complex m,

2H), 3.33 (m, 1H), 2.48 (m, 1H), 2.25 (m, 1H), 1.48 (s, 3H), 1.43 (s, 3H), 1.42 (s,

3H), 1.35 (s, 3H), 1.16 (t, J = 7.0 Hz, 3H), 1.10 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 160.2, 128.2, 128.0, 113.7, 107.8, 101.6, 82.6, 80.0,

77.9, 76.1, 74.2, 65.2, 55.4, 41.5, 41.4, 29.2, 28.0, 27.2, 17.6, 15.6 (one signal

obscured or overlapping).

IR (KBr) νmax 2975, 2933, 1616, 1518, 1248, 1172, 1151, 1054, 1033, 827 cm–1.

MS (ESI, +ve) m/z 427 [(M+Na)+, 100%], 405 [(M+H)+, 35], 309 (50), 177 (30), 61

(90).

HRMS (M+Na)+ calcd for C23H32NaO6 427.2097, found 427.2098.

Specific rotation [α]D = −110.3 (c = 1.9, CHCl3).

(3aS,4S,5S,6R,7R,9R)-9-Ethoxy-5-((4-methoxybenzyl)oxy)-2,2,4,7a-tetramethyl-

hexahydro-4,7-ethanobenzo[d][1,3]dioxol-6-ol (26)

!

A magnetically stirred solution of acetal 25 (1.60 g, 4.0 mmol) in dichloromethane

(42 mL) maintained under a nitrogen atmosphere was cooled to −78 °C then treated

OO

O

PMBOOH

26

Page 57: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S26!

with DIBAL-H (29.7 mL of a 1 M solution in hexane, 29.7 mmol). The resulting

mixture was stirred at −78 °C for 1 h then at 0 °C for 1 h and after which time it was

quenched with iced-water (50 mL) (CAUTION! EXOTHERMIC REACTION AND

POSSIBILITY OF HYDROGEN EVOLUTION). The mixture thus obtained was

poured into HCl (50 mL of a 1 M aqueous solution) and extracted with ethyl acetate

(3 × 200 mL). The combined organic phases were then dried (MgSO4), filtered, and

concentrated under reduced pressure. The residue so produced was subjected to flash

column chromatography (silica, 0:1→1:9 v/v ethyl acetate/40-60 petroleum ether

gradient elution) and concentration of the appropriate fractions (Rf = 0.4 in 3:7 v/v

ethyl acetate/40-60 petroleum ether) gave compound 26 (1.53 g, 95%) as a colorless,

crystalline solid, mp = 110-113 °C. 1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 8.4 Hz, 2H), 4.58

(ABq, J = 10.8 Hz, 2H), 4.18 (m, 1H), 3.99 (s, 1H), 3.88 (d, J = 8.2 Hz, 1H), 3.81 (s,

3H), 3.56 (m, 1H), 3.37 (d, J = 8.2 Hz, 1H), 3.28 (m, 1H), 2.20 (m, 1H), 1.90 (s, 1H),

1.49 (s, 3H), 1.42 (s, 3H), 1.39 (s, 3H), 1.29 (s, 3H), 1.26 (m, 1H), 1.14 (t, J = 7.0 Hz,

3H) (signal due to hydroxyl group proton not observed). 13C NMR (100 MHz, CDCl3) δ 159.6, 130.2, 129.4, 114.1, 107.6, 82.9, 79.9, 79.2,

76.6, 75.2, 68.5, 64.6, 55.4, 44.3, 42.7, 29.4, 28.1, 26.8, 26.7, 19.1, 15.6.

IR (KBr) νmax 3494, 2974, 2935, 1613, 1515, 1379, 1247, 1206, 1182, 1094, 1054,

872 cm–1.

MS (ESI, +ve) m/z 429 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C23H34NaO6 429.2253, found 429.2259.

Specific rotation [α]D = −62.6 (c = 0.3, CHCl3).

O-((3aS,4S,5S,6R,7R,9R)-9-Ethoxy-5-((4-methoxybenzyl)oxy)-2,2,4,7a-tetrameth-

ylhexahydro-4,7-ethanobenzo[d][1,3]dioxol-6-yl) S-methyl Carbonodithioate (27)

!

A magnetically stirred solution of alcohol 26 (150 mg, 0.37 mmol) in dry THF (6 mL)

maintained under a nitrogen atmosphere at 22 °C was treated with sodium hydride (74

OO

O

PMBOOC(S)SMe

27

Page 58: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S27!

mg of a 60% dispersion in mineral oil, 3.1 mmol). After 1.5 h carbon disulfide (330

µL, 5.5 mmol) was added to the reaction mixture that was then heated under reflux

for 2 h. The ensuing mixture was cooled to 22 °C then methyl iodide (120 µL, 1.9

mmol) added and stirring continued for 5 h. After this time, the reaction mixture was

cooled to 0 °C and quenched with iced water (12 mL) (CAUTION! EXOTHERMIC

REACTION AND POSSIBILITY OF HYDROGEN EVOLUTION). The ensuing

mixture was diluted with ethyl acetate (50 mL) then water (24 mL). The separated

aqueous phase was extracted with ethyl acetate (3 × 50 mL) and the combined organic

phases then dried (MgSO4), filtered, and concentrated under reduced pressure. The

residue thus obtained was subjected to flash column chromatography (silica, 1:19 v/v

ethyl acetate/40-60 petroleum ether elution) to give, after concentration of the

relevant fractions (Rf = 0.6), xanthate 27 (176 mg, 96%) as a clear, pale-yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.2 Hz, 2H), 6.87 (d, J = 8.2 Hz, 2H), 5.99

(m, 1H), 4.59 (d, J = 10.5 Hz, 1H), 4.32 (d, J = 10.5 Hz, 1H), 4.07 (s, 1H), 4.00 (d, J

= 7.6 Hz, 1H), 3.81 (s, 3H), 360 (m, 1H), 3.41 (d, J = 8.0 Hz, 1H), 3.29 (m, 1H), 2.54

(s, 3H), 2.26 (m, 1H), 2.14 (broad s, 1H), 1.58 (s, 3H), 1.45-1.41 (complex m, 4H),

1.38 (s, 3H), 1.27 (s, 3H), 1.16 (t, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 215.4, 159.2, 131.1, 129.4, 113.7, 107.6, 82.6, 80.4,

79.7, 77.1, 75.7, 74.7, 64.6, 55.4, 43.3, 41.8, 28.9, 27.1, 26.6, 26.5, 19.2, 18.7, 15.6.

IR (KBr) νmax 2972, 2935, 1515, 1248, 1206, 1062 cm–1.

MS (ESI, +ve) m/z 519 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C25H36NaO6S2 519.1851, found 519.1851.

Specific rotation [α]D = −9.0 (c = 0.6, CHCl3).

(3aS,4S,5R,7R,9R)-5-Ethoxy-9-((4-methoxybenzyl)oxy)-2,2,4,7a-tetramethyl-

hexahydro-4,7-ethanobenzo[d][1,3]dioxole (28)

!!

A magnetically stirred and de-oxygenated solution of xanthate 27 (468 mg, 0.94

OO

O

28

PMBO

Page 59: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S28!

mmol) in toluene (84 mL) maintained under an atmosphere of nitrogen at 22 °C was

treated with AIBN (47 mg, 0.28 mmol) then (Me3Si)3SiH (840 µL, 2.72 mmol). The

ensuing mixture was heated at 100 °C for 1 h then cooled and concentrated under

reduced pressure. The residue thus obtained was subjected to flash column

chromatography (silica, 1:37.5:350 v/v ethyl acetate/dichloromethane/40-60

petroleum ether elution) to give, after concentration of the appropriate fractions (Rf =

0.6 twice in 1:2.5:8.5 v/v ethyl acetate/dichloromethane/40-60 petroleum ether),

compound 28 (291 mg, 79%) as a white, crystalline solid, mp = 80-84 °C. 1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 4.50

(d, J = 11.2 Hz, 1H), 4.25 (d, J = 11.2 Hz, 1H), 4.00 (s, 1H), 3.81 (s, 3H), 3.68 (d, J =

8.3 Hz, 1H), 3.56 (complex m, 1H), 3.46 (d, J = 8.3 Hz, 1H), 3.30 (m, 1H), 2.23 (m,

1H), 1.88 (m, 1H), 1.80-1.73 (complex m, 2H), 1.50 (s, 3H), 1.43 (s, 3H), 1.38 (s,

3H), 1.24 (s, 3H), 1.21 (m, 1H), 1.14 (t, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 159.0, 131.4, 129.0, 113.8, 107.0, 82.7, 80.7, 76.1,

75.2, 70.9, 64.7, 55.4, 42.1, 37.6, 30.2, 30.1, 26.7, 26.5, 25.9, 18.6, 15.6.

IR (KBr) νmax 2973, 2934, 1614, 1514, 1377, 1247, 1094, 1053, 821 cm–1.

MS (EI, 70 eV) m/z 390 (M+•, 10%), 375 [(M−CH3•)+, 75], 211 (75), 165 (90), 122

(95), 121 (100).

HRMS M+• calcd for C23H34O5 390.2406, found 390.2410.

Specific rotation [α]D = −84.1 (c = 0.4, CHCl3).

(3aS,4R,5R,7S,9R)-9-Ethoxy-2,2,4,7a-tetramethylhexahydro-4,7-ethanobenzo-

[d][1,3]dioxol-5-ol (29)

!!

!A magnetically stirred solution of ether 28 (109 mg, 0.28 mmol) in dichloromethane

(3.5 mL) maintained at 22 °C was treated with water (400 µL) then 2,3-dichloro-5,6-

dicyano-1,4-benzoquinone (95 mg, 0.42 mmol) and the resulting deep-green mixture

stirred for 0.25 h then quenched with NaHCO3 (20 mL of a saturated aqueous

solution). The mixture thus formed was extracted with dichloromethane (3 × 30 mL)

OO

O

29HO

Page 60: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S29!

and the combined organic extracts were then dried (MgSO4), filtered and concentrated

under reduced pressure. The residue thus obtained was subjected to flash column

chromatography (silica, 1:9 v/v ethyl acetate/40-60 petroleum ether elution) to give,

after concentration of the appropriate fractions (Rf = 0.4 in 3:7 v/v ethyl acetate/40-60

petroleum ether), alcohol 29 (67 mg, 89%) as a clear, colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.02 (d, J = 9.2 Hz, 1H), 3.98 (s, 1H), 3.52 (m, 1H),

3.46 (d, J = 8.6 Hz, 1H), 3.28 (m, 1H), 2.23 (m, 1H), 2.05 (m, 1H), 1.81 (broad s,

1H), 1.59 (m, 1H), 1.53 (s, 3H), 1.48 (s, 1H), 1.44 (s, 3H), 1.41 (s, 3H), 1.22 (s, 3H),

1.19 (m, 1H), 1.13 (t, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 107.2, 82.6, 80.7, 75.3, 68.7, 64.7, 42.3, 37.8, 33.5,

30.1, 26.7, 26.6, 25.8, 18.3, 15.6.

IR (KBr) νmax 3493, 2973, 2938, 1377, 1247, 1207, 1096, 1052 cm–1.

MS (EI, 70 eV) m/z 255 [(M−CH3•)+, 100%], 195 (45), 194 (40), 151 (85), 149 (40),

123 (70).

HRMS (M−CH3•)+ calcd for C14H23O4 255.1596, found 255.1602.

Specific rotation [α]D = −74.5 (c = 0.4, CHCl3).

(3aS,4R,7R,9R)-9-Ethoxy-2,2,4,7a-tetramethyltetrahydro-4,7-ethanobenzo-

[d][1,3]dioxol-5(4H)-one (30)

!

A magnetically stirred solution of alcohol 29 (120 mg, 0.44 mmol) in dry

dichloromethane (12 mL) maintained at 0 °C under an atmosphere of nitrogen was

treated with pyridine (240 µL, 2.97 mmol) then the Dess-Martin periodinane (DMP)

(339 mg, 0.80 mmol). After being maintained at 0 °C for a further 0.66 h the reaction

mixture was warmed to 22 °C, kept at this temperature for 0.5 h then poured into

water (30 mL) and extracted with dichloromethane (3 × 50 mL). The combined

organic phases were then dried (MgSO4), filtered and concentrated under reduced

pressure and the residue so formed subjected to flash column chromatography (silica,

1:9 v/v ethyl acetate/40-60 petroleum ether elution) to give, after concentration of the

OO

O

30

O

Page 61: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S30!

appropriate fractions (Rf = 0.5 in 3:7 v/v ethyl acetate/40-60 petroleum ether),

compound 30 (94 mg, 79%) as a colorless, crystalline solid, mp = 62-64 °C. 1H NMR (400 MHz, CDCl3) δ 3.66 (d, J = 7.8 Hz, 1H), 3.62-3.58 (complex m, 1H),

3.56 (s, 1H), 3.29 (m, 1H), 2.49 (m, 1H), 2.35 (m, 1H), 2.21 (m, 2H), 1.60 (m, 1H),

1.50 (s, 3H), 1.39 (s, 3H), 1.34 (s, 3H), 1.22 (s, 3H), 1.09 (t, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 212.0, 110.0, 84.6, 80.6, 75.4, 64.9, 54.5, 39.4, 38.4,

29.0, 26.5, 26.3, 25.7, 15.4, 14.8.

IR (KBr) νmax 2977, 2936, 2875, 1733, 1380, 1244, 1205, 1092, 1054, 890 cm–1.

MS (ESI, +ve) m/z 291 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C15H24NaO4 291.1572, found 291.1574.

Specific rotation [α]D = −27.2 (c = 0.3, CHCl3).

!(3aS,4R,7R,9R)-9-Ethoxy-2,2,4,7a-tetramethyl-3a,4,7,7a-tetrahydro-4,7-ethano-

benzo[d][1,3]dioxol-5-yl (2E,4E)-hexa-2,4-dienoate (31)

!

A magnetically stirred solution of ketone 30 (49 mg, 0.18 mmol) in THF (5 mL)

maintained under a nitrogen atmosphere was cooled to −78 °C then treated with

KHMDS (540 µL of a 0.5 M solution in toluene, 0.27 mmol). The resulting mixture

was stirred at −78 °C for 1 h then sorbic chloride10 (27 µL, 0.22 mmol) was added

dropwise over 0.16 h. The ensuing mixture was stirred at −78 °C for 2 h then warmed

to 0 °C, quenched with NH4Cl (1 × 5 mL, a saturated aqueous solution) and extracted

with ethyl acetate (3 × 20 mL). The combined organic phases were washed with

NaHCO3 (1 × 20 mL of a saturated aqueous solution) before being dried (MgSO4),

filtered and concentrated under reduced pressure. The light-yellow oil thus obtained

was subjected to flash column chromatography (silica, 1:19→1:9 v/v ethyl acetate/40-

60 petroleum ether gradient elution) to give, after concentration of the appropriate

fractions (Rf = 0.6 in 3:7 v/v ethyl acetate/40-60 petroleum ether), the O-acylation

product 31 (55 mg, 84%) as a clear, colorless but unstable oil.

OO

O

31

OO

Page 62: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S31!

1H NMR (400 MHz, CDCl3) δ 7.32 (m, 1H), 6.25-6.12 (complex m, 2H), 5.84 (m,

2H), 3.90 (s, 1H), 3.77 (d, J = 6.6 Hz, 1H), 3.57 (m, 1H), 3.39 (m, 1H), 2.57 (complex

m, 1H), 2,46 (m, 1H), 1.86 (d, J = 5.6 Hz, 3H), 1.48 (s, 3H), 1.46 (s, 3H), 1.40 (s,

3H), 1.24 (m, 1H), 1.22 (s, 3H), 1.14 (t, J = 6.9 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 166.7, 151.0, 146.8, 140.6, 129.9, 117.8, 116.8, 112.0,

86.5, 84.5, 77.5, 65.0, 48.0, 41.8, 30.3, 28.6, 27.3, 27.2, 18.8, 15.5, 14.5.

(3aS,4R,7R,9R,Z)-9-Ethoxy-6-((2E,4E)-1-hydroxyhexa-2,4-dien-1-ylidene)-

2,2,4,7a-tetramethyltetrahydro-4,7-ethanobenzo[d][1,3]dioxol-5(4H)-one (32)

!

A magnetically stirred solution of ketone 30 (89 mg, 0.33 mmol) in THF (20 mL)

maintained at −78 °C under a nitrogen atmosphere was treated, dropwise over 0.08 h,

with KHMDS (1.33 mL of a 0.5 M solution in toluene, 0.66 mmol). The resulting

mixture was stirred at −78 °C for 0.75 h then a solution of sorbyl cyanide10,11 (60 mg,

0.50 mmol) in THF (6 mL) was added dropwise over 0.16 h. The ensuing mixture

was stirred at −78 °C for 2 h, warmed to 0 °C, quenched at this temperature with

NH4Cl (30 mL of a saturated aqueous solution) and then extracted with ethyl acetate

(3 × 50 mL). The combined organic phases were then dried (MgSO4), filtered and

concentrated under reduced pressure to give a light-yellow oil that was subjected to

flash column chromatography (silica, 1:19 v/v ethyl acetate/40-60 petroleum ether

elution) and thereby affording two fractions, A and B.

Concentration of fraction A (Rf = 0.6, in 3:7 v/v ethyl acetate/40-60 petroleum

ether) gave compound 32 (66 mg, 55% or 81% brsm) as a pale-yellow, crystalline

solid, mp = 92-94 °C. 1H NMR (400 MHz, CDCl3) δ 14.12 (s, 1H), 7.21 (dd, J = 15.0 and 10.9 Hz, 1H),

6.24 (m, 1H), 6.10 (m, 2H), 3.74 (d, J = 6.9 Hz, 1H), 3.66 (s, 1H), 3.52 (m, 1H), 3.30

(m, 1H), 2.85 (broad s, 1H), 2.57 (m, 1H), 1.86 (d, J = 6.7 Hz, 3H), 1.50 (s, 3H), 1.44

(m, 1H), 1.41 (s, 3H), 1.30 (s, 6H), 1.09 (t, J = 7.0 Hz, 3H).

32

OO

O

OH

O

Page 63: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S32!

13C NMR (100 MHz, CDCl3) δ 203.1, 165.9, 140.6, 138.1, 131.1, 118.7, 110.9, 109.9,

85.0, 82.2, 75.5, 65.0, 53.8, 40.3, 29.9, 27.1, 26.9(4), 26.8(6), 18.9, 15.3, 14.0.

IR (KBr) νmax 3463, 2977, 2934, 1737, 1607, 1569, 1446, 1378, 1239, 1096, 1053,

873 cm–1.

MS (ESI, +ve) m/z 385 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C21H30NaO5 385.1991, found 385.1994.

Specific rotation [α]D = +116.6 (c = 0.2, CHCl3).

Concentration of the fraction B (Rf = 0.2, in 3:7 v/v ethyl acetate/40-60

petroleum ether) gave compound 30 (29 mg, 33% recovery) as a clear, colorless solid

that was identical, in all respects, with an authentic sample.

!(1S,4R,5R,6S,7R,Z)-7-Ethoxy-5,6-dihydroxy-3-((2E,4E)-1-hydroxyhexa-2,4-dien-

1-ylidene)-1,5-dimethylbicyclo[2.2.2]octan-2-one (33)

!!

A magnetically stirred mixture of compound 32 (63 mg, 0.17 mmol) in acetic

acid/water (7.0 mL of a 4:1 v/v mixture) maintained at 22 °C was treated with AG-

50W-X8 resin (151 mg of H+ form) and the ensuing mixture was heated at 70 °C for

24 h before being cooled to 22 °C and treated with pyridinium p-toluenesulfonate (43

mg, 0.17 mmol). The ensuing mixture was stirred at 70 °C for 24 h then cooled and

filtered. The solid thus retained was washed with ethyl acetate (20 mL) and the

combined filtrates washed with water (1 x 20 mL). The separated aqueous phase was

extracted with ethyl acetate (1 x 50 mL) and the combined organic phases

concentrated under reduced pressure to give a light-yellow oil. Subjection of this

material to flash column chromatography (silica, 1:19 → 3:7 v/v ethyl acetate/40-60

petroleum ether elution) afforded two fractions, A and B.

Concentration of the fraction A (Rf = 0.6, in 3:7 v/v ethyl acetate/40-60

petroleum ether) gave compound 32 (15 mg, 24% recovery) as a light-yellow solid

that was identical, in all respects, with an authentic sample.

33

OOH

O

OH

OH

Page 64: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S33!

Concentration of the fraction B (Rf = 0.2, in 3:7 v/v ethyl acetate/40-60

petroleum ether) gave diol 33 (35 mg, 63% or 82% brsm) as a white, amorphous

powder, mp = 51-54 °C. 1H NMR (600 MHz, CDCl3) δ 14.20 (s, 1H), 7.22 (dd, J = 14.9 and 11.0 Hz, 1H),

6.25 (m, 1H), 6.20-6.08 (complex m, 2H), 3.70 (m, 1H), 3.52 (m, 1H), 3.31 (m, 1H),

3.19 (s, 1H), 2.86 (m, 1H), 2.68 (m, 1H), 1.87 (d, J = 6.8 Hz, 3H), 1.38 (m, 1H), 1.27

(s, 3H), 1.22 (s, 3H), 1.10 (t, J = 7.0 Hz, 3H) (signals due to hydroxyl group protons

not observed). 13C NMR (150 MHz, CDCl3) δ 203.5, 165.9, 140.8, 138.3, 131.1, 118.7, 110.8, 76.1,

73.9, 70.8, 65.0, 54.9, 41.1, 31.0, 29.3, 18.9, 15.4, 12.9. 1H NMR (600 MHz, CD3OD) δ 7.20 (dd, J = 15.0 and 11.0 Hz, 1H), 6.43-6.26

(complex m, 2H), 6.14 (m, 1H), 3.75 (dd, J = 8.6 and 3.4 Hz, 1H), 3.53 (m, 1H), 3.29

(m, 1H), 3.05 (s, 1H), 2.88 (t, J = 2.0 Hz, 1H), 2.72 (m, 1H), 1.87 (dd, J = 6.9 and 1.5

Hz, 3H), 1.29 (m, 1H), 1.18 (s, 3H), 1.11 (s, 3H), 1.09 (t, J = 7.0 Hz, 3H). 13C NMR (150 MHz, CD3OD) δ 205.8, 166.3, 141.7, 138.8, 132.4, 119.9, 112.4, 77.0,

75.6, 71.0, 65.8, 56.2, 42.2, 32.0, 29.1, 18.8, 15.6, 13.4.

IR (KBr) νmax 3391, 2971, 2931, 1631, 1602, 1562, 1389, 1144, 1091, 991, 920, 732

cm–1.

MS (ESI, +ve) m/z 345 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C18H26NaO5 345.1678, found 345.1680.

Specific rotation [α]D = +16.0 (c = 0.8, CHCl3).

(1S,3R,4R,7R,Z)-7-Ethoxy-3-hydroxy-5-((2E,4E)-1-hydroxyhexa-2,4-dien-1-

ylidene)-1,3-dimethylbicyclo[2.2.2]octane-2,6-dione (ent-4)

A magnetically stirred solution of diol 33 (50 mg, 0.16 mmol) in dichloromethane (19

mL) was treated with 4-methylmorpholine N-oxide (49 mg, 0.418 mmol) and

molecular sieves (39 mg of powdered 4 Å material) then tetra-n-propylammonium

O

OOH

O

OH

ent-4

Page 65: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S34!

perruthenate (11 mg, 0.031 mmol). The resulting mixture was stirred at 22 °C for 0.75

h then filtered through a pad of TLC-grade silica. The filtrate was concentrated under

reduced pressure to give a light-yellow oil and subjection of this material to flash

chromatography (silica, 1:19 → 1:9 v/v ethyl acetate/30-40 petroleum ether gradient

elution) afforded two fractions, A and B.

Concentration of the fraction A (Rf = 0.2 in 3:7 v/v ethyl acetate/40-60

petroleum ether) gave compound 33 (6 mg, 12% recovery) as a light-yellow,

amorphous powder that was identical with an authentic sample.

Concentration of the fraction B (Rf = 0.5 in 3:7 v/v ethyl acetate/40-60

petroleum ether) gave an oil that was subjected to flash chromatography (silica,

6:15:100 → 6:15:80 v/v ethyl acetate/dichloromethane/30-40 petroleum ether

gradient elution) to give, after concentration of the appropriate fractions (Rf = 0.5 in

3:7 v/v ethyl acetate/40-60 petroleum ether), compound ent-4 (26 mg, 52% or 59%

brsm) as a light-yellow, amorphous powder, mp = 83-85 °C. 1H NMR (600 MHz, CDCl3) δ 13.95 (s, 1H), 7.29 (dd, J = 14.9 and 10.9 Hz, 1H),

6.28 (m, 1H), 6.20-6.13 (complex m, 2H), 3.55 (m, 2H), 3.37 (m, 1H), 3.15 (m, 1H),

2.78 (m, 1H), 2.56 (broad s, 1H), 1.89 (dd, J = 6.8 and 1.3 Hz, 3H), 1.68 (m, 1H),

1.31 (s, 3H), 1.20 (s, 3H), 1.11 (t, J = 7.0 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 211.1, 196.5, 166.5, 141.9, 139.3, 131.0, 118.2, 110.5,

79.3, 74.7, 67.2, 65.8, 39.9, 30.8, 24.5, 19.0, 15.2, 9.1. 1H NMR (600 MHz, CD3OD) δ 7.27 (dd, J = 14.9 and 11.0 Hz, 1H), 6.38 (m, 2H),

6.18 (m, 1H), 3.61 (m, 1H), 3.58 (m, 1H), 3.34 (m, 1H), 3.16 (m, 1H), 2.83 (m, 1H),

1.87 (dd, J = 6.9 and 1.3 Hz, 3H), 1.63 (m, 1H), 1.20 (s, 3H), 1.14 (s, 3H), 1.10 (t, J =

7.0 Hz, 3H) (signals due to hydroxyl group protons not observed). 13C NMR (150 MHz, CD3OD) δ 210.3, 198.3, 167.2, 142.9, 139.8, 132.3, 119.5,

112.3, 79.9, 74.9, 68.7, 66.3, 41.7, 31.8, 24.0, 18.8, 15.5, 9.6. 1H NMR (600 MHz, C6D6) δ 14.65 (s, 1H), 7.33 (dd, J = 14.9 and 11.1 Hz, 1H), 5.97-

5.90 (complex m, 2H), 5.58 (m, 1H), 3.33 (m, 1H), 3.14 (m, 1H), 3.00 (m, 1H), 2.92

(m, 1H), 2.76 (m, 1H), 2.28 (s, 1H), 1.65 (s, 3H), 1.56 (m, 1H), 1.46 (dd, J = 6.9 and

1.4 Hz, 3H), 0.96 (s, 3H), 0.84 (t, J = 7.0 Hz, 3H). 13C NMR (150 MHz, C6D6) δ 210.2, 197.1, 166.4, 141.7, 138.3, 131.2, 118.7, 111.0,

79.4, 74.6, 67.6, 65.5, 40.2, 31.0, 24.1, 18.6, 15.2, 9.7. 1H NMR [600 MHz, (CD3)2CO] δ 14.08 (s, 1H), 7.26 (dd, J = 14.9 and 11.1 Hz, 1H),

6.53 (d, J = 10.0 Hz, 1H), 6.41 (m, 1H), 6.23 (m, 1H), 4.81 (s, 1H), 3.64 (m, 1H),

Page 66: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S35!

3.58 (m, 1H), 3.35 (m, 1H), 3.25 (m, 1H), 2.89 (m, 1H), 1.86 (d, J = 4.2 Hz, 3H), 1.64

(m, 1H), 1.20 (s, 3H), 1.16 (s, 3H), 1.07 (t, J = 7.0 Hz, 3H).

13C NMR [150 MHz, (CD3)2CO] δ 209.5, 198.0, 166.9, 142.0, 139.2, 132.0, 119.8,

112.2, 79.2, 74.3, 68.0, 65.6, 41.0, 31.5, 24.0, 18.8, 15.5, 9.5.

IR (KBr) νmax 3456, 2976, 2936, 2874, 1731, 1632, 1605, 1563, 1446, 1373, 1094,

1023, 998 cm–1.

MS (ESI, +ve) m/z 343 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C18H24NaO5 343.1521, found 343.1521.

Specific rotation [α]D = −234.0 (c = 0.1, MeOH) {lit.12 value (for 1) [α]D20 = +219 (c

0.1, methanol)}

Page 67: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S36!

Scheme S1: Reaction Sequence Used for the Conversion of Diol 23 into Ketone 30

Experimental Protocols for the Conversion of Diol 23 into Ketone 30

(3aS,4R,5R,6S,7R,9R)-6-((tert-Butyldimethylsilyl)oxy)-9-ethoxy-2,2,4,7a-tetra

methylhexahydro-4,7-ethanobenzo[d][1,3]dioxol-5-ol (34)

Sodium hydride (370 mg of a 60% dispersion in mineral oil, 9.17 mmol) was added,

in one portion, to a magnetically stirred solution of diol 23 (530 mg, 1.85 mmol) in

THF (27 mL) maintained at 0 °C under an atmosphere of nitrogen. The ensuing

mixture was stirred at 0 °C for 0.5 h, warmed to 22 °C and then maintained at this

temperature for another 0.5 h before being re-cooled 0 °C then treated, dropwise over

0.16 h, with a solution of TBSCl (310 mg, 2.06 mmol) in THF (20 mL). The ensuing

mixture was stirred at 0 °C for 0.25 h then quenched with ice water (50 mL)

(CAUTION! EXOTHERMIC REACTION AND POSSIBILITY OF HYDROGEN

EVOLUTION) and extracted with ethyl acetate (3 × 100 mL). The combined organic

phases were then dried (MgSO4), filtered and concentrated under reduced pressure

and the residue thus obtained subjected to flash column chromatography (silica,

1:19→1:9 v/v ethyl acetate/40-60 petroleum ether gradient elution) to afford, after

OOHO O

23

HO OOTBSOO

34

HO OOTBSOO

35

O

OO

O

O

30

NaH thenTBSCl

THF0 - 22 oC

1.4 h, 61%

DMP, pyridine

CH2Cl20 - 22 °C

1.7 h, 89%

SmI2THF/MeOH

0 oC20 min, 93%

OOTBSOO

34

HO

Page 68: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S37!

concentration of the appropriate fractions (Rf = 0.5 in 1:4 v/v ethyl acetate/40-60

petroleum ether), alcohol 34 (452 mg, 61%) as a colorless, crystalline solid, mp = 78-

80 °C. 1H NMR (800 MHz, CDCl3) δ 4.04 (dd, J = 7.5 and 4.3 Hz, 1H), 3.61 (m, 1H), 3.47

(s, 1H), 3.46 (s, 1H), 3.21-3.13 (complex m, 3H), 1.95 (m, 2H), 1.85 (s, 1H), 1.43 (s,

3H), 1.39 (s, 3H), 1.37 (s, 3H), 1.18 (s, 3H), 1.14 (t, J = 7.0 Hz, 3H), 0.91 (s, 9H),

0.08 (s, 3H), 0.06 (s, 3H). 13C NMR (200 MHz, CDCl3) δ 109.0, 86.3, 79.3, 76.1, 69.7, 66.6, 64.6, 43.9, 41.6,

27.1, 26.6, 25.9, 21.7, 18.4(9), 18.4(7), 15.6, −4.8, −5.1 (one signal obscured or

overlapping).

IR (KBr) νmax 3538, 2957, 2935, 2858, 1739, 1376, 1253, 1211, 1093, 1048, 895, 840,

778 cm–1.

MS (ESI, +ve) m/z 423 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C21H40NaO5Si 423.2543, found 423.2547.

Specific rotation [α]D = −16.2 (c = 0.4, CHCl3).

(3aS,4R,6S,7R,9R)-6-((tert-Butyldimethylsilyl)oxy)-9-ethoxy-2,2,4,7a-tetramethyl-

tetrahydro-4,7-ethanobenzo[d][1,3]dioxol-5(4H)-one (35)

A magnetically stirred solution of alcohol 34 (350 mg, 0.88 mmol) in dry

dichloromethane (45 mL) maintained at 0 °C under an atmosphere of nitrogen was

treated with pyridine (420 µL, 5.19 mmol) then the Dess-Martin periodinane (DMP)

(669 mg, 1.65 mmol). After stirring the reaction mixture at 0 °C for a further 0.66 h it

was warmed to 22 °C and maintained at this temperature for 1 h then poured into

water (100 mL) and extracted with dichloromethane (3 × 100 mL). The combined

organic phases were then dried (MgSO4), filtered and concentrated under reduced

pressure. The residue thus obtained was subjected to flash column chromatography

(silica, 1:19 v/v ethyl acetate/40-60 petroleum ether elution) and gave, after

concentration of the appropriate fractions (Rf = 0.7 in 3:7 v/v ethyl acetate/40-60

OOTBSOO

35

O

Page 69: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S38!

petroleum ether), ketone 35 (311 mg, 89%) as a colorless, crystalline solid, mp = 61-

63 °C. 1H NMR (400 MHz, CDCl3) δ 3.72-3.69 (complex m, 2H), 3.60 (s, 1H), 3.55 (m, 1H),

3.23 (m, 1H), 2.26 (m, 1H), 2.15 (m, 1H), 2.03 (m, 1H), 1.50 (s, 3H), 1.42 (s, 3H),

1.40 (s, 3H), 1.18 (s, 3H), 1.08 (t, J = 7.0 Hz, 3H), 0.87 (s, 9H), 0.10 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 210.6, 110.2, 84.5, 79.5, 75.2, 70.5, 64.3, 54.8, 46.4,

26.9, 26.7, 26.4, 25.8, 22.6, 18.3, 15.4, 14.4, −4.4, −5.1.

IR (KBr) νmax 2933, 2858, 1740, 1249, 1150, 1103, 1035, 837, 779 cm–1.

MS (ESI, +ve) m/z 421 [(M+Na)+, 100%].

HRMS (M+Na)+ calcd for C21H38NaO5Si 421.2386, found 421.2377.

Specific rotation [α]D = −60.0 (c = 0.4, CHCl3).

(3aS,4R,7R,9R)-9-Ethoxy-2,2,4,7a-tetramethyltetrahydro-4,7-ethanobenzo-

[d][1,3]dioxol-5(4H)-one (30)

A magnetically stirred solution of compound 35 (265 mg, 0.67 mmol) in

THF/methanol (40 mL of a 2:1 v/v mixture) maintained under an atmosphere of

nitrogen at 0 °C was treated, dropwise, with samarium diiodide (a 0.07-0.12 M

solution in THF, about 4.90 mmol) until the reaction mixture maintained a pale-

green/blue color for 0.16 h. At this point, the reaction mixture was poured into

NaHCO3 (100 mL of a saturated aqueous solution) and extracted with ethyl acetate (3

× 200 mL). The combined organic phases were then dried (MgSO4), filtered and

concentrated under reduced pressure. The residue thus obtained was subjected to flash

column chromatography (silica, 3:17 v/v ethyl acetate/40-60 petroleum ether elution)

and gave, after concentration of the appropriate fractions (Rf = 0.5 in 3:7 v/v ethyl

acetate/40-60 petroleum ether), ketone 30 (166 mg, 93%) as a colorless, crystalline

solid that was identical with an authentic sample.

!

OO

O

O

30

Page 70: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S39!

Table S1. Comparison of the 13C NMR Spectral Data Sets Derived From Rezishanone C and ent-Rezishanone C in Various Solvents

CD3OD CDCl3 C6D6 (CD3)2CO

δca δcb △δ δcc δcb △δ δcd δcb △δ δce δcb △δ

210.4 210.3 −0.1 210.9 211.1 +0.2 210.5 210.2 −0.3 209.5 209.5 0

198.3 198.3 0 196.4 196.5 +0.1 197.0 197.1 +0.1 197.9 198.0 +0.1

167.3 167.2 −0.1 166.4 166.5 +0.1 166.4 166.4 0 166.9 16.9 0

142.9 142.9 0 141.8 141.9 +0.1 141.7 141.7 0 142.0 142.0 0

139.7 139.8 +0.1 139.2 139.3 +0.1 138.2 138.3 +0.1 139.2 139.2 0

132.3 132.3 0 130.9 131.0 +0.1 131.2 131.2 0 132.0 132.0 0

119.5 119.5 0 118.0 118.2 +0.2 118.6 118.7 +0.1 119.8 119.8 0

112.3 112.3 0 110.4 110.5 +0.1 111.0 111.0 0 112.1 122.2 +0.1

79.9 79.9 0 79.1 79.3 +0.2 79.3 79.4 +0.1 79.2 79.2 0

74.9 74.9 0 74.6 74.7 +0.1 74.3 74.6 +0.3 74.3 74.3 0

68.7 68.7 0 67.0 67.2 +0.2 67.6 67.6 0 68.0 68.0 0

66.3 66.3 0 65.6 65.8 +0.2 65.5 65.5 0 65.6 65.6 0

41.7 41.7 0 39.7 39.9 +0.2 40.2 40.2 0 40.9 41.0 +0.1

31.8 31.8 0 30.6 30.8 +0.2 30.9 31.0 +0.1 31.4 31.5 +0.1

24.0 24.0 0 24.3 24.5 +0.2 24.1 24.1 0 24.0 24.0 0

18.8 18.8 0 18.8 19.0 +0.2 18.6 18.6 0 18.8 18.8 0

15.4 15.5 +0.1 15.1 15.2 +0.1 15.2 15.2 0 15.5 15.5 0

9.6 9.6 0 8.9 9.1 +0.2 9.6 9.7 +0.1 9.5 9.5 0 aData obtained from reference 12 - recorded in CD3OD. bData obtained from present work-recorded at 150 MHz in CD3OD, CDCl3, C6D6, (CD3)2CO, respectively. cData obtained from reference 13 - recorded in CDCl3. dData obtained from reference 14 -recorded in C6D6 at 75 MHz. eData obtained from reference 15 - recorded in (CD3)2CO at 75 MHz.

Page 71: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S40!

X-ray Crystallographic Studies

Crystallographic Data.

Compound 7. C12H16O3, M = 208.26, T = 150 K, trigonal, space group P3221, Z = 6, a

= 10.5437(1) Å, c = 17.0184(1) Å; V = 1638.46(2) Å3, Dx = 1.266 g cm–3, 2160

unique data (2θmax = 144.8°), R = 0.024 [for 2139 reflections with I > 2.0σ(I)]; Rw =

0.064 (all data), S = 1.01.

Compound 8. C9H12O3, M = 168.19, T = 150 K, orthorhombic, space group P212121, Z

= 4, a = 6.9885(1) Å, b = 7.9474(1) Å, c = 14.4684(1) Å; V = 803.58(2) Å3, Dx =

1.390 g cm–3, 1583 unique data (2θmax = 144.6°), R = 0.056 [for 1574 reflections with

I > 2.0σ(I)]; Rw = 0.056 (all data), S = 1.01.

!Compound 9. C11H16O4, M = 212.25, T = 200 K, orthorhombic, space group P212121,

Z = 4, a = 5.2471(3) Å, b = 10.1800(4) Å, c = 19.7165(9) Å; V = 1053.17(9) Å3, Dx =

1.339 g cm–3, 1121 unique data (2θmax = 50.0°), R = 0.47 [for 886 reflections with I >

2.0σ(I)]; Rw = 0.111 (all data), S = 0.95.

Compound 11. C15H28O3Si, M = 284.47, T = 150 K, monoclinic, space group C2, Z =

8, a = 31.7863(3) Å, b = 6.3670(1) Å, c = 18.8067(2) Å; β = 117.7194(12) °; V =

3369.35(8) Å3, Dx = 1.122 g cm–3, 5835 unique data (2θmax = 144.8°), R = 0.027 [for

5748 reflections with I > 2.0σ(I)]; Rw = 0.073 (all data), S = 1.00.

Compound 14. C13H18O5, M = 254.28, T = 150 K, orthorhombic, space group P212121,

Z = 4, a = 7.0640(1) Å, b = 8.5640(1) Å, c = 21.1355(2) Å; V = 1278.62(3) Å3, Dx =

1.321 g cm–3, 2534 unique data (2θmax = 144.8°), R = 0.025 [for 2492 reflections with

I > 2.0σ(I)]; Rw = 0.065 (all data), S = 1.00.

Compound 16. C12H18O4, M = 226.27, T = 150 K, orthorhombic, space group P212121,

Z = 4, a = 8.2169(1) Å, b = 10.8611(1) Å, c = 13.4792(1) Å; V = 1202.95(2) Å3, Dx =

1.249 g cm–3, 2380 unique data (2θmax = 144.8°), R = 0.026 [for 2350 reflections with

I > 2.0σ(I)]; Rw = 0.072 (all data), S = 1.00.

Page 72: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S41!

Compound 17. C10H16O3, M = 184.24, T = 150 K, orthorhombic, space group P212121,

Z = 4, a = 6.4980(1) Å, b = 11.4064(1) Å, c = 12.4797(1) Å; V = 924.98(2) Å3, Dx =

1.323 g cm–3, 1733 unique data (2θmax = 139.6°), R = 0.025 [for 1723 reflections with

I > 2.0σ(I)]; Rw = 0.067 (all data), S = 1.01.

Compound 22. C12H22O4, M = 230.30, T = 150 K, orthorhombic, space group P212121,

Z = 12, a = 12.6340(1) Å, b = 13.4519(1) Å, c = 21.7470(1) Å; V = 3695.93(4) Å3, Dx

= 1.242 g cm–3, 7216 unique data (2θmax = 144.0°), R = 0.025 [for 7015 reflections

with I > 2.0σ(I)]; Rw = 0.062 (all data), S = 1.00.

Compound 26. C23H34O6, M = 406.52, T = 150 K, orthorhombic, space group P212121,

Z = 4, a = 7.9838(1) Å, b = 14.1145(1) Å, c = 18.8516(1) Å; V = 2124.34(3) Å3, Dx =

1.271 g cm–3, 4199 unique data (2θmax = 144.8°), R = 0.024 [for 4133 reflections with

I > 2.0σ(I)]; Rw = 0.061 (all data), S = 1.00.

Compound 30. C15H24O4, M = 268.35, T = 150 K, orthorhombic, space group P212121,

Z = 4, a = 7.6721(1) Å, b = 9.3354(2) Å, c = 20.5773(3) Å; V = 1473.79(4) Å3, Dx =

1.209 g cm–3, 2911 unique data (2θmax = 144.8°), R = 0.025 [for 2839 reflections with

I > 2.0σ(I)]; Rw = 0.063 (all data), S = 1.00.

Compound 32. C21H30O5, M = 362.47, T = 150 K, orthorhombic, space group P212121,

Z = 4, a = 7.3104(2) Å, b = 8.4083(2) Å, c = 33.0483(10) Å; V = 2031.41(10) Å3, Dx

= 1.185 g cm–3, 3805 unique data (2θmax = 144.6°), R = 0.036 [for 3624 reflections

with I > 2.0σ(I)]; Rw = 0.093 (all data), S = 1.01.

Structure Determination. The image for compound 9 was measured on a

diffractometer (Mo Kα, graphite monochromator, λ = 0.71073 Å) fitted with an area

detector and the data extracted using the DENZO/Scalepack package.16 Images for

compounds 7, 8, 11, 14, 16, 17, 22, 26, 30 and 32 were measured on a diffractometer

(Cu Kα, mirror monochromator, λ = 1.54184 Å) fitted with an area detector and the

data extracted using the CrysAlis package.17 The structure solutions for all eleven

compounds were solved by direct methods (SIR92)18 then refined using the

CRYSTALS program package.19 Atomic coordinates, bond lengths and angles, and

Page 73: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S42!

displacement parameters have been deposited at the Cambridge Crystallographic Data

Centre (CCDC nos. 1526109-1526119). These data can be obtained free-of-charge via

www.ccdc.cam.ac.uk/data_request/cif, by emailing [email protected], or

by contacting The Cambridge Crystallographic Data Centre, 12 Union Road,

Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

Page 74: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S43!

References

1. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.;

Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.;

Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.;

Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.;

Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.;

Vreven, T.; Montgomery, J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd,

J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.;

Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi,

M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.;

Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin,

A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.;

Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.;

Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D.

J. Revision D.01 ed., Gaussian Inc., Wallingford CT, 2013.

2. Zhao, Y.; Truhlar, D. G. Theor. Chem. Acc. 2008, 120, 215.

3. Goerigk, L.; Grimme, S. Phys. Chem. Chem. Phys. 2011, 13, 6670.

4. (a) Ditchfield, R.; Hehre, W. J.; Pople, J. A. J. Chem. Phys. 1971, 54, 724; (b)

Hehre, W. J.; Ditchfield, R.; Pople, J. A. J. Chem. Phys. 1972, 56, 2257.

5. Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. J. Phys. Chem. B 2009, 113,

6378.

6. Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.

7. Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J.

Organometallics 1996, 15, 1518.

8. Banwell, M. G.; Dupuche, J. R.; Gable, R. W. Aust. J. Chem. 1996, 49, 639.

9. Banwell, M. G.; Darmos, P.; Hockless, D. C. R. Aust. J. Chem. 2004, 57, 41.

10. Volp, K. A.; Johnson, D. M.; Harned, A. M. Org. Lett. 2011, 13, 4486.

11. Santelli, M.; Abed, D. E.; Jellal, A. J. Org. Chem. 1986, 51, 1199.

12. Bringmann, G.; Lang, G.; Gulder, T. A. M.; Tsuruta, H.; Muhlbacher, J.;

Maksimenka, K.; Steffens, S.; Schaumann, K.; Stohr, R.; Wiese, J.; Imhoff, J.

F.; Perovic-Ottstadt, S.; Boreiko, O.; Muller, W. E. G. Tetrahedron 2005, 61,

7252.

13. Lee, D.; Lee, J. H.; Cai, X. F.; Shin, J. C.; Lee, K.; Hong, Y.; Lee, J. J. J.

Antibiot. 2005, 58, 615.

Page 75: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S44!

14. Maskey, R. P.; Grun-Wollny, I.; Laatsch, H. J. Nat. Prod. 2005, 68, 865.

15. Neumann, K.; Abdel-Lateff, A.; Wright, A. D.; Kehraus, S.; Krick, A.; Konig,

G. M. Eur. J. Org. Chem. 2007, 2268.

16. DENZO–SMN. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data

collected in oscillation mode. In Methods in Enzymology, Volume 276:

Macromolecular Crystallography, Part A; C. W. Carter Jr. and R. M. Sweet,

Eds.; Academic Press: New York, 1997; pp. 307–326.

17. CrysAlis PRO Version 1.171.37.35h (release 09-02-2015 CrysAlis171.NET)

(compiled Feb 9 2015,16:26:32) Agilent Technologies: Oxfordshire, UK.

18. SIR92. Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Burla, M.

C.; Polidori, G.; Camalli, M. J. Appl. Crystallogr. 1994, 27, 435.

19. Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.; Watkin, D. J. J.

Appl. Crystallogr. 2003, 36, 1487.

Page 76: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S45!

Figure S2: Structure of compound 7 (CCDC 1526109) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.

Page 77: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S46!

Figure S3: Structure of compound 8 (CCDC 1526110) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.

Page 78: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S47!

Figure S4: Structure of compound 9 (CCDC 1526111) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.!!!!!!!!!

Page 79: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S48!

Figure S5: Structure of compound 11 (CCDC 1526112) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.!!!

Page 80: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S49!

Figure S6: Structure of compound 14 (CCDC 1526113) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.!!

Page 81: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S50!

!

Figure S7: Structure of compound 16 (CCDC 1526114) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.!! !

Page 82: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S51!

Figure S8: Structure of compound 17 (CCDC 1526115) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.!!!

Page 83: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S52!

Figure S9: Structure of compound 22 (CCDC 1526116) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.

Page 84: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S53!

Figure S10: Structure of compound 26 (CCDC 1526117) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.

Page 85: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S54!

Figure S11: Structure of compound 30 (CCDC 1526118) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.

Page 86: The Application of Pericyclic, Photolytic, Chemoenzymatic

! S55!

Figure S12: Structure of compound 32 (CCDC 1526119) with labeling of selected atoms. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen

atoms are drawn as circles with small radii.!!!

Page 87: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S56!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

6.003.01

1.00

1.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

71

Page 88: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S57!

!5.6

5.7

5.8

5.9

6.0

6.1

6.2

6.3

6.4

6.5

f1 (

ppm

)

1.00

1.00

4.0

4.1

4.2

4.3

4.4

4.5

f1 (

ppm

)

1.00

1.00

1.9

2.0

2.1

f1 (

ppm

)

1.00

1.00

72

Page 89: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S58!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

14.53

25.1025.54

35.2735.59

54.81

76.84 CDCl377.16 CDCl377.48 CDCl379.3279.89

110.88

131.55133.66

210.51

73

Page 90: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S59!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.00

2.00

1.00

1.00

1.00

1.00

1.00

3.31 CD3OD_SPE

5.7

5.8

5.9

6.0

6.1

6.2

6.3

6.4

6.5

6.6

f1 (

ppm

)

1.00

1.00

74

Page 91: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S60!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

14.83

36.9240.4648.36 CD3OD_SPE48.57 CD3OD_SPE48.79 CD3OD_SPE49.00 CD3OD_SPE49.21 CD3OD_SPE49.42 CD3OD_SPE49.64 CD3OD_SPE57.17

79.9782.80

132.65136.88

213.10

75

Page 92: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S61!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.01

1.00

4.00

1.00

1.00

4.01

1.00

1.00

7.26 CDCl3

3.9

4.0

4.1

f1 (

ppm

)

4.01

76

Page 93: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S62!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.90

29.07

37.7039.20

65.4065.6373.9076.84 CDCl377.16 CDCl377.48 CDCl3

103.55

135.69

144.39

199.77

77

Page 94: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S63!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

6.03

9.04

3.01

1.002.00

1.01

1.00

1.00

1.00

1.00

7.26 CDCl3

78

Page 95: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S64!

6.3

56

.40

6.4

56

.50

f1 (

ppm

)

1.00

5.7

05

.75

5.8

0f1

(ppm

)

1.00

3.5

3.6

3.7

3.8

3.9

4.0

f1 (

ppm

)

1.00

1.00

2.8

02

.88

f1 (

ppm

)

1.01

1.9

01

.95

2.0

02

.05

2.1

02

.15

f1 (

ppm

)

1.00

2.00

79

Page 96: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S65!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

-4.61-4.57

14.3618.1925.92

35.9139.78

55.74

76.84 CDCl377.16 CDCl377.48 CDCl379.7683.34

130.63

135.99

210.34

80

Page 97: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S66!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.03

3.00

9.00

3.00

1.00

1.00

1.001.00

1.001.001.001.00

1.00

1.00

7.26 CDCl3

81

Page 98: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S67!

6.0

06.0

56.1

06.1

56.2

06.2

5f1

(ppm

)

1.00

5.7

5.8

f1 (

ppm

)

1.00

3.0

3.1

3.2

3.3

3.4

3.5

3.6

3.7

3.8

3.9

4.0

f1 (

ppm

)

1.00

1.00

1.00

1.00

2.0

2.1

2.2

2.3

2.4

2.5

2.6

2.7

f1 (

ppm

)

1.00

1.00

1.00

82

Page 99: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S68!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

-4.54-4.49

18.2518.4925.99

35.1838.3043.30

74.2276.84 CDCl377.16 CDCl377.48 CDCl380.5585.83

134.16134.34

13

4.0

13

4.2

13

4.4

13

4.6

f1 (

ppm

)

134.16

134.34

-4

.6-4

.5-4

.4f1

(ppm

)

-4.54

-4.49

83

Page 100: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S69!

-1

.5-1

.0-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.0f1

(ppm

)

6.03

9.03

1.013.00

1.04

0.97

0.98

0.98

1.00

1.00

1.00

7.26 CDCl3

84

Page 101: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S70!

5.7

5.8

5.9

6.0

6.1

6.2

6.3

6.4

f1 (

ppm

)

1.00

1.00

3.2

3.4

3.6

3.8

4.0

f1 (

ppm

)

0.98

0.98

1.00

1.8

2.0

2.2

2.4

2.6

f1 (

ppm

)

1.04

0.97

1.1

51.2

01.2

51.3

01.3

5f1

(ppm

)

1.01

3.00

85

Page 102: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S71!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

-4.57-4.54

18.0218.2125.96

36.8339.1645.50

68.4276.84 CDCl377.16 CDCl377.48 CDCl379.8183.19

132.41134.76

18

.01

8.3

f1 (

ppm

)18.02

18.21

-4

.6-4

.5-4

.4f1

(ppm

)-4.57-4.54

86

Page 103: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S72!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

5.98

9.003.001.00

3.003.001.001.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

87

Page 104: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S73!

5.7

5.8

5.9

6.0

6.1

6.2

6.3

6.4

6.5

f1 (

ppm

)

1.00

1.00

4.4

4.5

4.6

4.7

4.8

4.9

5.0

5.1

f1 (

ppm

)1.00

1.00

2.1

52

.20

2.2

52

.30

2.3

52

.40

2.4

52

.50

2.5

52

.60

f1 (

ppm

)

1.00

1.00

88

Page 105: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S74!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

-4.85-4.83

17.6818.1321.1421.2925.8334.3938.8442.58

71.8076.84 CDCl377.16 CDCl377.2877.48 CDCl382.87

132.22133.57

170.29171.25

-4

.85

-4

.80

f1 (

ppm

)-4.85

-4.83

76

.57

7.0

77

.5f1

(ppm

)

76.84 CDCl377.16 CDCl377.2877.48 CDCl3

89

Page 106: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S75!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.0f1

(ppm

)

3.011.08

3.023.011.17

1.03

1.00

1.04

1.00

1.01

0.99

1.00

7.26 CDCl3

90

Page 107: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S76!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

17.6921.0321.16

34.5436.4941.37

71.2476.84 CDCl376.9377.16 CDCl377.48 CDCl385.56

132.27133.50

171.05172.82

77

.07

7.5

f1 (

ppm

)

76.84 CDCl376.9377.16 CDCl377.48 CDCl3

91

Page 108: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S77!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.0f1

(ppm

)

3.02

1.00

3.003.01

1.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

92

Page 109: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S78!

5.8

5.9

6.0

6.1

6.2

6.3

6.4

6.5

6.6

f1 (

ppm

)

1.00

1.00

5.0

05

.05

5.1

05

.15

5.2

05

.25

5.3

0f1

(ppm

)1.00

2.4

2.5

2.6

2.7

2.8

2.9

3.0

3.1

3.2

f1 (

ppm

)

1.00

1.00

93

Page 110: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S79!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

17.1820.6921.06

35.54

45.4346.81

71.4072.1476.84 CDCl377.16 CDCl377.48 CDCl3

129.58

136.59

170.14170.79

204.04

94

Page 111: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S80!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

1.00

6.01

3.002.001.001.001.00

1.00

1.00

1.00

7.26 CDCl3

95

Page 112: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S81!

5.6

5.7

5.8

5.9

6.0

6.1

6.2

6.3

6.4

f1 (

ppm

)

1.00

1.00

5.0

05

.05

5.1

05

.15

f1 (

ppm

)

1.00

2.2

2.3

2.4

2.5

2.6

2.7

2.8

f1 (

ppm

)

2.00

1.00

1.00

0.9

60

.98

1.0

01

.02

1.0

41

.06

f1 (

ppm

)

1.00

96

Page 113: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S82!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

18.0421.34

30.5532.22

42.9644.07

69.6771.6976.84 CDCl377.16 CDCl377.3877.48 CDCl3

134.23134.51

171.40

76

.57

7.0

77

.57

8.0

f1 (

ppm

)

76.84 CDCl377.16 CDCl377.3877.48 CDCl3

97

Page 114: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S83!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

1.003.003.00

1.001.001.00

1.00

1.00

1.00

3.31 CD3OD_SPE

98

Page 115: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S84!

5.5

5.6

5.7

5.8

5.9

6.0

6.1

6.2

6.3

6.4

6.5

f1 (

ppm

)

1.00

1.00

3.8

3.9

4.0

f1 (

ppm

)1.00

2.2

2.3

2.4

2.5

2.6

f1 (

ppm

)

1.00

1.000

.90

0.9

51

.00

f1 (

ppm

)

1.00

99

Page 116: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S85!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

18.64

30.7434.8544.5646.7448.36 CD3OD_SPE48.57 CD3OD_SPE48.79 CD3OD_SPE49.00 CD3OD_SPE49.21 CD3OD_SPE49.43 CD3OD_SPE49.64 CD3OD_SPE68.1970.2578.55

135.35135.62

100

Page 117: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S86!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.0f1

(ppm

)

1.001.013.002.963.013.00

1.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

101

Page 118: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S87!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

19.0727.2527.2828.9133.99

42.8145.48

69.6076.84 CDCl377.16 CDCl377.48 CDCl383.9487.30

111.26

133.22136.57

102

Page 119: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S88!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.5f1

(ppm

)

4.003.003.003.003.00

1.001.00

1.002.001.00

1.00

1.00

7.26 CDCl3

103

Page 120: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S89!

5.6

5.7

5.8

5.9

6.0

6.1

6.2

6.3

6.4

f1 (

ppm

)

1.00

1.00

3.3

3.4

3.5

3.6

3.7

3.8

f1 (

ppm

)

1.00

2.00

1.00

2.3

52

.40

2.4

52

.50

2.5

5f1

(ppm

)

1.00

1.00

1.0

81

.10

1.1

21

.14

1.1

61

.18

f1 (

ppm

)

4.00

104

Page 121: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S90!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6119.1427.3627.4529.0431.09

42.6744.69

64.94

76.84 CDCl377.0377.16 CDCl377.48 CDCl383.8487.52

111.14

134.05134.56

76

.57

7.0

77

.5f1

(ppm

)

76.84 CDCl377.0377.16 CDCl377.48 CDCl3

105

Page 122: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S91!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.003.006.003.001.00

1.00

1.00

1.00

1.002.001.001.00

7.26 CDCl3

106

Page 123: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S92!

3.2

3.3

3.4

3.5

3.6

3.7

3.8

3.9

f1 (

ppm

)

1.00

2.00

1.00

1.00

2.7

52

.80

2.8

52

.90

f1 (

ppm

)

1.00

2.0

2.1

2.2

2.3

2.4

f1 (

ppm

)

1.00

1.001

.11

.21

.31

.41

.51

.6f1

(ppm

)

3.00

3.00

6.00

3.00

1.00

107

Page 124: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S93!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6919.1826.5927.3028.1228.18

40.6942.70

53.1754.61

66.1974.7676.84 CDCl377.16 CDCl377.48 CDCl382.6086.64

111.10

108

Page 125: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S94!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.003.003.003.004.002.001.011.001.00

2.031.001.001.00

7.26 CDCl3

109

Page 126: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S95!

3.3

3.4

3.5

3.6

3.7

3.8

3.9

f1 (

ppm

)

2.03

1.00

1.00

1.00

1.0

1.1

1.2

1.3

1.4

1.5

1.6

1.7

1.8

1.9

2.0

2.1

2.2

f1 (

ppm

)

3.00

3.00

3.003.004.00

2.00

1.01

1.00

1.00

110

Page 127: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S96!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6022.0023.1226.2526.4826.8135.3938.1243.03

64.9365.6775.6276.84 CDCl377.16 CDCl377.48 CDCl380.7386.81

108.48

111

Page 128: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S97!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.003.003.002.022.001.00

1.001.001.001.002.001.001.00

7.26 CDCl3

112

Page 129: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S98!

2.4

2.5

2.6

2.7

2.8

2.9

3.0

3.1

3.2

3.3

3.4

3.5

3.6

3.7

3.8

3.9

4.0

4.1

f1 (

ppm

)

1.00

1.00

1.00

1.00

2.00

1.00

1.00

1.4

1.5

1.6

1.7

1.8

1.9

2.0

2.1

2.2

2.3

f1 (

ppm

)

2.02

2.00

1.00

113

Page 130: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S99!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6221.1223.0228.8736.3039.5744.57

65.0065.6269.8774.8876.84 CDCl377.16 CDCl377.48 CDCl379.39

114

Page 131: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S100!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.0f1

(ppm

)

3.003.006.013.00

1.00

2.00

2.011.001.001.00

1.00

7.26 CDCl3

115

Page 132: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S101!

3.1

3.2

3.3

3.4

3.5

3.6

3.7

3.8

3.9

4.0

4.1

f1 (

ppm

)

2.01

1.00

1.00

1.00

1.00

1.7

1.8

1.9

2.0

2.1

2.2

2.3

f1 (

ppm

)

1.00

2.00

0.9

51

.00

1.0

51

.10

1.1

51

.20

f1 (

ppm

)

3.00

3.00

116

Page 133: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S102!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.5418.3322.0426.6126.7126.83

41.0542.17

65.1265.2969.9376.84 CDCl376.8877.16 CDCl377.48 CDCl379.4785.89

109.15

76

.57

7.0

77

.5f1

(ppm

)

76.84 CDCl376.8877.16 CDCl3

77.48 CDCl3

117

Page 134: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S103!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.001.012.882.872.953.021.001.000.981.00

1.001.001.002.001.00

7.26 CDCl3

118

Page 135: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S104!

3.9

4.0

4.1

4.2

4.3

f1 (

ppm

)

2.00

1.00

3.2

3.3

3.4

3.5

3.6

f1 (

ppm

)

1.00

1.00

1.00

2.2

02

.25

2.3

02

.35

2.4

02

.45

2.5

02

.55

f1 (

ppm

)

1.00

0.98

1.001

.05

1.1

01

.15

1.2

01

.25

1.3

0f1

(ppm

)

3.00

1.01

2.88

119

Page 136: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S105!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6218.7726.6726.7527.8629.60

42.1944.21

64.7168.6170.0975.2776.84 CDCl377.16 CDCl377.48 CDCl379.9982.54

107.43

120

Page 137: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S106!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

1.003.003.003.003.003.00

1.00

1.00

1.002.003.001.002.00

1.00

2.00

2.007.26 CDCl3

121

Page 138: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S107!

6.8

7.0

7.2

7.4

f1 (

ppm

)

2.00

2.00

7.26 CDCl3

4.2

54

.30

4.3

5f1

(ppm

)

2.00

3.3

3.4

3.5

3.6

f1 (

ppm

)1.00

2.00

2.2

2.3

2.4

2.5

f1 (

ppm

)

1.00

1.00

1.1

01

.15

1.2

0f1

(ppm

)

1.00

3.00

122

Page 139: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S108!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6017.61

27.1828.0429.16

41.4241.49

55.36

65.1574.1576.1176.84 CDCl377.16 CDCl377.48 CDCl377.8679.9882.57

101.64107.76113.71

127.95128.22

160.17

123

Page 140: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S109!

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

f1 (

ppm

)

3.001.003.003.003.003.001.00

1.00

1.001.001.003.001.011.001.00

2.00

2.00

2.017.26 CDCl3

124

Page 141: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S110!

6.9

7.0

7.1

7.2

7.3

f1 (

ppm

)

2.00

2.017.26 CDCl3

3.2

3.3

3.4

3.5

3.6

f1 (

ppm

)

1.00

1.00

1.00

2.0

52

.10

2.1

52

.20

2.2

52

.30

2.3

5f1

(ppm

)1.001

.05

1.1

01

.15

1.2

01

.25

1.3

0f1

(ppm

)

3.00

1.00

3.00

125

Page 142: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S111!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6419.1026.7126.8028.0829.36

42.6644.34

55.4264.5968.5475.1876.6476.84 CDCl377.16 CDCl377.48 CDCl379.2479.8882.91

107.57

114.10

129.39130.17

159.56

126

Page 143: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S112!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.043.033.034.033.01

1.001.002.95

1.001.001.003.001.000.991.001.00

0.96

2.00

2.017.26 CDCl3

127

Page 144: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S113!

5.9

05

.95

6.0

06

.05

f1 (

ppm

)0.96

4.0

4.1

4.2

4.3

4.4

4.5

4.6

f1 (

ppm

)

1.00

0.99

1.00

1.00

3.2

53

.30

3.3

53

.40

3.4

53

.50

3.5

53

.60

3.6

5f1

(ppm

)

1.00

1.00

1.00

1.4

01

.41

1.4

21

.43

1.4

41

.45

1.4

61

.47

1.4

8f1

(ppm

)

4.03

128

Page 145: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S114!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6018.6819.1726.5426.6227.1428.92

41.8143.26

55.39

64.5974.6775.7076.84 CDCl377.1177.16 CDCl377.48 CDCl379.6980.3982.60

107.60

113.72

129.37131.06

159.18

215.36

76

.57

7.0

77

.5f1

(ppm

)

76.84 CDCl377.1177.16 CDCl377.48 CDCl3

129

Page 146: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S115!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.0f1

(ppm

)

3.011.013.013.003.003.052.021.01

1.01

1.021.011.001.003.001.001.001.00

2.00

2.007.26 CDCl3

7.1

7.2

7.3

7.4

f1 (

ppm

)

2.00

7.26 CDCl3

1.1

01

.15

1.2

01

.25

f1 (

ppm

)

3.01

1.01

3.01

130

Page 147: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S116!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6518.5525.8626.4926.6630.0830.1537.6442.14

55.3964.7370.9375.2376.0576.84 CDCl377.16 CDCl377.48 CDCl380.6682.69

107.02

113.78

129.01131.41

159.04

131

Page 148: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S117!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.001.003.013.003.001.003.001.001.001.011.01

1.001.001.00

1.001.00

7.26 CDCl3

132

Page 149: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S118!

3.1

3.2

3.3

3.4

3.5

3.6

3.7

3.8

3.9

4.0

f1 (

ppm

)

1.00

1.00

1.00

1.00

1.00

1.3

1.4

1.5

1.6

1.7

1.8

1.9

2.0

2.1

2.2

2.3

f1 (

ppm

)

3.003.001.003.001.00

1.00

1.01

1.01

1.0

81

.10

1.1

21

.14

1.1

61

.18

1.2

01

.22

f1 (

ppm

)

3.00

1.00

3.01

133

Page 150: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S119!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.6318.3025.8026.6126.7330.0833.4737.8442.26

64.7168.7375.2676.84 CDCl377.16 CDCl377.48 CDCl380.6882.56

107.17

134

Page 151: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S120!

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10

.0f1

(ppm

)

3.013.023.093.043.061.04

2.111.051.02

1.001.061.021.00

7.26 CDCl3

135

Page 152: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S121!

1.0

1.1

1.2

1.3

1.4

1.5

1.6

1.7

1.8

1.9

2.0

2.1

2.2

2.3

2.4

2.5

2.6

2.7

2.8

2.9

3.0

3.1

3.2

3.3

3.4

3.5

3.6

3.7

f1 (

ppm

)

3.01

3.02

3.093.04

3.06

1.04

2.11

1.05

1.02

1.00

1.061.021.00

136

Page 153: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S122!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

14.8215.39

25.6626.2626.5229.0038.4339.44

54.48

64.88

75.4276.84 CDCl377.16 CDCl377.48 CDCl380.6084.56

110.02

211.97

137

Page 154: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S123!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.003.001.023.003.003.013.01

1.011.00

1.001.011.001.00

2.00

2.00

1.007.26 CDCl3

138

Page 155: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S124!

5.8

6.0

6.2

6.4

6.6

6.8

7.0

7.2

7.4

f1 (

ppm

)

2.00

2.00

1.00

7.26 CDCl3

1.5

2.0

2.5

3.0

3.5

4.0

f1 (

ppm

)

3.003.001.023.003.003.01

3.01

1.01

1.00

1.00

1.01

1.00

1.00

139

Page 156: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S125!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

14.5115.5318.8227.1927.2628.6430.29

41.80

47.96

65.04

76.84 CDCl377.16 CDCl377.4677.48 CDCl384.5486.53

112.02116.82117.82

129.85

140.58146.81151.00

166.68

**

**

77

.47

7.5 f1 (

ppm

)77.4677.48 CDCl3

*=

im

pu

rity

140

Page 157: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S126!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

12

.51

3.0

13

.51

4.0

14

.51

5.0

f1 (

ppm

)

3.056.033.031.093.043.05

1.071.051.031.011.031.05

2.031.08

1.00

1.00

7.26 CDCl3

141

Page 158: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S127!

2.5

2.6

2.7

2.8

2.9

3.0

3.1

3.2

3.3

3.4

3.5

3.6

3.7

3.8

f1 (

ppm

)1.07

1.05

1.03

1.011.031.05

1.8

21.8

41.8

61.8

8f1

(ppm

)

3.05

1.3

81.4

01.4

21.4

41.4

61.4

81.5

0f1

(ppm

)

3.03

1.09

3.04

6.0

6.2

6.4

6.6

6.8

7.0

7.2

f1 (

ppm

)

2.03

1.08

1.007.26 CDCl3

142

Page 159: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S128!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

14.0215.3118.8826.8626.9427.0629.88

40.34

53.76

65.01

75.5176.84 CDCl377.16 CDCl377.48 CDCl382.2385.04

109.91110.94118.66

131.11138.14140.61

165.90

203.14

***

*

* =

tauto

mer?

143

Page 160: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S129!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

12

.51

3.0

13

.51

4.0

14

.5f1

(ppm

)

3.253.013.161.203.05

1.091.061.041.171.121.15

1.951.08

0.93

1.03

7.26 CDCl3

144

Page 161: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S130!

6.1

6.2

6.3

6.4

6.5

6.6

6.7

6.8

6.9

7.0

7.1

7.2

7.3

7.4

f1 (

ppm

)

1.95

1.08

0.937.26 CDCl3

2.6

2.8

3.0

3.2

3.4

3.6

3.8

f1 (

ppm

)

1.09

1.06

1.04

1.17

1.12

1.15

1.0

51

.10

1.1

51

.20

1.2

51

.30

1.3

51

.40

f1 (

ppm

)

3.25

3.01

3.16

1.20

145

Page 162: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S131!

01

02

03

04

05

06

07

08

09

01

00

11

01

20

13

01

40

15

01

60

17

01

80

19

02

00

21

02

20

f1 (

ppm

)

12.9415.3818.92

29.2831.03

41.12

54.8765.0570.7973.8876.1176.95 CDCl377.16 CDCl377.37 CDCl3

110.81

118.69

131.09138.34140.82

165.90

203.45

**

**

** =

tauto

mer?

146

Page 163: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S132!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

12

.51

3.0

13

.51

4.0

14

.5f1

(ppm

)

3.173.053.091.303.00

1.110.980.890.831.181.16

0.882.10

0.92

3.31 MeOD

147

Page 164: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S133!

6.0

6.1

6.2

6.3

6.4

6.5

6.6

6.7

6.8

6.9

7.0

7.1

7.2

7.3

f1 (

ppm

)

0.88

2.10

0.92

2.7

2.8

2.9

3.0

3.1

3.2

3.3

3.4

3.5

3.6

3.7

3.8

f1 (

ppm

)

1.11

0.98

0.89

0.83

1.18

1.16

3.31 MeOD

148

Page 165: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S134!

01

02

03

04

05

06

07

08

09

01

00

11

01

20

13

01

40

15

01

60

17

01

80

19

02

00

21

02

20

23

0f1

(ppm

)

13.4315.5718.77

29.1431.9542.2048.57 MeOD48.72 MeOD48.86 MeOD49.00 MeOD49.14 MeOD49.28 MeOD49.43 MeOD56.2265.7871.0475.6076.99

112.40

119.94

132.35138.77141.66

166.31

205.80

***

**

* =

tauto

mer?

149

Page 166: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S135!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.0f1

(ppm

)

3.003.00

9.003.003.003.003.003.00

1.002.00

3.001.020.941.00

1.00

7.26 CDCl3

150

Page 167: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S136!

3.0

3.1

3.2

3.3

3.4

3.5

3.6

3.7

3.8

3.9

4.0

4.1

4.2

f1 (

ppm

)

3.00

1.020.94

1.00

1.00

1.1

1.2

1.3

1.4

1.5

1.6

1.7

1.8

1.9

2.0

2.1

2.2

f1 (

ppm

)

3.00

3.00

3.003.003.00

1.00

2.00

151

Page 168: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S137!

-2

0-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

0f1

(ppm

)

-5.09-4.80

15.6418.4718.4921.7325.9226.5527.05

41.6243.89

64.5566.6169.7176.0977.00 CDCl377.16 CDCl377.32 CDCl379.2886.29

108.98

152

Page 169: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S138!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

6.00

9.003.003.003.003.003.00

1.001.001.00

1.001.001.002.00

7.26 CDCl3

153

Page 170: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S139!

1.0

1.1

1.2

1.3

1.4

1.5

1.6

1.7

1.8

1.9

2.0

2.1

2.2

2.3

2.4

2.5

2.6

2.7

2.8

2.9

3.0

3.1

3.2

3.3

3.4

3.5

3.6

3.7

3.8

f1 (

ppm

)

3.00

3.00

3.003.003.00

1.00

1.00

1.00

1.00

1.00

1.00

2.00

154

Page 171: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S140!

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

-5.14-4.42

14.3815.3618.3222.6425.8126.3826.7226.93

46.40

54.75

64.3170.5475.1576.84 CDCl377.16 CDCl377.48 CDCl379.4884.53

110.19

210.63

155

Page 172: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S141!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

12

.51

3.0

13

.51

4.0

14

.5f1

(ppm

)

3.083.073.001.173.07

1.001.081.071.082.02

2.041.16

1.00

1.01

7.26 CDCl3

156

Page 173: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S142!

6.2

6.4

6.6

6.8

7.0

7.2

7.4

f1 (

ppm

)

2.04

1.16

1.007.26 CDCl3

2.5

3.0

3.5

f1 (

ppm

)

1.00

1.08

1.07

1.08

2.02

1.6

51.7

01.7

51.8

01.8

51.9

0f1

(ppm

)

1.17

3.07

1.0

91.1

01.1

11.1

21.1

3f1

(ppm

)

3.08

157

Page 174: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S143!

01

02

03

04

05

06

07

08

09

01

00

11

01

20

13

01

40

15

01

60

17

01

80

19

02

00

21

02

20

f1 (

ppm

)

9.0915.2318.9924.4730.80

39.91

65.7867.1874.7376.95 CDCl377.16 CDCl377.37 CDCl379.30

110.52

118.17

131.01139.30141.94

166.51

196.54

211.07

**

**

*

* =

tauto

mer?

158

Page 175: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S144!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

12

.51

3.0

13

.51

4.0

14

.5f1

(ppm

)

3.043.103.001.043.03

1.091.031.061.171.06

1.002.00

1.00

3.31 MeOD

159

Page 176: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S145!

7.2

47.2

87.3

2f1

(ppm

)

1.00

6.2

6.3

6.4

f1 (

ppm

)

1.00

2.00

3.3

53.4

03.4

53.5

03.5

53.6

03.6

5f1

(ppm

)

1.06

1.17

1.06

2.8

2.9

3.0

3.1

f1 (

ppm

)

1.09

1.03

1.6

1.7

1.8

f1 (

ppm

)

1.04

3.03

160

Page 177: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S146!

01

02

03

04

05

06

07

08

09

01

00

11

01

20

13

01

40

15

01

60

17

01

80

19

02

00

21

02

20

23

0f1

(ppm

)

9.6115.4618.8323.9631.76

41.6548.57 MeOD48.72 MeOD48.86 MeOD49.00 MeOD49.14 MeOD49.28 MeOD49.43 MeOD66.3168.6674.8679.87

112.26

119.52

132.31139.75142.88

167.23

198.30

210.32

* **

**

* =

tauto

mer?

161

Page 178: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S147!

01

23

45

67

89

10

11

12

13

14

15

f1 (

ppm

)

3.003.003.001.013.001.001.001.011.001.011.00

1.00

2.01

1.00

1.00

7.16 C6D6

162

Page 179: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S148!

7.3

27

.36

f1 (

ppm

)

1.00

5.5

5.6

5.7

5.8

5.9

f1 (

ppm

)

1.00

2.01

2.8

2.9

3.0

3.1

3.2

3.3

f1 (

ppm

)

1.00

1.01

1.00

1.01

1.00

1.4

51

.50

1.5

5f1

(ppm

)

3.00

1.01

0.8

20

.83

0.8

40

.85

0.8

6f1

(ppm

)

3.00

163

Page 180: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S149!

01

02

03

04

05

06

07

08

09

01

00

11

01

20

13

01

40

15

01

60

17

01

80

19

02

00

21

02

20

f1 (

ppm

)

9.6515.2118.5924.1330.97

40.24

65.4967.5574.6079.43

111.01

118.66

127.90 C6D6128.06 C6D6128.22 C6D6131.20138.26141.65

166.36

197.08

210.20

* **

*

* =

tauto

mer?

164

Page 181: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S150!

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

12

.51

3.0

13

.51

4.0

14

.5f1

(ppm

)

3.053.013.041.113.00

1.140.971.141.031.09

0.88

0.991.011.00

1.00

0.95

2.05 Acetone

165

Page 182: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S151!

7.2

47

.26

7.2

87

.30

f1 (

ppm

)

1.00

6.2

6.3

6.4

6.5

f1 (

ppm

)

0.99

1.01

1.00

2.9

3.0

3.1

3.2

3.3

3.4

3.5

3.6

3.7

f1 (

ppm

)

1.14

0.97

1.14

1.03

1.09

1.6

51

.70

1.7

51

.80

1.8

5f1

(ppm

)

1.11

3.00

166

Page 183: The Application of Pericyclic, Photolytic, Chemoenzymatic

!

S152!

!!

01

02

03

04

05

06

07

08

09

01

00

11

01

20

13

01

40

15

01

60

17

01

80

19

02

00

21

0f1

(ppm

)

9.5415.4818.8324.0429.45 Acetone29.58 Acetone29.71 Acetone29.84 Acetone29.97 Acetone30.10 Acetone30.22 Acetone31.4840.96

65.6468.0474.3379.23

112.15

119.82

132.02139.16141.99

166.94

197.95

206.11 Acetone209.45

**

**

* =

tauto

mer?

167

Page 184: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 185: The Application of Pericyclic, Photolytic, Chemoenzymatic

168

Publication Two

Studies on the Photochemical Rearrangements of

Enantiomerically Pure, Polysubstituted and Variously

Annulated Bicyclo[2.2.2]octenones

Qiao Yan, Benoit Bolte, Yuhua Bai, Martin G. Banwell, Anthony C. Willis

and Paul D. Carr

J. Org. Chem., 2017, 82, 8008.

Page 186: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 187: The Application of Pericyclic, Photolytic, Chemoenzymatic

Studies on the Photochemical Rearrangements of EnantiomericallyPure, Polysubstituted, and Variously AnnulatedBicyclo[2.2.2]octenonesQiao Yan, Benoit Bolte, Yuhua Bai, Martin G. Banwell,* Anthony C. Willis, and Paul D. Carr

Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, ACT 2601, Australia

*S Supporting Information

ABSTRACT: A series of enantiomerically pure bicyclo[2.2.2]octenones, including the lactone-annulated system 26, has beenprepared by engaging derivatives of an enzymatically derived and homochiral cis-1,2-dihydrocatechol in inter- or intra-molecularDiels−Alder reactions. Systems such as 26 readily participate in photochemically promoted oxa-di-π-methane rearrangement or1,3-acyl migration processes to give products such as diquinane 34 or mixtures of cyclobutanone 36 and cyclopropane 38,respectively.

■ INTRODUCTION

Bicyclo[2.2.2]octenones including the parent system 1(Scheme 1) are excellent substrates for certain photochemicallypromoted rearrangement reactions.1 Specifically, on irradiationin the presence of photosensitizers such as acetophenone theyparticipate in oxa-di-π-methane rearrangements and, soaffording, via a triplet pathway, cyclopropannulated diquinanessuch as 2. In contrast, on direct irradiation they engage, now viaa singlet pathway, in a 1,3-acyl migration reaction (Givensrearrangement) to give bicyclo[4.2.0]oct-4-en-7-ones such as 3.Upon sustained irradiation, photoproduct 3 and many of its

derivatives can undergo decarbonylation to give the corre-sponding Δ2-norcarene, e.g. 4.The capacity to effectively exploit these valuable trans-

formations is contingent on having ready access tobicyclo[2.2.2]octenones, especially enantiomerically pureones. While various methods are available for the synthesis ofsuch systems,2 a particularly useful approach involves thefacially selective intermolecular cycloaddition of dienophiles toenantiomerically pure cis-1,2-dihydrocatechols such as 5(Figure 1) that are readily obtained through the whole-cell

biotransformation of the corresponding arene (toluene in thecase of compound 5).3 Indeed, we have exploited such adductsin the photochemically mediated total synthesis of a range ofsesquiterpenoid natural products including various triquinanes,4

protoilludanes,5 and the structure assigned to a sterpurene.6 Inseeking to extend such studies for the purposes of preparingnew molecular scaffolds, including those of use in drugdiscovery, we became interested in establishing the degree towhich the bicyclo[2.2.2]octenone framework could be sub-stituted and/or annulated and continue to engage in the above-

Received: May 21, 2017Published: July 3, 2017

Scheme 1. Oxa-di-π-methane, 1,3-Acyl Migration, andPhotodecarbonylation Reactions of the ParentBicyclo[2.2.2]octenone (1)

Figure 1. Homochiral cis-1,2-dihydrocatechol 5 and the derivedbicyclo[2.2.2]octenone-based photosubstrates 6 and 7.

Article

pubs.acs.org/joc

© 2017 American Chemical Society 8008 DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

Page 188: The Application of Pericyclic, Photolytic, Chemoenzymatic

mentioned photochemical processes. Herein, we detail researchthat serves to emphasize the remarkable extent to which theseprocesses can be applied in a reliable fashion.In connection with our recently reported studies7 on the

synthesis of the sorbicillinoid-derived isolate rezishanone C, weprepared,7 using intermolecular Diels−Alder cycloadditionprocesses, the oxygenated bicyclo[2.2.2]octenones 6 and 7 ingram quantities from cis-1,2-dihydrocatechol 5. Accordingly,compounds 6 and 7 became the substrates used in the openingstages of the present work.

■ RESULTS AND DISCUSSIONIndependent irradiation (using a medium-pressure mercurylamp) of an acetone solution of each of compounds 6 and 7held in a round-bottomed flask made from borosilicate glassand containing ca. 1.4 molar equiv of acetophenone (Scheme2) afforded the anticipated oxa-di-π-methane rearrangement

products 8 (87% or 98% brsm) and 9 (90% or 99% brsm),respectively. All of the spectral data acquired on compounds 8and 9 were entirely consistent with the assigned structures, butfinal confirmation of these followed from single-crystal X-rayanalyses (see the Experimental Section and SupportingInformation for details).When dichloromethane solutions of substrates 6 and 7 were

subjected to direct irradiation for brief periods (less than 1 h)with the same type of lamp then the anticipated Givensrearrangement products 10 (70% or 84% brsm) and 11 (67%),respectively, were obtained. Upon sustained irradiation (5 h) ofthe same substrates, significant quantities of the correspondingdecarbonylated systems 12 (32%) and 13 (33%) were obtainedalong with reduced amounts of the corresponding andchromatographically separable cyclobutenones. Once again, allof the spectroscopic data acquired on compounds 10−13 werein accord with the assigned structures, but those of the first andthe last of these were confirmed by single-crystal X-ray analysis.Establishing the impact of various modes of ring-fusion on

the capacity of bicyclo[2.2.2]octenones to engage in oxa-di-π-

methane and 1,3-acyl migration reactions was another topic ofinterest. Therefore, building upon our earlier studies8 on theassembly of the relevant frameworks through the intramolecularDiels−Alder (IMDA) reactions of crotonate esters derivedfrom cis-1,2-dihydrocatechols, compound 5 was converted(Scheme 3) into the diesters 14 (81%) and 15 (74%) underpreviously established8 conditions. When each of compounds14 and 15 was heated in refluxing toluene they engaged in thetwo possible modes of cycloaddition and thus giving rise to thecorresponding pair of adducts, viz. lactones 16 (40% from 14),17 (41% from 15), 18 (26% from 14), and 19 (12% from 15),that could be separated from one another by conventionalchromatographic means. The remaining ester residues withineach of adducts 18 and 19 were cleaved by standard methodsand the resulting alcohols 20 (74%) and 21 (76%) oxidized tothe corresponding ketones 22 (86%) and 23 (82%),respectively, using the Dess−Martin periodinane.9 Similarly,esters 16 and 17 were cleaved using potassium carbonate inmethanol and the product alcohols 24 (79%) and 25 (94%),respectively, oxidized to the corresponding ketones, namely,compounds 26 (94%) and 27 (78%). Single-crystal X-rayanalyses were conducted on compounds 23 and 27, details ofwhich are presented in the Experimental Section and SI.The oxa-di-π-methane rearrangement of the lactone-annu-

lated bicyclo[2.2.2]octenones 22 and 23 took place readilywhen acetone solutions of each of these was irradiated in thepresence of acetophenone (Scheme 4). By such means thecyclopropane-annulated oxatriquinanes 28 (40%) and 29(43%) were obtained. In contrast, direct irradiation ofsubstrates 22 and 23 led to the corresponding mixtures ofcyclobutanones 30 (up to 75%) and 31 (up to 73%),respectively, as well as their decarbonylated counterparts 32(up to 37%) and 33 (up to 52%), respectively. The structuresof compounds 30 and 32 were confirmed by single-crystal X-ray analyses.Equivalent studies on the photochemical behaviors of the

isomeric lactone annulated bicyclo[2.2.2]octenones 26 and 27(Scheme 5) led to analogous outcomes. Specifically, theanticipated oxatriquinanes 34 (45%) and 35 (49%) wereobtained on photosensitized irradiation of these substrateswhile direct irradiation afforded mixtures of cyclobutanones 36(up to 70%) and 37 (up to 71%) as well as their decarbonylatedcongeners 38 (up to 35%) and 39 (up to 40%), respectively.The structures of compounds 34, 35, 36, and 38 were eachconfirmed by single-crystal X-ray analyses.It is worth noting that both the substrates and the

photoproducts shown in Scheme 5 are pseudoenantiomers oftheir counterparts shown in Scheme 4. Thus, for example, ifeach of compounds 30 (Scheme 4) and 36 (Scheme 5) lackedthe two methyl groups then they would be enantiomers.Accordingly, the protocols just described provide a means bywhich the single enantiomeric form of starting material 5 can beconverted into either enantiomeric form of a range of relativelycomplex molecular frameworks.In seeking to establish the effects of alternate modes of ring

fusion and other substituents on the capacity of bicyclo[2.2.2]-octenones to engage in photochemically promoted rearrange-ments, the behaviors of various polyhydro-4,7-ethanoindenonederivatives were explored. The routes shown in Scheme 6 wereused to prepare these cyclopentannulated systems. Thus, thepreviously described4d tricyclic system 40, prepared by areaction sequence involving an initial Diels−Alder cyclo-addition reaction between 2-cyclopenten-1-one and the

Scheme 2. Photochemical Behaviors ofBicyclo[2.2.2]octenones 6 and 7 under Either DirectIrradiation or Photosensitized Conditions

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8009

Page 189: The Application of Pericyclic, Photolytic, Chemoenzymatic

acetonide derived from cis-diol 5, was reduced with LiAlH4, andthe previously reported4d,5b alcohol 41 (39%) obtained in pureform after chromatographic separation from its coproducedepimer.4d,5b Compound 41, the structure of which wasconfirmed by single-crystal X-ray analysis, was acetylatedunder standard conditions to give ester 42 (97%), and theacetonide moiety associated with this last compound washydrolyzed by treating a methanol/water solution of it withacidified AG-50W-X8 resin. The product diol 43 (97%) wasselectively oxidized using the sterically demanding oxammo-

nium salt derived from p-TsOH·H2O-promoted disproportio-nation of 4-acetamido-TEMPO,10 and thus producing acyloin44 (97%) that was also subjected to single-crystal X-rayanalysis. Compound 44 was converted into derivatives 45(91%), 46 (77%), 47 (82%), and 48 (93%) by standardmethods, while samarium iodide mediated deoxygenation ofbenzoate 48 also allowed for the preparation of bicyclo[2.2.2]-octenone 49 (85%). Once again, the structures of compounds45, 47, and 48 were confirmed by single-crystal X-ray analyses.

Scheme 3. Synthesis of Lactone-Annulated Bicyclo[2.2.2]octenones 22, 23, 26, and 27

Scheme 4. Photochemical Behaviors ofBicyclo[2.2.2]octenones 22 and 23 under Either DirectIrradiation or Sensitized Conditions

Scheme 5. Photochemical Behaviors ofBicyclo[2.2.2]octenones 26 and 27 under Either DirectIrradiation or Sensitized Conditions

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8010

Page 190: The Application of Pericyclic, Photolytic, Chemoenzymatic

On direct irradiation of dichloromethane solutions of each ofcompounds 45−49 they engaged in 1,3-acyl migrationreactions to give the cyclobutanones 50 (43% or 99% brsm),51 (27% or 98% brsm), 52 (18% or 99% brsm), 53 (17% orquant brsm), and 54 (23% or 92% brsm), respectively.Irradiation of compounds 50 and 47 led to cyclopropanes 55(98%) and 56 (80%), respectively. The structures of all of these

photoproducts were determined through comprehensivespectroscopic analyses. In particular, the infrared spectrum ofeach of cyclobutanones 50−54 exhibited a characteristiccarbonyl absorption band in the range 1778−1792 cm−1 aswell as a carbonyl carbon resonance above δ 200 ppm in thecorresponding 13C NMR spectrum. The structure of compound53 was confirmed by single-crystal X-ray analysis.Given our extensive earlier studies4 on the oxa-di-π-methane

rearrangements of substrates very closely related to compounds45−49, we have not subjected these to photosensitizedirradiation but would fully expect them to behave in a similarmanner and thus leading to the corresponding cyclopropannu-lated triquinanes.In contrast to outcomes noted above (Scheme 6), when the

mesylate 57 (Scheme 7), which was readily prepared in 56%

yield from acyloin 44, was subjected (as a solution indichloromethane) to direct irradiation it engaged in an oxa-di-π-methane rearrangement reaction rather than a 1,3-acylmigration reaction and so affording the cyclopentannulated andstereochemically pure triquinane 58 in 48% yield (or 98% yieldbrsm). The configuration at the carbon bearing the mesyloxygroup is tentatively assigned as illustrated although the alternateone cannot be discounted as a result of the intervention of aphotoepimerization process.4b−d The precise origins of thisseemingly anomalous behavior of sulfonate ester 57 remainunclear at the present time and serve to highlight the verylimited understanding of the photochemical properties of suchsystems.11 These matters are the subject of ongoing studies inour laboratories.

■ CONCLUSIONSThe studies reported here have established that a wide range ofextensively substituted and variously annulated bicyclo[2.2.2]-octenones are capable of engaging in either oxa-di-π-methaneor 1,3-acyl migration reactions depending upon the mode ofphotoactivation (sensitized vs direct irradiation). The 1,3-acylmigration reactions leading to the isomeric cyclobutanones canbe followed by rapid photodecarbonylation processes to

Scheme 6. Synthesis of CyclopentannulatedBicyclo[2.2.2]octenones 45−49 and Their PhotochemicalBehaviors under Direct Irradiation Conditions

Scheme 7. Synthesis and Anomalous PhotochemicalBehavior of the Mesyloxy-SubstitutedBicyclo[2.2.2]octenone 57

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8011

Page 191: The Application of Pericyclic, Photolytic, Chemoenzymatic

coproduce the corresponding (but normally readily separable)cyclopropanes. A noteworthy feature of the photochemicalbehaviors of the annulated bicyclo[2.2.2]octenones studiedhere is that the mode of ring fusion (annulation) can have asignificant impact on the rates of both types of processes. Thus,for example, the lactone-annulated systems 22, 23, 26, and 27appear to engage in more rapid 1,3-acyl migration reactionsthan their cyclopentannulated counterparts 45−49. The samecould be said of the corresponding oxa-di-π-methane process,especially when the outcomes of our earlier studies4 are takeninto account. That is to say, the lactone annulated compoundsjust mentioned also appear to participate in more rapid triplet-sensitized rearrangement reactions than their cyclopentannu-lated counterparts. The origins of these variations are thesubject of ongoing studies, the outcomes of which will bereported in due course.

■ EXPERIMENTAL SECTIONGeneral Experimental Procedures. Unless otherwise specified,

proton (1H) and carbon (13C) NMR spectra were recorded at 18 °Cin base-filtered CDCl3 on a spectrometer operating at 400 MHz forproton and 100 MHz for carbon nuclei. 1H NMR data are recorded asfollows: chemical shift (δ) [multiplicity, coupling constant(s) J (Hz),relative integral] where multiplicity is defined as s = singlet; d =doublet; t = triplet; q = quartet; m = multiplet or combinations of theabove. In relevant cases, the signal due to residual CHCl3 appearing atδH 7.26 and the central resonance of the CDCl3 “triplet” appearing atδC 77.0 were used to reference 1H and 13C NMR spectra, respectively.Samples were analyzed by infrared spectroscopy (νmax) as thin films onKBr plates. Optical rotations were recorded using the sodium D-line(589 nm) in a cell with a path length of 1 dm, at the concentrationsindicated and in the specified solvent at 22 °C. Specific rotations werethen calculated in the usual manner. Low- and high-resolution electronimpact (EI) mass spectra were recorded on a double focusing, triplesector machine. Low- and high-resolution ESI mass spectra wererecorded on a triple-quadrupole mass spectrometer operating inpositive ion mode. Melting points are uncorrected. Analytical thinlayer chromatography (TLC) was performed on aluminum-backed 0.2mm thick silica gel 60 F254 plates. Eluted plates were visualized using a254 nm UV lamp and/or by treatment with a suitable dip followed byheating. These dips included phosphomolybdic acid/ceric sulfate/sulfuric acid (conc)/water (37.5 g: 7.5 g: 37.5 g: 720 mL), potassiumpermanganate/potassium carbonate/5% sodium hydroxide aqueoussolution/water (3 g: 20 g: 5 mL: 300 mL), and p-anisaldehyde orvanillin/sulfuric acid (conc)/ethanol (15 g: 2.5 mL: 250 mL). Flashchromatographic separations were carried out following protocolsdefined by Still et al.12 with silica gel 60 (40−63 μm) as the stationaryphase and using the AR- or HPLC-grade solvents indicated. Themelting points of solids purified by such means were recorded directly(ie after they had crystallized from the concentrated chromatographicfractions). Starting materials, reagents, drying agents, and otherinorganic salts were generally commercially available and were used assupplied. Tetrahydrofuran (THF), methanol, and dichloromethanewere dried using a solvent purification system that is based upon atechnology originally described by Grubbs et al.13 Where necessary,reactions were performed under a nitrogen atmosphere.Specific Chemical Transformations. (2a′R,3S,4S,4aR)-3,4-Dihy-

droxy-2b-methylhexahydrocyclopropa[cd]pentalen-2(1H)-one (8).A deoxygenated solution of compound 67 (94 mg, 0.56 mmol) andacetophenone (90 μL, 0.77 mmol) in acetone (100 mL) maintainedunder nitrogen was subjected to irradiation with a Hanovia 450 Wmedium-pressure mercury-vapor lamp for 2.5 h and then cooled andconcentrated under reduced pressure to give a yellow oil. This materialwas subjected to flash column chromatography (silica, 1:1 → 1:0 v/vethyl acetate/40−60 petroleum ether gradient elution) to afford twofractions, A and B.

Concentration of fraction A (Rf = 0.3 in ethyl acetate) afforded thestarting compound 6 (10 mg, 11% recovery) as a colorless, crystallinesolid that was identical, in all respects, with an authentic sample.

Concentration of fraction B (Rf = 0.1 in ethyl acetate) affordedcompound 8 (82 mg, 87% or 98% brsm) as a white, crystalline solid:mp = 169−171 °C; [α]D = +71.4 (c 1.0, methanol); 1H NMR (400MHz, CD3OD) δ 4.15 (d, J = 2.6 Hz, 1H), 3.74 (s, 1H), 2.81 (t, J =5.0 Hz, 1H), 2.72 (m, 1H), 2.42 (m, 1H), 2.08 (m, 1H), 1.82 (d, J =5.0 Hz, 1H), 1.37 (s, 3H) (signals due to O−H group protons notobserved); 13C NMR (100 MHz, CD3OD) δ 217.3, 88.2, 86.3, 47.8,47.0, 46.3(0), 46.2(8), 44.2, 21.5; IR νmax 3356, 2962, 2904, 1706,1693, 1290, 1040, 898 cm−1; MS (ESI, + ve) m/z 191 [(M + Na)+,100]; HRMS m/z (M + Na)+ calcd for C9H12O3Na 191.0684, found191.0685.

(2a′R,3S,4S,4aR)-4-((tert-Butyldimethylsilyl)oxy)-3-hydroxy-2b-methylhexahydrocyclopropa[cd]pentalen-2(1H)-one (9). A deoxy-genated solution of compound 77 (158 mg, 0.56 mmol) andacetophenone (90 μL, 0.77 mmol) in acetone (100 mL) maintainedunder nitrogen was subjected to irradiation with a Hanovia 450 Wmedium-pressure mercury-vapor lamp for 2.5 h. The cooled reactionmixture was concentrated under reduced pressure to give a clear,yellow oil, and this was subjected to flash column chromatography(silica, 1:9 → 3:7 v/v ethyl acetate/40−60 petroleum ether gradientelution) to afford two fractions, A and B.

Concentration of fraction A (Rf = 0.4 in 3:7 v/v ethyl acetate/40−60 petroleum ether) afforded compound 7 (13 mg, 8% recovery) as acolorless crystalline solid that was identical, in all respects, with anauthentic sample.

Concentration of fraction B (Rf = 0.2 in 3:7 v/v ethyl acetate/40−60 petroleum ether) afforded compound 9 (143 mg, 90% or 99%brsm) as a white, crystalline solid: mp = 99−100 °C; [α]D = +41.8 (c1.0, CHCl3);

1H NMR (800 MHz, CDCl3) δ 4.20 (d, J = 2.5 Hz, 1H),3.81 (s, 1H), 2.76 (t, J = 5.1 Hz, 1H), 2.66 (m, 1H), 2.38 (m, 1H),2.13 (d, J = 17.9 Hz, 1H), 1.86 (d, J = 5.0 Hz, 1H), 1.79 (broad s, 1H),1.35 (s, 3H), 0.90 (s, 9H), 0.08 (s, 6H); 13C NMR (200 MHz, CDCl3)δ 213.3, 86.8, 85.8, 45.3, 45.0(4), 44.9(8), 44.4, 42.2, 24.9, 20.4, 17.2,− 5.6; IR νmax 3351, 2957, 2929, 2886, 2857, 1719, 1254, 1092, 867,836, 771 cm−1; MS (ESI, + ve) m/z 305 [(M + Na)+, 100], 283 [(M +H)+, 30]; HRMS m/z (M + Na)+ calcd for C15H26O3SiNa 305.1549,found 305.1548.

(1R,2S,3S,6R)-2,3-Dihydroxy-4-methylbicyclo[4.2.0]oct-4-en-7-one (10). A magnetically stirred and deoxygenated solution ofcompound 6 (100 mg, 0.59 mmol) in dichloromethane (100 mL)maintained under nitrogen was subjected to direct irradiation with aHanovia 450 W medium-pressure mercury-vapor lamp for 0.83 h. Thecooled reaction mixture was concentrated under reduced pressure togive a yellow solid that was subjected to flash column chromatography(silica, 2:3 → 1:0 v/v ethyl acetate/40−60 petroleum ether gradientelution) to afford two fractions, A and B.

Concentration of fraction A (Rf = 0.4 in ethyl acetate) affordedcompound 10 (70 mg, 70% or 84% brsm) as a white, crystalline solid:mp = 83−85 °C; [α]D = −234.4 (c 1.0, MeOH); 1H NMR (400 MHz,CD3OD) δ 5.40 (m, 1H), 3.96 (d, J = 6.9 Hz, 1H), 3.88 (m, 1H), 3.47(t, J = 7.5 Hz, 1H), 3.24 (m, 1H), 2.98 (m, 1H), 2.57 (m, 1H), 1.81 (s,3H) (signals due to O−H group protons not observed); 13C NMR(100 MHz, CD3OD) δ 209.0, 140.2, 116.7, 76.2, 73.6, 61.0, 50.1, 30.2,20.0; IR νmax 3391, 2882, 1769, 1066, 1047, 1014, 884 cm

−1; MS (ESI,+ ve) m/z 223 [(M + MeOH + Na)+, 40], 191 [(M + Na)+, 100];HRMS m/z (M + Na)+ calcd for C9H12O3Na 191.0684, found191.0684.

Concentration of fraction B (Rf = 0.3 in ethyl acetate) affordedcompound 6 (14 mg, 14% recovery) as a colorless, crystalline solidthat was identical, in all respects, with an authentic sample.

(1R,2S,3S,6R)-2-((tert-Butyldimethylsilyl)oxy)-3-hydroxy-4-methylbicyclo[4.2.0]oct-4-en-7-one (11). A magnetically stirred anddeoxygenated solution of compound 7 (100 mg, 0.35 mmol) indichloromethane (100 mL) maintained under nitrogen was subjectedto direct irradiation with a Hanovia 450 W medium-pressure mercury-vapor lamp for 0.67 h. The cooled reaction mixture was concentratedunder reduced pressure to give a pale-yellow oil. This was subjected to

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8012

Page 192: The Application of Pericyclic, Photolytic, Chemoenzymatic

flash column chromatography (silica, 1:9 v/v ethyl acetate/40−60petroleum ether elution) to give, after concentration of the appropriatefractions (Rf = 0.6 in 3:7 v/v ethyl acetate/40−60 petroleum ether),compound 11 (67 mg, 67%) as a white, crystalline solid: mp = 67−69°C; [α]D = −139.6 (c 1.0, CHCl3);

1H NMR (400 MHz, CDCl3) δ5.38 (m, 1H), 4.04 (d, J = 7.0 Hz, 1H), 3.86 (m, 1H), 3.57 (t, J = 7.7Hz, 1H), 3.24 (m, 1H), 2.94 (m, 1H), 2.57 (m, 1H), 2.18 (broad s,1H), 1.82 (s, 3H), 0.90 (s, 9H), 0.13 (s, 3H), 0.10 (s, 3H); 13C NMR(100 MHz, CDCl3) δ 207.0, 138.4, 115.1, 77.9, 73.4, 60.6, 50.2, 29.9,25.9, 19.1, 18.3, − 3.8, − 4.2; IR νmax 3499, 2954, 2930, 2857, 1779,1126, 1087, 836 cm−1; MS (ESI, + ve) m/z 337 [(M + MeOH + Na)+,30], 305 [(M + Na)+, 100]; HRMS m/z (M + Na)+ calcd forC15H26O3SiNa 305.1549, found 305.1554.(1R,2S,3S,6R)-4-Methylbicyclo[4.1.0]hept-4-ene-2,3-diol (12). A

magnetically stirred and deoxygenated solution of compound 6 (100mg, 0.59 mmol) in dichloromethane (100 mL) maintained under anitrogen atmosphere was subjected to direct irradiation with a Hanovia450 W medium-pressure mercury-vapor lamp for 5 h. The cooledreaction mixture was concentrated under reduced pressure to give abrown oil that was subjected to flash column chromatography (silica,1:4 → 1:1 v/v ethyl acetate/40−60 petroleum ether gradient elution)to afford two fractions, A and B.Concentration of fraction A (Rf = 0.6 in ethyl acetate) afforded

compound 12 (27 mg, 32%) as a pale-yellow oil: [α]D = +93.2 (c 0.8,CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.00 (m, 1H), 4.04−3.99(complex m, 2H), 1.92 (broad s, 2H), 1.76 (s, 3H), 1.48−1.35(complex m, 2H), 1.03 (m, 1H), 0.64 (m, 1H); 13C NMR (100 MHz,CDCl3) δ 130.3, 127.8, 73.3, 70.1, 21.4, 19.6, 18.7, 11.0; IR νmax 3367,2920, 1445, 1260, 1048, 1001, 724 cm−1; MS (EI, 70 eV) m/z 140(M•+, 30), 122 [(M − H2O)

•+, 60], 93 (100), 79 (90), 77 (70), 70(60), 55 (60); HRMS m/z M•+ calcd for C8H12O2 140.0837, found140.0842.Concentration of fraction B (Rf = 0.4 in ethyl acetate) afforded

compound 10 (48 mg, 48%) as a white, crystalline solid that wasidentical, in all respects, with an authentic sample.(1R,2S,3S,6R)-2-((tert-Butyldimethylsilyl)oxy)-4-methylbicyclo-

[4.1.0]hept-4-en-3-ol (13). A magnetically stirred and deoxygenatedsolution of compound 7 (100 mg, 0.35 mmol) in dichloromethane(100 mL) maintained under a nitrogen atmosphere was subjected toirradiation with a Hanovia 450 W medium-pressure mercury-vaporlamp for 5 h. The cooled reaction mixture was concentrated underreduced pressure to give a brown oil that was subjected to flashcolumn chromatography (silica, 1:9 → 1:4 v/v ethyl acetate/40−60petroleum ether gradient elution) to afford two fractions, A and B.Concentration of fraction A (Rf = 0.7 in 3:7 v/v ethyl acetate/40−

60 petroleum ether) afforded compound 13 (30 mg, 33%) as acolorless, crystalline solid: mp = 32−33 °C; [α]D = +35.3 (c 1.0,CHCl3).

1H NMR (400 MHz, CDCl3) δ 5.71 (m, 1H), 4.08 (d, J = 5.9Hz, 1H), 3.59 (m, 1H), 1.97 (broad s, 1H), 1.74 (s, 3H), 1.33−1.17(complex m, 2H), 0.99−0.94 (complex m, 1H), 0.92 (s, 9H), 0.32 (m,1H), 0.14 (s, 3H), 0.12 (s, 3H); 13C NMR (100 MHz, CDCl3) δ134.4, 124.7, 75.1, 74.0, 26.0, 19.6, 19.3, 18.7, 18.3, 12.0, − 4.1, − 4.6;IR νmax 3458, 2929, 2857, 1254, 1075, 1003, 835, 775 cm−1; MS (EI,70 eV) m/z 239 [(M − CH3

•)+, 30], 211 (35), 197 [(M − C4H9•)+,

35], 105 (60), 75 (100), 73 (95); HRMS m/z (M − CH3•)+ calcd for

C13H23O2Si 239.1467, found 239.1468.Concentration of fraction B (Rf = 0.6 in 3:7 v/v ethyl acetate/40−

60 petroleum ether) afforded compound 11 (33 mg, 33%) as acolorless, crystalline solid that was identical, in all respects, with anauthentic sample.(1S,2R)-3-Methylcyclohexa-3,5-diene-1,2-diyl (2E,2′E)-Bis(but-2-

enoate) (14). A magnetically stirred solution of (1S,2R)-3-methyl-cyclohexa-3,5-diene-1,2-diol (5) (2.40 g, 19.0 mmol) in dry THF (284mL) was cooled to −78 °C and then treated, dropwise over 0.5 h, withn-BuLi (12.5 mL of a 1.6 M solution in hexane, 20.0 mmol). Theresulting solution was stirred at −78 °C for 0.17 h and then treatedwith crotonoyl chloride (1.80 mL, 19.02 mmol) over 0.33 h. Theresulting solution was stirred for 2 h at −78 °C and then treated,dropwise over 0.5 h, with n-BuLi (12.5 mL of a 1.6 M solution inhexane, 20.0 mmol). After 0.17 h, another portion of crotonoyl

chloride (1.80 mL, 19.02 mmol) was added over 0.33 h, and thenstirring of the recation mixture was continued at −78 °C for 1 h. Theensuing mixture was warmed to 22 °C and then quenched withNaHCO3 (96 mL of a saturated aqueous solution) before beingdiluted with diethyl ether (390 mL). The separated organic phase waswashed with NH4Cl (1 × 96 mL of a saturated aqueous solution) andthen dried (MgSO4), filtered, and concentrated under reducedpressure. The residue thus obtained was subjected to flash columnchromatography to give, after concentration of the appropriatefractions (Rf = 0.5 in 1:4 v/v ethyl acetate/40−60 petroleum ether),compound 14 (4.04 g, 81%) as a pale-yellow oil. The spectral datarecorded on this material matched those reported previously.8

(1S,2R)-3-Methylcyclohexa-3,5-diene-1,2-diyl (2E,2′E)-Bis(4-methylpent-2-enoate) (15). A magnetically stirred solution of(1S,2R)-3-methylcyclohexa-3,5-diene-1,2-diol (5) (2.40 g, 19.02mmol) in dry THF (284 mL) was cooled to −78 °C and thentreated, dropwise over 0.5 h, with n-BuLi (12.5 mL of a 1.6 M solutionin hexane, 20.0 mmol). The resulting solution was stirred at −78 °Cfor 0.17 h and then treated, dropwise over 0.33 h, with (E)-4-methylpent-2-enoyl chloride14 (2.50 mL, 19.02 mmol). The ensuingmixture was stirred at −78 °C for 2 h and again treated, dropwise over0.5 h, with n-BuLi (12.5 mL of a 1.6 M solution in hexane, 20.0mmol). After 0.17 h, further (E)-4-methylpent-2-enoyl chloride (1.80mL, 19.02 mmol) was added, again dropwise over 0.33 h, and stirringwas continued at −78 °C for 1 h. The reaction mixture was thenallowed to warm to 22 °C before being quenched with NaHCO3 (96mL of a saturated aqueous solution) and diluted with diethyl ether(390 mL). The separated organic phase was washed with NH4Cl (1 ×96 mL of a saturated aqueous solution), dried (MgSO4), filtered, andconcentrated under reduced pressure. The residue thus obtained wassubjected to flash column chromatography to give, after concentrationof the appropriate fractions (Rf = 0.6 in 1:4 v/v ethyl acetate/40−60petroleum ether), compound 15 (4.47 g, 74%) as a pale-yellow oil:[α]D = +71.6 (c 1.0, CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.98−6.88 (complex m, 2H), 6.06 (m, 1H), 5.88 (broadened d, J = 5.2 Hz,1H), 5.81−5.72 (complex m, 3H), 5.62 (s, 2H), 2.43 (m, 2H), 1.84 (s,3H), 1.05−1.02 (complex m, 12H); 13C NMR (100 MHz, CDCl3) δ166.5, 166.3, 156.5, 156.2, 134.7, 126.6, 123.0, 121.9, 118.3, 118.1,69.5, 68.0, 31.1, 31.0, 21.3, 21.2, 19.8 (two signals obscured oroverlapping); IR νmax 2963, 1717, 1651, 1297, 1260, 1157, 982, 859cm−1; MS (ESI, + ve) m/z 341 [(M + Na)+, 100]; HRMS m/z: (M +Na)+ calcd for C19H26O4Na 341.1729, found 341.1728.

3a,8-Dimethyl-2-oxo-2,3,3a,6,7,7a-hexahydro-3,6-methanoben-zofuran-7-yl (E)-But-2-enoate (16) and 6,8-Dimethyl-2-oxo-2,3,3a,6,7,7a-hexahydro-3,6-methanobenzofuran-7-yl (E)-But-2-enoate (18). A magnetically stirred solution of compound 14 (4.04g, 15.40 mmol) in toluene (97 mL) maintained under a nitrogenatmosphere was heated at reflux for 24 h then cooled to 22 °C andconcentrated under reduced pressure. The resulting yellow oil wassubjected to flash chromatography (silica, 1:19 v/v ethyl acetate/40−60 petroleum ether elution) to give two fractions, A and B.

Concentration of fraction A [Rf = 0.2(5) in 1:4 v/v ethyl acetate/40−60 petroleum ether] afforded compound 16 (1.62 g, 40%) as awhite, crystalline solid, mp = 45−47 °C. The spectral data recorded onthis material matched those reported previously.8

Concentration of fraction B (Rf = 0.2 in 1:4 v/v ethyl acetate/40−60 petroleum ether) afforded compound 18 (1.06 g, 26%) as a clear,colorless oil. The spectral data recorded on this material matchedthose reported previously.8

8-Isopropyl-3a-methyl-2-oxo-2,3,3a,6,7,7a-hexahydro-3,6-meth-anobenzofuran-7-yl (E)-4-Methylpent-2-enoate (17) and 8-Iso-propyl-6-methyl-2-oxo-2,3,3a,6,7,7a-hexahydro-3,6-methanoben-zofuran-7-yl (E)-4-Methylpent-2-enoate (19). A magnetically stirredsolution of compound 15 (4.47 g, 14.04 mmol) in toluene (88 mL)maintained under a nitrogen atmosphere was heated at reflux for 72 hthen cooled to 22 °C, and concentrated under reduced pressure. Theresulting yellow oil was subjected to flash chromatography (silica, 1:19v/v ethyl acetate/40−60 petroleum ether elution) to afford twofractions, A and B.

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8013

Page 193: The Application of Pericyclic, Photolytic, Chemoenzymatic

Concentration of fraction A (Rf = 0.4 in 1:4 v/v ethyl acetate/40−60 petroleum ether) afforded compound 17 (1.83 g, 41%) as a white,crystalline solid: mp = 69−71 °C; [α]D = −115.4 (c 1.0, CHCl3);

1HNMR (400 MHz, CDCl3) δ 6.97 (dd, J = 15.7 and 6.5 Hz, 1H), 6.38(t, J = 7.6 Hz, 1H), 5.84 (m, 2H), 4.37 (dd, J = 6.7 and 2.2 Hz, 1H),4.24 (d, J = 6.7 Hz, 1H), 2.98 (m, 1H), 2.47 (m, 1H), 1.93−1.88(complex m, 2H), 1.40 (s, 3H), 1.27 (m, 1H), 1.08 (s, 3H), 1.06 (s,3H), 0.97 (d, J = 6.5 Hz, 3H), 0.90 (d, J = 6.6 Hz, 3H); 13C NMR(100 MHz, CDCl3) δ 179.3, 166.5, 156.8, 133.1, 132.2, 117.9, 77.3,70.6, 49.7, 46.9, 45.1, 38.8, 31.1, 30.5, 21.3, 21.2, 20.9, 20.8, 20.7; IRνmax 2962, 1783, 1717, 1264, 1160, 1038, 1009, 902 cm

−1; MS (EI, 70eV) m/z 318 (M•+, 5), 156 (15), 133 (10), 97 (100), 69 (10), 41 (20);HRMS m/z M•+ calcd for C19H26O4 318.1831, found 318.1834.Concentration of fraction B [Rf = 0.3(5) in 1:4 v/v ethyl acetate/

40−60 petroleum ether] afforded compound 19 (537 mg, 12%) as aclear, colorless oil: [α]D = +176.0 (c 1.0, CHCl3);

1H NMR (400MHz, CDCl3) δ 6.97 (dd, J = 15.7 and 6.5 Hz, 1H), 6.09 (d, J = 8.2Hz, 1H), 6.00 (dd, J = 8.2 and 6.6 Hz, 1H), 5.83 (dd, J = 15.7 and 1.5Hz, 1H), 4.57 (m, 1H), 4.05 (d, J = 6.7 Hz, 1H), 3.45 (m, 1H), 2.47(m, 1H), 2.30 (m, 1H), 2.16 (m, 1H), 2.01 (m, 1H), 1.24 (s, 3H), 1.08(s, 3H), 1.06 (s, 3H), 0.99 (d, J = 6.9 Hz, 3H), 0.61 (d, J = 6.8 Hz,3H); 13C NMR (100 MHz, CDCl3) δ 179.7, 166.7, 156.8, 140.3,124.6, 117.8, 74.4, 72.9, 48.0, 42.2, 40.6, 40.2, 31.1, 27.4, 22.8, 21.3,21.2, 19.9, 19.1; IR νmax 2961, 1786, 1718, 1264, 1158, 1027, 982, 907cm−1; MS (EI, 70 eV) m/z 318 (M•+, 5), 205 (5), 97 (100), 69 (15),41 (25); HRMS m/z M•+ calcd for C19H26O4 318.1831, found318.1832.7-Hydroxy-6,8-dimethyl-3a,6,7,7a-tetrahydro-3,6-methanoben-

zofuran-2(3H)-one (20). A magnetically stirred solution of compound18 (918 mg, 3.50 mmol) in methanol (55 mL) maintained at 0 °C wastreated, in one portion, with potassium carbonate (242 mg, 1.75mmol). The ensuing mixture was stirred at 0 °C for a further 0.5 h andthen warmed to 22 °C, stirred at this temperature for 1 h, and thenrecooled to 0 °C and treated with water (30 mL) before beingconcentrated under reduced pressure. The residue thus obtained wasextracted with ethyl acetate (3 × 100 mL), and the combined organicphases were then dried (MgSO4), filtered, and concentrated underreduced pressure. The resulting light-yellow oil was subjected to flashcolumn chromatography (silica, 3:7 → 1:1 v/v ethyl acetate/40−60petroleum ether gradient elution) to give, after concentration of theappropriate fractions (Rf = 0.1 in 3:7 v/v ethyl acetate/40−60petroleum ether), compound 20 (503 mg, 74%) as a white, crystallinesolid: mp = 114−116 °C; [α]D = +67.5 (c 1.0, CHCl3);

1H NMR (400MHz, CDCl3) δ 6.06−6.00 (complex m, 2H), 4.39 (t, J = 6.0 Hz, 1H),3.43 (m, 1H), 3.26 (t, J = 6.7 Hz, 1H), 2.23 (d, J = 6.8 Hz, 1H), 2.11(m, 1H), 2.01 (d, J = 4.5 Hz, 1H), 1.25 (s, 3H), 0.89 (d, J = 7.1 Hz,3H); 13C NMR (100 MHz, CDCl3) δ 178.9, 141.2, 124.2, 74.9, 71.9,46.9, 44.1, 40.4, 36.5, 18.8, 17.3; IR νmax 3417, 2968, 1760, 1750, 1184,1102, 1015, 713 cm−1; MS (ESI, + ve) m/z 217 [(M + Na)+, 100];HRMS m/z (M + Na)+ calcd for C11H14O3Na 217.0841, found217.0844.7-Hydroxy-8-isopropyl-6-methyl-3a,6,7,7a-tetrahydro-3,6-meth-

anobenzofuran-2(3H)-one (21). A magnetically stirred solution ofcompound 19 (1.11 g, 3.50 mmol) in methanol (55 mL) maintainedat 0 °C was treated, in one portion, with potassium carbonate (242mg, 1.75 mmol). After being kept for 0.5 h at 0 °C, the reactionmixture was warmed to 22 °C, maintained at this temperature for 1 h,and then recooled to 0 °C and treated with water (30 mL) beforebeing concentrated under reduced pressure. The residue thus obtainedwas extracted with ethyl acetate (3 × 100 mL), and the combinedorganic phases were then dried (MgSO4), filtered, and concentratedunder reduced pressure to give a light-yellow oil. This material wassubjected to flash column chromatography (silica, 3:17 → 3:7 v/vethyl acetate/40−60 petroleum ether gradient elution) and gave, afterconcentration of the appropriate fractions (Rf = 0.3 in 3:7 v/v ethylacetate/40−60 petroleum ether), compound 21 (590 mg, 76%) as awhite solid: mp = 120−122 °C; [α]D = +100.7 (c 1.0, CHCl3);

1HNMR (400 MHz, CDCl3) δ 6.09 (d, J = 8.1 Hz, 1H), 5.93 (m, 1H),4.35 (m, 1H), 3.43 (m, 1H), 3.12 (d, J = 6.9 Hz, 1H), 2.28 (m, 1H),2.03−1.95 (complex m, 2H), 1.26 (s, 3H), 0.97 (d, J = 6.7 Hz, 3H),

0.60 (d, J = 6.7 Hz, 3H) (signal due to O−H group proton notobserved); 13C NMR (100 MHz, CDCl3) δ 179.3, 141.8, 123.3, 74.8,72.9, 47.6, 44.0, 40.2 (3), 40.1 (7), 27.3, 22.7, 19.8, 18.8; IR νmax 3425,2958, 1765, 1170, 1100, 978, 723 cm−1; MS (ESI, + ve) m/z 467 [(2M+ Na)+, 30], 245 [(M + Na)+, 100], 223 [(M + H)+, 70]; HRMS m/z(M + Na)+ calcd for C13H18O3Na 245.1154, found 245.1156.

6,8-Dimethyl-3a,7a-dihydro-3,6-methanobenzofuran-2,7-(3H,6H)-dione (22). A magnetically stirred solution of compound 20(466 mg, 2.40 mmol) in dry dichloromethane (78 mL) maintained at0 °C under an atmosphere of nitrogen was treated with pyridine (1.2mL, 15.05 mmol) and then Dess−Martin periodinane (1.83 g, 4.32mmol). After a further 0.5 h, the reaction mixture was warmed to 22°C, maintained at this temperature for 3 h, and then poured into water(100 mL) and extracted with dichloromethane (3 × 100 mL). Thecombined organic phases were washed with NaOH (1 × 100 mL of a 1M aqueous solution) and then HCl (1 × 100 mL of a 1 M aqueoussolution) before being dried (MgSO4), filtered, and then concentratedunder reduced pressure. The residue thus obtained was subjected toflash column chromatography (silica, 1:9 → 3:17 v/v ethyl acetate/40−60 petroleum ether gradient elution) to give, after concentrationof the appropriate fractions (Rf = 0.3 in 3:7 v/v ethyl acetate/40−60petroleum ether), compound 22 (397 mg, 86%) as a white, crystallinesolid: mp = 121−124 °C; [α]D = +518.8 (c 1.0, CHCl3);

1H NMR(400 MHz, CDCl3) δ 6.32 (dd, J = 8.1 and 6.5 Hz, 1H), 6.02 (d, J =8.1 Hz, 1H), 4.15 (dd, J = 5.0 and 1.0 Hz, 1H), 3.66 (m, 1H), 2.37 (d,J = 5.0 Hz, 1H), 2.21 (m, 1H), 1.32 (s, 3H), 1.02 (d, J = 7.0 Hz, 3H);13C NMR (100 MHz, CDCl3) δ 201.5, 177.8, 136.7, 128.3, 73.9, 53.8,47.1, 41.3, 40.9, 16.1, 15.2; IR νmax 2976, 2937, 1785, 1736, 1159, 989,837, 713 cm−1; MS (ESI, + ve) m/z 247 [(M + MeOH + Na)+, 100],215 [(M + Na)+, 20]; HRMS m/z (M + MeOH + Na)+ calcd forC12H16O4Na 247.0946, found 247.0946.

8-Isopropyl-6-methyl-3a,7a-dihydro-3,6-methanobenzofuran-2,7(3H,6H)-dione (23). A magnetically stirred solution of compound21 (533 mg, 2.40 mmol) in dry dichloromethane (78 mL) maintainedat 0 °C under an atmosphere of nitrogen was treated with pyridine(1.2 mL, 15.05 mmol) and then the Dess−Martin periodinane (1.83 g,4.32 mmol). After a further 0.5 h the reaction mixture was warmed to22 °C, stirred at this temperature for 3 h, and then poured into water(100 mL) and extracted with dichloromethane (3 × 100 mL). Thecombined organic phases were washed with NaOH (1 × 100 mL of a 1M aqueous solution) then HCl (1 × 100 mL of a 1 M aqueoussolution) before being dried (MgSO4), filtered, and concentratedunder reduced pressure. The residue thus obtained was subjected toflash column chromatography (silica, 3:17 → 3:7 v/v ethyl acetate/40−60 petroleum ether gradient elution) and gave, after concentrationof the appropriate fractions (Rf = 0.3 in 3:7 v/v ethyl acetate/40−60petroleum ether), compound 23 (433 mg, 82%) as a white, crystallinesolid: mp = 114−116 °C; [α]D = +396.1 (c 0.8, CHCl3);

1H NMR(400 MHz, CDCl3) δ 6.19 (dd, J = 8.1 and 6.6 Hz, 1H), 6.04 (m, 1H),4.12 (dd, J = 5.0 and 1.1 Hz, 1H), 3.67 (m, 1H), 2.64 (m, 1H), 2.11(m, 1H), 1.99 (m, 1H), 1.36 (s, 3H), 1.01 (d, J = 6.9 Hz, 3H), 0.72 (d,J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 200.7, 178.5, 136.8,127.3, 73.9, 53.6, 51.7, 40.9, 40.4, 28.2, 22.8, 20.0, 15.3; IR νmax 2961,1802, 1786, 1734, 1151, 1002, 981, 899 cm−1; MS (ESI, + ve) m/z 275[(M + MeOH + Na)+, 100], 243 [(M + Na)+, 40]; HRMS m/z (M +MeOH + Na)+ calcd for C14H20O3Na 275.1259, found 275.1251.

7-Hydroxy-3a,8-dimethyl-3a,6,7,7a-tetrahydro-3,6-methanoben-zofuran-2(3H)-one (24). A magnetically stirred solution of compound16 (918 mg, 3.50 mmol) in methanol (55 mL) maintained at 0 °Cunder an atmosphere of nitrogen was treated, in one portion, withpotassium carbonate (242 mg, 1.75 mmol). After a further 0.5 h, thereaction mixture was warmed to 22 °C, stirred at this temperature for1 h, and then recooled to 0 °C and treated with water (30 mL) beforebeing concentrated under reduced pressure. The residue thus obtainedwas extracted with ethyl acetate (3 × 100 mL), and the combinedorganic phases were then dried (MgSO4), filtered, and concentratedunder reduced pressure to give a light-yellow oil. This material wassubjected to flash column chromatography (silica, 1:4 → 3:7 v/v ethylacetate/40−60 petroleum ether gradient elution) and gave, afterconcentration of the appropriate fractions (Rf = 0.2 in 3:7 v/v ethyl

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8014

Page 194: The Application of Pericyclic, Photolytic, Chemoenzymatic

acetate/40−60 petroleum ether), compound 24 (538 mg, 79%) as awhite, crystalline solid: mp = 146−148 °C; [α]D = +15.8 (c 1.0,CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.36 (t, J = 7.6 Hz, 1H), 5.81(dd, J = 7.6 and 1.0 Hz, 1H), 3.98 (d, J = 6.9 Hz, 1H), 3.57 (dd, J = 6.9and 2.2 Hz, 1H), 2.68 (m, 1H), 2.47 (m, 2H), 1.68 (s, 1H), 1.39 (s,3H), 0.93 (d, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 179.0,135.4, 130.8, 79.0, 69.0, 52.2, 45.2, 45.0, 33.1, 21.1, 20.1; IR νmax 3402,2964, 1740, 1347, 1182, 1085, 992, 948, 713, 703 cm−1; MS (ESI, +ve) m/z 217 [(M + Na)+, 100%]; HRMS m/z (M + Na)+ calcd forC11H14O3Na 217.0841, found 217.0842.7-Hydroxy-8-isopropyl-3a-methyl-3a,6,7,7a-tetrahydro-3,6-

methanobenzofuran-2(3H)-one (25). A magnetically stirred solutionof compound 17 (1.11 g, 3.50 mmol) in methanol (55 mL)maintained at 0 °C under an atmosphere of nitrogen was treated, inone portion, with potassium carbonate (242 mg, 1.75 mmol). After afurther 0.5 h at 0 °C, the reaction mixture was warmed to 22 °C,stirred at this temperature for 1 h, and then recooled to 0 °C andtreated with water (30 mL) before being concentrated under reducedpressure. The ensuing mixture was extracted with ethyl acetate (3 ×100 mL), and the combined organic phases were dried (MgSO4),filtered, and concentrated under reduced pressure. The residue thusobtained was subjected to flash column chromatography (silica, 3:7 →1:1 v/v ethyl acetate/40−60 petroleum ether gradient elution) andgave, after concentration of the appropriate fractions (Rf = 0.2 in 3:7v/v ethyl acetate/40−60 petroleum ether), compound 25 (732 mg,94%) as a white, crystalline solid: mp = 60−61 °C; [α]D = +2.8 (c 0.9,CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.35 (t, J = 8.3 Hz, 1H), 5.78(dd, J = 8.3 and 1.2 Hz, 1H), 3.99 (d, J = 6.9 Hz, 1H), 3.54 (dd, J = 6.9and 2.3 Hz, 1H), 2.89 (m, 1H), 2.48 (broad s, 1H), 1.85 (m, 2H), 1.38(s, 3H), 1.25 (m, 1H), 0.93 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 6.6 Hz,3H); 13C NMR (100 MHz, CDCl3) δ 179.1, 134.6, 131.1, 79.3, 68.9,49.7, 46.4, 44.9, 41.7, 30.7, 21.1, 20.8(0), 20.7(6); IR νmax 3452, 2962,1778, 1166, 1117, 993, 706 cm−1; MS (ESI, + ve) m/z 245 [(M +Na)+, 40], 223 [(M + H)+, 100], 205 (50), 159 (100), 109 (90), 90(70); HRMS m/z (M + H)+ calcd for C13H19O3 223.1334, found223.1331.3a,8-Dimethyl-3a,7a-dihydro-3,6-methanobenzofuran-2,7-

(3H,6H)-dione (26). A magnetically stirred solution of compound 24(466 mg, 2.40 mmol) in dry dichloromethane (78 mL) maintained at0 °C under an atmosphere of nitrogen was treated with pyridine (1.2mL, 15.05 mmol) and then the Dess−Martin periodinane (1.83 g, 4.32mmol). After being kept at 0 °C for a further 0.5 h, the reactionmixture was warmed to 22 °C and maintained at this temperature for 3h before being poured into water (100 mL) and extracted withdichloromethane (3 × 100 mL). The combined organic phases werewashed with NaOH (1 × 100 mL of a 1 M aqueous solution) and HCl(1 × 100 mL of a 1 M aqueous solution) and then dried (MgSO4),filtered, and concentrated under reduced pressure. The residue thusobtained was subjected to flash column chromatography (silica, 1:9 →3:17 v/v ethyl acetate/40−60 petroleum ether gradient elution) andgave, after concentration of the appropriate fractions (Rf = 0.3 in 3:7v/v ethyl acetate/40−60 petroleum ether), compound 26 (434 mg,94%) as a white, crystalline solid: mp = 135−136 °C; [α]D = −445.7(c 1.0, CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.37 (t, J = 7.5 Hz,1H), 6.13 (dd, J = 7.5 and 1.0 Hz, 1H), 3.75 (s, 1H), 3.27 (dd, J = 6.7and 3.1 Hz, 1H), 2.59 (m, 1H), 1.98 (s, 1H), 1.47 (s, 3H), 1.02 (d, J =7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 200.0, 177.7, 134.5,130.4, 78.5, 54.0, 51.9, 46.5, 37.2, 19.9, 18.4; IR νmax 2964, 1788, 1742,1312, 1161, 995, 875, 723 cm−1; MS (ESI, + ve) m/z 247 [(M +MeOH + Na)+, 100]; HRMS m/z (M + MeOH + Na)+ Calcd forC12H16O3Na 247.0946, found 247.0943.8-Isopropyl-3a-methyl-3a,7a-dihydro-3,6-methanobenzofuran-

2,7(3H,6H)-dione (27). A magnetically stirred solution of compound25 (533 mg, 2.40 mmol) in dry dichloromethane (78 mL) maintainedat 0 °C under an atmosphere of nitrogen was treated with pyridine(1.2 mL, 15.05 mmol) and then the Dess−Martin periodinane (1.83 g,4.32 mmol). After a further 0.5 h at 0 °C, the reaction mixture waswarmed to 22 °C and then stirred at this temperature for 3 h beforebeing poured into water (100 mL) and extracted with dichloro-methane (3 × 100 mL). The combined organic phases were washed

with NaOH (1 × 100 mL of a 1 M aqueous solution) and HCl (1 ×100 mL of a 1 M aqueous solution) then dried (MgSO4), filtered, andconcentrated under reduced pressure. The residue thus obtained wassubjected to flash column chromatography (silica, 1:9 → 3:17 v/vethyl acetate/40−60 petroleum ether gradient elution) and gave, afterconcentration of the appropriate fractions (Rf = 0.5 in 3:7 v/v ethylacetate/40−60 petroleum ether), compound 27 (413 mg, 78%) as awhite, crystalline solid: mp = 121−123 °C; [α]D = −332.5 (c 1.0,CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.37 (t, J = 8.2 Hz, 1H), 6.09(dd, J = 8.2 and 1.1 Hz, 1H), 3.77 (s, 1H), 3.49 (dd, J = 6.7 and 3.1Hz, 1H), 2.19 (s, 1H), 1.93 (dd, J = 10.2 and 2.5 Hz, 1H), 1.47 (s,3H), 1.42 (m, 1H), 1.00 (d, J = 6.5 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H);13C NMR (100 MHz, CDCl3) δ 200.4, 177.7, 134.8, 129.8, 78.8, 51.1,50.2, 49.4, 46.2, 29.2, 20.6, 20.4, 19.9; IR νmax 2968, 17909, 1775, 1741,1160, 985, 713 cm−1; MS (ESI, + ve) m/z 275 [(M + MeOH + Na)+,100], 221 [(M + H)+, 10]; HRMS m/z (M + MeOH + Na)+ calcd forC14H20O3Na 275.1259, found 275.1260.

(1aS,1a′R,3aS,4S,4aR,4a′R)-4,4a-Dimethylhexahydro-1H-cyclopropa[3,4]pentaleno[1,6-bc]furan-1,3(1aH)-dione (28). A de-oxygenated and magnetically stirred solution of compound 22 (108mg, 0.56 mmol) and acetophenone (90 μL, 0.77 mmol) in acetone(100 mL) maintained under a nitrogen atmosphere was subjected toirradiation with a Hanovia 450 W medium-pressure mercury-vaporlamp for 0.83 h. The reaction mixture was then cooled andconcentrated under reduced pressure to give a brown oil that wassubjected to flash column chromatography (silica, 3:17 → 3:7 v/vethyl acetate/40−60 petroleum ether gradient elution). Concentrationof the appropriate fractions (Rf = 0.3 in 1:1 v/v ethyl acetate/40−60petroleum ether) then gave compound 28 (44 mg, 40%) as a pale-yellow oil: [α]D = +5.1 (c 1.0, CHCl3);

1H NMR (400 MHz, CDCl3)δ 4.57 (dd, J = 9.0 and 2.2 Hz, 1H), 3.59 (m, 1H), 2.80 (t, J = 8.0 Hz,1H), 2.60 (m, 1H), 2.45 (m, 1H), 1.98 (m, 1H), 1.30 (d, J = 7.2 Hz,3H), 1.22 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 206.9, 176.8, 82.4,57.2, 46.1, 45.1, 45.0, 44.7, 38.1, 19.5, 18.4; IR νmax 2969, 2928, 1779,1726, 1192, 1152, 1054, 1031, 983 cm−1; MS (ESI, + ve) m/z 215 [(M+ Na)+, 100]; HRMS m/z (M + Na)+ calcd for C11H12O3Na 215.0684,found 215.0687.

(1aS,1a′R,3aS,4S,4aS,4a′R)-4-Isopropyl-4a-methylhexahydro-1H-cyclopropa[3,4]pentaleno[1,6-bc]furan-1,3(1aH)-dione (29). A de-oxygenated and magnetically stirred solution of compound 23 (123mg, 0.56 mmol) and acetophenone (90 μL, 0.77 mmol) in acetone(100 mL) maintained under a nitrogen atmosphere was subjected toirradiation with a Hanovia 450 W medium-pressure mercury-vaporlamp for 0.67 h. The reaction mixture thus formed was cooled andconcentrated under reduced pressure to give a yellow oil that wassubjected to flash column chromatography (silica, 3:17 → 1:3 v/vethyl acetate/40−60 petroleum ether gradient elution). Concentrationof the appropriate fractions (Rf = 0.4 in 1:1 v/v ethyl acetate/40−60petroleum ether) then gave compound 29 (53 mg, 43%) as a white,crystalline solid: mp = 107−109 °C; [α]D = −7.6 (c 1.0, CHCl3).

1HNMR (400 MHz, CDCl3) δ 4.60 (dd, J = 8.9 and 2.0 Hz, 1H), 3.61(m, 1H), 3.10 (dd, J = 8.5 and 6.5 Hz, 1H), 2.62 (m, 1H), 2.38 (m,1H), 2.15 (m, 1H), 1.88 (m, 1H), 1.27 (s, 3H), 1.05 (d, J = 6.9 Hz,3H), 0.97 (d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 206.9,177.4, 82.5, 55.0, 47.8, 46.6, 45.6, 44.0, 38.3, 29.2, 22.1, 19.5, 17.0; IRνmax 2963, 1780, 1728, 1196, 1150, 1049, 983 cm−1; MS (EI, 70 eV)m/z 220 (M•+, 25), 153 (40), 149 (90), 133 (40), 105 (60), 93 (100),91 (70), 84 (60), 77 (50), 59 (70); HRMS m/z M•+ calcd forC13H16O3 220.1099, found 220.1092.

(2aS,2a′R,3aR,6S,6aS)-5,6-Dimethyl-2a1,3a,6,6a-tetrahydro-1H-cyclobuta[cd]isobenzofuran-1,3(2aH)-dione (30). A deoxygenatedand magnetically stirred solution of compound 22 (100 mg, 0.52mmol) in dichloromethane (100 mL) maintained under a nitrogenatmosphere was subjected to irradiation with a Hanovia 450 Wmedium-pressure mercury-vapor lamp for 0.5 h. The reaction thusobtained was then cooled and concentrated under reduced pressure togive a yellow solid. Subjection of this material to flash columnchromatography (silica, 1:4 → 3:7 v/v ethyl acetate/40−60 petroleumether gradient elution) gave, after concentration of the appropriatefractions (Rf = 0.2 in 3:7 v/v ethyl acetate/40−60 petroleum ether),

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8015

Page 195: The Application of Pericyclic, Photolytic, Chemoenzymatic

compound 30 (75 mg, 75%) as a white, crystalline solid: mp = 161−163 °C; [α]D = −344.2 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3)δ 5.37 (m, 1H), 5.33 (m, 1H), 3.93 (m, 1H), 3.48 (m, 1H), 2.97 (dd, J= 10.0 and 2.1 Hz, 1H), 2.67 (m, 1H), 1.78 (s, 3H), 1.19 (d, J = 7.2Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 200.3, 177.5, 140.6, 112.9,89.8, 58.8, 43.3, 33.9, 26.8, 23.0, 19.8; IR νmax 2968, 1782, 1256, 1148,1141, 1130, 1004 cm−1; MS (ESI, + ve) m/z 247 [(M + MeOH +Na)+, 100]; HRMS m/z (M + MeOH + Na)+ calcd for C12H16O3Na247.0946, found 247.0945.(2aS,2a′R,3aR,6S,6aS)-6-Isopropyl-5-methyl-2a′,3a,6,6a-tetrahy-

dro-1H-cyclobuta[cd]isobenzofuran-1,3(2aH)-dione (31). A deoxy-genated and magnetically stirred solution of compound 23 (100 mg,0.45 mmol) in dichloromethane (100 mL) maintained under nitrogenwas subjected to irradiation with a Hanovia 450 W medium-pressuremercury-vapor lamp for 0.5 h. The reaction mixture thus obtained wascooled and concentrated under reduced pressure to give a yellow oil.Subjection of this material to flash column chromatography (silica, 1:4→ 3:7 v/v ethyl acetate/40−60 petroleum ether gradient elution)gave, after concentration of the appropriate fractions (Rf = 0.2 in 3:7v/v ethyl acetate/40−60 petroleum ether), compound 31 (73 mg,73%) as a clear, colorless oil: [α]D = −163.3 (c 0.7, CHCl3). 1H NMR(400 MHz, CDCl3) δ 5.47 (s, 1H), 5.27 (dd, J = 6.4 and 4.0 Hz, 1H),3.88 (m, 1H), 3.43 (m, 1H), 3.08 (dd, J = 10.1 and 1.4 Hz, 1H), 2.45(d, J = 3.9 Hz, 1H), 1.90 (m, 1H), 1.79 (s, 3H), 1.06 (d, J = 6.8 Hz,3H), 0.89 (d, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 200.4,178.7, 138.9, 114.7, 89.1, 59.4, 45.9, 38.1, 30.8, 28.3, 24.5, 21.6, 19.6;IR νmax 2963, 1782, 1168, 1147, 1131, 1005, 838 cm

−1; MS (ESI, + ve)m/z 275 [(M + MeOH + Na)+, 100], 221 [(M + H)+, 25]; HRMS m/z (M + MeOH + Na)+ calcd for C14H20O3Na 275.1259, found275.1260.( 2 a S , 2 a ′R , 3 S , 5 aR , 5 bR ) - 3 , 4 -D ime t h y l - 2 a ′ , 3 , 5 a , 5 b -

tetrahydrocyclopropa[cd]isobenzofuran-2(2aH)-one (32). A deoxy-genated and magnetically stirred solution of compound 22 (100 mg,0.52 mmol) in dichloromethane (100 mL) maintained under anitrogen atmosphere was irradiated with a Hanovia 450 W medium-pressure mercury-vapor lamp for 5 h. The ensuing reaction mixturewas cooled to ca. 22 °C then concentrated under reduced pressure togive a brown oil. Subjection of this material to flash columnchromatography (silica, 1:9 → 3:7 v/v ethyl acetate/40−60 petroleumether gradient elution) gave two fractions, A and B.Concentration of fraction A (Rf = 0.5 in 3:7 v/v ethyl acetate/40−

60 petroleum ether) afforded compound 32 (32 mg, 37%) as acolorless, crystalline solid: mp = 73−75 °C; [α]D = −102.8 (c 0.4,CHCl3);

1H NMR (400 MHz, CDCl3) δ 5.34 (s, 1H), 4.33 (dd, J =6.3 and 5.4 Hz, 1H), 2.89 (dd, J = 7.7 and 3.0 Hz, 1H), 2.23 (m, 1H),1.95 (m, 1H), 1.69 (s, 3H), 1.46 (m, 1H), 1.21 (d, J = 7.0 Hz, 3H);13C NMR (100 MHz, CDCl3) δ 180.3, 142.7, 112.7, 60.5, 44.7, 35.9,22.4, 18.7, 17.8, 11.6; IR νmax 2965, 1773, 1453, 1150, 1086, 1074, 922,794 cm−1; MS (ESI, + ve) m/z 187 [(M + Na)+, 100]; HRMS m/z (M+ Na)+ calcd for C10H12O2Na 187.0735, found 187.0735.Concentration of fraction B (Rf = 0.2 in 3:7 v/v ethyl acetate/40−

60 petroleum ether) afforded compound 30 (28 mg, 28%) as a whitesolid that was identical with an authentic sample.(2aS,2a′R,3S,5aR,5bR)-3-Isopropyl-4-methyl-2a′,3,5a,5b-

tetrahydrocyclopropa[cd]isobenzofuran-2(2aH)-one (33). A deoxy-genated and magnetically stirred solution of compound 23 (100 mg,0.45 mmol) in dichloromethane (100 mL) maintained under anitrogen atmosphere was subjected to irradiation with a Hanovia 450W medium-pressure mercury-vapor lamp for 1.5 h. The ensuingmixture was cooled then concentrated under reduced pressure to givea brown oil. Subjection of this material to flash columnchromatography (silica, 1:9 → 3:7 v/v ethyl acetate/40−60 petroleumether gradient elution) afforded two fractions, A and B.Concentration of fraction A (Rf = 0.6 in 3:7 v/v ethyl acetate/40−

60 petroleum ether) gave compound 33 (45 mg, 52%) as a clear,colorless oil: [α]D = −29.8 (c 1.0, CHCl3);

1H NMR (400 MHz,CDCl3) δ 5.45 (s, 1H), 4.33 (m, 1H), 3.03 (dd, J = 7.7 and 2.4 Hz,1H), 2.02−1.88 (complex m, 3H), 1.71 (s, 3H), 1.45 (m, 1H), 1.06 (d,J = 6.5 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz,CDCl3) δ 181.1, 141.1, 114.8, 61.4, 47.6, 40.3, 30.7, 24.2, 21.7, 19.9,

18.0, 13.5; IR νmax 2960, 1769, 1149, 1127, 1087, 933, 781 cm−1; MS(ESI, + ve) m/z 215 [(M + Na)+, 100]; HRMS m/z (M + Na)+ calcdfor C12H16O2Na 215.1048, found 215.1048.

Concentration of fraction B (Rf = 0.2 in 3:7 v/v ethyl acetate/40−60 petroleum ether) afforded compound 31 (25 mg, 25%) as a whitesolid that was identical with an authentic sample.

(1aR,1a ′S,3aR,4S,4a1R)-1a ′ ,4-Dimethylhexahydro-1H-cyclopropa[3,4]pentaleno[1,6-bc]furan-1,3(1aH)-dione (34). A de-oxygenated and magnetically stirred solution of compound 26 (108mg, 0.56 mmol) and acetophenone (90 μL, 0.77 mmol) in acetone(100 mL) maintained under nitrogen was subjected to irradiation witha Hanovia 450 W medium-pressure mercury-vapor lamp for 2.5 h. Theensuing reaction mixture was cooled then concentrated under reducedpressure to give a yellow oil. Subjection of this material to flash columnchromatography (silica, 3:17 → 3:7 v/v ethyl acetate/40−60petroleum ether gradient elution) gave, after concentration of theappropriate fractions (Rf = 0.3 in 1:1 v/v ethyl acetate/40−60petroleum ether), compound 34 (49 mg, 45%) as a white, crystallinesolid: mp = 154−156 °C, [α]D = +68.6 (c 1.0, CHCl3).

1H NMR (400MHz, CDCl3) δ 4.21 (s, 1H), 2.55−2.47 (complex m, 3H), 2.18 (m,1H), 1.97 (m, 1H), 1.54 (s, 3H), 1.38 (d, J = 6.8 Hz, 3H); 13C NMR(100 MHz, CDCl3) δ 206.9, 176.5, 87.7, 64.3, 55.0, 42.6, 40.3, 38.0,35.6, 22.6, 20.8; IR νmax 2970, 1781, 1726, 1238, 1163, 1033, 884, 874cm−1; MS (ESI, + ve) m/z 247 [(M + MeOH + Na)+, 20], 215 [(M +Na)+, 100], 193 (30); HRMS m/z (M + Na)+ calcd for C11H12O3Na215.0684, found 215.0676.

(1aR,1a′S,3aR,4S,4a′R)-4-Isopropyl-1a′-methylhexahydro-1H-cyclopropa[3,4]pentaleno[1,6-bc]furan-1,3(1aH)-dione (35). A de-oxygenated and magnetically stirred solution of compound 27 (123mg, 0.56 mmol) and acetophenone (90 μL, 0.77 mmol) in acetone(100 mL) maintained under a nitrogen atmosphere was irradiated witha Hanovia 450 W medium-pressure mercury-vapor lamp for 2.5 h. Thecooled reaction mixture was concentrated under reduced pressure togive a yellow oil and this subjected to flash column chromatography(silica, 3:17 → 1:3 v/v ethyl acetate/40−60 petroleum ether gradientelution). Concentration of the appropriate fractions (Rf = 0.5 in 1:1 v/v ethyl acetate/40−60 petroleum ether) then gave compound 35 (60mg, 49%) as a white, crystalline solid: mp = 102−103 °C; [α]D =+83.8 (c 1.0, CHCl3);

1H NMR (400 MHz, CDCl3) δ 4.22 (s, 1H),2.72 (d, J = 6.4 Hz, 1H), 2.41 (t, J = 4.0 Hz, 1H), 2.22−2.15 (complexm, 2H), 2.08 (m, 1H), 1.94 (m, 1H), 1.53 (s, 3H), 1.03 (d, J = 3.0 Hz,3H), 1.02 (d, J = 3.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 207.1,176.8, 87.6, 59.1, 54.6, 53.7, 37.4, 37.3, 35.5, 32.9, 20.6, 20.2, 19.4; IRνmax 2961, 1790, 1781, 1732, 1240, 1160, 1047, 889 cm

−1; MS (ESI, +ve) m/z 275 [(M + MeOH + Na)+, 20], 243 [(M + Na)+, 100];HRMS m/z (M + Na)+ calcd for C13H16O3Na 243.0997, found243.0993.

(2aR,2a′S,3aS,6S,6aR)-2a′,6-Dimethyl-2a′,3a,6,6a-tetrahydro-1H-cyclobuta[cd]isobenzofuran-1,3(2aH)-dione (36). A deoxygen-ated and magnetically stirred solution of compound 26 (100 mg, 0.52mmol) in dichloromethane (100 mL) maintained under a nitrogenatmosphere was irradiated with a Hanovia 450 W medium-pressuremercury-vapor lamp for 0.58 h then cooled and concentrated underreduced pressure to give a yellow solid. Subjection of this material toflash column chromatography (silica, 1:4 → 3:7 v/v ethyl acetate/40−60 petroleum ether gradient elution) then gave, after concentration ofthe appropriate fractions (Rf = 0.2 in 3:7 v/v ethyl acetate/40−60petroleum ether), compound 36 (70 mg, 70%) as a white, crystallinesolid: mp = 100−101 °C; [α]D = +220.5 (c 1.0, CHCl3).

1H NMR(400 MHz, CDCl3) δ 6.02 (m, 1H), 5.69 (dd, J = 10.0 and 4.0 Hz,1H), 4.82 (d, J = 4.0 Hz, 1H), 3.60 (m, 1H), 2.93 (m, 1H), 2.66 (s,1H), 1.70 (s, 3H), 1.23 (d, J = 7.3 Hz, 3H); 13C NMR (100 MHz,CDCl3) δ 200.1, 177.7, 132.6, 119.1, 93.5, 63.8, 48.5, 35.5, 30.1, 24.9,21.2; IR νmax 2965, 1779, 1191, 1096, 997, 744, 725 cm

−1; MS (ESI, +ve) m/z 247 [(M + MeOH + Na)+, 100%]; HRMS m/z (M + MeOH+ Na)+ calcd for C12H16O3Na 247.0946, found 247.0947.

(2aR,2a′S,3aS,6S,6aR)-6-Isopropyl-2a′-methyl-2a′,3a,6,6a-tetra-hydro-1H-cyclobuta[cd]isobenzofuran-1,3(2aH)-dione (37). A de-oxygenated and magnetically stirred solution of compound 27 (100mg, 0.45 mmol) in dichloromethane (100 mL) maintained under a

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8016

Page 196: The Application of Pericyclic, Photolytic, Chemoenzymatic

nitrogen atmosphere was irradiated with a Hanovia 450 W medium-pressure mercury-vapor lamp for 0.55 h then cooled and concentratedunder reduced pressure to give a yellow solid. Subjection of thismaterial to flash column chromatography (silica, 1:4 → 3:7 v/v ethylacetate/40−60 petroleum ether gradient elution) then gave, afterconcentration of the appropriate fractions (Rf = 0.2 in 3:7 v/v ethylacetate/40−60 petroleum ether), compound 37 (71 mg, 71%) as awhite, crystalline solid: mp = 96−98 °C; [α]D = +196.2 (c 1.0,CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.11 (m, 1H), 5.73 (dd, J =10.1 and 3.6 Hz, 1H), 4.79 (d, J = 3.6 Hz, 1H), 3.56 (m, 1H), 2.95 (d,J = 1.7 Hz, 1H), 2.43 (t, J = 8.0 Hz, 1H), 1.68 (s, 3H), 1.66−1.60(complex m, 1H), 1.09 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H);13C NMR (100 MHz, CDCl3) δ 199.9, 178.5, 131.8, 120.0, 93.5, 64.2,44.8, 42.6, 35.9, 33.1, 24.1, 21.4, 21.3; IR νmax 2964, 1782, 1471, 1293,1193, 1000, 722 cm−1; MS (ESI, + ve) m/z 527 [(2M + 2MeOH +Na)+, 15], 275 [(M + MeOH + Na)+, 100], 221 [(M + H)+, 15];HRMS m/z (M + MeOH + Na)+ calcd for C14H20O3Na 275.1259,found 275.1257.( 2aR ,2a ′S ,3S , 5aS ,5bS ) -2a ′ , 3 -D imethy l - 2a 1 , 3 , 5a ,5b -

tetrahydrocyclopropa[cd]isobenzofuran-2(2aH)-one (38). A deoxy-genated and magnetically stirred solution of compound 26 (100 mg,0.52 mmol) in dichloromethane (100 mL) maintained under anitrogen atmosphere was irradiated with a Hanovia 450 W medium-pressure mercury-vapor lamp for 3.1 h then cooled and concentratedunder reduced pressure to give a brown oil. Subjection of this materialto flash column chromatography (silica, 1:9 → 3:7 v/v ethyl acetate/40−60 petroleum ether gradient elution) then gave two fractions, Aand B.Concentration of fraction A (Rf = 0.5 in 3:7 v/v ethyl acetate/40−

60 petroleum ether) afforded compound 38 (30 mg, 35%) as acolorless, crystalline solid: mp = 40−42 °C; [α]D = +152.0 (c 0.5,CHCl3);

1H NMR (400 MHz, CDCl3) δ 5.95 (dd, J = 9.9 and 6.0 Hz,1H), 5.66 (dd, J = 9.9 and 4.5 Hz, 1H), 4.03 (d, J = 5.6 Hz, 1H), 2.65(s, 1H), 2.54 (m, 1H), 1.39 (s, 3H), 1.35 (m, 1H), 1.22 (d, J = 7.1 Hz,3H); 13C NMR (100 MHz, CDCl3) δ 180.7, 134.8, 119.4, 65.2, 49.3,31.7, 23.5, 20.6, 19.3, 18.9; IR νmax 2962, 2929, 1783, 1769, 1143,1090, 846, 750 cm−1; MS (EI, 70 eV) m/z 164 (M+•, 20%), 121 (30),107 (100), 91 (70), 77 (25), 65 (15); HRMS m/z M•+ calcd forC10H12O2 164.0837, found 164.0835.Concentration of fraction B (Rf = 0.2 in 3:7 v/v ethyl acetate/40−

60 petroleum ether) afforded compound 36 (32 mg, 32%) as a white,crystalline solid that was identical, in all respects, with an authenticsample.(2aR,2a′S,3S,5aS,5bS)-3-Isopropyl-2a′-methyl-2a′,3,5a,5b-

tetrahydrocyclopropa[cd]isobenzofuran-2(2aH)-one (39). A deoxy-genated and magnetically stirred solution of compound 27 (100 mg,0.45 mmol) in dichloromethane (100 mL) maintained under anitrogen atmosphere was irradiated with a Hanovia 450 W medium-pressure mercury-vapor lamp for 3.1 h then cooled and concentratedunder reduced pressure to give a brown oil. Subjection of this materialto flash column chromatography (silica, 1:9 → 3:7 v/v ethyl acetate/40−60 petroleum ether elution) then gave two fractions, A and B.Concentration of fraction A (Rf = 0.6 in 3:7 v/v ethyl acetate/40−

60 petroleum ether) afforded compound 39 (35 mg, 40%) as a yellowoil, [α]D = +166.7 (c 1.0, CHCl3).

1H NMR (400 MHz, CDCl3) δ 6.02(dd, J = 9.9 and 6.1 Hz, 1H), 5.70 (dd, J = 9.9 and 4.2 Hz, 1H), 4.02(d, J = 5.5 Hz, 1H), 2.92 (s, 1H), 2.02 (m, 1H), 1.79 (m, 1H), 1.36 (s,3H), 1.34 (m, 1H), 1.05 (d, J = 6.6 Hz, 3H), 0.99 (d, J = 6.6 Hz, 3H);13C NMR (100 MHz, CDCl3) δ 181.2, 134.0, 120.3, 65.5, 46.0, 43.8,32.3, 23.7, 21.8, 20.9, 20.1, 19.3; IR νmax 2966, 2872, 1778, 1148, 1092,834, 752 cm−1; MS (ESI, + ve) m/z 215 [(M + Na)+, 100%]; HRMSm/z (M + Na)+ calcd for C12H16O2Na 215.1048, found 215.1047.Concentration of fraction B (Rf = 0.2 in 3:7 v/v ethyl acetate/40−

60 petroleum ether) afforded compound 37 (34 mg, 34%) as a white,crystalline solid that was identical, in all respects, with an authenticsample.( 3aR ,4R ,4aR ,5S ,7aR ,8S ,8aS ) -2 ,2 ,4 ,6 ,6 -Pentamethy l -

3a,4a,5,6,7,7a,8,8a-octahydro-4H-4,8-ethenoindeno[5,6-d][1,3]-dioxol-5-yl Acetate (42). A magnetically stirred solution of compound414d,5b (5.00 g, 17.96 mmol), acetic anhydride (3.40 mL, 35.97 mmol)

and 4-(N,N-dimethylamino)pyridine (440 mg, 3.60 mmol) intriethylamine (7.50 mL, 53.8 mmol) was stirred at 0 °C for 2 h andthen warmed to 22 °C and stirred at this temperature for another 2 h.After this time, NH4Cl (50 mL of a saturated aqueous solution) wasadded to the reaction mixture, and the resulting suspension wasextracted with dichloromethane (3 × 50 mL). The combined organicfractions were washed with water (2 × 50 mL) and brine (1 × 50 mL)before being dried (MgSO4), filtered, and concentrated under reducedpressure. The residue thus obtained was subjected to flash columnchromatography (silica, 1:19 v/v ethyl acetate/40−60 petroleum etherelution) and gave, after concentration of the appropriate fractions (Rf= 0.3 in 1:9 v/v ethyl acetate/40−60 petroleum ether), compound 42(5.58 g, 97%) as a white, crystalline solid: mp = 135−137 °C; [α]D =+7.6 (c 1.0, CHCl3);

1H NMR (400 MHz, CDCl3) δ 5.86−5.80(complex m, 2H), 4.98 (d, J = 6.1 Hz, 1H), 4.22 (dd, J = 7.2 and 3.1Hz, 1H), 3.79 (d, J = 7.2 Hz, 1H), 2.75 (m, 1H), 2.22 (m, 1H), 2.07(m, 1H), 2.04 (s, 3H), 1.37 (m, 2H), 1.32 (s, 3H), 1.27 (s, 3H), 1.14(s, 3H), 0.95 (s, 3H), 0.82 (s, 3H); 13C NMR (100 MHz, CDCl3) δ170.4, 137.3, 125.7, 109.1, 84.1, 81.0, 80.1, 49.7, 44.7, 42.0, 40.8, 40.0,38.0, 25.6 (5), 25.6 (2), 25.2, 22.4, 21.6, 19.9; IR νmax 2961, 2934,1733, 1370, 1234, 1073, 723 cm−1; MS (ESI, + ve) m/z 343 [(M +Na)+, 100]; HRMS m/z (M + Na)+ calcd for C19H28O4Na 343.1885,found 343.1884.

(3S,3aR,4R,7S,7aR,8S,9R)-8,9-Dihydroxy-2,2,4-trimethyl-2,3,3a,4,7,7a-hexahydro-1H-4,7-ethanoinden-3-yl Acetate (43).AG-50W-X8 resin (3.32 g of H+ form) was added to a magneticallystirred solution of compound 42 in methanol/water (72 mL of a 5:1v/v mixture) and the resulting suspension heated under reflux for 67 hand then cooled to 22 °C before being filtered through a sintered glassfunnel. The filtrate was concentrated under reduced pressure and theresidue thus obtained subjected to flash column chromatography(silica, 3:7 v/v ethyl acetate/40−60 petroleum ether elution).Concentration of the appropriate fractions (Rf = 0.1 in 3:7 v/v ethylacetate/40−60 petroleum ether) gave compound 43 (1.80 g, 97%) asa white solid: mp = 73−74 °C; [α]D = −2.3 (c 1.1, CHCl3); 1H NMR(400 MHz, CDCl3) δ 5.99−5.91 (complex m, 2H), 4.97 (d, J = 6.1 Hz,1H), 3.88 (dd, J = 7.5 and 2.4 Hz, 1H), 3.40 (d, J = 7.5 Hz, 1H), 2.73(m, 1H), 2.52 (broad s, 2H), 2.27 (m, 1H), 2.13 (m, 1H), 2.03 (s,3H), 1.39 (m, 1H), 1.25 (t, J = 11.6 Hz, 1H), 1.15 (s, 3H), 0.93 (s,3H), 0.80 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.4, 138.8,126.8, 81.6, 75.4, 71.7, 50.4, 44.1, 42.0, 41.5, 41.3, 40.8, 25.5, 22.3,21.6, 19.6; IR νmax 3394, 2965, 2932, 1732, 1374, 1240, 1057 cm−1;MS m/z 583 [(2M + Na)+, 5], 303 [(M + Na)+, 100]; HRMS m/z (M+ Na)+ calcd for C16H24O4Na 303.1572, found 303.1577.

(3S,3aR,4R,7S,7aS,9R)-9-Hydroxy-2,2,4-trimethyl-8-oxo-2,3,3a,4,7,7a-hexahydro-1H-4,7-ethanoinden-3-yl Acetate (44). Amagnetically stirred mixture of p-toluenesulfonic acid monohydrate(448 mg, 2.36 mmol) and 4-acetamido-TEMPO (502 mg, 2.35 mmol)in dichloromethane (10 mL) was maintained at 0 °C under a nitrogenatmosphere for 0.5 h and the resulting solution then added, dropwiseover 2 h, to a magnetically stirred solution of compound 43 (300 mg,1.07 mmol) in dichloromethane (10 mL) maintained at 0 °C. Theensuing mixture was stirred for a further 2 h at this temperature andthen quenched with NaHCO3 (50 mL of a saturated aqueoussolution). The resulting suspension was extracted with dichloro-methane (3 × 50 mL), and the combined organic phases were washedwith water (2 × 50 mL) and brine (1 × 50 mL) before being dried(Na2SO4), filtered, and concentrated under reduced pressure. Theresidue thus obtained was subjected to flash column chromatography(silica, 3:17 v/v ethyl acetate/40−60 petroleum ether elution) to give,after concentration of the appropriate fractions (Rf = 0.2 in 3:7 v/vethyl acetate/40−60 petroleum ether), compound 44 (289 mg, 97%)as a white, crystalline solid: mp = 147−149 °C; [α]D = +215.0 (c 1.1,CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.08 (d, J = 7.9 Hz, 1H), 5.92(t, J = 7.9 Hz, 1H), 5.09 (d, J = 6.0 Hz, 1H), 3.34 (s, 1H), 3.15 (d, J =6.0 Hz, 1H), 2.72−2.49 (complex m, 3H), 2.06 (s, 3H), 1.52 (dd, J =12.2 and 7.4 Hz, 1H), 1.40 (t, J = 12.2 Hz, 1H), 1.22 (s, 3H), 1.00 (s,3H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 211.0, 170.2,142.2, 121.9, 81.1, 75.2, 51.8, 50.1, 44.8, 43.9, 41.7, 39.3, 25.6, 22.2,21.6, 18.1; IR νmax 3451, 3239, 2965, 1730, 1374, 1236, 1081, 1039

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8017

Page 197: The Application of Pericyclic, Photolytic, Chemoenzymatic

cm−1; MS (ESI, + ve) m/z 579 [(2M + Na)+, 10], 301 [(M + Na)+,100]; HRMS m/z (M + Na)+ calcd for C16H22O4Na 301.1416, found301.1411.(3S,3aR,4R,7S,7aS,9R)-2,2,4-Trimethyl-8-oxo-2,3,3a,4,7,7a-hexa-

hydro-1H-4,7-ethanoindene-3,9-diyl Diacetate (45). A magneticallystirred solution of compound 44 (239 mg, 0.86 mmol), 4-(N,N-dimethylamino)pyridine (11 mg, 0.09 mmol), and triethylamine (180μL, 1.29 mmol) in dichloromethane (10 mL) maintained at 0 °Cunder a nitrogen atmosphere was treated with acetic anhydride (97 μL,1.03 mmol). The ensuing mixture was kept at 0 °C for 2 h and then at22 °C for 16 h before being quenched with NH4Cl (10 mL of asaturated aqueous solution). The resulting mixture was extracted withdichloromethane (2 × 20 mL), and the combined organic phases werewashed with water (2 × 20 mL) and brine (1 × 20 mL) before beingdried (Na2SO4), filtered, and concentrated under reduced pressure.The residue thus obtained was subjected to flash columnchromatography (silica, 3:17 v/v ethyl acetate/40−60 petroleumether elution) and gave, after concentration of the appropriatefractions (Rf = 0.4 in 3:7 v/v ethyl acetate/40−60 petroleum ether),compound 45 (250 mg, 91%) as a white, crystalline solid: mp = 175−177 °C; [α]D = +200.0 (c 1.0, CHCl3);

1H NMR (400 MHz, CDCl3)δ 6.09 (d, J = 8.1 Hz, 1H), 5.97 (t, J = 8.1 Hz, 1H), 5.09 (d, J = 6.0 Hz,1H), 4.85 (s, 1H), 3.17 (d, J = 6.0 Hz, 1H), 2.74 (m, 1H), 2.64 (dd, J= 10.6 and 6.0 Hz, 1H), 2.10 (s, 3H), 2.06 (s, 3H), 1.53 (dd, J = 12.2and 7.3 Hz, 1H), 1.39 (t, J = 12.2 Hz, 1H), 1.05 (s, 3H), 1.01 (s, 3H),0.86 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 205.2, 170.7, 170.1,141.4, 122.2, 81.1, 74.2, 51.5, 50.7, 44.9, 42.6, 41.7, 39.6, 25.5, 22.2,21.5, 20.7, 17.9; IR νmax 2979, 2965, 2932, 1721, 1374, 1230, 1053,1020 cm−1; MS (ESI, + ve) m/z 663 [(2M + Na)+, 20], 343 [(M +Na)+, 100], 321 [(M + H)+, 5]; HRMS m/z (M + Na)+ calcd forC18H24O5Na 343.1521, found 343.1505.(3S,3aR,4R,7S,7aS,9R)-9-(Methoxymethoxy)-2,2,4-trimethyl-8-

oxo-2,3,3a,4,7,7a-hexahydro-1H-4,7-ethanoinden-3-yl Acetate(46). A magnetically stirred solution of compound 44 (280 mg, 1.00mmol), chloromethyl methyl ether (122 μL, 1.60 mmol), tetra-n-butylammonium iodide (37 mg, 0.10 mmol), and N,N-diisopropyle-thylamine (348 μL, 2.00 mmol) in dichloromethane (5 mL)maintained under a nitrogen atmosphere was stirred at 22 °C for 48h and then treated with NH4Cl (10 mL of a saturated aqueoussolution) and extracted with dichloromethane (2 × 20 mL). Thecombined organic phases were washed with water (2 × 20 mL) andbrine (1 × 20 mL) before being dried (Na2SO4), filtered, andconcentrated under reduced pressure. The residue thus obtained wassubjected to flash column chromatography (silica, 1:4 v/v ethylacetate/40−60 petroleum ether elution) and gave, after concentrationof the appropriate fractions (Rf = 0.3 in 1:4 v/v ethyl acetate/40−60petroleum ether), compound 46 (251 mg, 77%) as a pale-yellow oil:[α]D = +213.0 (c 1.0, CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.06 (d,J = 8.0 Hz, 1H), 5.90 (t, J = 8.0 Hz, 1H), 5.03 (d, J = 6.7 Hz, 2H), 4.59(d, J = 6.7 Hz, 1H), 3.38 (s, 3H), 3.31 (s, 1H), 3.04 (d, J = 6.3 Hz,1H), 2.61 (m, 1H), 2.46 (dd, J = 10.6 and 6.1 Hz, 1H), 2.03 (s, 3H),1.46 (dd, J = 12.1 and 7.4 Hz, 1H), 1.35 (t, J = 12.1 Hz, 1H), 1.14 (s,3H), 0.95 (s, 3H), 0.82 (s, 3H); 13C NMR (100 MHz, CDCl3) δ209.3, 170.1, 141.0, 121.5, 97.5, 81.1, 77.1, 56.3, 51.0, 50.7, 44.8, 43.2,41.5, 40.2, 25.3, 22.1, 21.5, 18.4; IR νmax 2966, 1731, 1372, 1239, 1150,1035, 710 cm−1; MS (ESI, + ve) m/z 667 [(2M + Na)+, 5], 345 [(M +Na)+, 100]; HRMS m/z (M + Na)+ calcd for C18H26O5Na 345.1678,found 345.1665.(3S,3aR,4R,7S,7aS,9R)-9-((tert-Butyldimethylsilyl)oxy)-2,2,4-tri-

methyl-8-oxo-2,3,3a,4,7,7a-hexahydro-1H-4,7-ethanoinden-3-ylAcetate (47). A magnetically stirred solution of compound 44 (400mg, 1.44 mmol), tert-butyldimethylsilyl chloride (1.73 g, 11.48 mmol),and imidazole (980 mg, 14.39 mmol) in 1,2-dichloroethane (20 mL)kept under a nitrogen atmosphere was heated at reflux for 65 h andthen cooled, quenched with NH4Cl (10 mL of a saturated aqueoussolution), and extracted with dichloromethane (2 × 40 mL). Thecombined organic phases were washed with water (2 × 40 mL) andbrine (1 × 40 mL) before being dried (Na2SO4), filtered, andconcentrated under reduced pressure. The residue thus obtained wassubjected to flash column chromatography (silica, 2:5:100 v/v/v ethyl

acetate/dichloromethane/40−60 petroleum ether elution) and gave,after concentration of the appropriate fractions (Rf = 0.6 in 3:7 v/vethyl acetate/40−60 petroleum ether), compound 47 (465 mg, 82%)as a white, crystalline solid: mp = 71−72 °C; [α]D = +121.0 (c 1.0,CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.03 (d, J = 8.0 Hz, 1H), 5.87(t, J = 8.0 Hz, 1H), 5.06 (d, J = 6.0 Hz, 1H), 3.27 (s, 1H), 3.02 (dd, J =6.0 and 1.8 Hz, 1H), 2.62 (m, 1H), 2.42 (dd, J = 10.6 and 6.0 Hz, 1H),2.06 (s, 3H), 1.51−1.37 (complex m, 2H), 1.12 (s, 3H), 0.99 (s, 3H),0.86 (s, 12H), 0.10 (s, 3H), 0.09 (s, 3H); 13C NMR (100 MHz,CDCl3) δ 209.5, 170.3, 141.7, 120.9, 81.4, 76.0, 51.1, 50.5, 44.9, 44.4,41.7, 40.3, 26.0, 25.5, 22.3, 21.6, 19.0, 18.6, − 4.0, − 5.0; IR νmax 2959,2930, 2856, 1733, 1237, 1129, 1112, 1093, 858, 837, 778, 709 cm−1;MS m/z 415 [(M + Na)+, 100]; HRMS m/z (M + Na)+ calcd forC22H36O4SiNa 415.2281, found 415.2275.

(3S,3aR,4R,7S,7aS,9R)-3-Acetoxy-2,2,4-trimethyl-8-oxo-2,3,3a,4,7,7a-hexahydro-1H-4,7-ethanoinden-9-yl Benzoate (48). Amagnetically stirred solution of compound 44 (2.90 g, 10.42 mmol), 4-(N,N-dimethylamino)pyridine (127 mg, 1.04 mmol), and triethyl-amine (2.9 mL, 21.00 mmol) in dichloromethane (50 mL) maintainedunder a nitrogen atmosphere at 0 °C was treated with benzoyl chloride(1.50 mL, 12.50 mmol). The ensuing mixture was allowed to warm toand then stirred at 22 °C for 16 h before being quenched with NH4Cl(50 mL of a saturated aqueous solution) and then extracted withdichloromethane (2 × 100 mL). The combined organic phases werewashed with water (2 × 100 mL) and then brine (1 × 100 mL) beforebeing dried (Na2SO4), filtered, and concentrated under reducedpressure. The residue thus obtained was subjected to flash columnchromatography (silica, 2:5:100 v/v/v ethyl acetate/dichloromethane/40−60 petroleum ether elution) and gave, after concentration of theappropriate fractions [Rf = 0.2(5) in 1:19 v/v ethyl acetate/40−60petroleum ether], compound 48 (3.69 g, 93%) as a white, crystallinesolid: mp = 134−136 °C; [α]D = +196.0 (c 1.1, CHCl3);

1H NMR(400 MHz, CDCl3) δ 7.99 (d, J = 7.3 Hz, 2H), 7.54 (t, J = 7.3 Hz,1H), 7.41 (t, J = 7.3 Hz, 2H), 6.20 (d, J = 8.1 Hz, 1H), 6.04 (t, J = 8.1Hz, 1H), 5.12−5.10 (complex m, 2H), 3.23 (dd, J = 6.6 and 1.6 Hz,1H), 2.80 (m, 1H), 2.72 (dd, J = 10.6 and 6.6 Hz, 1H), 2.07 (s, 3H),1.55 (dd, J = 12.1 and 7.3 Hz, 1H), 1.43 (m, 1H), 1.11 (s, 3H), 1.02 (s,3H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 205.0, 170.1,166.2, 141.3, 133.4, 130.0, 129.5, 128.5, 122.4, 81.1, 74.4, 51.3, 50.7,44.9, 42.9, 41.7, 39.7, 25.4, 22.2, 21.5, 18.0; IR νmax 2967, 1722, 1268,1238, 1108, 729, 706 cm−1; MS (ESI, + ve) m/z 787 [(2M + Na)+,100], 405 [(M + Na)+, 85]; HRMS m/z (M + Na)+ calcd forC23H26O5Na 405.1678, found 405.1682.

(1S,3aS,4S,7R,7aR)-2,2,7-Trimethyl-9-oxo-2,3,3a,4,7,7a-hexahy-dro-1H-4,7-ethanoinden-1-yl Acetate (49). A magnetically stirredsolution of compound 48 (3.30 g, 8.63 mmol) in deoxygenated THF/methanol (30 mL of a 9:1 v/v mixture) maintained at −78 °C underan argon atmosphere was treated, dropwise over 1 h, withsamarium(II) iodide (ca. 250 mL of a 0.086 M solution in THF) atwhich point a dark-blue color persisted for 0.25 h. The resultingmixture was then quenched with NH4Cl (100 mL of a saturatedaqueous solution) and the ensuing suspension extracted with diethylether (2 × 100 mL). The combined organic phases were washed withHCl (2 × 50 mL of a 1 M aqueous solution) and brine (1 × 100 mL)before being dried (Na2SO4), filtered, and concentrated under reducedpressure. The residue thus obtained was subjected to flash columnchromatography (silica, 1:9 v/v diethyl ether/n-hexane elution) andgave, after concentration of the appropriate fractions [Rf = 0.4(5) in1:9 v/v diethyl ether/n-hexane)], compound 49 (1.91 g, 85%) as aclear, colorless oil: [α]D = +161.0 (c 1.0, CHCl3);

1H NMR (400MHz, CDCl3) δ 6.10 (d, J = 8.1 Hz, 1H), 5.86 (t, J = 8.1 Hz, 1H), 4.93(d, J = 6.0 Hz, 1H), 2.96 (dd, J = 6.0 and 1.8 Hz, 1H), 2.60 (m, 1H),2.46 (m, 1H), 1.98 (s, 3H), 1.79 (s, 2H), 1.38 (m, 1H), 1.26 (t, J =11.5 Hz, 1H), 1.05 (s, 3H), 0.90 (s, 3H), 0.76 (s, 3H); 13C NMR (100MHz, CDCl3) δ 212.3, 170.0, 142.9, 123.0, 80.4, 53.6, 52.1, 47.7, 44.8,42.0, 41.2, 39.2, 25.4, 22.2, 22.0, 21.4; IR νmax 2965, 1726, 1373, 1239,1069, 707 cm−1; MS (ESI, + ve) m/z 547 [(2M + Na)+, 10], 285 [(M+ Na)+, 100], 263 [(M + H)+, 1]; HRMS m/z (M + H)+ calcd forC16H23O3 263.1647, found 263.1649.

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8018

Page 198: The Application of Pericyclic, Photolytic, Chemoenzymatic

(1R,2aR,4aR,7S,7aR,7bS)-1-(Methoxymethoxy)-6,6,7b-trimethyl-2-oxo-2,2a,4a,5,6,7,7a,7b-octahydro-1H-cyclobuta[e]inden-7-yl Ac-etate (50). A magnetically stirred solution of compound 45 (100 mg,0.31 mmol) in dry, deoxygenated dichloromethane (30 mL)maintained under a nitrogen atmosphere was irradiated with aHanovia 100 W medium-pressure mercury-vapor lamp (maintained at5 °C) for 16 h. The reaction mixture was then cooled andconcentrated under reduced pressure and the residue thus obtainedsubjected to flash column chromatography (silica, 1:19 v/v ethylacetate/n-hexane elution) to afford two fractions, A and B.Concentration of fraction A [Rf = 0.3(5) in 1:19 v/v ethyl acetate/n-

hexane] gave compound 50 (43 mg, 43% or 99% brsm) as a clear,colorless oil: [α]D = −157.0 (c 0.7, CHCl3);

1H NMR (400 MHz,CDCl3) δ 5.76 (m, 1H), 5.73 (m, 1H), 5.54 (m, 1H), 4.97 (d, J = 4.2Hz, 1H), 3.02 (m, 1H), 2.96 (m, 1H), 2.87 (dd, J = 9.3 and 4.2 Hz,1H), 2.14 (s, 3H), 2.06 (m, 1H), 1.98 (s, 3H), 1.51 (dd, J = 13.3 and5.0 Hz, 1H), 1.09 (s, 3H), 1.03 (s, 3H), 0.92 (s, 3H); 13C NMR (100MHz, CDCl3) δ 201.3, 170.6, 169.9, 134.3, 117.2, 83.4, 83.2, 59.0,45.4, 43.5, 42.8, 34.8, 34.7, 28.8, 24.3, 21.3, 20.5, 18.4; IR νmax 2933,2873, 1792, 1735, 1373, 1224, 1087 cm−1; MS (ESI, + ve) m/z 375[(M + MeOH + Na)+, 20], 343 [(M + Na)+, 100]; HRMS m/z (M +Na)+ calcd for C18H24O5Na 343.1521, found 343.1520.Concentration of the fraction B [Rf = 0.2(5) in 1:19 v/v ethyl

acetate/n-hexane] gave compound 45 (56 mg, 56% recovery) as acolorless, crystalline solid that was identical, in all respects, with anauthentic sample.(1R,2aR,4aR,7S,7aR,7bS)-1-(Methoxymethoxy)-6,6,7b-trimethyl-

2-oxo-2,2a,4a,5,6,7,7a,7b-octahydro-1H-cyclobuta[e]inden-7-yl Ac-etate (51). A magnetically stirred solution of compound 46 (100 mg,0.31 mmol) in dry, deoxygenated dichloromethane (30 mL)maintained under a nitrogen atmosphere was irradiated with aHanovia 100 W medium-pressure mercury-vapor lamp (maintained at5 °C) for 16 h. The cooled reaction mixture was concentrated underreduced pressure and the residue thus obtained subjected to flashcolumn chromatography (silica, 1:9 v/v ethyl acetate/n-hexaneelution), thus affording two fractions, A and B.Concentration of the fraction A [Rf = 0.3(5) in 1:9 v/v ethyl

acetate/n-hexane] gave compound 51 (27 mg, 27% or 98% brsm) as aclear, colorless oil: [α]D = −324.0 (c 0.2, CHCl3);

1H NMR (400MHz, CDCl3) δ 5.70 (m, 1H), 5.55 (m, 1H), 5.00 (d, J = 4.1 Hz, 1H),4.67 (m, 3H), 3.42 (s, 3H), 2.90 (m, 1H), 2.85 (m, 1H), 2.76 (dd, J =9.4 and 4.1 Hz, 1H), 2.05 (m, 1H), 1.98 (s, 3H), 1.51 (dd, J = 13.2 and5.2 Hz, 1H), 1.11 (s, 3H), 1.06 (s, 3H), 0.93 (s, 3H); 13C NMR (100MHz, CDCl3) δ 204.5, 170.7, 133.4, 118.0, 97.3, 89.4, 83.2, 58.5, 56.1,45.4, 43.5, 43.2, 34.7, 34.4, 28.7, 24.2, 21.4, 18.5; IR νmax 2962, 2933,1787, 1733, 1373, 1240, 1110, 1067, 1012 cm−1; MS (ESI, + ve) m/z345 [(M + Na)+, 100]; HRMS m/z (M + Na)+ calcd for C18H26O5Na345.1678, found 345.1672.Concentration of the fraction B [Rf = 0.2(5) in 1:9 v/v ethyl

acetate/n-hexane] gave compound 46 (71 mg, 71% recovery) as aclear, colorless oil that was identical, in all respects, with an authenticsample.(3S,3aR,4R,7S,7aS,9R)-9-((tert-Butyldimethylsilyl)oxy)-2,2,4-tri-

methyl-8-oxo-2,3,3a,4,7,7a-hexahydro-1H-4,7-ethanoinden-3-ylAcetate (52). A magnetically stirred solution of compound 47 (100mg, 0.25 mmol) in dry, deoxygenated dichloromethane (30 mL)maintained under a nitrogen atmosphere was irradiated with a Hanovia100 W medium-pressure mercury-vapor lamp (maintained at 5 °C) for16 h. The cooled reaction mixture was concentrated under reducedpressure and the residue thus obtained subjected to flash columnchromatography (silica, 1:19 v/v ethyl acetate/n-hexane elution), thusthereby affording two fractions, A and B.Concentration of the fraction A (Rf = 0.4 in 1:19 v/v ethyl acetate/

n-hexane) gave compound 52 (18 mg, 18% or 99% brsm) as a clear,colorless oil: [α]D = −189.0 (c 2.3, CHCl3);

1H NMR (400 MHz,CDCl3) δ 5.64 (m, 1H), 5.55 (m, 1H), 4.98 (d, J = 4.1 Hz, 1H), 4.71(d, J = 2.8 Hz, 1H), 2.86−2.78 (complex m, 2H), 2.65 (dd, J = 9.3 and4.1 Hz, 1H), 2.03 (m, 1H), 1.97 (s, 3H), 1.50 (dd, J = 13.2 and 5.1 Hz,1H), 1.10 (s, 3H), 0.97 (s, 3H), 0.92 (s, 3H), 0.90 (s, 9H), 0.10 (s,3H), 0.07 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 206.1, 170.6,

132.8, 118.7, 85.0, 83.3, 58.0, 45.5, 43.5, 43.2, 34.8, 34.5, 28.8, 25.8,24.2, 21.3, 18.4, 18.2, − 4.6, − 4.9; IR νmax 2958, 2931, 2859, 1788,1736, 1239, 1108, 883, 838, 780 cm−1; MS (ESI, + ve) m/z 415 [(M +Na)+, 100], 393 [(M + H)+, 5]; HRMS m/z (M + Na)+ calcd forC22H36O4SiNa 415.2281, found 415.2284.

Concentration of the fraction B (Rf = 0.3 in 1:19 v/v ethyl acetate/n-hexane) gave compound 47 (81 mg, 81% recovery) as a colorless,crystalline solid that was identical, in all respects, with an authenticsample.

(1R,2aR,4aR,7S,7aR,7bS)-7-Acetoxy-6,6,7b-trimethyl-2-oxo-2,2a,4a,5,6,7,7a,7b-octahydro-1H-cyclobuta[e]inden-1-yl Benzoate(53). A magnetically stirred solution of compound 48 (100 mg, 0.26mmol) in dry, deoxygenated dichloromethane (30 mL) maintainedunder a nitrogen atmosphere was irradiated with a Hanovia 100 Wmedium-pressure mercury-vapor lamp (maintained at 5 °C) for 16 h.The reaction mixture was then cooled and concentrated under reducedpressure and the residue so obtained subjected to flash columnchromatography (silica, 1:19 v/v ethyl acetate/n-hexane elution), thusaffording two fractions, A and B.

Concentration of the fraction A [Rf = 0.3(5) in 1:19 v/v ethylacetate/n-hexane] gave compound 53 (17 mg, 17% or 100% brsm) asa colorless, crystalline solid: mp = 180−181 °C; [α]D = −672.0 (c 1.5,CHCl3);

1H NMR (400 MHz, CDCl3) δ 8.06 (m, 2H), 7.59 (t, J = 7.4Hz, 1H), 7.45 (t, J = 7.4 Hz, 2H), 5.97 (d, J = 2.8 Hz, 1H), 5.80 (m,1H), 5.59 (m, 1H), 4.98 (d, J = 4.2 Hz, 1H), 3.10 (m, 1H), 3.04 (m,1H), 2.97 (dd, J = 9.3 and 4.2 Hz, 1H), 2.08 (dd, J = 13.3 and 9.8 Hz,1H), 1.99 (s, 3H), 1.53 (dd, J = 13.3 and 5.0 Hz, 1H), 1.12 (s, 3H),1.10 (s, 3H), 0.92 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 201.1,170.6, 165.3, 134.3, 133.8, 130.1, 128.8, 128.7, 117.3, 83.6, 83.2, 59.2,45.4, 43.5, 42.9, 35.1, 34.8, 28.8, 24.3, 21.3, 18.5; IR νmax 2963, 2934,2872, 1790, 1724, 1372, 1237, 1104, 709 cm−1; MS (ESI, + ve) m/z787 [(2M + Na)+, 10], 437 [(M + MeOH + Na)+, 50], 405 [(M +Na)+, 100]; HRMS m/z (M + Na)+ calcd for C23H26O5Na 405.1678,found 405.1670.

Concentration of the fraction B [Rf = 0.2(5) in 1:19 v/v ethylacetate/n-hexane] gave compound 48 (83 mg, 83% recovery) as acolorless, crystalline solid that was identical, in all respects, with anauthentic sample.

( 2 a R , 4 a R , 7 S , 7 a R , 7 b S ) - 6 , 6 , 7 b - T r i m e t h y l - 2 - o x o -2,2a,4a,5,6,7,7a,7b-octahydro-1H-cyclobuta[e]inden-7-yl Acetate(54). A magnetically stirred solution of compound 49 (100 mg, 0.38mmol) in dry, deoxygenated dichloromethane (30 mL) maintainedunder a nitrogen atmosphere was irradiated with a Hanovia 100 Wmedium-pressure mercury-vapor lamp (maintained at 5 °C) for 16 h.The reaction mixture was then cooled and concentrated under reducedpressure and the ensuing residue subjected to flash columnchromatography (silica, 1:19 v/v ethyl acetate/n-hexane elution),thus affording two fractions, A and B.

Concentration of the fraction A [Rf = 0.3(5) in 1:19 v/v ethylacetate/n-hexane] gave compound 54 (23 mg, 23% or 92% brsm) as aclear, colorless oil, [α]D = −254.0 (c 3.4, CHCl3).

1H NMR (400MHz, CDCl3) δ 5.73 (m, 1H), 5.48 (m, 1H), 4.97 (d, J = 4.2 Hz, 1H),3.12 (dd, J = 16.2 and 2.1 Hz, 1H), 3.05 (m, 1H), 2.84 (m, 1H), 2.59(dd, J = 9.2 and 4.3 Hz, 1H), 2.51 (dd, J = 16.2 and 6.0 Hz, 1H), 2.01(dd, J = 13.2 and 9.7 Hz, 1H), 1.95 (s, 3H), 1.50 (dd, J = 13.2 and 4.8Hz, 1H), 1.19 (s, 3H), 1.08 (s, 3H), 0.90 (s, 3H); 13C NMR (100MHz, CDCl3) δ 206.4, 170.7, 133.7, 118.2, 83.5, 64.1, 56.7, 45.7, 44.3,43.4, 34.9, 29.0, 28.1, 25.5, 24.3, 21.3; IR νmax 3020, 2966, 2871, 1778,1731, 1373, 1239, 1020, 711 cm−1; MS (ESI, + ve) m/z 285 [(M +Na)+, 100]; HRMS m/z (M + Na)+ calcd for C16H22O3Na 285.1467,found 285.1472.

Concentration of the fraction B (Rf = 0.3 in 1:19 v/v ethyl acetate/n-hexane) gave compound 49 (69 mg, 69% recovery) as a colorless,crystalline solid that was identical, in all respects, with an authenticsample.

(1S,1aR,3aR,6S,6aR,6bR)-5,5,6b-Trimethyl-1,1a,3a,4,5,6,6a,6b-octahydrocyclopropa[e]indene-1,6-diyl Diacetate (55). A magneti-cally stirred solution of compound 50 (40 mg, 0.12 mmol) in dry,deoxygenated dichloromethane (10 mL) maintained under a nitrogenatmosphere was irradiated with a Hanovia 450 W medium-pressure

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8019

Page 199: The Application of Pericyclic, Photolytic, Chemoenzymatic

mercury-vapor lamp for 0.5 h. The reaction mixture was then cooledand concentrated under reduced pressure and the residue thusobtained subjected to flash column chromatography (silica, 1:9 v/vethyl acetate/n-hexane elution). Concentration of the appropriatefractions [Rf = 0.6(5) in 1:9 v/v ethyl acetate/n-hexane] gavecompound 55 (39 mg, 98%) as a clear, colorless oil: [α]D = +167.0 (c0.5, CHCl3);

1H NMR (400 MHz, CDCl3) δ 5.90 (m, 1H), 5.22 (dd, J= 10.0 and 1.9 Hz, 1H), 5.04 (d, J = 3.9 Hz, 1H), 3.77 (d, J = 2.3 Hz,1H), 2.82 (dd, J = 10.1 and 3.9 Hz, 1H), 2.64 (m, 1H), 2.05 (s, 3H),2.00 (s, 3H), 1.90 (dd, J = 13.1 and 9.6 Hz, 1H), 1.33 (dd, J = 13.1 and5.2 Hz, 1H), 1.22 (dd, J = 11.1 and 2.3 Hz, 1H), 1.06 (s, 6H), 0.90 (s,3H); 13C NMR (100 MHz, CDCl3) δ 171.8, 171.1, 129.9, 123.1, 84.0,63.4, 46.6, 42.8, 40.8, 35.4, 28.6, 24.3, 24.2, 22.1, 21.3, 20.9, 15.9; IRνmax 3026, 2966, 2933, 2872, 1733, 1371, 1227 cm−1; MS (ESI, + ve)m/z 347 [(M + MeOH + Na)+, 100%], 331 [(M + K)+, 20], 329 (50),315 [(M + Na)+, 60]; HRMS m/z (M + Na)+ calcd for C17H24O4Na315.1572, found 315.1570.(1S,1aR,3aR,6S,6aR,6bS)-1-((tert-Butyldimethylsilyl)oxy)-5,5,6b-

trimethyl-1,1a,-3a,4,5,6,6a,6b-octahydrocyclopropa[e]inden-6-ylAcetate (56). A magnetically stirred solution of compound 47 (100mg, 0.25 mmol) in dry, deoxygenated dichloromethane (30 mL)maintained under a nitrogen atmosphere was irradiated with a Hanovia450 W medium-pressure mercury-vapor lamp for 1.67 h. The reactionmixture was then cooled, concentrated under reduced pressure and theresidue thus obtained subjected to flash column chromatography(silica, 1:19 v/v ethyl acetate/40−60 petroleum ether) to afford twofractions, A and B.Concentration of the fraction A (Rf = 0.6 in 1:4 v/v ethyl acetate/

40−60 petroleum ether) gave compound 56 (74 mg, 80% or 87%brsm) as a clear, colorless oil: [α]D = −65.5 (c 1.0, CHCl3);

1H NMR[400 MHz, (CD3)2CO] δ 5.92 (m, 1H), 5.11 (dd, J = 10.0 and 2.1 Hz,1H), 5.01 (d, J = 4.1 Hz, 1H), 3.14 (d, J = 2.2 Hz, 1H), 2.78 (m, 1H),2.63 (m, 1H), 1.95 (s, 3H), 1.89 (m, 1H), 1.30 (dd, J = 13.0 and 5.2Hz, 1H), 1.09 (s, 3H), 1.06 (s, 3H), 0.97 (dd, J = 5.5 and 2.4 Hz, 1H),0.90 (s, 9H), 0.87 (s, 3H), 0.10(1) (s, 3H), 0.09(8) (s, 3H); 13C NMR[100 MHz, (CD3)2CO] δ 170.7, 128.9, 125.2, 84.4, 63.9, 47.3, 43.3,41.9, 36.2, 28.9, 27.7, 26.2, 24.7, 23.1, 21.1, 18.6, 15.9, − 4.9 (onesignal obscured or overlapping); IR νmax 3021, 2958, 2930, 2859, 1734,1240, 1153, 859, 835, 776 cm−1; MS (ESI, + ve) m/z 387 [(M + Na)+,100]; HRMS m/z (M + Na)+ calcd for C21H36O3SiNa 387.2331,found 387.2331.Concentration of the fraction B (Rf = 0.5 in 1:4 v/v ethyl acetate/

40−60 petroleum ether) gave compound 47 (8 mg, 8% recovery) as awhite, crystalline solid that was identical, in all respects, with anauthentic sample.(3S,3aR,4R,7S,7aS,9R)-2,2,4-Trimethyl-9-((methylsulfonyl)oxy)-8-

oxo-2,3,3a,4,-7,7a-hexahydro-1H-4,7-ethanoinden-3-yl Acetate(57). A magnetically stirred solution of compound 44 (280 mg, 1.01mmol), methanesulfonyl chloride (94 μL, 1.21 mmol) and triethyl-amine (212 μL, 1.52 mmol) in dichloromethane (5 mL) maintainedunder a nitrogen atmosphere was stirred at 22 °C for 48 h and thenquenched with NH4Cl (10 mL of a saturated aqueous solution) beforebeing extracted with dichloromethane (2 × 50 mL). The combinedorganic fractions were washed with water (2 × 50 mL) and brine (1 ×50 mL) and then dried (MgSO4), filtered, and concentrated underreduced pressure. The residue thus obtained was subjected to flashcolumn chromatography (silica, 1:9 v/v ethyl acetate/40−60petroleum ether elution) to give, after concentration of the appropriatefractions (Rf = 0.3 in 1:9 v/v ethyl acetate/40−60 petroleum ether),compound 57 (198 mg, 56%) as a light-yellow oil: [α]D = +114.0 (c4.3, CHCl3);

1H NMR (400 MHz, CDCl3) δ 6.08 (d, J = 8.1 Hz, 1H),5.95 (t, J = 8.1 Hz, 1H), 5.08 (d, J = 5.9 Hz, 1H), 4.31 (s, 1H), 3.19(m, 1H), 3.17 (s, 3H), 2.69 (m, 1H), 2.58 (dd, J = 10.6 and 6.0 Hz,1H), 2.05 (s, 3H), 1.53 (m, 1H), 1.39 (t, J = 12.0 Hz, 1H), 1.20 (s,3H), 0.98 (s, 3H), 0.85 (s, 3H); 13C NMR (100 MHz, CDCl3) δ204.1, 170.0, 140.9, 121.9, 81.3, 81.0, 50.7, 50.2, 44.9, 42.7, 41.6,39.5(1), 39.4(8), 25.3, 22.1, 21.5, 18.1; IR νmax 2968, 1730, 1358,1238, 1173, 965, 841 cm−1; MS (ESI, + ve) m/z 735 [(2M + Na)+,15], 379 [(M + Na)+, 100]; HRMS m/z (M + Na)+ calcd forC17H24O6SNa 379.1191, found 379.1193.

(1R,2a1S,2cR,5S,5aR,5bR)-4,4,5b-Trimethyl-1-((methylsulfonyl)-oxy)-2-oxodeca-hydro-1H-cyclopenta[a]cyclopropa[cd]pentalen-5-yl Acetate (58). A magnetically stirred solution of compound 57 (100mg, 0.28 mmol) in dry, deoxygenated dichloromethane (30 mL)maintained under a nitrogen atmosphere was irradiated with a Hanovia100 W medium-pressure mercury-vapor lamp (maintained at 5 °C) for12 h. The reaction mixture was then cooled and concentrated underreduced pressure and the residue thus obtained subjected to flashcolumn chromatography (silica, 1:9 v/v ethyl acetate/n-hexaneelution) to afford two fractions, A and B.

Concentration of the fraction A [Rf = 0.4(5) in 1:9 v/v ethylacetate/n-hexane] gave compound 58 (48 mg, 48% or 98% brsm) as aclear, colorless oil: [α]D = +161.0 (c 1.0, CHCl3).

1H NMR (400 MHz,CDCl3) δ 5.54 (s, 1H), 5.09 (d, J = 4.8 Hz, 1H), 3.05 (s, 3H), 2.85−2.72 (complex m, 2H), 2.50 (d, J = 4.8 Hz, 1H), 2.23 (s, 3H), 2.18 (s,1H), 1.71 (d, J = 4.8 Hz, 1H), 1.59 (dd, J = 8.7 and 2.3 Hz, 2H), 1.07(s, 3H), 0.97(2) (s, 3H), 0.96(7) (s, 3H); 13C NMR (100 MHz,CDCl3) δ 211.1, 170.2, 80.9, 78.8, 50.4, 45.2, 42.5, 42.4, 41.1, 39.3,37.6, 36.1, 32.9, 25.1, 22.7, 22.5, 21.2; IR νmax 2966, 2936, 2875, 1729,1356, 1236, 1172, 917, 842 cm−1; MS m/z 735 [(2M + Na)+, 5], 379[(M + Na)+, 100]; HRMS m/z (M + Na)+ calcd for C17H24O6SNa379.1191, found 379.1189.

Concentration of the fraction B (Rf = 0.3 in 1:9 v/v ethyl acetate/n-hexane) gave compound 57 (50 mg, 50% recovery) as a clear, colorlessoil that was identical, in all respects, with an authentic sample.

X-ray Crystallographic Studies. Crystallographic Data. Com-pound 8: C9H12O3, M = 168.19, T = 150 K, orthorhombic, spacegroup P212121, Z = 4, a = 7.3238(1) Å, b = 7.5553(1) Å, c =14.5389(2) Å; V = 804.49(2) Å3, Dx = 1.389 g cm−3, 1585 unique data(2θmax = 144.6°), R = 0.023 [for 1569 reflections with I > 2.0σ(I)]; Rw

= 0.057 (all data), S = 1.00.Compound 9: C15H26O3Si, M = 282.46, T = 150 K, monoclinic,

space group C2, Z = 4, a = 18.9377(5) Å, b = 6.2442(1) Å, c =14.6275(5) Å; β = 105.950(3)°; V = 1663.12(8) Å3, Dx = 1.128 gcm−3, 3042 unique data (2θmax = 144.8°), R = 0.032 [for 2889reflections with I > 2.0σ(I)]; Rw = 0.080 (all data), S = 0.99.

Compound 10: C9H12O3, M = 168.19, T = 150 K, orthorhombic,space group P212121, Z = 8, a = 8.23350(7) Å, b = 8.68949(8) Å, c =23.6396(2) Å; V = 1691.29(3) Å3, Dx = 1.321 g cm−3, 3334 uniquedata (2θmax = 144.6°), R = 0.04 [for 3257 reflections with I > 2.0σ(I)];Rw = 0.112 (all data), S = 1.01.

Compound 13: C14H26O2Si,M = 254.45, T = 150 K, orthorhombic,space group P21212, Z = 8, a = 18.3637(1) Å, b = 14.1093(1) Å, c =12.0122(1) Å; V = 3112.35(4) Å3, Dx = 1.086 g cm−3, 6159 uniquedata (2θmax = 145.0°), R = 0.025 [for 6101 reflections with I >2.0σ(I)]; Rw = 0.067 (all data), S = 1.01.

Compound 23: C13H16O3, M = 220.27, T = 150 K, orthorhombic,space group P212121, Z = 4, a = 7.27015(5) Å, b = 11.05109(8) Å, c =13.78627(9) Å; V = 1107.63(1) Å3, Dx = 1.321 g cm−3, 2186 uniquedata (2θmax = 144.8°), R = 0.022 [for 2152 reflections with I >2.0σ(I)]; Rw = 0.057 (all data), S = 1.01.Compound 27: C13H16O3, M = 220.27, T = 200 K, monoclinic,

space group P21, Z = 2, a = 7.2003(2) Å, b = 8.4682(2) Å, c =9.4258(3) Å; β = 91.1279(17)°; V = 574.61(3) Å3, Dx = 1.273 g cm−3,1778 unique data (2θmax = 60.0°), R = 0.048 [for 1655 reflections withI > 2.0σ(I)]; Rw = 0.156 (all data), S = 1.03.

Compound 30: C11H12O3, M = 192.21, T = 150 K, monoclinic,space group P21, Z = 2, a = 8.4949(4) Å, b = 5.9702(2) Å, c =9.3840(4) Å; β = 95.383(4)°; V = 473.82(3) Å3, Dx = 1.347 g cm−3,1032 unique data (2θmax = 144.8°), R = 0.045 [for 998 reflections withI > 2.0σ(I)]; Rw = 0.130 (all data), S = 1.03.

Compound 32: C10H12O2, M = 164.20, T = 150 K, orthorhombic,space group P212121, Z = 4, a = 7.8054(1) Å, b = 9.7920(1) Å, c =11.0580(1) Å; V = 845.17(2) Å3, Dx = 1.290 g cm−3, 1677 unique data(2θmax = 144.6°), R = 0.022 [for 1645 reflections with I > 2.0σ(I)]; Rw

= 0.057 (all data), S = 1.01.Compound 34: C11H12O3, M = 192.21, T = 150 K, monoclinic,

space group P21, Z = 2, a = 6.9303(2) Å, b = 7.7696(2) Å, c =8.6272(2) Å; β = 92.403(2)°; V = 464.13(2) Å3, Dx = 1.375 g cm−3,

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8020

Page 200: The Application of Pericyclic, Photolytic, Chemoenzymatic

993 unique data (2θmax = 145.2°), R = 0.037 [for 980 reflections with I> 2.0σ(I)]; Rw = 0.117 (all data), S = 1.04.Compound 35: C13H16O3, M = 220.27, T = 150 K, orthorhombic,

space group P212121, Z = 4, a = 7.3877(1) Å, b = 7.8178(1) Å, c =19.8494(2) Å; V = 1146.41(2) Å3, Dx = 1.276 g cm−3, 2267 uniquedata (2θmax = 144.8°), R = 0.030 [for 2238 reflections with I >2.0σ(I)]; Rw = 0.056 (all data), S = 1.00.Compound 36: C11H12O3, M = 192.21, T = 150 K, orthorhombic,

space group P212121, Z = 4, a = 7.4666(2) Å, b = 12.0831(5) Å, c =10.8645(4) Å; V = 980.19(6) Å3, Dx = 1.302 g cm−3, 1491 unique data(2θmax = 58.4°), R = 0.047 [for 1303 reflections with I > 2.0σ(I)]; Rw =0.108 (all data), S = 1.00.Compound 38: C10H12O2, M = 164.20, T = 150 K, hexagonal,

space group P65, Z = 6, a = 14.7787(4) Å, c = 7.6213(2) Å; V =1441.56(7) Å3, Dx = 1.135 g cm−3, 1379 unique data (2θmax = 58.8°),R = 0.045 [for 1283 reflections with I > 2.0σ(I)]; Rw = 0.111 (all data),S = 1.03.Compound 41: C17H26O3, M = 278.39, T = 150 K, orthorhombic,

space group P212121, Z = 4, a = 6.26451(4) Å, b = 12.09608(9) Å, c =20.26568(14) Å; V = 1535.65(2) Å3, Dx = 1.204 g cm−3, 3025 uniquedata (2θmax = 144.6°), R = 0.024 [for 2974 reflections with I >2.0σ(I)]; Rw = 0.062 (all data), S = 1.00.Compound 44: C16H22O4, M = 278.35, T = 150 K, orthorhombic,

space group P212121, Z = 4, a = 6.4307(1) Å, b = 8.7685(1) Å, c =26.1929(2) Å; V = 1476.95(3) Å3, Dx = 1.252 g cm−3, 2913 uniquedata (2θmax = 144.8°), R = 0.024 [for 2859 reflections with I >2.0σ(I)]; Rw = 0.063 (all data), S = 1.00.Compound 45: C18H24O5, M = 320.39, T = 150 K, monoclinic,

space group P21, Z = 2, a = 7.4300(3) Å, b = 9.7667(3) Å, c =12.1277(3) Å; β = 92.279(3)°; V = 879.37(5) Å3, Dx = 1.210 g cm−3,2377 unique data (2θmax = 58.6°), R = 0.038 [for 2242 reflections withI > 2.0σ(I)]; Rw = 0.093 (all data), S = 1.02.Compound 47: C22H36O4Si,M = 392.61, T = 150 K, orthorhombic,

space group P212121, Z = 4, a = 25.6494(7) Å, b = 14.1949(4) Å, c =6.2343(2) Å; V = 2269.85(11) Å3, Dx = 1.149 g cm−3, 5914 uniquedata (2θmax = 58.8°), R = 0.045 [for 5443 reflections with I > 2.0σ(I)];Rw = 0.102 (all data), S = 1.04.Compound 48: C23H26O5, M = 382.46, T = 150 K, orthorhombic,

space group P212121, Z = 4, a = 19.9195(6) Å, b = 11.6626(3) Å, c =8.7386(2) Å; V = 2030.09(9) Å3, Dx = 1.251 g cm−3, 2980 unique data(2θmax = 58.6°), R = 0.041 [for 2759 reflections with I > 2.0σ(I)]; Rw =0.101 (all data), S = 1.03.Compound 53: C23H26O5, M = 382.46, T = 150 K, orthorhombic,

space group P212121, Z = 4, a = 8.9344(2) Å, b = 15.4099(3) Å, c =14.9268(3) Å; V = 2055.09(7) Å3, Dx = 1.236 g cm−3, 3065 uniquedata (2θmax = 59.0°), R = 0.042 [for 2868 reflections with I > 2.0σ(I)];Rw = 0.112 (all data), S = 1.04.Structure Determination. Images for compound 27, 36, 38, 45, 47,

48, and 53 were measured on a diffractometer (Mo Kα, graphitemonochromator, λ = 0.71073 Å) fitted with an area detector and thedata extracted using the DENZO/Scalepack or CrysAlis package.15

Images for compounds 8, 9, 10, 13, 23, 30, 32, 34, 35, 41, and 44 weremeasured on a diffractometer (Cu Kα, mirror monochromator, λ=1.54184 Å) fitted with an area detector and the data extracted usingthe CrysAlis package.16 The structure solutions for all six compoundswere solved by direct methods (SIR92)17 then refined using theCRYSTALS program package.18 Atomic coordinates, bond lengthsand angles, and displacement parameters have been deposited at theCambridge Crystallographic Data Centre (CCDC nos. 1545223,154224, 1545225, 1545226, 1545227, 1545228, 1545229, 1545230,1545231, 1545232, 1545233, 1545234, 1545235, 1545236, 1545237,1545238, 1545239 and 1545240). These data can be obtained free ofcharge via www.ccdc.cam.ac.uk/data_request/cif, by emailing [email protected], or by contacting the Cambridge Crystallo-graphic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

■ ASSOCIATED CONTENT*S Supporting InformationThe Supporting Information is available free of charge on theACS Publications website at DOI: 10.1021/acs.joc.7b01243.

Anisotropic displacement ellipsoid plots from the single-crystal X-ray analyses of compounds 8−10, 13, 23, 27,30, 32, 34−36, 38, 41, 44, 45, 47, 48, and 53; 1H and13C NMR spectra of compounds 8−39 and 42−58(PDF)X-ray crystallographic data for compounds 8−10, 13, 23,27, 30, 32, and 34 (CIF)X-ray crystallographic data for compounds 35, 36, 38, 41,44, 45, 47, 48, and 53 (CIF)

■ AUTHOR INFORMATIONCorresponding Author*Tel: +61-2-6125-8202. Fax: +61-2-6125-8114. E-mail: [email protected] G. Banwell: 0000-0002-0582-475XNotesThe authors declare no competing financial interest.

■ ACKNOWLEDGMENTSWe thank the Australian Research Council and the Institute ofAdvanced Studies for financial support. Q.Y. is the gratefulrecipient of a CSC PhD Scholarship provided by theGovernment of the People’s Republic of China.

■ REFERENCES(1) For a relevant and recent review, see: Banwell, M. G.; Bon, D. J.-Y. D. Applications of the Di-π-Methane and Related RearrangementReactions in Chemical Synthesis. In Molecular Rearrangements inOrganic Synthesis; Rojas, C. M., Ed.; Wiley: Hoboken, NJ, 2015;Chapter 9, pp 261−288.(2) Luo, S.-Y.; Jang, Y.-J.; Liu, J.-Y.; Chu, C.-S.; Liao, C.-C.; Hung, S.-C. Angew. Chem., Int. Ed. 2008, 47, 8082 and references cited therein.(3) For reviews on cis-1,2-dihydrocatechols, see: (a) Johnson, R. A.Org. React. 2004, 63, 117. (b) Hudlicky, T.; Reed, J. W. Synlett 2009,2009, 685. (c) Lewis, S. E. Chem. Commun. 2014, 50, 2821.(d) Banwell, M. G.; Bolte, B.; Buckler, J. N.; Chang, E. L.; Lan, P.;Taher, E. S.; White, L. V.; Willis, A. C. J. Proc. R. Soc. New South Wales2016, 149, 34.(4) (a) Banwell, M. G.; Edwards, A. J.; Harfoot, G. J.; Jolliffe, K. A.Tetrahedron 2004, 60, 535. (b) Banwell, M. G.; Austin, K. A. B.; Willis,A. C. Tetrahedron 2007, 63, 6388. (c) Reekie, T. A.; Austin, K. A. B.;Banwell, M. G.; Willis, A. C. Aust. J. Chem. 2008, 61, 94. (d) Bon, D. J.-Y. D.; Banwell, M. G.; Willis, A. C. Tetrahedron 2010, 66, 7807.(e) Bon, D. J.-Y. D.; Banwell, M. G.; Cade, I. A.; Willis, A. C.Tetrahedron 2011, 67, 8348. (f) Bon, D. J.-Y. D.; Banwell, M. G.;Ward, J. S.; Willis, A. C. Tetrahedron 2013, 69, 1363.(5) (a) Schwartz, B. D.; Matousova, E.; White, R.; Banwell, M. G.;Willis, A. C. Org. Lett. 2013, 15, 1934. (b) Chang, E. L.; Bolte, B.; Lan,P.; Willis, A. C.; Banwell, M. G. J. Org. Chem. 2016, 81, 2078.(6) Lan, P.; Banwell, M. G.; Willis, A. C. Org. Lett. 2015, 17, 166.(7) Yan, Q.; Banwell, M. G.; Coote, M. L.; Lee, R.; Willis, A. C.Chem. - Asian J. 2017, 12, 1480.(8) Banwell, M. G.; Chun, C.; Edwards, A. J.; Vogtle, M. M. Aust. J.Chem. 2003, 56, 861.(9) Ireland, R. E.; Liu, L. J. Org. Chem. 1993, 58, 2899.(10) This protocol is based on one first described by Ma and Bobbitt:Ma, Z.; Bobbitt, J. M. J. Org. Chem. 1991, 56, 6110. For examples ofrelated oxidations see refs 4b−d.

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8021

Page 201: The Application of Pericyclic, Photolytic, Chemoenzymatic

(11) Ravelli, D.; Fagnoni, M. Photochemistry of Phosphate andSulfonate Esters In CRC Handbook of Organic Photochemistry, 3rd ed.;Griesbeck, A., Oelgemoller, M., Ghetti, F., Ed.; CRC Press, BocaRaton, FL, 2012; Chapter 17, pp 393−417.(12) Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.(13) Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.;Timmers, F. J. Organometallics 1996, 15, 1518.(14) Foley, D. A.; O’Leary, P.; Buckley, N. R.; Lawrence, S. E.;Maguire, A. R. Tetrahedron 2013, 69, 1778.(15) DENZO−SMN: Otwinowski, Z.; Minor, W. Processing of X-raydiffraction data collected in oscillation mode. In Methods inEnzymology; Carter, C. W., Jr., Sweet, R. M., Eds.; Academic Press:New York, 1997; Vol. 276: Macromolecular Crystallography, Part A,pp 307−326.(16) CrysAlis PRO, version 1.171.37.35h (release 09-02-2015CrysAlis171.NET) (compiled Feb 9 2015, 16:26:32) AgilentTechnologies: Oxfordshire, UK, 2015.(17) SIR92: Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi,A.; Burla, M. C.; Polidori, G.; Camalli, M. J. Appl. Crystallogr. 1994, 27,435.(18) Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.;Watkin, D. J. J. Appl. Crystallogr. 2003, 36, 1487.

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b01243J. Org. Chem. 2017, 82, 8008−8022

8022

Page 202: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 203: The Application of Pericyclic, Photolytic, Chemoenzymatic

S1

SUPP

ORT

ING

INFO

RMAT

ION

FO

R:

Stud

ies o

n th

e Ph

otoc

hem

ical

Rea

rran

gem

ents

of E

nant

iom

eric

ally

Pur

e, P

olys

ubst

itute

d an

d V

ario

usly

Ann

ulat

ed

Bic

yclo

[2.2

.2]o

cten

ones

Qia

o Y

an, B

enoi

t Bol

te, Y

uhua

Bai

, Mar

tin G

. Ban

wel

l* A

ntho

ny C

. Will

is a

nd P

aul D

. Car

r

Rese

arch

Sch

ool o

f Che

mis

try,

Inst

itute

of A

dvan

ced

Stud

ies,

The

Aust

ralia

n N

atio

nal U

nive

rsity

, Can

berr

a, A

CT

2601

, Aus

tral

ia

CO

NT

EN

TS

PA

GE

(i)A

niso

tropi

c D

ispl

acem

ent E

llips

oid

Plot

s fro

m th

e Si

ngle

-cry

stal

X-r

ay

Ana

lyse

s of C

ompo

unds

8, 9

, 10,

13,

23,

27,

30,

32,

34,

35,

36,

38,

41,

44, 4

5, 4

7, 4

8 an

d 53

S

2

(ii)

1 H a

nd 13

C N

MR

Spe

ctra

of C

ompo

unds

8-3

9 an

d 42

-58

S

20

184

Page 204: The Application of Pericyclic, Photolytic, Chemoenzymatic

S2

Figu

re S

1: S

truct

ure

of c

ompo

und

8 (C

CD

C 1

5452

23) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.

185

Page 205: The Application of Pericyclic, Photolytic, Chemoenzymatic

S3

Figu

re S

2: S

truct

ure

of c

ompo

und

9 (C

CD

C 1

5452

24) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.

186

Page 206: The Application of Pericyclic, Photolytic, Chemoenzymatic

S4

Figu

re S

3: S

truct

ure

of c

ompo

und

10 (C

CD

C 1

5452

25) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.

187

Page 207: The Application of Pericyclic, Photolytic, Chemoenzymatic

S5

Figu

re S

4: S

truct

ure

of c

ompo

und

13 (C

CD

C 1

5452

26) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

188

Page 208: The Application of Pericyclic, Photolytic, Chemoenzymatic

S6

Figu

re S

5: S

truct

ure

of c

ompo

und

23 (C

CD

C15

4522

7) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

189

Page 209: The Application of Pericyclic, Photolytic, Chemoenzymatic

S7

Figu

re S

6: S

truct

ure

of c

ompo

und

27 (C

CD

C 1

5452

28) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.  

190

Page 210: The Application of Pericyclic, Photolytic, Chemoenzymatic

S8

Figu

re S

7: S

truct

ure

of c

ompo

und

30 (C

CD

C 1

5452

29) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

191

Page 211: The Application of Pericyclic, Photolytic, Chemoenzymatic

S9

Figu

re S

8: S

truct

ure

of c

ompo

und

32 (C

CD

C 1

5452

30) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

192

Page 212: The Application of Pericyclic, Photolytic, Chemoenzymatic

S10

Figu

re S

9: S

truct

ure

of c

ompo

und

34 (C

CD

C15

4523

1) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

193

Page 213: The Application of Pericyclic, Photolytic, Chemoenzymatic

S11

Figu

re S

10: S

truct

ure

of c

ompo

und

35 (C

CD

C 1

5452

32) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

194

Page 214: The Application of Pericyclic, Photolytic, Chemoenzymatic

S12

Figu

re S

11: S

truct

ure

of c

ompo

und

36 (C

CD

C 1

5452

33) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

195

Page 215: The Application of Pericyclic, Photolytic, Chemoenzymatic

S13

Figu

re S

12: S

truct

ure

of c

ompo

und

38 (C

CD

C 1

5452

34) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

196

Page 216: The Application of Pericyclic, Photolytic, Chemoenzymatic

S14

Figu

re S

13: S

truct

ure

of c

ompo

und

41 (C

CD

C15

4523

5) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

197

Page 217: The Application of Pericyclic, Photolytic, Chemoenzymatic

S15

Figu

re S

14: S

truct

ure

of c

ompo

und

44 (C

CD

C15

4523

6) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

198

Page 218: The Application of Pericyclic, Photolytic, Chemoenzymatic

S16

Figu

re S

15: S

truct

ure

of c

ompo

und

45 (C

CD

C15

4523

7) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

199

Page 219: The Application of Pericyclic, Photolytic, Chemoenzymatic

S17

Figu

re S

16: S

truct

ure

of c

ompo

und

47 (C

CD

C15

4523

8) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

200

Page 220: The Application of Pericyclic, Photolytic, Chemoenzymatic

S18

Figu

re S

17: S

truct

ure

of c

ompo

und

48 (C

CD

C 1

5452

39) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

201

Page 221: The Application of Pericyclic, Photolytic, Chemoenzymatic

S19

Figu

re S

18: S

truct

ure

of c

ompo

und

53 (C

CD

C15

4524

0) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

202

Page 222: The Application of Pericyclic, Photolytic, Chemoenzymatic

S20

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.02

1.001.031.001.001.00

1.00

1.00

3.31 CD3OD_SPE

203

Page 223: The Application of Pericyclic, Photolytic, Chemoenzymatic

S21

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

220

f1 (

ppm

)

21.4544.1746.2846.3047.0047.7548.36 MeOD48.57 MeOD48.79 MeOD49.00 MeOD49.21 MeOD49.43 MeOD49.64 MeOD

86.3288.16

217.26

204

Page 224: The Application of Pericyclic, Photolytic, Chemoenzymatic

S22

-1

.0-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.5f1

(ppm

)

6.00

9.01

3.00

1.061.051.021.001.011.00

1.01

1.00

7.26 CDCl3

205

Page 225: The Application of Pericyclic, Photolytic, Chemoenzymatic

S23

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

02

30

24

02

50

f1 (

ppm

)

-5.55

17.1520.3524.87

42.2144.4244.9845.0445.26

76.00 CDCl376.16 CDCl376.32 CDCl385.7786.79

213.26

44

.54

5.0

45

.5f1

(ppm

)44.42

44.9845.04

45.26

206

Page 226: The Application of Pericyclic, Photolytic, Chemoenzymatic

S24

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.03

1.01

1.011.021.00

1.001.00

1.00

3.31 MeOD

207

Page 227: The Application of Pericyclic, Photolytic, Chemoenzymatic

S25

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

220

f1 (

ppm

)

19.98

30.1748.36 MeOD48.57 MeOD48.79 MeOD49.00 MeOD49.21 MeOD49.42 MeOD49.64 MeOD50.0860.96

73.5576.15

116.70

140.16

209.02

208

Page 228: The Application of Pericyclic, Photolytic, Chemoenzymatic

S26

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.003.00

9.00

3.00

1.001.001.001.00

1.001.001.00

1.00

7.26 CDCl3

209

Page 229: The Application of Pericyclic, Photolytic, Chemoenzymatic

S27

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

-4.22-3.82

18.2519.1325.9429.89

50.18

60.62

73.3676.84 CDCl377.16 CDCl377.48 CDCl377.86

115.06

138.35

207.02

-4

.5-4

.0-3

.5f1

(ppm

)

-4.22

-3.82

210

Page 230: The Application of Pericyclic, Photolytic, Chemoenzymatic

S28

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10

.0f1

(ppm

)

1.00

1.00

2.003.012.00

2.01

1.00

7.26 CDCl3

211

Page 231: The Application of Pericyclic, Photolytic, Chemoenzymatic

S29

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

10.9518.7019.6021.35

70.1173.3376.84 CDCl377.16 CDCl377.48 CDCl3

127.84130.34

212

Page 232: The Application of Pericyclic, Photolytic, Chemoenzymatic

S30

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.003.001.01

9.031.012.03

3.00

1.00

1.00

1.00

1.00

7.26 CDCl3

213

Page 233: The Application of Pericyclic, Photolytic, Chemoenzymatic

S31

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

-4.62-4.10

12.0218.3018.7419.2519.6326.04

74.0275.1076.84 CDCl377.16 CDCl377.48 CDCl3

124.66

134.38

-5

05

10

15

20

f1 (

ppm

)

-4.62-4.10

12.02

18.3018.7419.2519.63

214

Page 234: The Application of Pericyclic, Photolytic, Chemoenzymatic

S32

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

9.09

2.004.001.03

2.01

7.26 CDCl3

215

Page 235: The Application of Pericyclic, Photolytic, Chemoenzymatic

S33

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

18.1718.1919.77

68.0369.7076.84 CDCl377.16 CDCl377.48 CDCl3

121.91122.40122.55123.01126.72134.79

145.37145.61

165.89166.09

**

*

* i

mpuri

ty

16

5.8

16

6.0

16

6.2

f1 (

ppm

)165.89

166.09

12

21

23

f1 (

ppm

)

121.91122.40122.55123.01

216

Page 236: The Application of Pericyclic, Photolytic, Chemoenzymatic

S34

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

12.01

3.08

2.05

2.013.011.001.00

2.00

7.26 CDCl3

217

Page 237: The Application of Pericyclic, Photolytic, Chemoenzymatic

S35

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

19.7721.2221.2631.0331.06

68.0369.5276.84 CDCl377.16 CDCl377.48 CDCl3

118.14118.32121.93123.01126.56134.65

156.22156.49

166.25166.50

31

.03

1.1 f1

(ppm

)31.0331.06

21

.12

1.2

21

.32

1.4

f1 (

ppm

)21.2221.26

16

01

65

f1 (

ppm

)

156.22156.49

166.25166.50

11

8.0

11

8.2

11

8.4 f1

(ppm

)

118.14

118.32

218

Page 238: The Application of Pericyclic, Photolytic, Chemoenzymatic

S36

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.00

3.001.003.00

1.00

1.00

1.00

1.00

2.00

1.00

1.00

7.26 CDCl3

219

Page 239: The Application of Pericyclic, Photolytic, Chemoenzymatic

S37

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

18.2419.8420.89

33.5141.8745.3552.17

70.5576.84 CDCl376.9977.16 CDCl377.48 CDCl3

122.08

131.86133.75

145.97

165.86

179.27

76

.57

7.0

77

.5f1

(ppm

)

76.84 CDCl376.9977.16 CDCl3

77.48 CDCl3

220

Page 240: The Application of Pericyclic, Photolytic, Chemoenzymatic

S38

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.003.013.003.001.013.00

2.00

1.00

1.00

0.981.00

2.00

1.00

1.00

7.26 CDCl3

221

Page 241: The Application of Pericyclic, Photolytic, Chemoenzymatic

S39

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.7120.8020.9421.2021.2630.5231.1438.7745.1346.8849.67

70.5676.84 CDCl377.16 CDCl377.2777.48 CDCl3

117.87

132.19133.09

156.82

166.50

179.26

76

.57

7.0

77

.57

8.0

f1 (

ppm

)

76.84 CDCl377.16 CDCl377.2777.48 CDCl3

20

.52

1.0

21

.5f1

(ppm

)

20.7120.8020.9421.2021.26

222

Page 242: The Application of Pericyclic, Photolytic, Chemoenzymatic

S40

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10

.0f1

(ppm

)

3.04

3.03

3.011.001.00

1.00

1.00

1.00

1.00

2.00

0.98

7.26 CDCl3

223

Page 243: The Application of Pericyclic, Photolytic, Chemoenzymatic

S41

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

17.1218.2319.03

37.0240.7642.1546.89

72.9573.4076.84 CDCl377.16 CDCl377.48 CDCl3

122.05125.47

139.53

145.84

165.99

179.27

224

Page 244: The Application of Pericyclic, Photolytic, Chemoenzymatic

S42

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.00

3.013.013.003.00

0.991.011.021.03

1.00

1.00

1.00

1.000.991.00

1.00

7.26 CDCl3

225

Page 245: The Application of Pericyclic, Photolytic, Chemoenzymatic

S43

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

19.1119.8821.2021.2722.7527.3731.1440.2240.6242.2447.96

72.8574.4376.84 CDCl377.16 CDCl377.48 CDCl3

117.83

124.60

140.28

156.79

166.73

179.74

40

41 f1

(ppm

)40.2240.62

21

.02

1.2

21

.4f1

(ppm

)21.2021.27

226

Page 246: The Application of Pericyclic, Photolytic, Chemoenzymatic

S44

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.00

3.02

1.001.001.00

1.00

1.00

1.00

2.00

7.26 CDCl3

227

Page 247: The Application of Pericyclic, Photolytic, Chemoenzymatic

S45

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

17.2818.77

36.4740.3644.0746.93

71.8574.8976.84 CDCl377.16 CDCl377.48 CDCl3

124.24

141.19

178.94

228

Page 248: The Application of Pericyclic, Photolytic, Chemoenzymatic

S46

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.023.013.00

2.00

1.00

1.01

1.00

1.00

0.99

1.00

7.26 CDCl3

229

Page 249: The Application of Pericyclic, Photolytic, Chemoenzymatic

S47

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

18.8319.7722.7127.33

40.1740.2344.0347.58

72.9074.8476.84 CDCl377.16 CDCl377.48 CDCl3

123.32

141.84

179.28

40

.14

0.2

40

.3f1

(ppm

)

40.17

40.23

230

Page 250: The Application of Pericyclic, Photolytic, Chemoenzymatic

S48

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.05

3.03

1.00

1.00

1.01

0.97

1.00

1.00

7.26 CDCl3

231

Page 251: The Application of Pericyclic, Photolytic, Chemoenzymatic

S49

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.1616.14

40.9341.2547.1353.78

73.9476.84 CDCl377.16 CDCl377.48 CDCl3

128.31

136.74

177.81

201.54

40

.84

1.2

f1 (

ppm

)

40.93

41.25

232

Page 252: The Application of Pericyclic, Photolytic, Chemoenzymatic

S50

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.5f1

(ppm

)

3.003.003.00

1.001.00

1.01

1.00

0.97

1.001.00

7.26 CDCl3

233

Page 253: The Application of Pericyclic, Photolytic, Chemoenzymatic

S51

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

15.3119.9622.7628.20

40.4440.89

51.7353.58

73.9076.84 CDCl377.16 CDCl377.48 CDCl3

127.28

136.75

178.45

200.65

234

Page 254: The Application of Pericyclic, Photolytic, Chemoenzymatic

S52

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.07

3.07

1.00

1.93

1.02

1.00

1.00

1.00

1.02

7.26 CDCl3

235

Page 255: The Application of Pericyclic, Photolytic, Chemoenzymatic

S53

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.0721.14

33.09

44.9845.1552.19

69.0276.84 CDCl377.16 CDCl377.48 CDCl379.01

130.77

135.35

178.98

44

.54

5.0

45

.5f1

(ppm

)

44.98

45.15

236

Page 256: The Application of Pericyclic, Photolytic, Chemoenzymatic

S54

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

f1 (

ppm

)

3.003.001.003.00

2.00

1.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

237

Page 257: The Application of Pericyclic, Photolytic, Chemoenzymatic

S55

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.7620.8021.14

30.72

41.6644.9346.4449.74

68.9376.84 CDCl377.16 CDCl377.48 CDCl379.30

131.06134.61

179.05

20

24

f1 (

ppm

)

20.7620.8021.14

238

Page 258: The Application of Pericyclic, Photolytic, Chemoenzymatic

S56

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.5f1

(ppm

)

3.04

3.04

1.00

1.00

1.00

1.00

1.00

1.01

7.26 CDCl3

239

Page 259: The Application of Pericyclic, Photolytic, Chemoenzymatic

S57

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

18.3619.86

37.20

46.5051.9353.98

76.84 CDCl377.16 CDCl377.48 CDCl378.45

130.43134.54

177.67

199.95

240

Page 260: The Application of Pericyclic, Photolytic, Chemoenzymatic

S58

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.043.08

1.023.01

1.05

1.00

1.01

1.00

1.00

1.01

7.26 CDCl3

241

Page 261: The Application of Pericyclic, Photolytic, Chemoenzymatic

S59

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

19.9320.4420.63

29.21

46.2349.3850.2051.14

76.84 CDCl377.16 CDCl377.48 CDCl378.82

129.78

134.75

177.72

200.35

17

18

19

20

21

22

23

f1 (

ppm

)

19.9320.4420.63

242

Page 262: The Application of Pericyclic, Photolytic, Chemoenzymatic

S60

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.003.01

1.00

1.031.031.00

1.02

0.97

7.26 CDCl3

243

Page 263: The Application of Pericyclic, Photolytic, Chemoenzymatic

S61

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

18.3619.50

38.0644.7245.0045.1346.11

57.15

76.84 CDCl377.16 CDCl377.48 CDCl382.42

176.80

206.93

44

.54

5.0

45

.5f1

(ppm

)44.7245.0045.13

244

Page 264: The Application of Pericyclic, Photolytic, Chemoenzymatic

S62

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.023.013.00

1.021.011.001.00

1.01

1.02

1.00

7.26 CDCl3

245

Page 265: The Application of Pericyclic, Photolytic, Chemoenzymatic

S63

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

16.9919.5422.0529.19

38.3043.9545.6246.6347.8054.96

76.84 CDCl377.16 CDCl377.48 CDCl382.45

177.40

206.92

246

Page 266: The Application of Pericyclic, Photolytic, Chemoenzymatic

S64

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.12

3.16

1.02

1.04

1.03

1.00

0.991.00

7.26 CDCl3

247

Page 267: The Application of Pericyclic, Photolytic, Chemoenzymatic

S65

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

19.7922.9926.7633.87

43.33

58.84

76.84 CDCl377.16 CDCl377.48 CDCl3

89.75

112.85

140.60

177.49

200.30

248

Page 268: The Application of Pericyclic, Photolytic, Chemoenzymatic

S66

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10

.0f1

(ppm

)

3.013.00

3.011.01

1.02

1.03

1.03

1.00

1.00

1.00

7.26 CDCl3

249

Page 269: The Application of Pericyclic, Photolytic, Chemoenzymatic

S67

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

19.6021.6024.4628.3230.8038.1445.94

59.43

76.84 CDCl377.16 CDCl377.48 CDCl3

89.14

114.73

138.87

178.72

200.43

250

Page 270: The Application of Pericyclic, Photolytic, Chemoenzymatic

S68

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.091.013.011.021.03

1.03

1.01

1.00

7.26 CDCl3

251

Page 271: The Application of Pericyclic, Photolytic, Chemoenzymatic

S69

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

11.6017.7518.7222.41

35.94

44.71

60.46

76.84 CDCl377.16 CDCl377.48 CDCl3

112.67

142.67

180.28

252

Page 272: The Application of Pericyclic, Photolytic, Chemoenzymatic

S70

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.5f1

(ppm

)

3.003.00

1.003.003.00

1.00

1.00

1.00

7.26 CDCl3

253

Page 273: The Application of Pericyclic, Photolytic, Chemoenzymatic

S71

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

13.5218.0219.9021.7424.1530.69

40.31

47.57

61.36

76.84 CDCl377.16 CDCl377.48 CDCl3

114.80

141.14

181.06

254

Page 274: The Application of Pericyclic, Photolytic, Chemoenzymatic

S72

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.023.01

1.001.003.00

1.00

7.26 CDCl3

255

Page 275: The Application of Pericyclic, Photolytic, Chemoenzymatic

S73

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

20.8222.61

35.5737.9640.3142.55

54.98

64.34

76.84 CDCl377.16 CDCl377.48 CDCl3

87.70

176.50

206.86

256

Page 276: The Application of Pericyclic, Photolytic, Chemoenzymatic

S74

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.013.00

3.00

1.001.002.001.001.00

0.97

7.26 CDCl3

257

Page 277: The Application of Pericyclic, Photolytic, Chemoenzymatic

S75

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

19.3520.1920.58

32.8835.4737.2837.44

53.6754.6359.12

76.84 CDCl377.16 CDCl377.48 CDCl3

87.59

176.81

207.11

18

20

22

24

26

28

30

32

34

36

38

f1 (

ppm

)

19.3520.1920.58

32.88

35.4737.2837.44

258

Page 278: The Application of Pericyclic, Photolytic, Chemoenzymatic

S76

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.15

3.09

1.04

1.04

1.01

1.00

1.02

1.02

7.26 CDCl3

259

Page 279: The Application of Pericyclic, Photolytic, Chemoenzymatic

S77

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

21.1624.9130.0535.52

48.51

63.83

76.84 CDCl377.16 CDCl377.48 CDCl3

93.49

119.06

132.58

177.74

200.14

260

Page 280: The Application of Pericyclic, Photolytic, Chemoenzymatic

S78

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.083.06

1.003.06

1.02

1.06

1.00

1.00

1.02

1.04

7.26 CDCl3

261

Page 281: The Application of Pericyclic, Photolytic, Chemoenzymatic

S79

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

21.3421.4424.07

33.0735.8842.5644.83

64.15

76.84 CDCl377.16 CDCl377.48 CDCl3

93.52

120.01

131.79

178.52

199.87

21

.32

1.4

21

.5f1

(ppm

)

21.34

21.44

262

Page 282: The Application of Pericyclic, Photolytic, Chemoenzymatic

S80

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10

.0f1

(ppm

)

3.001.003.00

1.001.00

1.00

1.00

1.00

7.26 CDCl3

263

Page 283: The Application of Pericyclic, Photolytic, Chemoenzymatic

S81

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

18.8719.3120.5923.5131.72

49.34

65.21

76.84 CDCl377.16 CDCl377.48 CDCl3

119.41

134.78

180.65

18

.51

9.0

19

.52

0.0

20

.52

1.0

f1 (

ppm

)

18.87

19.31

20.59

264

Page 284: The Application of Pericyclic, Photolytic, Chemoenzymatic

S82

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.5f1

(ppm

)

3.003.001.003.00

1.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

265

Page 285: The Application of Pericyclic, Photolytic, Chemoenzymatic

S83

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

19.3320.0820.8521.8023.6632.33

43.7946.04

65.47

76.84 CDCl377.16 CDCl377.48 CDCl3

120.31

134.04

181.21

266

Page 286: The Application of Pericyclic, Photolytic, Chemoenzymatic

S84

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.003.003.003.005.00

3.001.001.00

1.00

1.00

1.00

1.00

2.00

7.26 CDCl3

267

Page 287: The Application of Pericyclic, Photolytic, Chemoenzymatic

S85

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

19.8921.6122.4425.2125.6225.6537.9640.0340.8341.9544.7049.66

76.84 CDCl377.16 CDCl377.48 CDCl380.0581.0184.06

109.11

125.73

137.31

170.43

25

.02

5.5

26

.0f1

(ppm

)

25.21

25.6225.65

268

Page 288: The Application of Pericyclic, Photolytic, Chemoenzymatic

S86

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

f1 (

ppm

)

3.003.003.001.001.00

3.001.001.002.001.00

1.00

1.00

1.00

2.00

7.26 CDCl3

269

Page 289: The Application of Pericyclic, Photolytic, Chemoenzymatic

S87

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

19.5721.6122.3425.51

40.7841.3341.4842.0344.1450.44

71.7175.3976.84 CDCl377.16 CDCl377.48 CDCl381.61

126.82

138.75

170.43

40

41

42

43

f1 (

ppm

)

40.7841.3341.4842.03

270

Page 290: The Application of Pericyclic, Photolytic, Chemoenzymatic

S88

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.5f1

(ppm

)

3.003.003.001.001.00

3.00

3.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

271

Page 291: The Application of Pericyclic, Photolytic, Chemoenzymatic

S89

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

18.08

21.56

22.23

25.56

39.33

41.68

43.87

44.82

50.10

51.81

75.16

76.84 CDCl3

77.16 CDCl3

77.48 CDCl3

81.11

121.90

142.16

170.19

210.99

272

Page 292: The Application of Pericyclic, Photolytic, Chemoenzymatic

S90

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.5f1

(ppm

)

3.003.003.001.001.003.003.001.001.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

273

Page 293: The Application of Pericyclic, Photolytic, Chemoenzymatic

S91

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

17.9220.7221.5322.2025.47

39.6241.6942.6044.9350.6551.45

74.1576.84 CDCl377.16 CDCl377.48 CDCl381.09

122.24

141.36

170.08170.67

205.16

274

Page 294: The Application of Pericyclic, Photolytic, Chemoenzymatic

S92

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.00

3.00

3.00

1.00

1.00

3.00

1.00

1.00

1.00

1.00

3.00

1.00

2.00

1.00

1.00

7.26 CDCl3

275

Page 295: The Application of Pericyclic, Photolytic, Chemoenzymatic

S93

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

18.4421.4622.1225.33

40.2241.5143.1844.7550.7451.0456.29

76.84 CDCl377.1377.16 CDCl377.48 CDCl381.09

97.52

121.52

141.01

170.11

209.32

76

.57

7.0

77

.5f1

(ppm

)

76.84 CDCl377.1377.16 CDCl377.48 CDCl3

50

.65

0.8

51

.05

1.2

f1 (

ppm

)

50.74

51.04

276

Page 296: The Application of Pericyclic, Photolytic, Chemoenzymatic

S94

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

f1 (

ppm

)

3.00

3.00

12.003.003.002.00

3.00

1.001.001.001.00

1.00

1.00

1.00

7.26 CDCl3

277

Page 297: The Application of Pericyclic, Photolytic, Chemoenzymatic

S95

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

-5.04-3.96

18.5519.0121.5822.2725.5125.9940.3041.7144.3944.8750.5351.06

75.9876.84 CDCl377.16 CDCl377.48 CDCl381.39

120.93

141.71

170.29

209.45

278

Page 298: The Application of Pericyclic, Photolytic, Chemoenzymatic

S96

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.11

3.05

3.03

1.07

1.01

2.99

1.00

1.01

0.99

2.00

1.01

1.00

2.03

1.01

1.99

7.26 CDCl3

279

Page 299: The Application of Pericyclic, Photolytic, Chemoenzymatic

S97

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

18.04

21.50

22.18

25.44

39.69

41.68

42.89

44.90

50.69

51.30

74.44

76.84 CDCl3

77.16 CDCl3

77.48 CDCl3

81.12

122.38

128.46

129.45

129.99

133.38

141.29

166.22

170.09

205.02

280

Page 300: The Application of Pericyclic, Photolytic, Chemoenzymatic

S98

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.00

3.00

3.00

1.00

1.00

2.00

3.00

1.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

281

Page 301: The Application of Pericyclic, Photolytic, Chemoenzymatic

S99

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

21.4021.9522.1725.3539.2241.1841.9744.7547.6652.0953.64

76.84 CDCl377.16 CDCl377.48 CDCl380.36

123.04

142.95

169.98

212.28

21

.42

1.6

21

.82

2.0

22

.22

2.4

f1 (

ppm

)

21.40

21.95

22.17

282

Page 302: The Application of Pericyclic, Photolytic, Chemoenzymatic

S100

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.01

3.01

3.01

1.01

3.00

1.01

3.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

283

Page 303: The Application of Pericyclic, Photolytic, Chemoenzymatic

S101

-1

00

10

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

18.4220.5121.3424.2528.7834.7234.8042.8043.5145.41

59.03

76.84 CDCl377.16 CDCl377.48 CDCl383.1883.35

117.19

134.27

169.88170.61

201.32

83

.08

3.2

83

.4f1

(ppm

)

83.18

83.35

34

.65

34

.70

34

.75

34

.80

34

.85

f1 (

ppm

)

34.72

34.80

284

Page 304: The Application of Pericyclic, Photolytic, Chemoenzymatic

S102

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.00

3.01

3.01

1.01

3.00

1.02

0.99

0.96

1.00

3.00

3.00

1.00

1.00

1.00

7.26 CDCl3

285

Page 305: The Application of Pericyclic, Photolytic, Chemoenzymatic

S103

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

18.5321.3524.2328.7334.3834.7343.2343.5445.40

56.0858.47

76.84 CDCl377.16 CDCl377.48 CDCl383.2389.3597.34

118.03

133.43

170.66

204.52

43

.04

3.2

43

.44

3.6

43

.8f1

(ppm

)

43.23

43.54

34

.03

4.5

35

.0f1

(ppm

)

34.38

34.73

286

Page 306: The Application of Pericyclic, Photolytic, Chemoenzymatic

S104

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.00

3.01

9.01

3.00

3.00

3.01

1.01

2.89

1.01

1.00

2.00

0.96

1.00

0.93

1.00

7.26 CDCl3

287

Page 307: The Application of Pericyclic, Photolytic, Chemoenzymatic

S105

-1

00

10

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

-4.88-4.63

18.1518.4021.3324.2125.8428.7634.4534.7643.1943.4945.46

57.98

76.84 CDCl377.16 CDCl377.48 CDCl383.2784.96

118.71

132.78

170.63

206.08

35

40

45

f1 (

ppm

)

34.4534.76

43.1943.4945.46

17

.51

8.0

18

.5 f1 (

ppm

)18.15

18.40-5

.0-4

.8-4

.6f1

(ppm

)

-4.88

-4.63

288

Page 308: The Application of Pericyclic, Photolytic, Chemoenzymatic

S106

-0

.50.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.00

3.00

3.00

1.00

3.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

2.00

1.00

2.00

7.26 CDCl3

289

Page 309: The Application of Pericyclic, Photolytic, Chemoenzymatic

S107

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

18.4621.3224.2528.8034.8035.1042.8543.4945.42

59.16

76.84 CDCl377.16 CDCl377.48 CDCl383.1783.58

117.25

128.65128.78130.12133.79134.30

165.31

170.56

201.10

12

81

29

13

01

31

13

21

33

13

41

35

f1 (

ppm

)

128.65128.78

130.12

133.79134.30

34

.53

5.0

35

.5f1

(ppm

)34.80

35.10

290

Page 310: The Application of Pericyclic, Photolytic, Chemoenzymatic

S108

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.00

3.00

3.00

1.00

3.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

291

Page 311: The Application of Pericyclic, Photolytic, Chemoenzymatic

S109

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

21.25

24.30

25.54

28.09

28.99

34.89

43.36

44.25

45.74

56.72

64.09

76.84 CDCl3

77.16 CDCl3

77.48 CDCl3

83.51

118.15

133.72

170.67

206.39

292

Page 312: The Application of Pericyclic, Photolytic, Chemoenzymatic

S110

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.06

6.01

1.00

1.13

1.07

3.01

3.00

1.04

1.00

1.00

1.00

1.00

1.00

7.26 CDCl3

293

Page 313: The Application of Pericyclic, Photolytic, Chemoenzymatic

S111

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

15.8920.8821.2922.1024.2124.3028.5535.3740.7542.7546.55

63.42

76.84 CDCl377.16 CDCl377.48 CDCl384.01

123.09

129.92

171.07171.77

21

22

23

24

f1 (

ppm

)

20.88

21.29

22.10

24.2124.30

294

Page 314: The Application of Pericyclic, Photolytic, Chemoenzymatic

S112

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.0f1

(ppm

)

3.003.00

3.009.001.023.003.001.01

1.003.00

1.001.00

1.00

1.00

1.00

1.00

2.05 Acetone

295

Page 315: The Application of Pericyclic, Photolytic, Chemoenzymatic

S113

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

-4.85

15.9418.6321.0723.1324.6726.2027.6528.8529.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.42 Acetone36.2141.8843.2547.2763.88

84.37

125.18128.93

170.74

205.98 Acetone

296

Page 316: The Application of Pericyclic, Photolytic, Chemoenzymatic

S114

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.00

3.00

3.01

1.01

1.01

3.00

1.00

1.00

4.01

1.00

1.00

1.00

1.00

7.26 CDCl3

297

Page 317: The Application of Pericyclic, Photolytic, Chemoenzymatic

S115

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

18.1221.4522.1025.30

39.4839.5141.5642.7244.8950.1850.69

76.84 CDCl377.16 CDCl377.48 CDCl380.9781.28

121.90

140.88

169.97

204.09

80

.58

1.0

81

.5f1

(ppm

)80.97

81.28

39

.43

9.6 f1

(ppm

)39.4839.51

298

Page 318: The Application of Pericyclic, Photolytic, Chemoenzymatic

S116

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

f1 (

ppm

)

3.00

3.00

3.00

2.00

1.00

1.00

3.00

1.00

2.00

3.00

0.98

1.00

7.26 CDCl3

299

Page 319: The Application of Pericyclic, Photolytic, Chemoenzymatic

S117

-1

00

10

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

21.2122.5022.7325.0732.8736.0637.5639.3141.0942.3842.4945.1550.36

76.84 CDCl377.16 CDCl377.48 CDCl378.7680.87

170.21

211.07

42

.34

2.4

42

.54

2.6

f1 (

ppm

)

42.38

42.49

22

.42

2.6

22

.8f1

(ppm

)

22.50

22.73

300

Page 320: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 321: The Application of Pericyclic, Photolytic, Chemoenzymatic

301

Publication Three

A Palladium-Catalyzed Ullmann Cross-

Coupling/Reductive Cyclization Route to the

Carbazole Natural Products 3-Methyl-9H-carbazole,

Glycoborine, Glycozoline, Clauszoline K, Mukonine,

and Karapinchamine

Qiao Yan, Emma Gin, Malgorzata Wasinska-Kalwa,

Martin G. Banwell, and Paul D. Carr

J. Org. Chem., 2017, 82, 4148.

Page 322: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 323: The Application of Pericyclic, Photolytic, Chemoenzymatic

A Palladium-Catalyzed Ullmann Cross-Coupling/ReductiveCyclization Route to the Carbazole Natural Products3‑Methyl‑9H‑carbazole, Glycoborine, Glycozoline, Clauszoline K,Mukonine, and Karapinchamine AQiao Yan, Emma Gin, Malgorzata Wasinska-Kalwa, Martin G. Banwell,* and Paul D. Carr

Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, Australian CapitalTerritory 2601, Australia

*S Supporting Information

ABSTRACT: The title natural products 2−7 have been prepared byreductive cyclization of the relevant 2-arylcyclohex-2-en-1-one (e.g.20) to the corresponding tetrahydrocarbazole and dehydrogenation(aromatization) of this to give the target carbazole (e.g. 4).Compounds such as 20 were prepared using a palladium-catalyzedUllmann cross-coupling reaction between the appropriate 2-iodocyclohex-2-en-1-one and o-halonitrobenzene.

■ INTRODUCTION9H-Carbazole (1) (Figure 1) was first isolated from coal tarmore than 100 years ago,1 and since that time this aromatic

heterocycle and its various derivatives have fascinated organicchemists because of their value in both medicine and materialsscience.2 Many biologically active natural products embodyingthis framework have also been isolated, particularly from higherplants.2d,e,3 As such, the development of methods for thesynthesis of the carbazoles has been an ongoing field ofresearch. A suite of approaches to these compounds has beenreported, ranging from the classical Fischer−Borsche4 andGraebe−Ullmann5 routes to more contemporary ones such asthe cyclization of biarylnitrenes (Cadogan synthesis)6 orvariants thereof and the annulation of indoles,7 includingthrough electrocyclization processes. Despite the demonstratedutility of these and other approaches,8 perhaps the mosteffective route to carbazoles involves the cyclization ofdiarylamines, especially under oxidative conditions.9 Variationson this last approach have been used to great effect indeveloping total syntheses of a plethora of carbazole-containingnatural products, with particularly notable contributions havingbeing made, especially in recent times, by the Knolkergroup.2,9e−i,k,m

Sometime ago we reported10 that 1,2,3,4-tetrahydro-9H-carbazoles (formally 2,3,4,9-tetrahydro-1H-carbazoles) can beformed by a two-step process involving an initial the palladium-catalyzed Ullmann cross-coupling of 2-halocyclohex-2-en-1-ones with o-halonitrobenzenes and then subjecting the resulting2-arylcyclohex-2-en-1-ones to a reductive cyclization reaction.11

Since various methods are available for or could be applied tothe oxidation of tetrahydrocarbazoles to carbazoles,12 wesought to establish if the reaction sequence just mentionedcould provide a useful means for obtaining natural productsembodying the latter ring system. Herein we report theoutcomes of such studies and by which means we have beenable to realize syntheses of the parent carbazole (1) as well asthe natural products 3-methyl-9H-carbazole (2),13 glycoborine(3, aka glycrophylamine),3a,14 glycozoline (4),3a,15 clauszoline K(5),16 mukonine (6),17 and karapinchamine A (7)18 togetherwith their monomethoxylated congener 8 (Figure 2).

■ RESULTS AND DISCUSSIONOur initial studies focused on acquiring targets 1 and 2, and thisinvolved (Scheme 1) the initial palladium-catalyzed Ullmanncross-coupling of 2-iodocyclohex-2-en-1-one (9)19 or its C4-methylated counterpart 1011 with commercially available o-bromonitrobenzene (11) under conditions defined earlier,10

and thereby affording the anticipated and previously reported2-arylcyclohex-2-en-1-ones 1210,11 (85%) and 1311 (86%),respectively. A methanolic solution of each of compounds 12and 13 was then subjected to reaction with hydrogen in thepresence of commercially available W-2 Raney nickel at roomtemperature, and so affording the tetrahydrocarbazoles1410,11,12b (64%) and 1511,12b (58%), respectively. Various

Received: January 8, 2017Published: February 22, 2017

Figure 1. Structure of parent 9H-carbazole (1) and the associated ringlabeling and atom numbering.

Article

pubs.acs.org/joc

© 2017 American Chemical Society 4148 DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

302

Page 324: The Application of Pericyclic, Photolytic, Chemoenzymatic

attempts to modify these reductive cyclization conditions in aneffort to obtain dihydrocarbazoles (or perhaps even thecarbazoles themselves as a result of conducting the workupunder aerobic conditions) were unsuccessful. In the final step ofthe reaction sequence, then, mesitylene solutions of com-pounds 14 and 15 were each heated to 150 °C with an equalweight of 10% palladium on carbon, and thus affordingcarbazoles 1 (55%) and 212b (57%), respectively. All of thespectroscopic and physical data acquired on these reactionproducts were in complete accord with the assigned structuresand matched those derived from a commercially availablesample (in the former case) or reported6h,12b in the literature(in the latter case). Furthermore, each was subjected to single-crystal X-ray analysis.20

The preparation of glycoborine (3), a synthetic targetpursued by others,6e,g,k,9h,k,14 was readily accomplished asshown in Scheme 2 by coupling 2-iodo-4-methylcyclohex-2-en-1-one (10)11 with nitroarene 1621 and thereby producing thearylated cyclohexenone 17 (88%), the structure of which was

secured by a single-crystal X-ray analysis.20 The appearance of28 signals in the 13C NMR spectrum of this C14 compoundsuggested that it existed as diastereoisomeric atropisomersunder ambient conditions. Reductive cyclization of compound17 using hydrogen in the presence of W-2 Raney nickel gavethe tetrahydrocarbazole 1811a (72%), and dehydrogenation ofthis compound under the same conditions as employed beforethen afforded the target natural product 3, that was obtained in75% yield. Once again, all of the appropriate spectralcomparisons left no doubt that the glycoborine had beenobtained but final confirmation of this followed from a single-crystal X-ray analysis.20

A reaction sequence essentially analogous to that describedabove was used to synthesize glycozoline (4), a compound thathas also been the target of previous studies.3c,4c,6i,12b,22 Thus, asshown in Scheme 3, reaction of 2-iodo-4-methylcyclohex-2-en-1-one (10) with commercially available nitroarene 19 under theby now standard palladium-catalyzed Ullmann cross-couplingconditions gave the anticipated product 20 (87%), which wasreductively cyclized with hydrogen in the presence of W-2

Figure 2. Structures of natural products 2-7 and the monosubstituted congener 8.

Scheme 1. Reaction Sequences Leading to Carbazoles 1 and2

Scheme 2. Synthesis of Glycoborine (3)

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4149

303

Page 325: The Application of Pericyclic, Photolytic, Chemoenzymatic

Raney nickel and so providing the tetrahydrocarbazole2112b,d,22b in 72% yield. Dehydrogenation of compound 21through brief treatment with 10% Pd on C in diphenyl ether at210 °C then gave glycozoline (4) in 89% yield, the structure ofwhich was confirmed by single-crystal X-ray analysis.20

The reaction sequence leading to clauszoline K (5) (Scheme4), another popular target,22d,23 provided some insights into thepropensity of 2,3,4,9-tetrahydro-1H-carbazoles to engage inalternate oxidation reactions.12a Thus, the palladium-catalyzedUllmann cross-coupling of the iodinated cyclohexenone 10with the commercially available 2-iodonitroarene 22 proceededas anticipated to give the required arylated cyclohexenone 23

(80%), and this in turn engaged in the same type of reductivecyclization reaction as seen before to give tetrahydrocarbazole2411a,14 (65%). However, compound 24 proved rather prone tooxidation, with the hydroperoxide 25 being formed inincreasing quantities when its precursor was allow to stand at22 °C as a solution (in various solvents) left open to theatmosphere. Compound 25, the structure of which wasestablished by single-crystal X-ray analysis,20 may arise througha facially selective ene reaction between indole 24 and singletoxygen, the latter reactant (most likely) being producedthrough the other (24) serving as a sensitizer. Despite theease of the conversion 24 → 25, the tetrahydrocarbazole wasreadily dehydrogenated in the same manner as described in theother instances reported herein, producing carbazole269c,h,22d,23a,b in 88% yield. Unlike isomer 4, compound 26 isnot a naturally occurring material but is readily converted intoone, namely aldehyde 5 (clauszoline K) (66%), on treatmentwith DDQ in aqueous methanol9h,23a,b at ambient temperaturefor 4 h. The structure of compound 5 was confirmed by single-crystal X-ray analysis.20

The carbazole natural product mukonine (6), anotherpopular target compound,9a,12d,17a,24 carries both the methoxyand carbomethoxy substituents in the same ring and sorequiring, as the first step in the present synthesis, thepalladium-catalyzed Ullmann cross-coupling of the “parent” 2-iodocyclohexeneone 9 with the readily obtained (see below)tetrasubstituted arene 27 (Scheme 5), affording the required 2-arylated cyclohexenone 28, albeit in just 39% yield. Reductivecyclization of compound 28 under standard conditions gavetetrahydrocarbazole 29 (79%), which upon dehydrogenationunder the usual conditions afforded mukonine (6) (66%) as awhite, crystalline solid. Once again, all of the derived spectral

Scheme 3. Synthesis of Glycozoline (4)

Scheme 4. Synthesis of Clauszoline K (5)

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4150

304

Page 326: The Application of Pericyclic, Photolytic, Chemoenzymatic

data were fully consistent with the assigned structure as well asthose reported for the natural product, but final confirmation ofthis followed from a single-crystal X-ray analysis.20 The arene27 used in this sequence was prepared by first brominatingcommercially available methyl 4-amino-3-methoxybenzoatewith N-bromosuccinimide (NBS) and then oxidizing thepreviously reported25 bromide to the corresponding nitrocompound (viz. 27) using m-chloroperbenzoic acid (mCPBA)(see the Experimental Section for details).The trisubstituted carbazole natural product karapinchamine

A (7), the subject of just one previous synthetic study,7e wasreadily obtained (Scheme 6) by treating compound 26 withboron tribromide so as to effect cleavage of the methyl ethermoiety and then treating the product hydroxycarbazole 309h

(84%), as a solution in THF, with an excess of n-butyllithiumand then ca. 1.5 equiv of geranyl bromide. By such meanskarapinchamine A (7) was obtained in 50% yield after columnchromatography. Interestingly, there was no evidence for theformation of the isomeric O-geranylated product during thecourse of this reaction. All of the spectral data acquired onproduct 7 matched those recorded for the natural product (seethe Supporting Information for relevant spectral comparisons).Monosubstituted carbazoles wherein the single substituent

derives from the arene coupling partner are also readilyavailable by the procedures reported here. Thus, as shown inScheme 7, cross-coupling of compounds 9 and 22 under theusual conditions afforded enone 3110,11b (91%), which onsubjection to reductive cyclization using hydrogen in thepresence of Raney nickel afforded the tetrahydrocarazole3210,11b,26 (76%). Dehydrogenation of compound 32 using10% Pd on C in hot mesitylene then afforded carbazole 86f,k,l,9j

(64%), the spectral data for which matched those reportedpreviously.

■ CONCLUSIONSThe procedures detailed here allow for the straightforwardpreparation, in a fully regiocontrolled manner, of a range ofcarbazoles carrying various combinations of substituents inboth the A and the C rings as well as on the nitrogen of the Bring. Substitution patterns encountered in naturally occurringand biologically active carbazoles appear to be completelyaccessible using the methods described here. As a furtherindication of the utility of the title protocol, it is worth notingthat carbazole 30 is an established precursor to the pyrano[3,2-a]carbazole alkaloids isogirinimbine and mahanimbicine.9h In arelated vein, clauszoline K (5) is an established syntheticprecursor to the alkaloids clauszoline M and N (thecorresponding methyl ester and acid, respectively).22d,23a Thepresent study also serves to highlight the continued utility ofthe palladium-catalyzed Ullmann cross-coupling reaction,27

especially when it is used in combination with reductivecyclization protocols.28

■ EXPERIMENTAL SECTIONGeneral Experimental Procedures. Unless otherwise specified,

proton (1H) and carbon (13C) NMR spectra were recorded at 18 °Cin base-filtered CDCl3 on a spectrometer operating at 400 MHz forproton and 100 MHz for carbon nuclei. 1H NMR data are recorded asfollows: chemical shift (δ) [multiplicity, coupling constant(s) J (Hz),relative integral], where multiplicity is defined as s = singlet, d =doublet, t = triplet, q = quartet, and m = multiplet, or combinations ofthe above. In relevant cases, the signal due to residual CHCl3appearing at δH 7.26 and the central resonance of the CDCl3 “triplet”

Scheme 5. Synthesis of Mukonine (6)

Scheme 6. Synthesis of Karapinchamine A (7)

Scheme 7. Synthesis of 2-Methoxy-9H-carbazole (8)

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4151

305

Page 327: The Application of Pericyclic, Photolytic, Chemoenzymatic

appearing at δC 77.0 were used to reference 1H and 13C NMR spectra,respectively. Samples were analyzed by infrared spectroscopy (νmax) asthin films on KBr plates. Low- and high-resolution electron impact(EI) mass spectra were recorded on a double-focusing, triple-sectormachine. Low- and high-resolution ESI mass spectra were recorded ona triple-quadrupole mass spectrometer operating in either positive ornegative ion mode. Melting points are uncorrected. Analytical thin-layer chromatography (TLC) was performed on aluminum-backed 0.2mm thick silica gel 60 F254 plates. Eluted plates were visualized using a254 nm UV lamp and/or by treatment with a suitable dip followed byheating. These dips included phosphomolybdic acid/ceric sulfate/sulfuric acid (concentrated)/water (37.5 g/7.5 g/37.5 g/720 mL),potassium permanganate/potassium carbonate/5% sodium hydroxideaqueous solution/water (3 g/20 g/5 mL/300 mL), and p-anisaldehydeor vanillin/sulfuric acid (concentrated)/ethanol (15 g/2.5 mL/250mL). Flash chromatographic separations were carried out followingprotocols defined by Still et al.29 with silica gel 60 (40−63 μm) as thestationary phase and using the AR- or HPLC-grade solvents indicated.The melting points of solids purified by such means were recordeddirectly (i.e. after they had crystallized from the concentratedchromatographic fractions). Starting materials, reagents, drying agents,and other inorganic salts were generally commercially available andwere used as supplied. The copper powder used in the palladium-catalyzed Ullmann cross-coupling reactions had a particle size of <75μm. Tetrahydrofuran (THF), methanol, and dichloromethane weredried using a solvent purification system that is based upon atechnology originally described by Grubbs et al.30 Where necessary,reactions were performed under a nitrogen atmosphere.Specific Chemical Transformations. 2-Iodocyclohex-2-en-1-

one (9). Following a procedure reported by Johnson et al.,31 amagnetically stirred solution of cyclohex-2-en-1-one (2.00 g, 20.8mmol) in chloroform/pyridine (80 mL of a 1/1 v/v mixture)maintained at 0 °C under a nitrogen atmosphere was treated, dropwiseover 2 h, with a solution of molecular iodine (18.5 g, 72.8 mmol) inchloroform/pyridine (80 mL of a 1/1 v/v mixture). The ensuingmixture was warmed to 22 °C, stirred at this temperature for 16 h thendiluted with diethyl ether (200 mL) and washed with water (1 × 100mL), Na2S2O3 (2 × 100 mL of a 20% w/v aqueous solution), HCl (2× 100 mL of a 1 M aqueous solution), water (2 × 100 mL) and brine(1 × 100 mL) before being dried (MgSO4), filtered, and concentratedunder reduced pressure to give a yellow oil. This was subjected to flashcolumn chromatography (silica, 2/5/70 v/v/v ethyl acetate/dichloro-methane/40−60 petroleum ether elution) to give, after concentrationof the appropriate fractions (Rf = 0.6 in 2/5/11 v/v/v ethyl acetate/dichloromethane/40−60 petroleum ether), 2-iodocyclohex-2-en-1-one919 (3.85 g, 83%) as a light yellow solid, mp 47−50 °C (lit.19 mp 47−49 °C): 1H NMR (400 MHz, CDCl3) δ 7.77 (t, J = 4.4 Hz, 1H), 2.67(m, 2H), 2.44 (m, 2H), 2.09 (m, 2H); 13C NMR (100 MHz, CDCl3) δ192.3, 159.6, 104.0, 37.4, 30.1, 23.0; IR νmax 2949, 2939, 1675, 1585,1421, 1314, 1120, 966, 914, 803, 703 cm−1; MS (EI, 70 eV) m/z 222(M+•, 100%), 194 (75), 67 (40); HRMS M+• calcd for C6H7

127IO221.9542, found 221.9540.2-Iodo-4-methylcyclohex-2-en-1-one (10). A magnetically stirred

solution of 4-methylcyclohex-2-en-1-one32 (2.29 g, 20.8 mmol) inchloroform/pyridine (80 mL of a 1/1 v/v mixture) maintained at 0 °Cunder a nitrogen atmosphere was treated, dropwise over 2 h, with asolution of molecular iodine (18.5 g, 72.8 mmol) in chloroform/pyridine (80 mL of a 1/1 v/v mixture). The ensuing mixture waswarmed to 22 °C, stirred at this temperature for 16 h, and then dilutedwith diethyl ether (200 mL) and washed with water (1 × 100 mL),Na2S2O3 (2 × 100 mL of a 20% w/v aqueous solution), HCl (2 × 100mL of a 1 M aqueous solution), water (2 × 100 mL), and brine (1 ×100 mL) before being dried (MgSO4), filtered, and concentratedunder reduced pressure to give a yellow oil. Subjection of this materialto flash column chromatography (silica, 1/19 v/v ethyl acetate/40−60petroleum ether elution) gave, after concentration of the appropriatefractions (Rf = 0.5 in 1/5 v/v ethyl acetate/40−60 petroleum ether),compound 1011b (3.98 g, 81%) as a light yellow oil: 1H NMR (400MHz, CDCl3) δ 7.50 (d, J = 2.6 Hz, 1H), 2.66−2.56 (complex m, 2H),2.48−2.39 (complex m, 1H), 2.07 (m, 1H), 1.64 (m, 1H), 1.08 (d, J =

7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 191.8, 164.7, 102.9, 35.6,35.5, 30.6, 19.7; IR νmax 2959, 2930, 2870, 1686, 1585, 1454, 1318,1109, 790 cm−1; MS (EI, 70 eV) m/z 236 (M+•, 100%), 208 (25), 109(75), 81 (50), 53 (60); HRMS M+• calcd for C7H9

127IO 235.9698,found 235.9691.

2′-Nitro-4,5-dihydro-[1,1′-biphenyl]-2(3H)-one (12). A magneti-cally stirred mixture of o-bromonitrobenzene (11) (941 mg, 4.7mmol), 2-iodocyclohex-2-en-1-one (9) (470 mg, 2.1 mmol), copperpowder (673 mg, 10.6 g atom), CuI (605 mg, 3.2 mmol), andPd(dppf)Cl2·CH2Cl2 (87 mg, 0.1 mmol) in deoxygenated DMSO (21mL) maintained under nitrogen was heated to 50 °C for 10 h. Thereaction mixture was then cooled to room temperature, quenched withwater (1 × 20 mL), diluted with ethyl acetate (1 × 40 mL), andfiltered through a pad of diatomaceous earth and silica gel. The padand the solids thus retained were washed with ethyl acetate (2 × 50mL), and the filtrate was washed with water (2 × 100 mL) and thenbrine (2 × 100 mL). The separated organic phase was dried (Na2SO4),filtered, and concentrated under reduced pressure to give a brown oil,and subjection of this material to flash chromatography (silica, 1/9 v/vethyl acetate/40−60 petroleum ether elution) gave, after concen-tration of the appropriate fractions (Rf = 0.4 in 1/1 v/v ethyl acetate/40−60 petroleum ether), compound 1210,11 (390 mg, 85%) as a lightyellow crystal, mp 96−99 °C (lit.10 mp 92−95 °C): 1H NMR (400MHz, CDCl3) δ 7.99 (m, 1H), 7.58 (m, 1H), 7.46 (m, 1H), 7.25 (m,1H), 7.00 (t, J = 4.2 Hz, 1H), 2.56 (m, 4H), 2.13 (m, 2H); 13C NMR(100 MHz, CDCl3) δ 196.6, 148.7, 146.8, 139.4, 133.4, 132.2, 131.8,128.8, 124.2, 38.4, 26.4, 22.7; IR νmax 2949, 2868, 1679, 1523, 1353,1158, 859, 788, 751, 709 cm−1; MS (ESI, +ve) m/z 240 [(M + Na)+,100%], 218 [(M + H)+, 10]; HRMS (M + H)+ calcd for C12H12NO3218.0817, found 218.0825.

5-Methyl-2′-nitro-4,5-dihydro-[1,1′-biphenyl]-2(3H)-one (13). Amagnetically stirred mixture of o-bromonitrobenzene (11) (960 mg,4.75 mmol), 2-iodo-4-methylcyclohex-2-en-1-one (10) (510 mg, 2.16mmol), copper powder (687 mg, 10.80 g atom), CuI (617 mg, 3.24mmol), and Pd(dppf)Cl2·CH2Cl2 (88 mg, 0.11 mmol) indeoxygenated DMSO (22 mL) was heated to 50 °C under a nitrogenatmosphere for 8 h. The reaction mixture was then cooled to roomtemperature, quenched with water (20 mL), diluted with ethyl acetate(40 mL), and then filtered through a pad of diatomaceous earth andsilica gel. The pad and the solids thus retained were washed with ethylacetate (2 × 50 mL), and the organic phase associated with the filtratewas then washed with water (2 × 100 mL) and brine (2 × 100 mL)before being dried (Na2SO4), filtered, and concentrated under reducedpressure to give a brown oil. Subjection of this material to flashchromatography (silica, 1/9 v/v ethyl acetate/40−60 petroleum etherelution) gave, after concentration of the appropriate fractions (Rf = 0.5in 1/1 v/v ethyl acetate/40−60 petroleum ether), compound 1311

(430 mg, 86%) as a light yellow oil: 1H NMR (400 MHz, CDCl3) δ7.99 (m, 1H), 7.58 (m, 1H), 7.45 (m, 1H), 7.40 (d, J = 7.6 Hz, 1H),6.80 (d, J = 1.6 Hz, 1H), 2.79 (broad s, 1H), 2.65−2.47 (complex m,2H), 2.20 (m, 1H), 1.86−1.76 (complex m, 1H), 1.24 (m, 3H); 13CNMR (100 MHz, CDCl3) δ 196.6, 152.3, 148.7, 138.4, 133.4, 132.1,131.8, 128.9, 124.3, 37.2, 31.8, 30.7, 20.4; IR νmax 2960, 2872, 1681,1525, 1354, 1159, 788, 750 cm−1; MS (ESI, +ve) m/z 254 [(M +Na)+, 100%], 232 [(M + H)+, 10]; HRMS (M + Na)+ calcd forC13H13NNaO3 254.0793, found 254.0799.

2,3,4,9-Tetrahydro-1H-carbazole (14). A magnetically stirredmixture of compound 12 (100 mg, 0.46 mmol) and commerciallyavailable W-2 Raney nickel (200 mg, washed twice with absoluteethanol) in methanol (23 mL) was deoxygenated and then stirredunder an atmosphere of hydrogen at 22 °C for 18 h. After this timeand using an externally applied magnet to hold the solid associatedwith the reaction mixture within the flask, the supernatant liquid wasdecanted and the retained solid washed with methanol (2 × 30 mL)(Caution! Af ter these washings water should be added to the residual solidso as to prevent a f ire.). The methanolic solutions were combined andthen concentrated under reduced pressure to give a white solid.Subjection of this material to flash column chromatography (silica, 1/9v/v ethyl acetate/40−60 petroleum ether elution) gave, afterconcentration of the appropriate fractions (Rf = 0.6 in 1/5 v/v ethyl

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4152

306

Page 328: The Application of Pericyclic, Photolytic, Chemoenzymatic

acetate/40−60 petroleum ether), compound 1410,11,12b (50 mg, 64%)as a white solid, mp 104−106 °C (lit.12b mp 104−106 °C): 1H NMR[400 MHz, (CD3)2CO] δ 9.70 (broad s, 1H), 7.36 (d, J = 7.8 Hz, 1H),7.26 (d, J = 7.8 Hz, 1H), 7.02−6.92 (complex m, 2H), 2.73 (t, J = 5.9Hz, 2H), 2.68−2.65 (complex m, 2H), 1.92−1.81 (complex m, 4H);13C NMR [100 MHz, (CD3)2CO] δ 137.1, 135.1, 128.8, 121.1, 119.1,118.0, 111.3, 109.7, 24.2, 24.0, 23.8, 21.7; IR νmax 3396, 2926, 2849,1467, 1450, 1439, 1325, 1304, 1233, 736, 635 cm−1; MS (ESI, +ve) m/z 226 [(M + MeOH + Na)+, 100%], 188 (56), 172 [(M + H)+, 70];HRMS (M + H)+ calcd for C12H14N 172.1126, found 172.1121.3-Methyl-2,3,4,9-tetrahydro-1H-carbazole (15). A magnetically

stirred mixture of compound 13 (320 mg, 1.38 mmol) andcommercially available W-2 Raney nickel (640 mg, washed twicewith absolute ethanol) in methanol (69 mL) was deoxygenated andthen stirred under an atmosphere of hydrogen at 22 °C for 18 h. Afterthis time and using an externally applied magnet to hold the solidassociated with the reaction mixture within the flask, the supernatantliquid was decanted and the retained solid washed with methanol (2 ×30 mL) (Caution! Af ter these washings water should be added to theresidual solid so as to prevent a f ire.). The methanolic solutions werecombined and then concentrated under reduced pressure to give awhite solid. Subjection of this material to flash column chromatog-raphy (silica, 1/9 v/v ethyl acetate/40−60 petroleum ether elution) togive, after concentration of the appropriate fractions (Rf = 0.6 in 1/5v/v ethyl acetate/40−60 petroleum ether), compound 1511,12b (148mg, 58%) as a white solid, mp 98−100 °C (lit.12b mp 98−100 °C): 1HNMR [400 MHz, (CD3)2CO] δ 9.70 (broad s, 1H), 7.36 (d, J = 7.6Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 7.02−6.92 (complex m, 2H), 2.83−2.75 (complex m, 3H), 2.24 (m, 1H), 1.98−1.86 (complex m, 2H),1.53 (m, 1H), 1.13 (d, J = 6.6 Hz, 3H); 13C NMR [100 MHz,(CD3)2CO] δ 137.4, 134.9, 128.7, 121.1, 119.1, 118.0, 111.3, 109.7,32.3, 30.6, 30.2, 23.4, 22.1; IR νmax 3405, 2949, 2923, 1620, 1467,1326, 1232, 1009, 740 cm−1; MS (ESI, +ve) m/z 240 [(M + MeOH +Na)+, 100%], 202 (45), 186 [(M + H)+, 30]; HRMS (M + H)+ calcdfor C13H16N 186.1283, found 186.1286.9H-Carbazole (1). A magnetically stirred mixture of compound 14

(46 mg, 0.27 mmol) and 10 wt % Pd/C (46 mg) in mesitylene (5 mL)was stirred at 150 °C under an atmosphere of nitrogen for 24 h. Thecooled reaction mixture was filtered through filter paper, and the solidsthus retained were washed with ethyl acetate (2 × 15 mL). The filtratewas concentrated under reduced pressure, and the ensuing mixture ofproduct 1 and mesitylene was then subjected to flash columnchromatography (silica, 1/19 v/v ethyl acetate/40−60 petroleum etherelution). Concentration of the appropriate fractions (Rf = 0.6 in 1/5 v/v ethyl acetate/40−60 petroleum ether) then gave compound 1 (25mg, 55%) as a white, crystalline solid, mp 237−238 °C (lit.33 mp 245°C): 1H NMR [400 MHz, (CD3)2CO] δ 10.32 (broad s, 1H), 8.11 (d,J = 7.8 Hz, 2H), 7.51 (d, J = 8.1 Hz, 2H), 7.39 (m, 2H), 7.18 (m, 2H);13C NMR [100 MHz, (CD3)2CO] δ 141.0, 126.4, 124.0, 120.9, 119.6,111.7; IR νmax 3416, 3049, 1597, 1449, 1233, 928, 745, 722 cm−1; MS(ESI, − ve) m/z 166 [(M − H)−, 100%]; HRMS (M − H)− calcd forC12H8N 166.0657, found 166.0656.3-Methyl-9H-carbazole (2). A magnetically stirred mixture of

compound 15 (145 mg, 0.78 mmol) and 10 wt % Pd/C (145 mg) inmesitylene (15 mL) was stirred at 150 °C under an atmosphere ofnitrogen for 24 h. The cooled reaction mixture was filtered throughfilter paper, and the solids thus retained were washed with ethyl acetate(2 × 15 mL). The filtrate was concentrated under reduced pressure,and the ensuing mixture of product 2 and mesitylene was thensubjected to flash column chromatography (silica, 1/19 v/v ethylacetate/40−60 petroleum ether elution) to give, after concentration ofthe appropriate fractions (Rf = 0.6 in 1/3 v/v ethyl acetate/40−60petroleum ether), compound 212b (80 mg, 57%) as a white solid, mp200−202 °C (lit.12b mp 205−210 °C): 1H NMR [400 MHz,(CD3)2CO] δ 10.17 (broad s, 1H), 8.07 (d, J = 7.8 Hz, 1H), 7.90(s, 1H), 7.47 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.37−7.33(complex m, 1H), 7.22 (dd, J = 8.2 and 1.2 Hz, 1H), 7.15 (m, 1H),2.48 (s, 3H); 13C NMR [100 MHz, (CD3)2CO] δ 141.3, 139.2, 128.6,127.7, 126.2, 124.2, 123.8, 120.8, 120.7, 119.4, 111.6, 111.4, 21.5; IRνmax 3403, 3050, 2914, 2853, 1605, 1459, 1333, 1238, 805, 746, 726

cm−1; MS (ESI, −ve) m/z 180 [(M − H)−, 100%]; HRMS (M − H)−

calcd for C13H10N 180.0813, found 180.0804.2′-Methoxy-5-methyl-6′-nitro-4,5-dihydro-[1,1′-biphenyl]-2(3H)-

one (17). A magnetically stirred mixture of 2-iodo-1-methoxy-3-nitrobenzene (16)21 (341 mg, 1.22 mmol), 2-iodo-4-methylcyclohex-2-en-1-one (10) (519 mg, 2.20 mmol), copper powder (311 mg, 4.89g atom), CuI (349 mg, 1.83 mmol), and Pd(dppf)Cl2·CH2Cl2 (100mg, 0.12 mmol) in deoxygenated DMSO (24 mL) was heated to 50°C under a nitrogen atmosphere for 4 h. The reaction mixture wasthen cooled to room temperature, quenched with water (10 mL),diluted with ethyl acetate (20 mL), and then filtered through a pad ofdiatomaceous earth and silica gel. The pad and the solids thus retainedwere washed with ethyl acetate (2 × 25 mL) and the organic phaseassociated with the filtrate then washed with water (2 × 50 mL) andbrine (2 × 50 mL) before being dried (Na2SO4), filtered, andconcentrated under reduced pressure to give a brown oil. Subjection ofthis material to flash chromatography (silica, 2/5/40 v/v/v ethylacetate/dichloromethane/40−60 petroleum ether elution) gave, afterconcentration of the appropriate fractions (Rf = 0.3 in 2/5/11 v/v/vethyl acetate/dichloromethane/40−60 petroleum ether), compound17 (281 mg, 88%) as a light yellow solid, mp 94−96 °C: 1H NMR(400 MHz, CDCl3) δ 7.53 (m, 1H), 7.40−7.10 (complex m, 2H), 6.63(m, 1H), 3.78 (m, 3H), 2.76−2.48 (complex m, 3H), 2.24−2.14(complex m, 1H), 1.90−1.76 (complex m, 1H), 1.20 (m, 3H); 13CNMR (100 MHz, CDCl3) δ 196.9, 196.7, 158.1, 158.0, 153.7, 153.5,150.3, 150.0, 133.0, 132.6, 129.1, 129.2, 121.5, 121.4, 116.1, 116.0,115.6, 115.4, 56.7, 56.6, 37.3, 37.1, 32.0, 31.6, 30.9, 30.5, 20.4, 20.1; IRνmax 2959, 1674, 1524, 1461, 1351, 1263, 1052, 794, 736 cm−1; MS(ESI, +ve) m/z 284 [(M + Na)+, 100%], 262 [(M + H)+, 15]; HRMS(M + Na)+ calcd for C14H15NNaO4 284.0899, found 284.0896.

5-Methoxy-3-methyl-2,3,4,9-tetrahydro-1H-carbazole (18). Amagnetically stirred mixture of compound 17 (211 mg, 0.81 mmol)and commercially available W-2 Raney nickel (422 mg, washed twicewith absolute ethanol) in methanol (40 mL) was deoxygenated andthen stirred under an atmosphere of hydrogen at 22 °C for 10 h. Afterthis time and using an externally applied magnet to hold the solidassociated with the reaction mixture within the flask, the supernatantliquid was decanted and the retained solid washed with methanol (2 ×15 mL) (Caution! Af ter these washings water should be added to theresidual solid so as to prevent a f ire.). The methanolic solutions werecombined and then concentrated under reduced pressure to give awhite solid. Subjection of this material to flash column chromatog-raphy (silica, 1/3/30 v/v/v acetone/dichloromethane/40−60 petro-leum ether elution) gave, after concentration of the appropriatefractions (Rf = 0.5 in 1/3/6 v/v/v acetone/dichloromethane/40−60petroleum ether), compound 1811a (125 mg, 72%) as a white solid,mp 126−128 °C: 1H NMR [400 MHz, (CD3)2CO] δ 9.63 (broad s,1H), 6.91−6.85 (complex m, 2H), 6.41 (dd, J = 6.5 and 1.9 Hz, 1H),3.84 (s, 3H), 3.11 (dd, J = 16.0 and 4.7 Hz, 1H), 2.72 (m, 2H), 2.41(m, 1H), 1.92−1.79 (complex m, 2H), 1.48 (m, 1H), 1.10 (d, J = 6.6Hz, 3H); 13C NMR [100 MHz, (CD3)2CO] δ 155.1, 138.8, 132.8,121.8, 118.6, 109.6, 105.1, 99.7, 55.3, 32.7, 32.1, 30.8, 23.4, 22.2; IRνmax 3397, 2948, 2923, 2836, 1565, 1505, 1349, 1253, 1244, 1104, 775,729 cm−1; MS (ESI, +ve) m/z 232 (100%), 216 [(M + H)+, 90];HRMS (M + H)+ calcd for C14H18NO 216.1388, found 216.1393.

Glycoborine (3). A magnetically stirred mixture of compound 18(50 mg, 0.23 mmol) and 10 wt % Pd/C (50 mg) in mesitylene (5 mL)was stirred at 150 °C under an atmosphere of nitrogen for 24 h. Thecooled reaction mixture was filtered through filter paper, and the solidsthus retained were washed with ethyl acetate (2 × 10 mL). Thecombined filtrates were concentrated under reduced pressure, and theensuing mixture of product 3 and mesitylene was then subjected toflash column chromatography (silica, 2/5/62 v/v/v ethyl acetate/dichloromethane/40−60 petroleum ether elution) to give, afterconcentration of the appropriate fractions (Rf = 0.4(5) in 2/5/11 v/v/v ethyl acetate/dichloromethane/40−60 petroleum ether), com-pound 33a (35 mg, 75%) as a white solid, mp 130−132 °C (lit.3a mp132.0−134.6 °C): 1H NMR [400 MHz, (CD3)2CO] δ 10.17 (broad s,1H), 8.07 (s, 1H), 7.36 (d, J = 8.2 Hz, 1H), 7.28 (t, J = 8.0 Hz, 1H),7.17 (dd, J = 8.2 and 1.2 Hz, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.68 (d, J =

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4153

307

Page 329: The Application of Pericyclic, Photolytic, Chemoenzymatic

8.0 Hz, 1H), 4.06 (s, 3H), 2.48 (s, 3H); 13C NMR [100 MHz,(CD3)2CO] δ 157.1, 142.7, 138.4, 128.5, 127.2, 126.7, 123.6, 123.5,113.0, 110.8, 104.7, 100.5, 55.6, 21.6; IR νmax 3402, 2917, 2838, 1608,1585, 1506, 1459, 1347, 1260, 1098, 750, 723 cm−1; MS (ESI, +ve) m/z 234 [(M + Na)+, 10%], 212 [(M + H)+, 100]; HRMS (M + H)+

calcd for C14H14NO 212.1075, found 212.1078.5′-Methoxy-5-methyl-2′-nitro-4,5-dihydro-[1,1′-biphenyl]-2(3H)-

one (20). A magnetically stirred mixture of commercially available 2-iodo-4-methoxynitrobenzene (19) (150 mg, 0.54 mmol), 2-iodo-4-methylcyclohex-2-en-1-one (10) (229 mg, 0.97 mmol), copperpowder (137 mg, 2.15 g atom), CuI (154 mg, 0.81 mmol), andPd(dppf)Cl2·CH2Cl2 (44 mg, 0.05 mmol) in deoxygenated DMSO(12 mL) was heated to 50 °C under a nitrogen atmosphere for 4 h.The reaction mixture was then cooled to room temperature, quenchedwith water (5 mL), diluted with ethyl acetate (10 mL), and thenfiltered through a pad of diatomaceous earth and silica gel. The padand the solids thus retained were washed with ethyl acetate (2 × 15mL), and the separated organic phase associated with the filtrate wasthen washed with water (2 × 25 mL) and brine (2 × 25 mL) beforebeing dried (Na2SO4), filtered, and concentrated under reducedpressure to give a brown oil. Subjection of this material to flashchromatography (silica, 1/3/25 v/v/v acetone/dichloromethane/40−60 petroleum ether elution) gave, after concentration of theappropriate fractions [Rf = 0.5(5) in 1/3/6 v/v/v acetone/dichloro-methane/40−60 petroleum ether], compound 20 (125 mg, 87%) as alight yellow oil: 1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 9.1 Hz,1H), 6.90 (dd, J = 9.1 and 2.6 Hz, 1H), 6.70 (m, 2H), 3.88 (s, 3H),2.76−2.51 (complex m, 3H), 2.21 (m, 1H), 1.84 (m, 1H), 1.25 (d, J =7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 196.8, 163.4, 151.2,141.7, 139.1, 135.2, 127.2, 117.2, 113.2, 56.1, 37.3, 31.8, 30.8, 20.5; IRνmax 2953, 1681, 1578, 1512, 1340, 1298, 1238, 1026, 844 cm−1; MS(ESI, +ve) m/z 284 [(M + Na)+, 100%], 262 [(M + H)+, 10]; HRMS(M + Na)+ calcd for C14H15NNaO4 284.0899, found 284.0890.6-Methoxy-3-methyl-2,3,4,9-tetrahydro-1H-carbazole (21). A

magnetically stirred mixture of compound 20 (100 mg, 0.38 mmol)and commercially available W-2 Raney nickel (200 mg, washed twicewith absolute ethanol) in methanol (19 mL) was deoxygenated andthen stirred under an atmosphere of hydrogen at 22 °C for 16 h. Afterthis time and using an externally applied magnet to hold the solidassociated with the reaction mixture within the flask, the supernatantliquid was decanted and the retained solid washed with methanol (2 ×10 mL) (Caution! Af ter these washings water should be added to theresidual solid so as to prevent a f ire.). The methanolic solutions werecombined and then concentrated under reduced pressure to give awhite solid. Subjection of this material to flash column chromatog-raphy (silica, 1/3/20 v/v/v acetone/dichloromethane/40−60 petro-leum ether elution) gave, after concentration of the appropriatefractions (Rf = 0.6 in 1/3/6 v/v/v acetone/dichloromethane/40−60petroleum ether), compound 2112b,d,22b (50 mg, 61%) as a white solid,mp 108−109 °C: 1H NMR [400 MHz, (CD3)2CO] δ 9.52 (broad s,1H), 7.14 (d, J = 8.6 Hz, 1H), 6.88 (s, 1H), 6.65 (d, J = 8.6 Hz, 1H),3.78 (s, 3H), 2.80−2.73 (complex m, 3H), 2.20 (m, 1H), 1.95−1.85(complex m, 2H), 1.52 (m, 1H), 1.12 (d, J = 6.5 Hz, 3H); 13C NMR[100 MHz, (CD3)2CO] δ 154.6, 135.7, 132.5, 129.1, 111.8, 110.7,109.6, 100.6, 55.8, 32.4, 30.6, 30.4, 23.6, 22.1; IR νmax 3401, 2947,2909, 2830, 1591, 1481, 1454, 1431, 1210, 1137, 1030, 831, 796 cm−1;MS (ESI, −ve) m/z 214 [(M − H)−, 100%]; HRMS (M − H)− calcdfor C14H16NO 214.1232, found 214.1235.Glycozoline (4). A magnetically stirred mixture of compound 21

(44 mg, 0.20 mmol) and 10 wt % Pd/C (44 mg) in diphenyl ether (5mL) was stirred at 210 °C under an atmosphere of nitrogen for 0.33 h.The cooled reaction mixture was filtered through filter paper, and thesolids thus retained were washed with ethyl acetate (2 × 5 mL). Thecombined filtrates were concentrated under reduced pressure, and theensuing mixture of product 4 and diphenyl ether was then subjected toflash column chromatography (silica, 1/9 v/v ethyl acetate/40−60petroleum ether elution) to give, after concentration of the appropriatefractions (Rf = 0.4 in 3/7 v/v ethyl acetate/40−60 petroleum ether),compound 43a,15 (39 mg, 89%) as a white, crystalline solid, mp 180−181 °C (lit.22b mp. = 177−178 °C): 1H NMR [400 MHz, (CD3)2CO]

δ 9.96 (broad s, 1H), 7.87 (s, 1H), 7.63 (d, J = 2.2 Hz, 1H), 7.36 (t, J =8.5 Hz, 2H), 7.18 (d, J = 8.2 Hz, 1H), 7.00 (dd, J = 8.5 and 2.2 Hz,1H), 3.88 (s, 3H), 2.47 (s, 3H); 13C NMR [100 MHz, (CD3)2CO] δ154.5, 140.0, 136.1, 128.1, 127.7, 124.2(2), 124.2(0), 120.8, 115.6,112.3, 111.5, 103.5, 56.1, 21.5; IR νmax 3398, 2928, 1493, 1470, 1457,1208, 1148, 1033, 806 cm−1; MS (ESI, −ve) m/z 210 [(M − H)−,60%], 195 (100); HRMS (M − H)− calcd for C14H12NO 210.0919,found 210.0912.

4′-Methoxy-5-methyl-2′-nitro-4,5-dihydro-[1,1′-biphenyl]-2(3H)-one (23). A magnetically stirred mixture of commercially available 1-iodo-4-methoxy-2-nitrobenzene (22) (341 mg, 1.22 mmol), 2-iodo-4-methylcyclohex-2-en-1-one (10) (519 mg, 2.20 mmol), copperpowder (311 mg, 4.89 g atom), CuI (349 mg, 1.83 mmol), andPd(dppf)Cl2·CH2Cl2 (100 mg, 0.12 mmol) in deoxygenated DMSO(24 mL) was heated to 50 °C under a nitrogen atmosphere for 6 h.The ensuing mixture was cooled to room temperature, quenched withwater (10 mL), diluted with ethyl acetate (20 mL), and then filteredthrough a pad of diatomaceous earth and silica gel. The pad and thesolids thus retained were washed with ethyl acetate (2 × 30 mL), andthe separated organic phase associated with the filtrate was washedwith water (2 × 50 mL) and brine (2 × 50 mL) before being dried(Na2SO4), filtered, and concentrated under reduced pressure to give abrown oil. Subjection of this material to flash column chromatography(silica, 2/5/64 v/v/v ethyl acetate/dichloromethane/40−60 petro-leum ether elution) gave, after concentration of the appropriatefractions (Rf = 0.4 in 2/5/11 v/v/v ethyl acetate/dichloromethane/40−60 petroleum ether), compound 23 (256 mg, 80%) as a lightyellow oil: 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 2.3 Hz, 1H),7.15−7.09 (complex m, 2H), 6.75 (dd, J = 2.7 and 1.1 Hz, 1H), 3.85(s, 3H), 2.75 (m, 1H), 2.65−2.40 (complex m, 2H), 2.19 (m, 1H),1.80 (m, 1H), 1.24 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3)δ 196.9, 159.7, 151.8, 149.2, 138.1, 132.7, 124.2, 119.7, 109.3, 56.0,37.3, 31.8, 30.8, 20.5; IR νmax 2960, 1681, 1529, 1353, 1302, 1266,1236, 1032, 800 cm−1; MS (ESI, +ve) m/z 284 [(M + Na)+, 100%],262 [(M + H)+, 15]; HRMS (M + Na)+ calcd for C14H15NNaO4284.0899, found 284.0901.

7-Methoxy-3-methyl-2,3,4,9-tetrahydro-1H-carbazole (24) andtrans-4a-Hydroperoxy-7-methoxy-3-methyl-2,3,4,4a-tetrahydro-1H-carbazole (25). A magnetically stirred mixture of compound 23(202 mg, 0.77 mmol) and commercially available W-2 Raney nickel(404 mg, washed twice with absolute ethanol) in methanol (38 mL)was deoxygenated and then stirred under an atmosphere of hydrogenat 22 °C for 16 h. After this time and using an externally appliedmagnet to hold the solid associated with the reaction mixture withinthe flask, the supernatant liquid was decanted and the retained solidwashed with methanol (2 × 20 mL) (Caution! Af ter these washingswater should be added to the residual solid so as to prevent a f ire.). Themethanolic solutions were combined and then concentrated underreduced pressure to give a white solid. Subjection of this material toflash column chromatography (silica, 1/3/20 v/v/v acetone/dichloro-methane/40−60 petroleum ether elution) gave two fractions, A and B.

Concentration of fraction A (Rf = 0.5 in 1/3/6 v/v/v acetone/dichloromethane/40−60 petroleum ether) afforded compound2411a,14 (109 mg, 65%) as a white, crystalline solid, mp 130−132°C: 1H NMR [400 MHz, (CD3)2CO] δ 9.50 (broad s, 1H), 7.22 (d, J= 8.5 Hz, 1H), 6.83 (d, J = 2.2 Hz, 1H), 6.63 (dd, J = 8.5 and 2.2 Hz,1H), 3.76 (s, 3H), 2.83−2.71 (complex m, 3H), 2.19 (m, 1H), 1.90(m, 2H), 1.50 (m, 1H), 1.11 (d, J = 6.5 Hz, 3H); 13C NMR [100MHz, (CD3)2CO] δ 156.6, 138.2, 133.4, 123.2, 118.5, 109.5, 108.6,95.4, 55.7, 32.3, 30.6, 30.3, 23.5, 22.1; IR νmax 3390, 2909, 2835, 1630,1570, 1496, 1459, 1335, 1291, 1203, 1157, 1029, 826, 805 cm−1; MS(ESI, +ve) m/z 238 [(M + Na)+, 20%], 218 (100), 216 [(M + H)+,90]; HRMS (M + H)+ calcd for C14H18NO 216.1388, found 216.1386.

Concentration of fraction B (Rf = 0.1 in 1/3/6 v/v/v acetone/dichloromethane/40−60 petroleum ether) afforded hydroperoxide 25(15 mg, 8%) as a white, crystalline solid, mp 106−108 °C: 1H NMR[700 MHz, (CD3)2CO] δ δ 10.81 (s, 1H), 7.26 (d, J = 8.0 Hz, 1H),6.97 (d, J = 2.3 Hz, 1H), 6.71 (dd, J = 8.0 and 2.3 Hz, 1H), 3.82 (s,3H), 2.82−2.76 (complex m, 1H), 2.68 (m, 1H), 2.43 (m, 1H), 2.14(m, 2H), 1.13 (m, 1H), 0.95 (m, 1H), 0.92 (d, J = 6.6 Hz, 3H); 13C

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4154

308

Page 330: The Application of Pericyclic, Photolytic, Chemoenzymatic

NMR [175 MHz, (CD3)2CO] δ 186.1, 162.2, 157.4, 131.5, 123.8,110.8, 107.4, 92.3, 55.8, 44.4, 37.4, 30.3, 28.1, 21.0; IR νmax 3100, 2954,2836, 1607, 1484, 1347, 1276, 1144, 1130, 1028, 845, 815 cm−1; MS(ESI, +ve) m/z 270 [(M + Na)+, 100%], 248 [(M + H)+, 10]; HRMS(ESI) (M + Na)+ calcd for C14H17NNaO3 270.1106, found 270.1107.2-Methoxy-6-methyl-9H-carbazole (26). A magnetically stirred

mixture of compound 24 (100 mg, 0.46 mmol) and 10 wt % Pd/C(100 mg) in diphenyl ether (10 mL) was stirred at 210 °C under anatmosphere of nitrogen for 0.5 h. The cooled reaction mixture wasfiltered through filter paper, and the solids thus retained were washedwith ethyl acetate (2 × 10 mL). The combined filtrates wereconcentrated under reduced pressure, and the ensuing mixture ofproduct 269c,h,22d,23a,b and diphenyl ether was then subjected to flashcolumn chromatography (silica, 2/5/60 v/v/v ethyl acetate/dichloro-methane/40−60 petroleum ether elution) to give, after concentrationof the appropriate fractions (Rf = 0.4 in 2/5/11 v/v/v ethyl acetate/dichloromethane/40−60 petroleum ether), compound 26 (87 mg,88%) as a white solid, mp 229−231 °C (lit.9c mp 228−229 °C): 1HNMR [400 MHz, (CD3)2CO] δ 10.03 (braod s, 1H), 7.92 (d, J = 8.6Hz, 1H), 7.78 (s, 1H), 7.32 (d, J = 8.2 Hz, 1H), 7.11 (d, J = 8.2 Hz,1H), 6.99 (d, J = 2.2 Hz, 1H), 6.77 (dd, J = 8.6 and 2.2 Hz, 1H), 3.85(s, 3H), 2.46 (s, 3H); 13C NMR [100 MHz, (CD3)2CO] δ 160.0,142.7, 139.3, 128.6, 126.3, 124.4, 121.5, 120.0, 117.6, 111.1, 108.6,95.3, 55.7, 21.5; IR νmax 3391, 2962, 1615, 1460, 1310, 1261, 1164,1035, 811 cm−1; MS (ESI, +ve) m/z 212 [(M + H)+, 100%]; HRMS(M + H)+ calcd for C14H14NO 212.1075, found 212.1077.Clauszoline K (5). A magnetically stirred solution of 2-methoxy-6-

methyl-9H-carbazole (26) (50 mg, 0.24 mmol) in methanol/water (16mL of 10/1 v/v mixture) was treated with DDQ (226 mg, 0.99 mmol).The ensuing mixture was stirred at room temperature for 4 h and thendiluted with ethyl acetate (30 mL). The separated organic phase waswashed with NaHCO3 (2 × 15 mL of a saturated aqueous solution),water (1 × 30 mL), and brine (1 × 30 mL) before being dried(Na2SO4), filtered, and concentrated under reduced pressure. Theresidue thus obtained was subjected to flash chromatography (silica, 1/3 v/v ethyl acetate/40−60 petroleum ether elution) to give, afterconcentration of the appropriate fractions (Rf = 0.5 in 1/1 v/v ethylacetate/40−60 petroleum ether), compound 5 (35 mg, 66%) as ayellow solid, mp 170−171 °C (lit.22d mp 184−185 °C): 1H NMR[400 MHz, (CD3)2CO] δ 10.72 (broad s, 1H), 10.07 (s, 1H), 8.58 (s,1H), 8.12 (d, J = 8.6 Hz, 1H), 7.88 (broadened d, J = 8.4 Hz, 1H),7.59 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 2.3 Hz, 1H), 6.91 (dd, J = 8.6 and2.3 Hz, 1H), 3.89 (s, 3H); 13C NMR [100 MHz, (CD3)2CO] δ 192.0,160.8, 144.8, 143.1, 130.1, 126.3, 124.4, 123.5, 122.2, 117.6, 111.8,110.1, 96.0, 55.8; IR νmax 3306, 2923, 2849, 1667, 1604, 1569, 1456,1317, 1159, 817, 807 cm−1; MS (ESI, −ve) m/z 224 [(M − H)−,100%], 209 (54); HRMS (M − H)− calcd for C14H10NO2 224.0712,found 224.0705.Methyl 3-Bromo-5-methoxy-4-nitrobenzoate (27). Step i. A

magnetically stirred and ice-cold solution of methyl 4-amino-3-methoxybenzoate (3.00 mg, 16.56 mmol) in chloroform (33 mL)was treated, in portions over 1 h, with N-bromosuccinimide (NBS)(2.95, 16.6 mmol). The ensuing mixture was stirred at 5−10 °C for 2 hbefore being diluted with dichloromethane (1 × 200 mL) then washedwith Na2S2O3 (2 × 100 mL of a 20% w/v aqueous solution), water (2× 100 mL), and brine (1 × 100 mL). The separated organic phase wasthen dried (Na2SO4), filtered, and concentrated under reducedpressure. The residue thus obtained was subjected to flash columnchromatography (silica, 3/17 v/v ethyl acetate/40−60 petroleum etherelution) to give, after concentration of the appropriate fractions (Rf =0.6 in 1/3 v/v ethyl acetate/40−60 petroleum ether), methyl 4-amino-3-bromo-5-methoxybenzoate25 (3.70 g, 86%) as a yellow solid, mp90−91 °C: 1H NMR (CDCl3, 400 MHz) δ 7.81 (s, 1H), 7.38 (s, 1H),4.65 (broad s, 2H), 3.91 (s, 3H), 3.87 (s, 3H); 13C NMR (100 MHz,CDCl3) δ 166.5, 146.3, 139.4, 127.1, 119.5, 109.9, 106.8, 56.2, 52.1; IRνmax 3503, 3399, 1692, 1603, 1566, 1502, 1435, 1270, 1209, 1041, 995,759 cm−1; MS (EI, 70 eV) m/z 261 and 259 (M+•, 98 and 100%,respectively), 246 and 244 (both 65 and 63, respectively), 230 and 228(both 54); HRMS M+• calcd for C9H10

79BrNO3 258.9844, found258.9846.

Step ii. A magnetically stirred solution of methyl 4-amino-3-bromo-5-methoxybenzoate (4.24 g, 16.31 mmol), obtained as describedimmediately above, in 1,2-dichloroethane (163 mL) was treated withm-chloroperbenzoic acid (mCPBA) (11.26 g of ca. 77% technicalgrade material, 65.3 mmol). The resulting mixture was heated to 70 °Cfor 14 h before being cooled, diluted with dichloromethane (150 mL),washed with NaOH (2 × 150 mL of a 1 M aqueous solution) followedby brine (1 × 100 mL), and then dried (MgSO4), filtered, andconcentrated under reduced pressure. The residue thus obtained wassubjected to flash column chromatography (silica, 1/8 v/v ethylacetate/40−60 petroleum ether elution) to give, after concentration ofthe appropriate fractions (Rf = 0.5 in 1/2 v/v ethyl acetate/40−60petroleum ether), methyl 3-bromo-5-methoxy-4-nitrobenzoate (27)(4.13 g, 87%) as a yellow solid, mp 103−104 °C: 1H NMR (400 MHz,CDCl3) δ 7.88 (d, J = 1.4 Hz, 1H), 7.65 (d, J = 1.4 Hz, 1H), 3.95(9)(s, 3H), 3.95(6) (s, 3H); 13C NMR (100 MHz, CDCl3) δ 164.4, 151.8,144.7, 133.1, 126.2, 113.8, 112.8, 57.1, 53.2; IR νmax 3097, 1730, 1540,1406, 1289, 1248, 1037, 984, 822, 764 cm−1; MS (EI, 70 eV) m/z 291and 289 (M+•, 98 and 100%, respectively) 259 and 257 (40 and 35,respectively) 199 and 197 (60 and 50, respectively); HRMS M+• calcdfor C9H8

79BrNO5 288.9586, found 288.9587.Methyl 5-Methoxy-6-nitro-2′-oxo-2′,3′,4′,5′-tetrahydro-[1,1′-bi-

phenyl]-3-carboxylate (28). A magnetically stirred mixture of methyl3-bromo-5-methoxy-4-nitrobenzoate (28) (2.56 g, 8.82 mmol), 2-iodocyclohex-2-en-1-one (9) (890 mg, 4.01 mmol), copper powder(1.27 g, 20.04 g atom), CuI (1.15 g, 6.01 mmol), and Pd(dppf)Cl2·CH2Cl2 (164 mg, 0.20 mmol) in deoxygenated DMSO (17 mL) washeated to 50 °C under a nitrogen atmosphere for 28 h. The reactionmixture was then cooled to room temperature, quenched with water(20 mL), diluted with ethyl acetate (40 mL) and filtered through a padof diatomaceous earth and silica gel. The pad and the solids thusretained were washed with ethyl acetate (2 × 60 mL), and the organicphase associated with the filtrate was washed with water (2 × 100 mL)and then brine (2 × 100 mL) before being dried (Na2SO4), filtered,and concentrated under reduced pressure to give a brown oil.Subjection of this material to flash column chromatography (silica, 1/9v/v ethyl acetate/40−60 petroleum ether elution) gave, afterconcentration of the appropriate fractions (Rf = 0.5 in 1/1 v/v ethylacetate/40−60 petroleum ether), compound 28 (478 mg, 39%) as ayellow oil: 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 1.3 Hz, 1H),7.51 (d, J = 1.3 Hz, 1H), 7.05 (t, J = 4.2 Hz, 1H), 3.96 (s, 3H), 3.94 (s,3H), 2.58−2.50 (complex m, 4H), 2.10 (m, 2H); 13C NMR (100MHz, CDCl3) δ 196.1, 165.4, 151.2, 150.2, 143.3, 136.3, 132.4, 131.6,124.2, 113.3, 57.0, 52.9, 38.3, 26.5, 22.7; IR νmax 2956, 2924, 1716,1683, 1535, 1360, 1245, 1022, 838, 766 cm−1; MS (ESI, +ve) m/z 328[(M + Na)+, 100%]; HRMS (M + Na)+ calcd for C15H15NNaO6

328.0797, found 328.0793.Methyl 8-Methoxy-2,3,4,9-tetrahydro-1H-carbazole-6-carboxy-

late (29). A magnetically stirred mixture of compound 28 (400 mg,1.31 mmol) and commercially available W-2 Raney nickel (800 mg,washed twice with absolute ethanol) in methanol (65 mL) wasdeoxygenated and then stirred under an atmosphere of hydrogen at 22°C for 16 h. After this time and using an externally applied magnet tohold the solid associated with the reaction mixture within the flask, thesupernatant liquid was decanted and the retained solid washed withmethanol (2 × 40 mL) (Caution! Af ter these washings water should beadded to the residual solid so as to prevent a f ire.). The methanolicsolutions were combined and then concentrated under reducedpressure to give a white solid. Subjection of this material to flashcolumn chromatography (silica, 3/17 v/v ethyl acetate/40−60petroleum ether elution) gave, after concentration of the appropriatefractions (Rf = 0.6 in 1/2 v/v ethyl acetate/40−60 petroleum ether),compound 29 (268 mg, 79%) as a white solid, mp 181−182 °C: 1HNMR [400 MHz, (CD3)2CO] δ 10.15 (broad s, 1H), 7.81 (s, 1H),7.25 (s, 1H), 3.96 (s, 3H), 3.86 (s, 3H), 2.77 (m, 2H), 2.70 (m, 2H),1.92−1.82 (complex m, 4H); 13C NMR [100 MHz, (CD3)2CO] δ168.5, 146.2, 136.6, 129.7, 129.4, 122.1, 114.8, 111.7, 102.5, 55.7, 51.8,24.0, 23.9, 23.7, 21.6; IR νmax 3339, 2928, 2836, 1696, 1628, 1366,1326, 1231, 1188, 993, 765 cm−1; MS (ESI, +ve) m/z 541 (65%), 282

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4155

309

Page 331: The Application of Pericyclic, Photolytic, Chemoenzymatic

[(M + Na)+, 100]; HRMS (M + Na)+ calcd for C15H17NNaO3282.1106, found 282.1105.Mukonine (6). A magnetically stirred mixture of compound 29 (264

mg, 1.02 mmol) and 10 wt % Pd/C (264 mg) in mesitylene (20 mL)was stirred at 150 °C under an atmosphere of nitrogen for 24 h. Thecooled reaction mixture was filtered through filter paper, and the solidsthus retained were washed with ethyl acetate (2 × 20 mL). The filtratewas concentrated under reduced pressure and the ensuing mixture ofproduct 6 and mesitylene then subjected to flash columnchromatography (silica, 1/19 v/v ethyl acetate/40−60 petroleumether elution) to give, after concentration of the appropriate fractions(Rf = 0.5 in 1/3 v/v ethyl acetate/40−60 petroleum ether), compound617 (171 mg, 66%) as a white solid, mp 196−198 °C (lit.17a mp 193−195 °C): 1H NMR (400 MHz, CDCl3) δ 8.52 (broad s, 1H), 8.48 (s,1H), 8.10 (d, J = 7.8 Hz, 1H), 7.60 (s, 1H), 7.49−7.43 (complex m,2H), 7.28 (m, 1H), 4.05 (s, 3H), 3.98 (s, 3H); 13C NMR (100 MHz,CDCl3) δ 168.1, 145.2, 139.6, 133.0, 126.5, 123.9, 123.7, 122.0, 120.9,120.4, 116.4, 111.4, 106.8, 55.9, 52.2; IR νmax 3350, 2941, 1689, 1608,1585, 1433, 1338, 1255, 758, 732 cm−1; MS (ESI, +ve) m/z 533(28%), 278 [(M + Na)+, 100]; HRMS (M + Na)+ calcd forC15H13NNaO3 278.0793, found 278.0792.6-Methyl-9H-carbazol-2-ol (30). A magnetically stirred solution of

compound 26 (50 mg, 0.24 mmol) in dichloromethane (15 mL)maintained at −78 °C under an atmosphere of nitrogen was treated,dropwise, with BBr3 (470 μL of a 1 M solution in dichloromethane,0.47 mmol). The resulting mixture was stirred at −78 °C for another 2h and then warmed to −40 °C. After 2 h the reaction mixture wasrecooled to −78 °C and a further portion of BBr3 (520 μL of a 1 Msolution in dichloromethane, 0.52 mmol) added dropwise. Thereaction mixture was then warmed to 22 °C, stirred at this temperaturefor 11 h, cooled to 0 °C, and then quenched by the slow addition ofNaHCO3 (30 mL of a saturated aqueous solution). The resultingmixture was extracted with dichloromethane (1 × 20 mL), and thecombined organic phases were washed with water (1 × 20 mL) andbrine (1 × 20 mL) before being dried (Na2SO4), filtered, andconcentrated under reduced pressure. The residue thus obtained wassubjected to flash chromatography (silica, 3/17 v/v ethyl acetate/40−60 petroleum ether elution) to give, after concentration of theappropriate fractions [Rf = 0.2(5) in 3/7 v/v ethyl acetate/40−60petroleum ether], compound 309h (39 mg, 84%) as a white, crystallinesolid, mp 259−261 °C (lit.9h mp 230−233 °C): 1H NMR [400 MHz,(CD3)2CO] δ 9.91 (broad s, 1H), 8.25 (s, 1H), 7.84 (d, J = 8.4 Hz,1H), 7.74 (s, 1H), 7.28 (d, J = 8.2 Hz, 1H), 7.08 (d, J = 8.2 Hz, 1H),6.90 (d, J = 2.1 Hz, 1H), 6.71 (dd, J = 8.4 and 2.1 Hz, 1H), 2.45 (s,3H); 13C NMR (100 MHz, (CD3)2CO) δ 157.4, 143.0, 139.2, 128.4,126.0, 124.7, 121.5, 119.8, 117.1, 110.9, 109.1, 97.4, 21.5; IR νmax 3403,2922, 2853, 1633, 1616, 1490, 1459, 1296, 1026, 804 cm−1; MS (ESI,−ve) m/z 196 [(M − H)−, 100%]; HRMS (M − H)− calcd forC13H10NO 196.0762, found 196.0767.Karapinchamine A (7). A magnetically stirred solution of

compound 30 (27 mg, 0.14 mmol) in anhydrous THF (7 mL)maintained at 0 °C under a nitrogen atmosphere was treated,dropwise, with n-BuLi (340 μL of a 1.6 M solution in n-hexane, 0.55mmol). After 0.17 h, a solution of geranyl bromide (51 mg, 0.21mmol) in THF (7 mL) was added dropwise over 0.5 h. The resultingmixture was warmed to 22 °C, stirred at this temperature for 1.5 h,then cooled to 0 °C and quenched with NH4Cl (15 mL of a saturatedaqueous solution). The resulting mixture was extracted with ethylacetate (2 × 30 mL), and the combined organic phases were washedwith water (1 × 20 mL) and brine (1 × 20 mL) before being dried(Na2SO4), filtered, and concentrated under reduced pressure. Theresidue thus obtained was subjected to flash chromatography (silica, 1/9 v/v ethyl acetate/40−60 petroleum ether elution) to give, afterconcentration of the appropriate fractions (Rf = 0.6 in 3/7 v/v ethylacetate/40−60 petroleum ether), compound 77e,18 (23 mg, 50%) as awhite solid, mp 118−119 °C (lit.7e mp 124.3−125.6 °C): 1H NMR(400 MHz, CDCl3) δ 7.87 (d, J = 8.3 Hz, 1H), 7.78 (s, 1H), 7.23−7.18 (complex m, 2H), 6.78 (d, J = 1.9 Hz, 1H), 6.70 (dd, J = 8.3 and2.0 Hz, 1H), 5.24 (m, 1H), 5.02 (m, 1H), 4.88 (s, 1H), 4.79 (d, J = 6.1Hz, 2H), 2.52 (s, 3H), 2.09−1.98 (complex m, 4H), 1.90 (s, 3H), 1.62

(s, 3H), 1.55 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 154.6, 142.2,138.9, 138.7, 131.9, 128.4, 125.8, 123.9, 123.4, 121.2, 120.0, 119.6,117.1, 108.4, 107.7, 95.2, 41.3, 39.5, 26.4, 25.8, 21.5, 17.8, 16.8; IR νmax3278, 2922, 2855, 1635, 1610, 1487, 1471, 1348, 1171, 801 cm−1; MS(ESI, +ve) m/z 356 [(M + Na)+, 100%], 334 [(M + H)+, 20]; HRMS(M + Na)+ calcd for C23H27NNaO 356.1990, found 356.1994.

4′-Methoxy-2′-nitro-4,5-dihydro-[1,1′-biphenyl]-2(3H)-one (31).A magnetically stirred mixture of 1-iodo-4-methoxy-2-nitrobenzene(22) (912 mg, 3.27 mmol), 2-iodocyclohex-2-en-1-one (9) (330 mg,1.49 mmol), copper powder (472 mg, 7.43 g atom), CuI (425 mg, 2.23mmol), and Pd(dppf)Cl2·CH2Cl2 (61 mg, 0.07 mmol) indeoxygenated DMSO (15 mL) was heated to 50 °C under a nitrogenatmosphere for 10 h. The reaction mixture was then cooled to roomtemperature, quenched with water (15 mL), diluted with ethyl acetate(30 mL), and then filtered through a pad of diatomaceous earth andsilica gel. The pad and the solids thus retained were washed with ethylacetate (2 × 40 mL), and the separated organic phase associated withthe filtrate was washed with water (2 × 80 mL) and brine (2 × 80 mL)before being dried (Na2SO4), filtered, and concentrated under reducedpressure to give a brown oil. Subjection of this material to flash columnchromatography (silica, 2/5/44 v/v/v ethyl acetate/dichloromethane/40−60 petroleum ether elution) gave, after concentration of theappropriate fractions (Rf = 0.3 in 2/5/11 v/v/v ethyl acetate/dichloromethane/40−60 petroleum ether), compound 3110,11b (334mg, 91%) as a light yellow oil: 1H NMR [400 MHz, (CD3)2CO] δ7.51 (d, J = 2.2 Hz, 1H), 7.28 (m, 2H), 7.10 (m, 1H), 3.92 (s, 3H),2.58 (m, 2H), 2.46 (m, 2H), 2.09 (m, 2H); 13C NMR [100 MHz,(CD3)2CO] δ 196.5, 160.5, 150.4, 147.5, 139.5, 133.6, 125.1, 120.0,109.9, 56.4, 39.0, 27.0, 23.5; IR νmax 2945, 1678, 1525, 1496, 1353,1232, 1035, 913, 830, 798 cm−1; MS (ESI, +ve) m/z 270 [(M + Na)+,100%], 248 [(M + H)+, 10]; HRMS (M + Na)+ calcd forC13H13NNaO4 270.0742, found 270.0739.

7-Methoxy-2,3,4,9-tetrahydro-1H-carbazole (32). A magneticallystirred mixture of compound 31 (100 mg, 0.40 mmol) andcommercially available W-2 Raney nickel (200 mg, washed twicewith absolute ethanol) in methanol (23 mL) was deoxygenated andthen stirred under an atmosphere of hydrogen at 22 °C for 16 h. Afterthis time and using an externally applied magnet to hold the solidassociated with the reaction mixture within the flask, the supernatantliquid was decanted and the retained solid washed with methanol (2 ×20 mL) (Caution! Af ter these washings water should be added to theresidual solid so as to prevent a f ire.). The methanolic solutions werecombined and then concentrated under reduced pressure to give awhite solid. Subjection of this material to flash column chromatog-raphy (silica, 1/3/20 v/v/v acetone/dichloromethane/40−60 petro-leum ether elution) gave, after concentration of the appropriatefractions (Rf = 0.4(5) in 1/3/6 v/v/v acetone/dichloromethane/40−60 petroleum ether), compound 3210,11b,26 (62 mg, 76%) as a white,crystalline solid, mp 138−139 °C (lit.10 mp 136−142 °C): 1H NMR(400 MHz, CDCl3) δ 7.54 (broad s, 1H), 7.33 (d, J = 8.5 Hz, 1H),6.80 (d, J = 2.2 Hz, 1H), 6.75 (dd, J = 8.5 and 2.2 Hz, 1H), 3.84 (s,3H), 2.69 (m, 4H), 1.88 (m, 4H); 13C NMR (100 MHz, CDCl3) δ155.9, 136.5, 132.9, 122.5, 118.3, 110.1, 108.4, 95.0, 56.0, 23.4,23.3(5), 23.3(4), 21.1; IR νmax 3405, 2919, 2842, 1628, 1464, 1307,1213, 1156, 1029, 826, 803 cm−1; MS (ESI, +ve) m/z 202 [(M + H)+,100%]; HRMS (M + H)+ calcd for C13H16NO 202.1232, found202.1230.

2-Methoxy-9H-carbazole (8). A magnetically stirred mixture ofcompound 32 (40 mg, 0.20 mmol) and 10 wt % Pd/C (40 mg) inmesitylene (5 mL) was stirred at 150 °C under an atmosphere ofnitrogen for 24 h. The cooled reaction mixture was filtered throughfilter paper, and the solids thus retained were washed with ethyl acetate(2 × 10 mL). The combined filtrates were concentrated under reducedpressure, and the ensuing mixture of product 6 and mesitylene wasthen subjected to flash column chromatography (silica, 1/19 v/v ethylacetate/40−60 petroleum ether elution) to give, after concentration ofthe appropriate fractions (Rf = 0.3 in 1/5 v/v ethyl acetate/40−60petroleum ether), compound 86f,k,l,9j (25 mg, 64%) as a white,crystalline solid, mp 227−228 °C (lit.6f mp 233−235 °C): 1H NMR[400 MHz, (CD3)2CO] δ 10.18 (broad s, 1H), 7.97 (m, 2H), 7.44 (d,

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4156

310

Page 332: The Application of Pericyclic, Photolytic, Chemoenzymatic

J = 8.1 Hz, 1H), 7.28 (t, J = 7.9 Hz, 1H), 7.13 (m, 1H), 7.03 (broad s,1H), 6.80 (m, 1H), 3.86 (s, 3H); 13C NMR [100 MHz, (CD3)2CO] δ160.1, 142.4, 141.0, 125.0, 124.2, 121.6, 120.0, 119.7, 117.7, 111.4,108.8, 95.4, 55.7; IR νmax 3391, 2929, 1608, 1463, 1444, 1308, 1196,1163, 1033, 818, 727 cm−1; MS (ESI, −ve) m/z 196 [(M − H)−,100%]; HRMS (M − H)− calcd for C13H10NO 196.0762, found196.0753.X-ray Crystallographic Studies. Crystallographic Data. Com-

pound 1: C12H9N, Mr = 167.21, T = 150 K, orthorhombic, spacegroup Pnma, Z = 4, a = 7.6589(2) Å, b = 19.0353(5) Å, c = 5.6814(1)Å; V = 828.29(3) Å3, Dx = 1.341 g cm−3, 864 unique data (2θmax =147.4°), R = 0.035 [for 795 reflections with I > 2.0σ(I)]; Rw = 0.058(all data), S = 1.00.Compound 2: C13H11N, Mr = 181.24, T = 150 K, monoclinic, space

group P21/c, Z = 4, a = 20.3990(8) Å, b = 5.7846(2) Å, c = 7.8899(3)Å; β = 98.458(4)°; V = 920.88(6) Å3, Dx = 1.307 g cm−3, 1858 uniquedata (2θmax = 147.8°), R = 0.057 [for 1748 reflections with I >2.0σ(I)]; Rw = 0.096 (all data), S = 1.00.Compound 3: C14H13NO, Mr = 211.26, T = 150 K, monoclinic,

space group P21/n, Z = 4, a = 11.4714(17) Å, b = 5.6130(6) Å, c =16.915(2) Å; β = 95.648(12)°; V = 1083.9(2) Å3, Dx = 1.295 g cm−3,2160 unique data (2θmax = 151.8°), R = 0.058 [for 1763 reflectionswith I > 2.0σ(I)]; Rw = 0.164 (all data), S = 1.00.Compound 4: C14H13NO, Mr = 211.26, T = 150 K, orthorhombic,

space group P212121, Z = 4, a = 6.4420(1) Å, b = 7.5921(1) Å, c =21.9422(3) Å; V = 1073.16(3) Å3, Dx = 1.308 g cm−3, 2166 uniquedata (2θmax = 147.8°), R = 0.035 [for 2114 reflections with I >2.0σ(I)]; Rw = 0.064 (all data), S = 1.00.Compound 5: C14H11NO2, Mr = 225.25, T = 150 K, orthorhombic,

space group Pbca, Z = 8, a = 7.1367(1) Å, b = 13.2390(1) Å, c =22.5108(2) Å; V = 2126.88(4) Å3, Dx = 1.407 g cm−3, 2152 uniquedata (2θmax = 147.8°), R = 0.033 [for 2089 reflections with I >2.0σ(I)]; Rw = 0.058 (all data), S = 1.00.Compound 6: C15H13NO3, Mr = 255.27, T = 150 K, monoclinic,

space group C2/c, Z = 8, a = 15.7767(2) Å, b = 9.4629(1) Å, c =16.1402(2) Å; β = 91.7342(13)°; V = 2408.52(5) Å3, Dx = 1.408 gcm−3, 3284 unique data (2θmax = 59.6°), R = 0.039 [for 2869reflections with I > 2.0σ(I)]; Rw = 0.077 (all data), S = 1.00.Compound 17: C14H15NO4, Mr = 261.27, T = 150 K, monoclinic,

space group P21/c, Z = 8, a = 21.5986(4) Å, b = 6.89910(11) Å, c =17.6362(3) Å; β = 104.596(2)°; V = 2543.16(8) Å3, Dx = 1.365 gcm−3, 5147 unique data (2θmax = 147.6°), R = 0.084 [for 4826reflections with I > 2.0σ(I)]; Rw = 0.214 (all data), S = 1.12.Compound 25: C14H17NO3, Mr = 247.29, T = 150 K, monoclinic,

space group P21/c, Z = 4, a = 14.6135(2) Å, b = 5.8504(1) Å, c =14.6942 (2) Å; β = 96.2796(15)°; V = 1248.74(3) Å3, Dx = 1.315 gcm−3, 2542 unique data (2θmax = 147.6°), R = 0.036 [for 2433reflections with I > 2.0σ(I)]; Rw = 0.098 (all data), S = 1.00.Structure Determination. The image for compound 6 was

measured on a diffractometer (Mo Kα, graphite monochromator, λ= 0.71073 Å) fitted with an area detector, and the data were extractedusing the DENZO/Scalepack package.34 Images for compounds 1−5,17, and 25 were measured on a diffractometer (Cu Kα, mirrormonochromator, λ = 1.54184 Å) fitted with an area detector and thedata extracted using the CrysAlis package.35 The structure solutionsfor all eight compounds were solved by direct methods (SIR92)36 thenrefined using the CRYSTALS program package.37 Atomic coordinates,bond lengths and angles, and displacement parameters have beendeposited at the Cambridge Crystallographic Data Centre (CCDCnos. 1525166, 1525163, 1525164, 1525162, 1525167, 1525160,1525161, and 1525165 for compounds 1−6, 17, and 25, respectively).These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, by e-mailing [email protected], or bycontacting The Cambridge Crystallographic Data Centre, 12 UnionRoad, Cambridge CB2 1EZ, U.K. (fax: + 44 1223 336033). Single-crystal X-ray analyses of compound 1 have been reported previously.38

■ ASSOCIATED CONTENT*S Supporting InformationThe Supporting Information is available free of charge on theACS Publications website at DOI: 10.1021/acs.joc.7b00044.

Crystallographic data (CIF)Crystallographic data (CIF)Crystallographic data (CIF)Crystallographic data (CIF)Crystallographic data (CIF)Crystallographic data (CIF)Crystallographic data (CIF)Crystallographic data (CIF)Crystallographic data and anisotropic displacementellipsoid plots derived from the single-crystal X-rayanalyses of compounds 1−6, 17, and 25, 1H and 13CNMR spectra of compounds 1−15, 17, 18, 20, 21, 23−32, and methyl 4-amino-3-bromo-5-methoxybenzoate(precursor to compound 27) (PDF)

■ AUTHOR INFORMATIONCorresponding Author*E-mail for M.G.B.: [email protected] G. Banwell: 0000-0002-0582-475XNotesThe authors declare no competing financial interest.

■ ACKNOWLEDGMENTSWe thank the Australian Research Council and the Institute ofAdvanced Studies for financial support. Q.Y. is the gratefulrecipient of a PhD Scholarship provided by China ScholarshipCouncil of the People’s Republic of China. E.G. acknowledgesscholarship support from the ANU. M.W.-K. thanks theDepartment of Organic Chemistry, Faculty of Chemistry,Wroclaw University of Technology, Wroclaw, Poland for givingher leave to undertake research at the ANU.

■ REFERENCES(1) Graebe, C.; Glaser, C. Ber. Dtsch. Chem. Ges. 1872, 5, 12.(2) For useful points of entry into the relevant literature see:(a) Thevissen, K.; Marchand, A.; Chatlin, P.; Meert, E. M.; Cammue,B. P. Curr. Med. Chem. 2009, 16, 2205−2211. (b) Yaqub, G.; Huissain,E. A.; Rehman, M. A.; Mateen, B. Asian J. Chem. 2009, 21, 2485−2520.(c) Roy, J.; Jana, A. K.; Mal, D. Tetrahedron 2012, 68, 6099−6121.(d) Schmidt, A. W.; Reddy, K. R.; Knolker, H.-J. Chem. Rev. 2012, 112,3193−3328. (e) Gluszynska, A. Eur. J. Med. Chem. 2015, 94, 405−426.(f) Bashir, M.; Bano, A.; Ijaz, A. S.; Chaudhary, B. A. Molecules 2015,20, 13496−13517. (g) Sathiyan, G.; Sivakumar, E. K. T.;Ganesamoorthy, R.; Thangamuthu, R.; Sakthivel, P. Tetrahedron Lett.2016, 57, 243−252.(3) See, for example: (a) Cheenpracha, S.; Laphookhieo, S.Phytochem. Lett. 2011, 4, 187−189. (b) Miller, C. M.; McCarthy, F.O. RSC Adv. 2012, 2, 8883−8918. (c) Pieroni, M.; Girmay, S.; Sun, D.;Sahu, R.; Tekwani, B. L.; Tan, G. T. ChemMedChem 2012, 7, 1895−1900. (d) Russell, F.; Harmody, D.; McCarthy, P. J.; Pomponi, S. A.;Wright, A. E. J. Nat. Prod. 2013, 76, 1989−1992. (e) Kim, S.-H.; Ha,T.-K.-Q.; Oh, W. K.; Shin, J.; Oh, D.-C. J. Nat. Prod. 2016, 79, 51−58.(f) Patel, O. P. S.; Mishra, A.; Maurya, R.; Saini, D.; Pandey, J.; Taneja,I.; Raju, K. S. R.; Kanojiya, S.; Shukla, S. K.; Srivastava, M. N.;Wahajuddin, M.; Tamrakar, A. K.; Srivastava, A. K.; Yadav, P. P. J. Nat.Prod. 2016, 79, 1276−1284.(4) (a) Fischer, E.; Jourdan, F. Ber. Dtsch. Chem. Ges. 1883, 16,2241−2245. (b) Borsche, W.; Witte, A.; Bothe, W. Liebigs Ann. Chem.1908, 359, 49−80. For related and recent approaches see:

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4157

311

Page 333: The Application of Pericyclic, Photolytic, Chemoenzymatic

(c) Chakraborty, S.; Chattopadhyay, G.; Saha, C. J. Heterocyclic Chem.2013, 50, 91−98. (d) Wu, J.; Xie, Y.; Chen, X.; Deng, G.-J. Adv. Synth.Catal. 2016, 358, 3206−3211.(5) Graebe, C.; Ullmann, F. Liebigs Ann. Chem. 1896, 291, 16−17.(6) (a) Cadogan, J. I. G.; Cameron-Wood, M.; Mackie, R. K.; Searle,R. J. G. J. Chem. Soc. 1965, 4831−4837. For related and recentvariants see: (b) Smitrovich, J. H.; Davies, I. W. Org. Lett. 2004, 6,533−535. (c) Tsang, W. C. P.; Zheng, N.; Buchwald, S. L. J. Am.Chem. Soc. 2005, 127, 14560−14561. (d) Jordan-Hore, J. A.;Johansson, C. C. C.; Gulias, M.; Beck, E. M.; Gaunt, M. J. J. Am.Chem. Soc. 2008, 130, 16184−16186. (e) Kuethe, J. T.; Childers, K. G.Adv. Synth. Catal. 2008, 350, 1577−1586. (f) Stokes, B. J.; Jovanovic,H.; Dong, H.; Richert, K. J.; Riell, R. D.; Driver, T. G. J. Org. Chem.2009, 74, 3225−3228. (g) Gao, H.; Xu, Q.-L.; Yousufuddin, M.; Ess,D. H.; Kurti, L. Angew. Chem., Int. Ed. 2014, 53, 2701−2705.(h) Suzuki, C.; Hirano, K.; Satoh, T.; Miura, M. Org. Lett. 2015, 17,1597−1600. (i) Goo, D.-Y.; Woo, S. K. Org. Biomol. Chem. 2016, 14,122−130. (j) Yang, C.; Lin, K.; Huang, L.; Pan, W.-d.; Liu, S. BeilsteinJ. Org. Chem. 2016, 12, 2490−2494. (k) Yang, L.; Li, H.; Zhang, H.;Lu, H. Eur. J. Org. Chem. 2016, 2016, 5611−5615. (l) Alt, I. T.;Plietker, B. Angew. Chem., Int. Ed. 2016, 55, 1519−1522.(7) (a) Danheiser, R. L.; Brisbois, R. G.; Kowalczyk, J. J.; Miller, R. F.J. Am. Chem. Soc. 1990, 112, 3093−3100. (b) Praveen, C.; Perumal, P.T. Synlett 2011, 268−272. (c) Wang, J.; Zhu, H.-T.; Qiu, Y.-F.; Niu, Y.;Chen, S.; Li, Y.-X.; Liu, X.-Y.; Liang, Y.-M. Org. Lett. 2015, 17, 3186−3189. (d) James, M. J.; Clubley, R. E.; Palate, K. Y.; Procter, T. J.;Wyton, A. C.; O’Brien, P.; Taylor, R. J. K.; Unsworth, W. P. Org. Lett.2015, 17, 4372−4375. (e) Qiu, Y.; Zhou, J.; Fu, C.; Ma, S. Chem. - Eur.J. 2014, 20, 14589−14593. (f) Chen, S.; Li, Y.; Ni, P.; Huang, H.;Deng, G.-J. Org. Lett. 2016, 18, 5384−5387. (g) Huang, Y.-W.; Li, X.-Y.; Fu, L.-N.; Guo, Q.-X. Org. Lett. 2016, 18, 6200−6203. (h) Song,W.; Li, X.; Yang, K.; Zhao, X.-l.; Glazier, D. A.; Xi, B.-m.; Tang, W. J.Org. Chem. 2016, 81, 2930−2942. (i) Guo, B.; Huang, X.; Fu, C.; Ma,S. Chem. - Eur. J. 2016, 22, 18343−18348.(8) See, for example: (a) Knolker, H.-J.; Bauermeister, M.; Pannek, J.-B.; Wolpert, M. Synthesis 1995, 1995, 397−408. (b) Chakrabarty, S.;Chatterjee, I.; Tebben, L.; Studer, A. Angew. Chem., Int. Ed. 2013, 52,2968−2971.(9) See, for example: (a) Liegault, B.; Lee, D.; Huestis, M. P.; Stuart,D. R.; Fagnou, K. J. Org. Chem. 2008, 73, 5022−5028. (b) Ackermann,L.; Althammer, A.; Mayer, P. Synthesis 2009, 2009, 3493−3503.(c) Sridharan, V.; Martin, M. A.; Menendez, J. C. Eur. J. Org. Chem.2009, 2009, 4614−4621. (d) Hernandez-Perez, A. C.; Collins, S. K.Angew. Chem., Int. Ed. 2013, 52, 12696−12700. (e) Hesse, R.; Kataeva,O.; Schmidt, A. W.; Knolker, H.-J. Chem. - Eur. J. 2014, 20, 9504−9509. (f) Julich-Gruner, K. K.; Schmidt, A. W.; Knolker, H.-J. Synthesis2014, 46, 2651−2655. (g) Hesse, R.; Jager, A.; Schmidt, A. W.;Knolker, H.-J. Org. Biomol. Chem. 2014, 12, 3866−3876. (h) Gassner,C.; Hesse, R.; Schmidt, A. W.; Knolker, H.-J. Org. Biomol. Chem. 2014,12, 6490−6499. (i) Schuster, C.; Julich-Gruner, K. K.; Schnitzler, H.;Hesse, R.; Jager, A.; Schmidt, A. W.; Knolker, H.-J. J. Org. Chem. 2015,80, 5666−5673. (j) Wen, L.; Tang, L.; Yang, Y.; Zha, Z.; Wang, Z. Org.Lett. 2016, 18, 1278−1281. (k) Brutting, C.; Hesse, R.; Jager, A.;Kataeva, O.; Schmidt, A. W.; Knolker, H.-J. Chem. - Eur. J. 2016, 22,16897−16911. (l) Parisien-Collette, S.; Hernandez-Perez, A. C.;Collins, S. K. Org. Lett. 2016, 18, 4994−4997. (m) Kutz, S. K.;Schmidt, A. W.; Knolker, H.-J. Synthesis 2016, 49, 275−292.(10) Banwell, M. G.; Kelly, B. D.; Kokas, O. J.; Lupton, D. W. Org.Lett. 2003, 5, 2497−2500.(11) For a related approach involving Stille cross-coupling reactionssee: (a) Scott, T. L.; Yu, X.; Gorugantula, S. P.; Carrero-Martínez, G.;Soderberg, B. C. G. Tetrahedron 2006, 62, 10835−10842. (b) Scott, T.L.; Burke, N.; Carrero-Martinez, G.; Soderberg, B. C. G. Tetrahedron2007, 63, 1183−1190.(12) (a) Campaigne, E.; Lake, R. D. J. Org. Chem. 1959, 24, 478−487. (b) Humne, V.; Dangat, Y.; Vanka, K.; Lokhande, P. Org. Biomol.Chem. 2014, 12, 4832−4836. (c) Iosub, A. V.; Stahl, S. S. J. Am. Chem.Soc. 2015, 137, 3454−3457. (d) Humne, V. T.; Naykode, M. S.;Ghom, M. H.; Lokhande, P. D. Tetrahedron Lett. 2016, 57, 688−691.

(13) (a) Chakrabarty, M.; Nath, A. c.; Khasnobis, S.; Chakrabarty,M.; Konda, Y.; Harigaya, Y.; Komiyama, K. Phytochemistry 1997, 46,751−755. (b) Cui, C.-B.; Yan, S.-Y.; Cai, B.; Yao, X.-S. J. Asian Nat.Prod. Res. 2002, 4, 233−241.(14) Chakravarty, A. K.; Sarkar, T.; Masuda, K.; Takey, T.; Doi, H.;Kotani, E.; Shiojima, K. Indian J. Chem. Sec. B 2001, 40, 484−489.(15) (a) Chakraborty, D. P. Phytochemistry 1969, 8, 769−772. (b) Li,W. S.; McChesney, J. D.; El-Feraly, F. S. Phytochemistry 1991, 30,343−346.(16) (a) Birari, R.; Roy, S. K.; Singh, A.; Bhutani, K. Nat. Prod.Commun. 2009, 4, 1089−1092. (b) Lin, W.; Wang, Y.; Lin, S.; Li, C.;Zhou, C.; Wang, S.; Huang, H.; Liu, P.; Ye, G.; Shen, X. Eur. J. Med.Chem. 2012, 47, 214−220.(17) (a) Brenna, E.; Fuganti, C.; Serra, S. Tetrahedron 1998, 54,1585−1588. (b) Laphookhieo, S.; Sripisut, T.; Prawat, U.; Karalai, C.Heterocycles 2009, 78, 2115−2119.(18) Nakamura, S.; Nakashima, S.; Oda, Y.; Yokota, N.; Fujimoto, K.;Matsumoto, T.; Ohta, T.; Ogawa, K.; Maeda, S.; Nishida, S.; Matsuda,H.; Yoshikawa, M. Bioorg. Med. Chem. 2013, 21, 1043−1049.(19) Pandey, G.; Balakrishnan, M. J. Org. Chem. 2008, 73, 8128−8131.(20) Details of this X-ray analysis can be found in the ExperimentalSection and the Supporting Information.(21) Banwell, M. G.; Jones, M. T.; Loong, D. T. J.; Lupton, D. W.;Pinkerton, D. M.; Ray, J. K.; Willis, A. C. Tetrahedron 2010, 66, 9252−9262.(22) (a) Carruthers, W. Chem. Commun. 1966, 272. (b) Chakraborty,D. P.; Das, K. C.; Chowdhury, B. K. Phytochemistry 1969, 8, 773−776.(c) Forke, R.; Krahl, M. P.; Krause, T.; Schlechtingen, G.; Knolker, H.-J. Synlett 2007, 2007, 0268−0272. (d) Bautista, R.; Montoya, P. A.;Rebollar, A.; Burgueno, E.; Tamariz, J. Molecules 2013, 18, 10334−10351. (e) Naykode, M. S.; Humne, V. T.; Lokhande, P. D. J. Org.Chem. 2015, 80, 2392−2396. (f) Hesse, R.; Schmidt, A. W.; Knolker,H.-J. Tetrahedron 2015, 71, 3485−3490. (g) Momin, A. A.; Urmode,T. D.; Bhosale, S. M.; Kusurkar, R. S. Synth. Commun. 2016, 46, 1292−1298.(23) (a) Krahl, M. P.; Jager, A.; Krause, T.; Knolker, H.-J. Org.Biomol. Chem. 2006, 4, 3215−3219. (b) Mane, M. S.; Balaskar, R. S.;Gavade, S. N.; Pabrekar, P. N.; Shingare, M. S.; Mane, D. V. Chin.Chem. Lett. 2011, 22, 1039−1042. (c) Kong, W.; Fu, C.; Ma, S. Chem. -Eur. J. 2011, 17, 13134−13137.(24) (a) Bringmann, G.; Tasler, S.; Endress, H.; Peters, K.; Peters, E.-M. Synthesis 1998, 1998, 1501−1505. (b) Zempoalteca, A.; Tamariz, J.Heterocycles 2002, 57, 259−267. (c) Knolker, H.-J.; Wolpert, M.Tetrahedron 2003, 59, 5317−5322. (d) Kuwahara, A.; Nakano, K.;Nozaki, K. J. Org. Chem. 2005, 70, 413−419. (e) Liu, Z.; Larock, R. C.Tetrahedron 2007, 63, 347−355. (f) Tsang, W. C. P; Munday, R. H.;Brasche, G.; Zheng, N.; Buchwald, S. L. J. Org. Chem. 2008, 73, 7603−7610. (g) Hibino, S.; Tohyama, S.; Choshi, T.; Azuma, S.; Fujioka, H.Heterocycles 2009, 79, 955−965. (h) Borger, C.; Krahl, M. P.; Gruner,M.; Kataeva, O.; Knolker, H.-J. Org. Biomol. Chem. 2012, 10, 5189−5193. (i) Jana, A. K.; Pahari, P.; Mal, D. Synlett 2012, 23, 1769−1774.(j) Yu, J.; Wang, Y.; Zhang, P.; Wu, J. Synlett 2013, 24, 1448−1454.(25) Yang, W.; Zhou, J.; Wang, B.; Ren, H. Chem. - Eur. J. 2011, 17,13665−13669.(26) (a) Wender, P. A.; White, A. W. Tetrahedron 1983, 39, 3767−3776. (b) Johnson, P. D.; Sohn, J.-H.; Rawal, V. H. J. Org. Chem. 2006,71, 7899−7902.(27) Banwell, M. G.; Jones, M. T.; Reekie, T. A. Chem. New Zealand2011, 75, 122−127.(28) See, for example: (a) White, L. V.; Banwell, M. G. J. Org. Chem.2016, 81, 1617−1626. (b) Tang, F.; Banwell, M. G.; Willis, A. C. J.Org. Chem. 2016, 81, 2950−2957. (c) Tan, S. H.; Banwell, M. G.;Willis, A. C. J. Org. Chem. 2016, 81, 8022−8028. (d) Tang, F.;Banwell, M. G.; Willis, A. C. J. Org. Chem. 2016, 81, 10551−10557.(29) Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923−2925.(30) Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.;Timmers, F. J. Organometallics 1996, 15, 1518−1520.

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4158

312

Page 334: The Application of Pericyclic, Photolytic, Chemoenzymatic

(31) Johnson, C. R.; Adams, J. P.; Braun, M. P.; Senanayake, C. B.W.; Wovkulich, P. M.; Uskokovic, M. R. Tetrahedron Lett. 1992, 33,917−918.(32) Chong, B.-D.; Ji, Y. I.; Oh, S.-S.; Yang, J.-D.; Baik, W.; Koo, S. J.Org. Chem. 1997, 62, 9323−9325.(33) The Merck Index, 12th ed.; Merck and Co.: Kenilworth, NJ,1996; p 291.(34) DENZO-SMN: Otwinowski, Z.; Minor, W. Processing of X-raydiffraction data collected in oscillation mode. In Methods inEnzymology; Carter, C. W., Jr., Sweet, R. M., Eds.; Academic Press:New York, 1997; Vol. 276, Macromolecular Crystallography, Part A,pp 307−326.(35) CrysAlis PRO Version 1.171.37.35h (release 09-02-2015CrysAlis171.NET) (compiled Feb 9 2015,16:26:32); Agilent Tech-nologies, Oxfordshire, UK, 2015.(36) SIR92: Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi,A.; Burla, M. C.; Polidori, G.; Camalli, M. J. Appl. Crystallogr. 1994, 27,435−436.(37) Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.;Watkin, D. J. J. Appl. Crystallogr. 2003, 36, 1487.(38) (a) Gerkin, R. E.; Reppart, W. J. Acta Crystallogr., Sect. C: Cryst.Struct. Commun. 1986, 42, 480−482. (b) Gajda, K.; Zarychta, B.;Kopka, K.; Daszkiewicz, Z.; Ejsmont, K. Acta Crystallogr., Sect. C:Struct. Chem. 2014, 70, 987−991.

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00044J. Org. Chem. 2017, 82, 4148−4159

4159

313

Page 335: The Application of Pericyclic, Photolytic, Chemoenzymatic

S1

SUPP

ORT

ING

INFO

RMAT

ION

FO

R:

A P

alla

dium

-cat

alyz

ed U

llman

n C

ross

-cou

plin

g/R

educ

tive

Cyc

lisat

ion

Rou

te to

the

Car

bazo

le N

atur

al P

rodu

cts 3

-Met

hyl-9H

-car

bazo

le,

Gly

cobo

rine

, Gly

cozo

line,

Cla

uszo

line

K, M

ukon

ine

and

Kar

apin

cham

ine

A

Qia

o Y

an, E

mm

a G

in, M

algo

rzat

a W

asin

ska-

Kal

wa,

Mar

tin G

. Ban

wel

l* a

nd P

aul D

. Car

r

Rese

arch

Sch

ool o

f Che

mis

try,

Inst

itute

of A

dvan

ced

Stud

ies,

The

Aust

ralia

n N

atio

nal U

nive

rsity

, Can

berr

a, A

CT

2601

, Aus

tral

ia

CO

NT

EN

TS

PA

GE

(i)A

niso

tropi

c D

ispl

acem

ent E

llips

oid

Plot

s fro

m th

e Si

ngle

-cry

stal

X-r

ay

Ana

lyse

s of C

ompo

unds

1-6

, 17

and

25S2

(ii)

Tab

le S

1: C

ompa

rison

of t

he 13

C N

MR

Dat

a Re

cord

ed o

n Co

mpo

und 7

with

Lite

ratu

re V

alue

s for

Kar

apin

cham

ine

AS1

0

(iii)

1 H a

nd 13

C N

MR

Spe

ctra

of C

ompo

unds

1-1

5, 1

7, 1

8, 2

0, 2

1, 2

3-32

and

Met

hyl 4

-Am

ino-

3-br

omo-

5-m

etho

xybe

nzoa

te (p

recu

rsor

to c

ompo

und

27).

S11

314

Page 336: The Application of Pericyclic, Photolytic, Chemoenzymatic

S2

Figu

re S

1: S

truct

ure

of c

ompo

und

1 (C

CD

C 1

5251

66) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.

315

Page 337: The Application of Pericyclic, Photolytic, Chemoenzymatic

S3

Figu

re S

2: S

truct

ure

of c

ompo

und

2 (C

CD

C 1

5251

63) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.

316

Page 338: The Application of Pericyclic, Photolytic, Chemoenzymatic

S4

Figu

re S

3: S

truct

ure

of c

ompo

und

3 (C

CD

C 1

5251

64) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.

317

Page 339: The Application of Pericyclic, Photolytic, Chemoenzymatic

S5

Figu

re S

4: S

truct

ure

of c

ompo

und

4 (C

CD

C 1

5251

62) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

318

Page 340: The Application of Pericyclic, Photolytic, Chemoenzymatic

S6

Figu

re S

5: S

truct

ure

of c

ompo

und

5 (C

CD

C 1

5251

67) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

319

Page 341: The Application of Pericyclic, Photolytic, Chemoenzymatic

S7

Figu

re S

6: S

truct

ure

of c

ompo

und

6 (C

CD

C 1

5251

60) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

320

Page 342: The Application of Pericyclic, Photolytic, Chemoenzymatic

S8

Figu

re S

7: S

truct

ure

of c

ompo

und

17 (C

CD

C 1

5251

61) w

ith la

belin

g of

sele

cted

ato

ms.

Onl

y on

e of

the

two

mol

ecul

es p

rese

nt in

the

asym

met

ric u

nit i

s sho

wn.

The

re w

as so

me

diso

rder

ing

of a

tom

s C10

A a

nd C

11A

- on

ly th

e m

ajor

con

form

er is

show

n. T

his c

onfo

rmer

had

an

occu

panc

y of

81.

6%. A

niso

tropi

c di

spla

cem

ent e

llips

oids

show

30%

pro

babi

lity

leve

ls. H

ydro

gen

atom

s are

dra

wn

as c

ircle

s with

smal

l rad

ii.

321

Page 343: The Application of Pericyclic, Photolytic, Chemoenzymatic

S9

Figu

re S

8: S

truct

ure

of c

ompo

und

25 (C

CD

C 1

5251

65) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

322

Page 344: The Application of Pericyclic, Photolytic, Chemoenzymatic

S10

Tab

le S

1: C

ompa

riso

n of

the

13C

NM

R Sp

ectr

al D

ata

Repo

rted

by

Yosh

ikaw

a18 a

nd M

a7e fo

r Kar

apin

cham

ine

A w

ith th

e Eq

uiva

lent

Dat

a Re

cord

ed fo

r Com

poun

d 7

Prep

ared

by

the

Pres

ent R

oute

δ C

(e

x. Y

oshi

kaw

a)a

δ C

(ex.

Ma)

bδ C

(e

x. P

rese

nt R

oute

)cΔδ

δ C

(PR

d ) –δ C

(Y’k

awa)

15

4.5

154.

2 15

4.6

0.1

142.

0 14

1.9

142.

2 0.

2 13

8.8

138.

7 13

8.9

0.1

138.

5 13

8.4

138.

7 0.

2 13

1.8

131.

7 13

1.9

0.1

128.

3 12

8.1

128.

4 0.

1 12

5.6

125.

5 12

5.8

0.2

123.

7 12

3.7

123.

9 0.

2 12

3.3

123.

1 12

3.4

0.1

121.

0 12

1.0

121.

2 0.

2 11

9.8

119.

6 12

0.0

0.2

119.

5 11

9.4

119.

6 0.

1 11

7.0

116.

8 11

7.1

0.1

108.

3 10

8.3

108.

4 0.

1 10

7.5

107.

5 10

7.7

0.2

95.1

95

.1

95.2

0.

1 41

.2

40.9

41

.3

0.1

39.4

39

.3

39.5

0.

1 27

.2

26.2

26

.4

0.2

25.5

25

.5

25.8

0.

3 21

.4

21.3

21

.5

0.1

17.7

17

.6

17.8

0.

1 16

.6

16.4

16

.8

0.2

a Sp

ectru

m re

cord

ed in

CD

Cl 3

at 1

25 o

r 150

MH

z; b

Spec

trum

reco

rded

in C

DC

l 3 at

75

MH

z; c

Spec

trum

reco

rded

in

CD

Cl 3

at 1

00 M

Hz;

d PR

= p

rese

nt ro

ute.

323

Page 345: The Application of Pericyclic, Photolytic, Chemoenzymatic

S11

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

2.002.002.002.00

1.00

324

Page 346: The Application of Pericyclic, Photolytic, Chemoenzymatic

S12

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

220

f1 (

ppm

)

29.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.42 Acetone

111.69119.63120.86123.96126.40

140.99

206.16

325

Page 347: The Application of Pericyclic, Photolytic, Chemoenzymatic

S13

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.00

1.001.001.001.001.001.001.00

1.00

326

Page 348: The Application of Pericyclic, Photolytic, Chemoenzymatic

S14

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

21.4729.26 Acetone29.45 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.42 Acetone

111.41111.64119.40120.74120.77123.83124.15126.21127.74128.60139.24141.30

206.15

11

1.2

11

1.4

11

1.6

11

1.8

f1 (

ppm

)111.41

111.64

12

0.0

12

0.5

12

1.0

12

1.5

f1 (

ppm

)120.74120.77

12

3.7

12

3.9

12

4.1

f1 (

ppm

)

123.83

124.15

327

Page 349: The Application of Pericyclic, Photolytic, Chemoenzymatic

S15

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.08

3.09

1.001.001.001.001.00

1.00

1.00

328

Page 350: The Application of Pericyclic, Photolytic, Chemoenzymatic

S16

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

21.5929.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.23 Acetone30.42 Acetone

55.63

100.45104.66110.77112.96

123.51123.56126.72127.18128.54138.44142.67

157.13

206.17

12

3.4

01

23

.45

12

3.5

01

23

.55

12

3.6

01

23

.65

12

3.7

0f1

(ppm

)

123.51

123.56

329

Page 351: The Application of Pericyclic, Photolytic, Chemoenzymatic

S17

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.00

3.00

1.001.012.001.001.00

1.00

330

Page 352: The Application of Pericyclic, Photolytic, Chemoenzymatic

S18

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

21.4629.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.23 Acetone30.42 Acetone

56.07

103.54111.50112.30115.59120.75124.20124.22127.66128.07136.14140.01

154.54

206.15

12

3.9

12

4.0

12

4.1

12

4.2

12

4.3

12

4.4

f1 (

ppm

)

124.20124.22

331

Page 353: The Application of Pericyclic, Photolytic, Chemoenzymatic

S19

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.14

1.001.001.001.001.001.00

1.00

1.00

332

Page 354: The Application of Pericyclic, Photolytic, Chemoenzymatic

S20

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

29.26 Acetone29.45 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.42 Acetone

55.84

95.98

110.12111.78117.56122.20123.47124.43126.27130.12

143.13144.77

160.81

191.99

206.16

333

Page 355: The Application of Pericyclic, Photolytic, Chemoenzymatic

S21

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.003.00

1.011.951.001.001.001.00

7.26 CDCl3

334

Page 356: The Application of Pericyclic, Photolytic, Chemoenzymatic

S22

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

52.1855.87

76.84 CDCl377.16 CDCl377.48 CDCl3

106.81111.37116.36120.40120.87122.02123.73123.87126.47133.03139.64145.19

168.11

12

3.6

12

3.7

12

3.8

12

3.9

12

4.0

f1 (

ppm

)

123.73

123.87

335

Page 357: The Application of Pericyclic, Photolytic, Chemoenzymatic

S23

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.003.043.004.003.00

2.001.001.001.00

1.001.002.00

1.001.00

7.26 CDCl3

336

Page 358: The Application of Pericyclic, Photolytic, Chemoenzymatic

S24

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

16.7617.8221.5225.7526.44

39.5341.32

76.84 CDCl377.16 CDCl377.48 CDCl3

95.23

107.69108.43117.13119.64119.95121.19123.41123.86125.77128.38131.91138.68138.94142.16154.61

13

8.0

13

8.5

13

9.0

13

9.5

f1 (

ppm

)138.68

138.94

11

9.4

11

9.5

11

9.6

11

9.7

11

9.8

11

9.9

12

0.0

12

0.1

f1 (

ppm

)

119.64

119.95

337

Page 359: The Application of Pericyclic, Photolytic, Chemoenzymatic

S25

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.06

1.001.001.001.001.002.00

1.00

338

Page 360: The Application of Pericyclic, Photolytic, Chemoenzymatic

S26

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

29.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.42 Acetone

55.72

95.39

108.78111.38117.74119.70119.98121.56124.24125.03

141.02142.36

160.09

206.15

11

9.2

11

9.4

11

9.6

11

9.8

12

0.0

12

0.2

f1 (

ppm

)119.70

119.98

339

Page 361: The Application of Pericyclic, Photolytic, Chemoenzymatic

S27

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

2.002.002.00

1.00

7.26 CDCl3

340

Page 362: The Application of Pericyclic, Photolytic, Chemoenzymatic

S28

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

22.9930.0737.39

76.85 CDCl377.16 CDCl377.48 CDCl3

104.01

159.55

192.32

341

Page 363: The Application of Pericyclic, Photolytic, Chemoenzymatic

S29

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.001.001.001.031.97

0.95

7.26 CDCl3

342

Page 364: The Application of Pericyclic, Photolytic, Chemoenzymatic

S30

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

19.70

30.5835.4835.59

76.84 CDCl377.16 CDCl377.48 CDCl3

102.93

164.72

191.83

34

.53

5.0

35

.53

6.0

f1 (

ppm

)

35.4835.59

343

Page 365: The Application of Pericyclic, Photolytic, Chemoenzymatic

S31

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

2.00

4.00

1.001.001.001.000.98

7.26 CDCl3

344

Page 366: The Application of Pericyclic, Photolytic, Chemoenzymatic

S32

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

22.6526.36

38.39

76.84 CDCl377.16 CDCl377.48 CDCl3

124.22128.83131.76132.17133.41139.44146.80148.65

196.58

345

Page 367: The Application of Pericyclic, Photolytic, Chemoenzymatic

S33

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.041.121.042.041.01

1.000.991.001.000.97

7.26 CDCl3

346

Page 368: The Application of Pericyclic, Photolytic, Chemoenzymatic

S34

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.38

30.6831.8037.20

76.85 CDCl377.17 CDCl377.48 CDCl3

124.28128.87131.83132.09133.40138.37

148.70152.25

196.62

13

1.5

13

2.0

f1 (

ppm

)

131.83

132.09

347

Page 369: The Application of Pericyclic, Photolytic, Chemoenzymatic

S35

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

4.12

2.002.01

2.001.001.00

1.00

348

Page 370: The Application of Pericyclic, Photolytic, Chemoenzymatic

S36

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

21.6523.7724.0324.1729.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.23 Acetone30.42 Acetone

109.69111.25118.04119.12121.11128.83135.10137.10

206.16

23

.62

3.8

24

.02

4.2

24

.4f1

(ppm

)

23.77

24.03

24.17

349

Page 371: The Application of Pericyclic, Photolytic, Chemoenzymatic

S37

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.121.082.101.043.25

2.051.001.00

0.98

350

Page 372: The Application of Pericyclic, Photolytic, Chemoenzymatic

S38

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

22.1223.4429.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.2230.42 Acetone30.5832.32

109.65111.27118.03119.11121.09128.73134.86137.43

206.15

28

29

30

31

f1 (

ppm

)

29.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.2230.42 Acetone30.58

351

Page 373: The Application of Pericyclic, Photolytic, Chemoenzymatic

S39

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.05

1.121.103.17

3.08

0.981.001.001.00

7.26 CDCl3

352

Page 374: The Application of Pericyclic, Photolytic, Chemoenzymatic

S40

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.1020.4130.5430.8931.6031.9637.0737.33

56.6256.67

76.84 CDCl377.16 CDCl377.48 CDCl3

115.35115.55116.01116.08121.37121.47129.11129.15132.64133.00150.04150.33153.46153.73158.03158.10

196.69196.88

353

Page 375: The Application of Pericyclic, Photolytic, Chemoenzymatic

S41

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.101.132.141.042.071.03

3.06

1.00

2.02

0.95

354

Page 376: The Application of Pericyclic, Photolytic, Chemoenzymatic

S42

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

22.1723.4329.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.23 Acetone30.42 Acetone30.8232.1032.66

55.31

99.73105.05109.61

118.59121.81

132.75

138.76

155.10

206.17

29

30

31

32

33

f1 (

ppm

)

29.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.23 Acetone30.42 Acetone30.82

32.10

32.66

355

Page 377: The Application of Pericyclic, Photolytic, Chemoenzymatic

S43

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.00

1.001.053.01

3.00

2.00

1.00

1.00

7.26 CDCl3

356

Page 378: The Application of Pericyclic, Photolytic, Chemoenzymatic

S44

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.45

30.7831.7537.28

56.06

76.84 CDCl377.16 CDCl377.48 CDCl3

113.22117.18

127.15135.21139.11141.66

151.24

163.44

196.83

357

Page 379: The Application of Pericyclic, Photolytic, Chemoenzymatic

S45

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.041.042.071.053.13

3.11

1.001.001.00

0.98

358

Page 380: The Application of Pericyclic, Photolytic, Chemoenzymatic

S46

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

22.1423.5629.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.3530.42 Acetone30.6332.36

55.84

100.59

109.60110.69111.78

129.10132.50135.71

154.57

206.12

29

.22

9.4

29

.62

9.8

30

.03

0.2

30

.43

0.6

f1 (

ppm

)

29.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.3530.42 Acetone30.63

359

Page 381: The Application of Pericyclic, Photolytic, Chemoenzymatic

S47

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.101.031.041.041.071.06

3.08

1.002.001.00

7.26 CDCl3

360

Page 382: The Application of Pericyclic, Photolytic, Chemoenzymatic

S48

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.46

30.7631.8137.26

55.97

76.84 CDCl377.16 CDCl377.48 CDCl3

109.28

119.68124.24132.65138.05

149.21151.81159.66

196.93

361

Page 383: The Application of Pericyclic, Photolytic, Chemoenzymatic

S49

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.001.042.001.023.06

3.04

1.001.001.00

1.00

362

Page 384: The Application of Pericyclic, Photolytic, Chemoenzymatic

S50

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

22.1323.4529.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.2830.42 Acetone30.5932.34

55.69

95.43

108.59109.47

118.45

123.21

133.42

138.15

156.59

206.13

29

.02

9.5

30

.03

0.5

f1 (

ppm

)

29.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.2830.42 Acetone30.59

363

Page 385: The Application of Pericyclic, Photolytic, Chemoenzymatic

S51

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

3.000.911.00

2.001.001.001.02

3.01

1.001.001.00

0.80

364

Page 386: The Application of Pericyclic, Photolytic, Chemoenzymatic

S52

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

20.9928.1429.51 Acetone29.62 Acetone29.73 Acetone29.84 Acetone29.95 Acetone30.06 Acetone30.17 Acetone30.3137.3644.3555.81

92.30

107.39110.82

123.81

131.45

157.43

162.24

186.10

206.12

29

.53

0.0

30

.5f1

(ppm

)

29.51 Acetone29.62 Acetone29.73 Acetone29.84 Acetone29.95 Acetone30.06 Acetone30.17 Acetone30.31

365

Page 387: The Application of Pericyclic, Photolytic, Chemoenzymatic

S53

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.00

3.00

1.001.001.001.001.001.00

1.00

366

Page 388: The Application of Pericyclic, Photolytic, Chemoenzymatic

S54

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

21.4929.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.42 Acetone

55.69

95.35

108.55111.09117.64119.98121.46124.43126.29128.62

139.25142.65

159.98

206.13

367

Page 389: The Application of Pericyclic, Photolytic, Chemoenzymatic

S55

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.003.00

2.01

1.00

1.00

7.26 CDCl3

368

Page 390: The Application of Pericyclic, Photolytic, Chemoenzymatic

S56

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

52.0956.20

76.84 CDCl377.16 CDCl377.48 CDCl3

106.77109.91

119.47

127.13

139.41

146.34

166.49

369

Page 391: The Application of Pericyclic, Photolytic, Chemoenzymatic

S57

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.063.05

1.001.00

7.26 CDCl3

370

Page 392: The Application of Pericyclic, Photolytic, Chemoenzymatic

S58

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

53.1857.12

76.84 CDCl377.16 CDCl377.48 CDCl3

112.84113.82

126.15

133.12

144.68

151.83

164.43

371

Page 393: The Application of Pericyclic, Photolytic, Chemoenzymatic

S59

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

2.01

4.00

3.003.00

1.001.001.00

7.26 CDCl3

372

Page 394: The Application of Pericyclic, Photolytic, Chemoenzymatic

S60

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

22.6526.50

38.32

52.8956.95

76.84 CDCl377.16 CDCl377.48 CDCl3

113.34

124.18131.62132.42136.31143.31150.23151.22

165.42

196.14

373

Page 395: The Application of Pericyclic, Photolytic, Chemoenzymatic

S61

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

4.12

2.042.04

3.073.08

1.05

1.00

1.00

374

Page 396: The Application of Pericyclic, Photolytic, Chemoenzymatic

S62

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

21.6223.6923.8623.9829.26 Acetone29.45 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.42 Acetone

51.8155.72

102.53

111.73114.78122.08129.38129.71136.63

146.24

168.45

206.15

23

.42

3.6

23

.82

4.0

24

.2f1

(ppm

)

23.69

23.86

23.98

375

Page 397: The Application of Pericyclic, Photolytic, Chemoenzymatic

S63

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

3.00

1.001.001.001.001.001.000.90

1.00

376

Page 398: The Application of Pericyclic, Photolytic, Chemoenzymatic

S64

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

21.4929.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.42 Acetone

97.36

109.08110.93117.06119.78121.45124.67125.99128.44

139.19142.95

157.38

206.14

377

Page 399: The Application of Pericyclic, Photolytic, Chemoenzymatic

S65

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

2.022.002.00

3.00

1.002.001.00

378

Page 400: The Application of Pericyclic, Photolytic, Chemoenzymatic

S66

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

23.4826.9529.26 Acetone29.46 Acetone29.65 Acetone29.84 Acetone30.03 Acetone30.22 Acetone30.42 Acetone39.03

56.41

109.87

120.04

125.08

133.61139.48147.52150.42

160.54

196.47

206.10

379

Page 401: The Application of Pericyclic, Photolytic, Chemoenzymatic

S67

01

23

45

67

89

10

11

12

13

14

15

16

f1 (

ppm

)

4.10

4.00

3.16

1.001.001.001.00

7.26 CDCl3

380

Page 402: The Application of Pericyclic, Photolytic, Chemoenzymatic

S68

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

21.0823.3423.3523.44

55.97

76.84 CDCl377.16 CDCl377.48 CDCl3

95.00

108.40110.07118.31122.51

132.93136.49

155.94

23

.20

23

.25

23

.30

23

.35

23

.40

23

.45

23

.50

23

.55

f1 (

ppm

)

23.3423.35

23.44

381

Page 403: The Application of Pericyclic, Photolytic, Chemoenzymatic

382

Publication Four

A Unified Approach to the Isomericα-,β-,γ-,andδ-

Carbolines via their 6,7,8,9-Tetrahydro Counterparts

Qiao Yan, Emma Gin, Martin G. Banwell, Anthony C. Willis

and Paul D. Carr

J. Org. Chem., 2017, 82, 4328.

Page 404: The Application of Pericyclic, Photolytic, Chemoenzymatic
Page 405: The Application of Pericyclic, Photolytic, Chemoenzymatic

A Unified Approach to the Isomeric α‑, β‑, γ‑, and δ‑Carbolines viatheir 6,7,8,9-Tetrahydro CounterpartsQiao Yan, Emma Gin, Martin G. Banwell,* Anthony C. Willis, and Paul D. Carr

Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, ACT 2601, Australia

*S Supporting Information

ABSTRACT: A cross-coupling/reductive cyclization protocolhas been employed in a unified approach to all four carbolines.So, for example, the 2-nitropyridine 8, which is readily preparedthrough an efficient palladium-catalyzed Ullmann cross-couplingreaction, is reductively cyclized under conventional conditions togive 6,7,8,9-tetrahydro-α-carboline that is itself readily aromatizedto give α-carboline (1).

■ INTRODUCTIONThe isomeric α-, β-, γ-, and δ-carbolines (1−4, respectively, inFigure 1) are important heterocyclic rings systems.1 All are

found, albeit to varying extents, as key structural motifs innatural products. They also feature in a wide range ofmedicinally relevant compounds. The utility of their variousderivatives in materials science is a further focus of currentstudies.2 The α-carboline framework (1) is encountered in alimited number of naturally occurring anticancer agents and inthe neuro-protective alkaloid mescengricin.3 On the other hand,synthetically derived α-carbolines have shown anxiolytic, anti-inflammatory, central nervous system stimulating, and kinaseinhibitory properties.4 β-Carboline (2), itself a natural productisolated from both plants and micro-organisms, is the mostwell-known of the four systems and represents a keysubstructure associated with, for example, the eudistomineand manzamine classes of biologically active marine alkaloids.5

Many medicinal agents embodying this heterocyclic frameworkhave been identified.5,6 Derivatives of γ-carboline (3) have beenexplored extensively as anticancer and anti-Alzheimer agents,7

while those associated with δ-carboline (4) have been studied,inter alia, for their antibacterial and antitumor properties.1b,8 δ-Carboline-containing alkaloids have been isolated from, forexample, various West and Central African plants that areprized as sources of traditional medicines for treating malariaand certain infectious diseases.1b

A multitude of methods has been established for thesynthesis of the carbolines, including classical ones involvingGraebe−Ullmann, Fischer indolization, Bischler−Napieralski,and Pictet−Spengler reactions.9,10 Variations on the Cadogan

syntheses of carbazoles are also known,11 as are routesinvolving the annulation of pyridines onto indoles,9,10,12

including through Diels−Alder and electrocyclization pro-cesses. Generally speaking, though, “customized” approachesare required for the assembly of each of the α-, β-, γ-, and δ-carboline frameworks, thus prompting the search for moregeneral routes to them.13 There has been modest success in thisregard, with the most effective route involving the cyclization ofanilinopyridines.13g−j Recently, Driver13i and Ray13j have eachreported variations on such methods that allow access to threeof the four frameworks. It is against this background that wenow detail a distinct, operationally simple, and likely flexibleroute to all four of the isomeric carbolines and highlight theutility of this through the synthesis of the simple naturalproduct harman (5, Figure 2), a compound that displays anti-HIV and antibacterial properties.14

■ RESULTS AND DISCUSSIONThe pivotal steps associated with the unified approach to thecarbolines reported here are the palladium-catalyzed Ullmanncross-coupling15 of 2-iodocyclohex-2-en-1-one16 with therelevant halogenated nitropyridine and the reductive cyclizationof the ensuing 2-pyridylcyclohex-2-en-1-one to give thecorresponding 6,7,8,9-tetrahydrocarboline. Oxidation of thesetetrahydro compounds to their fully aromatic counterparts (viz.,the carbolines) was readily accomplished using 10 wt %palladium on carbon. This sequence mirrors that used in our

Received: February 10, 2017Published: March 17, 2017

Figure 1. Isomeric α-, β-, γ-, and δ-carbolines (1−4).

Figure 2. β-Carboline alkaloid harman (5).

Article

pubs.acs.org/joc

© 2017 American Chemical Society 4328 DOI: 10.1021/acs.joc.7b00323J. Org. Chem. 2017, 82, 4328−4335

383

Page 406: The Application of Pericyclic, Photolytic, Chemoenzymatic

recently reported syntheses of various carbazole-based naturalproducts, including glycoborine, glycozoline, clausazoline K,mukonine, and karapinchamine A.17

The synthesis of α-carboline (1), as shown in Scheme 1, isillustrative and starts with the palladium-catalyzed Ullmann

cross-coupling of the readily prepared17 2-iodocyclohex-2-en-1-one (6) with commercially available 3-bromo-2-nitropyridine(7), thus affording the 2-pyridylcyclohex-2-en-1-one (8) in 82%yield. In order to reduce the extent of homocoupling of thepyridine in this reaction, the iodo enone 6 was treated with acombination of copper metal, copper(I) iodide, and Pd(dppf)-Cl2·CH2Cl2 in DMSO at 50 °C for 0.75 h prior the addition ofcompound 7. Presumably this allows cupration of compound 6to take place prior to a palladium-catalyzed cross-couplingreaction with halide 7, thereby increasing the yields of product8. The reductive cyclization of compound 8 was effected usinghydrogen in the presence of catalytic amounts of 10 wt %palladium on carbon (Pd/C) in methanol at room temperaturefor 16 h, and this produced the 6,7,8,9-tetrahydrocarboline(9)18 in 75% yield. In our hands, the oxidation19 of compound9 to α-carboline (1)4a was best carried out by exposing theformer system to an equivalent mass of 10 wt % palladium oncarbon in diphenyl ether at 210 °C for 0.66 h. By such meanstarget 1 was obtained in 97% yield, and all of the spectral dataacquired on this material were in complete accord with theassigned structure and matched those reported in the literature.A single-crystal X-ray analysis was carried out on compound 1and details of this are provided in the Experimental Section andthe Supporting Information (SI).Given the use of 10 wt % palladium on carbon in both the

second and third steps of the reaction sequence, these could, inprinciple, be “telescoped” to establish a one-pot process. Todate, however, we have not been able to identify conditions thatallow for this to be conducted in both an operationally superiorway and with better outcomes.The synthesis of β-carboline (2) (Scheme 2) required 4-

iodo-3-nitropyridine (10)20 as a coupling partner, and this wasreadily obtained by reacting the commercially available chloroanalogue with sodium iodide in acetonitrile (see theExperimental Section for details). Cross-coupling of com-pounds 6 and 10 proceeded smoothly under essentially thesame conditions as employed for the conversion 6 + 7→ 8 andprovided the anticipated coupling product 11 in 86% yield.Reductive cyclization of compound 11 proceeded uneventfully

under the previously established conditions, and product 1221

(88%) was readily oxidized to target 2 (94%) upon briefexposure to an equal mass of 10 wt % palladium on carbon inhot diphenyl ether. Once again, all the spectral data acquiredfor β-carboline (2) matched those reported22 previously. Thestructure of compound 2 was also confirmed by single-crystalX-ray analysis.The analogous synthesis of γ-carboline (3) is shown in

Scheme 3, and in this instance the required pyridine (13) was a

commercially available material. Reductive cyclization of thecross-coupling product 14 (89%) produced from compound 6and 13 proceeded as anticipated to give the tetrahydrocarboline15,23 albeit in just 66% yield. Similarly, the oxidation of this lastcompound under the previously employed conditions was lessefficient than observed in the two previous cases, withcompound 324 being obtained in 77% yield. Once again, fullcharacterization of this product was undertaken, including bysingle-crystal X-ray analysis.The establishment of a unified approach to all the carbolines

followed from the successful synthesis of δ-carboline (4) by thepathway shown in Scheme 4. So, as before, the palladium-catalyzed Ullmann cross-coupling of iodo enone 6 with therequired and commercially available pyridine 16 proceededuneventfully to give product 17 (75%) that was reductivelycyclized in the usual manner to afford the tetrahydrocarboline1825 (65%). Oxidation of this last compound using an equal

Scheme 1. Synthesis of α-Carboline (1)

Scheme 2. Synthesis of β-Carboline (2)

Scheme 3. Synthesis of γ-Carboline (3)

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00323J. Org. Chem. 2017, 82, 4328−4335

4329

384

Page 407: The Application of Pericyclic, Photolytic, Chemoenzymatic

mass of 10 wt % palladium on carbon in hot diphenyl etherthen gave δ-carboline (4)26 (92%) that was subject to the usualrange of spectroscopic analyses, including a single-crystal X-raystudy.In order to test the capacities of the above-mentioned

protocols to deliver substituted carbolines, the β-carboline-based natural product harman (5, Figure 2) was targeted forsynthesis. The required pyridine was prepared by the routeshown in Scheme 5. Thus, commercially available 2-

methylpyridin-4-amine (19) was subjected to a Sandmeyerreaction using water as the nucleophile, thus providing thepreviously reported nitric acid salt27 20 of 2-methylpyridin-4-ol.Aromatic nitration of this last compound could only beachieved under rather forcing conditions, thus providing a 1:3and inseparable mixture of pyridines 21 and 22 (70% combinedyield). Accordingly, this mixture was treated with POBr3 inrefluxing toluene, thereby affording what is presumed to be thecorresponding mixture of bromides 23 and 24 (92% combinedyield). These regioisomers could only be separated by HPLCtechniques but sufficient quantities of the pure form of thelatter could be accumulated by such means. The formerproduct (presumed to be compound 23) was not purified orsubject to any spectroscopic characterization.With compound 24 in hand, the synthesis of harman (5) was

completed by the now standard pathway shown in Scheme 6.Thus, palladium-catalyzed Ullmann cross-coupling of iodo

enone 6 with pyridine 24 delivered the required product 25 in84% yield. Reductive cyclization of the last compound underthe usual conditions gave tetrahydroharman 2628 (83%), whichcould be oxidized to the natural product 514,29 (91%) ontreatment with an equal mass of 10 wt % palladium on carbonin hot diphenyl ether. Once again, all the spectral data,including those derived from a single-crystal X-ray analysis,acquired for compound 5 confirmed the assigned structure, andappropriate comparisons with those reported14 for the naturalproduct were entirely favorable.

■ CONCLUSIONSThe reaction sequences reported here should allow for therational/logical design of pathways to a wide range of α-, β-, γ-,and δ-carbolines. This is all the more so given the increasinglyready availability of a wide range of polysubstituted pyridines30

and 2-iodocyclohex-2-en-1-ones. For similar reasons, theprotocols defined here should allow for ready access to awide range of azaindoles, compounds of considerable interestfrom a medicinal chemistry perspective.31 Studies exploitingsuch possibilities will be reported in due course.

■ EXPERIMENTAL SECTIONGeneral Experimental Procedures. Unless otherwise specified,

proton (1H) and carbon (13C) NMR spectra were recorded at 18 °Cin base-filtered CDCl3 on a spectrometer operating at 400 MHz forproton and 100 MHz for carbon nuclei. 1H NMR data are recorded asfollows: chemical shift (δ) [multiplicity, coupling constant(s) J (Hz),relative integral], where multiplicity is defined as s = singlet; d =doublet; t = triplet; q = quartet; m = multiplet or combinations of theabove. In relevant cases, the signal due to residual CHCl3 appearing atδH 7.26 and the central resonance of the CDCl3 “triplet” appearing atδC 77.0 were used to reference 1H and 13C NMR spectra, respectively.Samples were analyzed by infrared spectroscopy (νmax) as thin filmson KBr plates. Low- and high-resolution electron impact (EI) massspectra were recorded on a double-focusing, triple-sector machine.Low- and high-resolution ESI mass spectra were recorded on a triple-quadrupole mass spectrometer operating in positive ion mode. Meltingpoints are uncorrected. Analytical thin-layer chromatography (TLC)was performed on aluminum-backed 0.2 mm thick silica gel 60 F254plates. Eluted plates were visualized using a 254 nm UV lamp and/orby treatment with a suitable dip followed by heating. These dipsincluded phosphomolybdic acid/ceric sulfate/sulfuric acid (concd)/water (37.5 g/7.5 g/37.5 g/720 mL), potassium permanganate/potassium carbonate/5% sodium hydroxide aqueous solution/water (3g/20 g/5 mL/300 mL), and p-anisaldehyde or vanillin/sulfuric acid

Scheme 4. Synthesis of δ-Carboline (4)

Scheme 5. Route to the Trisubstituted Pyridine 24 Requiredfor the Synthesis of the β-Carboline Alkaloid Harman (5)

Scheme 6. Completion of the Synthesis of Harman (5)

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00323J. Org. Chem. 2017, 82, 4328−4335

4330

385

Page 408: The Application of Pericyclic, Photolytic, Chemoenzymatic

(concd)/ethanol (15 g/2.5 mL/250 mL). Flash chromatographicseparations were carried out following protocols defined by Still et al.32

with silica gel 60 (40−63 μm) as the stationary phase and using theAR- or HPLC-grade solvents indicated. The melting points of solidspurified by such means were recorded directly (i.e., after they hadcrystallized from the concentrated chromatographic fractions). Startingmaterials, reagents, drying agents, and other inorganic salts weregenerally commercially available and were used as supplied. Thecopper powder used in the palladium-catalyzed Ullmann cross-coupling reactions had a particle size of <75 μm. Tetrahydrofuran(THF), methanol, and dichloromethane were dried using a solventpurification system that is based upon a technology originallydescribed by Grubbs et al.33 Where necessary, reactions wereperformed under a nitrogen atmosphere by subjecting the relevantsolution to reduced pressure for several minutes and then admittingnitrogen. This process was repeated three times.Specific Chemical Transformations. 2-(2-Nitropyridin-3-yl)-

cyclohex-2-en-1-one (8). A magnetically stirred mixture of 2-iodocyclohex-2-en-1-one (6)16 (2.63 g, 11.82 mmol), copper powder(1.50 g, 23.65 mmol), CuI (1.69 g, 8.87 mmol), and Pd(dppf)Cl2·CH2Cl2 (483 mg, 0.59 mmol) in degassed DMSO (118 mL) washeated at 50 °C under a nitrogen atmosphere for 0.75 h. After thistime, a solution of commercially available 3-bromo-2-nitropyridine (7)(1.20 g, 5.91 mmol) in degassed DMSO (30 mL) was added to thereaction mixture over 1.5 h. After a further 4 h, the reaction mixturewas cooled, quenched with water (30 mL), and then diluted with ethylacetate (50 mL). The ensuing mixture was filtered through a padcomprised of a mixture of diatomaceous earth and silica gel. The solidsthus retained were rinsed with ethyl acetate (2 × 50 mL), and theseparated organic phase associated with the combined filtrates waswashed with water (2 × 100 mL) and then brine (2 × 100 mL) beforebeing dried (Na2SO4), filtered, and concentrated under reducedpressure to give a brown oil. Subjection of this material to flash columnchromatography (silica, 1:3:11 v/v/v acetone/dichloromethane/40−60 petroleum ether elution) gave, after concentration of theappropriate fractions (Rf = 0.2 in 1:1 v/v ethyl acetate/40−60petroleum ether), compound 8 (1.06 g, 82%) as a light-brown solid:mp = 115−116 °C; 1H NMR (400 MHz, CDCl3) δ 8.52 (dd, J = 4.7and 1.7 Hz, 1H), 7.74 (dd, J = 7.6 and 1.7 Hz, 1H), 7.60 (dd, J = 7.6and 4.7 Hz, 1H), 7.08 (t, J = 4.2 Hz, 1H), 2.60 (m, 4H), 2.15 (m, 2H);13C NMR (100 MHz, CDCl3) δ 196.0, 157.0, 148.5, 147.8, 141.7,137.2, 128.1, 126.7, 38.2, 26.5, 22.6; IR νmax 2950, 1679, 1540, 1405,1366, 975, 864, 810, 707 cm−1; MS (ESI, +ve) m/z 241 [(M + Na)+,100%]; HRMS m/z (M + Na)+ calcd for C11H10N2NaO3 241.0589,found 241.0591.6,7,8,9-Tetrahydro-5H-pyrido[2,3-b]indole (9). A magnetically

stirred mixture of compound 8 (30 mg, 0.14 mmol) and 10 wt %Pd/C (12 mg) in degassed methanol (7 mL) was maintained under anatmosphere of hydrogen for 16 h at 22 °C and then filtered, and thesolids thus retained were washed with methanol (20 mL). Thecombined filtrates were concentrated under reduced pressure and thewhite solid thus obtained was subjected to flash column chromatog-raphy (silica, 1:4 v/v ethyl acetate/40−60 petroleum ether elution).Concentration of the appropriate fractions (Rf = 0.7 in ethyl acetate)then gave compound 918 (18 mg, 75%) as a white, crystalline solid: mp= 155−156 °C (lit.18 mp = 155−156 °C); 1H NMR (400 MHz,CDCl3) δ 10.65 (m, 1H), 8.19 (d, J = 4.3 Hz, 1H), 7.75 (dd, J = 7.7and 1.3 Hz, 1H), 7.01 (dd, J = 7.7 and 4.3 Hz, 1H), 2.84 (t, J = 6.0 Hz,2H), 2.70 (m, 2H), 1.98−1.86 (complex m, 4H); 13C NMR (100MHz, CDCl3) δ 148.9, 140.8, 135.4, 125.7, 120.8, 115.1, 108.4,23.3(4), 23.2(8), 23.1, 20.8; IR νmax 3149, 3075, 2921, 2846, 1587,1418, 1289, 786, 765, 677 cm−1; MS (ESI, +ve) m/z 173 [(M + H)+,100%]; HRMS m/z (M + H)+ calcd for C11H13N2 173.1079, found173.1078.9H-Pyrido[2,3-b]indole (α-Carboline, 1). A magnetically stirred

mixture of compound 9 (20 mg, 0.12 mmol) and 10 wt % Pd/C (20mg) in diphenyl ether (15 mL) maintained under a nitrogenatmosphere was heated at 210 °C for 0.66 h. The reaction mixturewas then cooled to room temperature and filtered (through filterpaper), and the solids so retained were washed with ethyl acetate (2 ×

15 mL). The combined filtrates were concentrated under reducedpressure, and the residue thus obtained was subjected to flash columnchromatography (silica, 0:1 → 1:4 v/v ethyl acetate/40−60 petroleumether gradient elution). Concentration of the appropriate fractions (Rf= 0.2 in 1:1 v/v ethyl acetate/40−60 petroleum ether) gave compound14a (19 mg, 97%) as a white, crystalline solid: mp = 200−202 °C (lit.4a

mp = 215−217 °C); 1H NMR (400 MHz, CD3OD) δ 8.44 (dd, J = 7.7and 1.5 Hz, 1H), 8.34 (dd, J = 4.9 and 1.2 Hz, 1H), 8.09 (d, J = 7.9 Hz,1H), 7.52 (d, J = 8.1 Hz, 1H), 7.48−7.44 (complex m, 1H), 7.26−7.19(complex m, 2H) (signal due to N−H group proton not observed);13C NMR (100 MHz, CD3OD) δ 152.9, 146.1, 140.6, 129.9, 128.0,122.0, 121.9, 121.0, 118.0, 116.1, 112.3; IR νmax 3048, 2984, 2906,1600, 1587, 1572, 1455, 1411, 1274, 998, 767, 736 cm−1; MS (ESI,+ve) m/z 169 [(M + H)+, 100%]; HRMS m/z (M + H)+ calcd forC11H9N2 169.0766, found 169.0768.

4-Iodo-3-nitropyridine (10). A magnetically stirred solution ofcommercially available 4-chloro-3-nitropyridine (1.00 g, 6.31 mmol) inacetonitrile (126 mL) maintained at ambient temperatures was treatedwith sodium iodide (17.02 g, 113.55 mmol). The ensuing mixture washeated under reflux for 2 h and then cooled to 22 °C and diluted withethyl acetate (200 mL). The resulting solution was washed withNa2CO3 (1 × 100 mL of a saturated aqueous solution), Na2SO3 (1 ×50 mL of a saturated solution), water (1 × 200 mL), and brine (1 ×100 mL) before being dried (Na2SO4,), filtered, and then concentratedunder reduced pressure. The residue thus obtained was subjected toflash column chromatography (silica, 1:19 v/v ethyl acetate/40−60petroleum ether elution) to give, after concentration of the appropriatefractions (Rf = 0.5 twice in 1:5 v/v ethyl acetate/40−60 petroleumether), 4-iodo-3-nitropyridine (10)20 (1.46 g, 92%) as a light-yellowsolid: mp = 80−82 °C; 1H NMR (400 MHz, CDCl3) δ 9.04 (broad s,1H), 8.35 (d, J = 5.1 Hz, 1H), 8.03 (d, J = 5.1 Hz, 1H); 13C NMR(100 MHz, CDCl3) δ 152.5, 149.6, 145.9, 136.5, 98.5; IR νmax 1572,1540, 1521, 1357, 1223, 1058, 835, 657 cm−1; MS (EI, 70 eV) m/z250 (M+•, 100%), 204 (70), 177 (60); HRMS m/z M+• calcd forC5H3

127IN2O2 249.9239, found 249.9236.2-(3-Nitropyridin-4-yl)cyclohex-2-en-1-one (11). A magnetically

stirred mixture of 2-iodocyclohex-2-en-1-one (6) (888 mg, 4.00mmol), copper powder (508 mg, 8.00 mmol), CuI (571 mg, 3.00mmol), and Pd(dppf)Cl2·CH2Cl2 (163 mg, 0.20 mmol) in degassedDMSO (40 mL) was heated at 50 °C under a nitrogen atmosphere for0.75 h. After this time a solution of compound 10 (500 mg, 2.00mmol) in degassed DMSO (10 mL) was added to the reaction mixtureover 1 h. After a further 0.75 h, the reaction mixture was cooled,quenched with water (10 mL), and then diluted with ethyl acetate (15mL). The ensuing mixture was filtered through a pad comprised of amixture of diatomaceous earth and silica gel. The solids thus retainedwere rinsed with ethyl acetate (2 × 15 mL), and the separated organicphase associated with the combined filtrates was washed with water (2× 30 mL) and then brine (2 × 30 mL) before being dried (Na2SO4),filtered, and concentrated under reduced pressure to give a brown oil.This was subjected to flash column chromatography (silica, 1:3:10 v/v/v acetone/dichloromethane/40−60 petroleum ether elution) andgave, after concentration of the appropriate fractions [Rf = 0.1(5) in1:1 v/v ethyl acetate/40−60 petroleum ether], compound 11 (374mg, 86%) as a light-yellow solid: mp = 105−107 °C; 1H NMR (400MHz, CDCl3) δ 9.18 (s, 1H), 8.78 (d, J = 4.9 Hz, 1H), 7.22 (d, J = 4.9Hz, 1H), 7.13 (t, J = 4.2 Hz, 1H), 2.63−2.57 (complex m, 4H), 2.19−2.13 (complex m, 2H); 13C NMR (100 MHz, CDCl3) δ 195.5, 153.9,148.7, 145.3, 145.0, 140.0, 137.5, 125.6, 38.2, 26.5, 22.5; IR νmax 2948,1679, 1600, 1542, 1523, 1357, 1217, 1159, 1121, 851, 716 cm−1; MS(ESI, +ve) m/z 219 [(M + H)+, 100%]; HRMS m/z (M + H)+ calcdfor C11H11N2O3 219.0770, found 219.0768.

6,7,8,9-Tetrahydro-5H-pyrido[3,4-b]indole (12). A magneticallystirred mixture of compound 11 (190 mg, 0.87 mmol) and 10 wt %Pd/C (76 mg) in degassed methanol (44 mL) was maintained underan atmosphere of hydrogen for 16 h at 22 °C and then filtered, and thesolids thus retained were washed with methanol (100 mL). Thecombined filtrates were concentrated under reduced pressure, and thewhite solid thus obtained was subjected to flash column chromatog-raphy (silica, 1:4 v/v methanol/dichloromethane elution) to give, after

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00323J. Org. Chem. 2017, 82, 4328−4335

4331

386

Page 409: The Application of Pericyclic, Photolytic, Chemoenzymatic

concentration of the appropriate fractions [Rf = 0.3(5) in 1:1 v/vmethanol/dichloromethane], compound 1221 (132 mg, 88%) as awhite, crystalline solid: mp = 163−164 °C (lit.21 mp = 199−200 °C);1H NMR (700 MHz, CD3OD) δ 8.49 (broad s, 1H), 7.97 (broad s,1H), 7.36 (d, J = 4.9 Hz, 1H), 2.77 (t, J = 6.0 Hz, 2H), 2.65 (t, J = 6.0Hz, 2H), 1.92−1.83 (complex m, 4H) (signal due to N−H groupproton not observed); 13C NMR (175 MHz, CD3OD) δ 142.2, 136.9,134.5, 134.2, 132.6, 113.7, 110.4, 24.2(2), 24.2(0), 24.0, 21.6; IR νmax3143, 3040, 2926, 2850, 2839, 1569, 1471, 1442, 1359, 1142, 1030,808 cm−1; MS (ESI, +ve) m/z 173 [(M + H)+, 100%]; HRMS m/z(M + H)+ calcd for C11H13N2 173.1079, found 173.1078.9H-Pyrido[3,4-b]indole (β-Carboline, 2). A magnetically stirred

mixture of compound 12 (20 mg, 0.12 mmol) and 10 wt % Pd/C (20mg) in diphenyl ether (15 mL) maintained under a nitrogenatmosphere was heated at 210 °C for 0.66 h. The reaction mixturewas then cooled to room temperature and filtered (through filterpaper), and the solids so retained were washed with ethyl acetate (2 ×15 mL). The combined filtrates were concentrated under reducedpressure, and the residue thus obtained was subjected to flash columnchromatography (silica, 0:1 → 1:1 v/v ethyl acetate/40−60 petroleumether gradient elution) to give, after concentration of the appropriatefractions (Rf = 0.5 in 1:2 v/v methanol/dichloromethane), compound222 (18 mg, 94%) as a white, crystalline solid: mp = 210−211 °C (lit.22

mp = 199−201 °C); 1H NMR (400 MHz, CD3OD) δ 8.79 (s, 1H),8.27 (d, J = 5.3 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 5.3 Hz,1H), 7.56 (m, 2H), 7.29−7.23 (complex m, 1H) (signal due to N−Hgroup proton not observed); 13C NMR (100 MHz, CD3OD) δ 142.7,138.4, 137.8, 134.1, 130.4, 129.7, 122.7, 122.2, 120.8, 116.1, 112.8; IRνmax 3134, 3052, 2963, 2754, 1628, 1449, 1331, 1245, 746, 732 cm−1;MS (ESI, +ve) m/z 191 [(M + Na)+, 70%], 169 [(M + H)+, 100];HRMS m/z (M + H)+ calcd for C11H9N2 169.0766, found 169.0766.2-(4-Nitropyridin-3-yl)cyclohex-2-en-1-one (14). A magnetically

stirred mixture of 2-iodocyclohex-2-en-1-one (6) (2.19 g, 9.85 mmol),copper powder (1.26 g, 19.70 mmol), CuI (1.41 g, 7.39 mmol), andPd(dppf)Cl2·CH2Cl2 (400 mg, 0.49 mmol) in degassed DMSO (98mL) was heated at 50 °C under a nitrogen atmosphere for 0.75 h.After this time, a solution of compound 13 (1.00 g, 4.93 mmol) indegassed DMSO (25 mL) was added to the reaction mixture over 1.5h. After a further 4 h, the reaction mixture was cooled, quenched withwater (20 mL), and then diluted with ethyl acetate (1 × 30 mL). Theensuing mixture was filtered through a pad comprised of a mixture ofdiatomaceous earth and silica gel. The solids thus retained were rinsedwith ethyl acetate (2 × 30 mL), and the separated organic phaseassociated with the combined filtrates was washed with water (2 × 60mL) and then brine (2 × 60 mL) before being dried (Na2SO4),filtered, and concentrated under reduced pressure to give a brown oil.Subjection of this material to flash column chromatography (silica,1:3:11 v/v/v acetone/dichloromethane/40−60 petroleum etherelution) gave, after concentration of the appropriate fractions (Rf =0.2 in 1:3:6 v/v/v acetone/dichloromethane/40−60 petroleum ether),compound 14 (956 mg, 89%) as a light-brown solid: mp = 94−95 °C;1H NMR (400 MHz, CDCl3) δ 8.82 (d, J = 5.3 Hz, 1H), 8.61 (s, 1H),7.81 (d, J = 5.3 Hz, 1H), 7.17 (t, J = 4.2 Hz, 1H), 2.66−2.58 (complexm, 4H), 2.18 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 196.1, 154.1,152.8, 151.4, 148.6, 136.0, 125.4, 116.6, 38.2, 26.5, 22.6; IR νmax 2945,1677, 1557, 1529, 1401, 1358, 1222, 1159, 839, 705, 675 cm−1; MS(ESI, +ve) m/z 241 [(M + Na)+, 100%], 219 [(M + H)+, 15]; HRMSm/z (M + Na)+ calcd for C11H10N2NaO3 241.0589, found 241.0589.6,7,8,9-Tetrahydro-5H-pyrido[4,3-b]indole (15). A magnetically

stirred mixture of compound 14 (50 mg, 0.23 mmol) and 10 wt %Pd/C (20 mg) in degassed methanol (12 mL) was maintained underan atmosphere of hydrogen at 22 °C for 16 h and then filtered, and thesolids so retained were washed with methanol (25 mL). The combinedfiltrates were concentrated under reduced pressure, and the white solidthus obtained was subjected to flash column chromatography (silica,1:4 v/v methanol/dichloromethane elution) to give, after concen-tration of the appropriate fractions [Rf = 0.3(5) in 1:1 v/v methanol/dichloromethane], compound 1523 (26 mg, 66%) as a white,crystalline solid: mp = 223−224 °C (lit.23 mp = 269−271 °C); 1HNMR (700 MHz, CD3OD) δ 8.58 (broad s, 1H), 8.05 (broad s, 1H),

7.28 (d, J = 5.3 Hz, 1H), 2.74 (m, 4H), 1.95−1.87 (complex m, 4H)(signal due to N−H group proton not observed); 13C NMR (175MHz, CD3OD) δ 141.6, 139.9, 139.1, 138.1, 126.2, 110.3, 107.5, 24.2,24.1, 23.9, 21.6; IR νmax 2926, 2839, 2693, 1625, 1466, 1294, 1169,1142, 989, 802, 684 cm−1; MS (ESI, +ve) m/z 173 [(M + H)+, 100%];HRMS m/z (M + H)+ calcd for C11H13N2 173.1079, found 173.1078.

5H-Pyrido[4,3-b]indole (γ-Carboline, 3). A magnetically stirredmixture of compound 15 (20 mg, 0.12 mmol) and 10 wt % Pd/C (20mg) in diphenyl ether (15 mL) maintained under a nitrogenatmosphere was heated at 210 °C for 0.66 h. The reaction mixturewas then cooled to room temperature and filtered (through filterpaper), and the solids thus retained were washed with ethyl acetate (2× 15 mL). The combined filtrates were concentrated under reducedpressure, and the residue thus obtained was subjected to flash columnchromatography (silica, 40−60 petroleum ether elution → 1:3 v/vmethanol/dichloromethane gradient elution) to give, after concen-tration of the appropriate fractions [Rf = 0.2(5) in 1:3 v/v methanol/dichloromethane], compound 324 (15 mg, 77%) as a white, crystallinesolid: mp = 223−225 °C (lit.24 mp = 225−227 °C); 1H NMR [700MHz, (CD3)2SO] δ 11.69 (s, 1H), 9.33 (s, 1H), 8.43 (s, 1H), 8.22 (d,J = 7.8 Hz, 1H), 7.56 (m, 1H), 7.47 (m, 2H), 7.26 (t, J = 7.4 Hz, 1H);13C NMR [175 MHz, (CD3)2SO] δ 144.5, 143.5, 142.7, 139.5, 126.5,120.7, 120.6, 119.9, 119.4, 111.4, 106.4; 1H NMR (700 MHz,CD3OD) δ 9.20 (s, 1H), 8.36 (s, 1H), 8.16 (d, J = 7.8 Hz, 1H), 7.53(d, J = 8.1 Hz, 1H), 7.49−7.46 (m, 2H), 7.28 (t, J = 7.4 Hz, 1H)(signal due to N−H group proton not observed); 13C NMR (175MHz, CD3OD) δ 145.8, 144.4, 142.7, 141.5, 128.2, 122.4, 121.6(4),121.6(0), 121.5, 112.4, 107.6; IR νmax 3062, 2956, 2806, 2679, 1607,1582, 1467, 1239, 999, 744 cm−1; MS (ESI, +ve) m/z 169 [(M + H)+,100%]; HRMS m/z (M + H)+ calcd for C11H9N2 169.0766, found169.0766.

2-(3-Nitropyridin-2-yl)cyclohex-2-en-1-one (17). A magneticallystirred mixture of 2-iodocyclohex-2-en-1-one (6) (1.09 g, 4.93 mmol),copper powder (630 mg, 9.85 mmol), CuI (704 mg, 3.69 mmol), andPd(dppf)Cl2·CH2Cl2 (200 mg, 0.25 mmol) in degassed DMSO (50mL) was heated at 50 °C under a nitrogen atmosphere for 0.75 h.After this time, a solution of compound 16 (500 mg, 4.93 mmol) indegassed DMSO (12 mL) was added to the reaction mixture over 1 h.After a further 2 h, the reaction mixture was cooled, quenched withwater (10 mL), diluted with ethyl acetate (15 mL), and then filteredthrough a pad comprised of a mixture of diatomaceous earth and silicagel. The solids thus retained were rinsed with ethyl acetate (2 × 15mL), and the separated organic phase associated with the combinedfiltrates was washed with water (2 × 30 mL) and then brine (2 × 30mL) before being dried (Na2SO4), filtered, and concentrated underreduced pressure to give a brown oil. Subjection of this material toflash column chromatography (silica, 1:3:12 v/v/v acetone/dichloro-methane/40−60 petroleum ether elution) gave, after concentration ofthe appropriate fractions [Rf = 0.1(5) in 1:3:6 v/v/v acetone/dichloromethane/40−60 petroleum ether], compound 17 (403 mg,75%) as a light-brown solid: mp = 104−106 °C; 1H NMR (400 MHz,CDCl3) δ 8.79 (dd, J = 4.7 and 1.3 Hz, 1H), 8.29 (dd, J = 8.2 and 1.3Hz, 1H), 7.49−7.43 (complex m, 2H), 2.65 (m, 2H), 2.58 (m, 2H),2.20−2.13 (complex m, 2H); 13C NMR (100 MHz, CDCl3) δ 196.2,152.9, 151.0, 149.4, 146.1, 139.2, 132.2, 123.4, 38.3, 26.6, 22.5; IR νmax2947, 1677, 1593, 1561, 1526, 1451, 1357, 765 cm−1; MS (ESI, +ve)m/z 241 [(M + Na)+, 100%], 219 [(M + H)+, 15]; HRMS m/z (M +Na)+ calcd for C11H10N2NaO3 241.0589, found 241.0589.

6,7,8,9-Tetrahydro-5H-pyrido[3,2-b]indole (18). A magneticallystirred mixture of compound 17 (213 mg, 0.98 mmol) and 10 wt %Pd/C (86 mg) in degassed methanol (49 mL) was maintained underan atmosphere of hydrogen for 16 h at 22 °C and then filtered, and thesolids so retained were washed with methanol (100 mL). Thecombined filtrates were concentrated under reduced pressure, and thewhite solid thus obtained was subjected to flash column chromatog-raphy (silica, 1:1 v/v ethyl acetate/40−60 petroleum ether elution) togive, after concentration of the appropriate fractions (Rf = 0.2 in 1:1 v/v ethyl acetate/40−60 petroleum ether), compound 1825 (109 mg,65%) as a white, crystalline solid: mp = 183−185 °C (lit.25 mp = 200−202 °C); 1H NMR (400 MHz, CDCl3) δ 8.86 (broad s, 1H), 8.38 (d, J

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00323J. Org. Chem. 2017, 82, 4328−4335

4332

387

Page 410: The Application of Pericyclic, Photolytic, Chemoenzymatic

= 4.3 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.00 (m, 1H), 2.84 (m, 2H),2.76 (m, 2H), 1.95−1.84 (complex m, 4H); 13C NMR (100 MHz,CDCl3) δ 145.6, 141.9, 139.2, 129.1, 117.4, 115.8, 110.8, 23.8, 23.2,23.1, 20.1; IR νmax 3136, 3083, 3053, 2929, 2847, 1483, 1414, 1362,1286, 1144, 904, 767, 729 cm−1; MS (ESI, +ve) m/z 173 [(M + H)+,100%]; HRMS m/z (M + H)+ calcd for C11H13N2 173.1079, found173.1080.5H-Pyrido[3,2-b]indole (δ-Carboline, 4). A magnetically stirred

mixture of compound 18 (20 mg, 0.12 mmol) and 10 wt % Pd/C (20mg) in diphenyl ether (15 mL) maintained under a nitrogenatmosphere was heated at 210 °C for 0.66 h. The reaction mixturewas then cooled to room temperature and filtered (through filterpaper), and the solids thus retained were washed with ethyl acetate (2× 15 mL). The combined filtrates were concentrated under reducedpressure, and the residue thus obtained was subjected to flash columnchromatography (silica, 0:1 → 1:4 v/v ethyl acetate/40−60 petroleumether gradient elution) to give, after concentration of the appropriatefractions [Rf = 0.2(5) in 1:1 v/v ethyl acetate/40−60 petroleumether], compound 426 (18 mg, 92%) as a white, crystalline solid: mp =211−212 °C (lit.26 mp = 206−207 °C); 1H NMR (400 MHz,CD3OD) δ 8.39 (dd, J = 4.8 and 1.4 Hz, 1H), 8.28 (d, J = 7.9 Hz, 1H),7.88 (d, J = 8.2 Hz, 1H), 7.52 (m, 2H), 7.40 (m, 1H), 7.26 (m, 1H)(signal due to N−H group proton not observed); 13C NMR (100MHz, CD3OD) δ 142.4, 142.3, 141.5, 135.1, 129.0, 122.4, 121.4, 121.3,120.8, 119.9, 112.6; IR νmax 3057, 2979, 2919, 2848, 2760, 1629, 1460,1396, 1320, 1223, 741, 724 cm−1; MS (ESI, +ve) m/z 169 [(M + H)+,100%]; HRMS m/z (M + H)+ calcd for C11H9N2 169.0766, found169.0766.2-Methylpyridin-4-ol Nitrate (20). Commercially available 2-

methylpyridin-4-amine (8.00 g, 73.98 mmol) was dissolved in amixture of concentrated HNO3 (44.1 mL) and H2O (59.4 mL), andthe resulting solution was cooled, with vigorous magnetic stirring, to 0°C. A chilled solution of NaNO2 (7.40 g, 107.25 mmol) in water (21.7mL) was then added dropwise over 0.5 h, and the mixture thus formedstirred at 0 °C for 4 h before being allowed to warm to 22 °C and thenstirred at this temperature for another 10 h and was recooled to 0 °C.The resulting solid was removed by filtration, the filtrate wasconcentrated to about one-third of its original volume and thencooled to 0 °C, and a second crop of solid was removed by filtration.The combined solids were then air-dried to give the nitric acid salt27 ofcompound 20 (10.49 g, 82%) as a white, crystalline solid: mp = 162−164 °C (lit.27 mp = 164−165 °C); 1H NMR (400 MHz, CD3OD) δ8.34 (d, J = 6.5 Hz, 1H), 7.11−7.09 (complex m, 2H), 2.62 (s, 3H)(signals due to O−H and N−H group protons not observed); 13CNMR (100 MHz, CD3OD) δ 173.4, 156.0, 143.2, 114.7, 113.0, 19.3;IR νmax 3098, 2919, 2617, 1627, 1501, 1305, 1216, 830 cm

−1; MS (ESI,+ve) m/z 110 [(M + H)+, 100%]; HRMS m/z (M + H)+ calcd forC6H8NO 110.0606, found 110.0608.2-Methyl-4-nitropyridin-3-ol (21) and 2-Methyl-3-nitropyridin-4-

ol (22). A magnetically stirred solution of salt 20 (3.00 g, 17.43 mmol)in concentrated H2SO4 (6.9 mL) was cooled to 0 °C and then treated,dropwise, with fuming HNO3 (6.9 mL). The ensuing mixture wasstirred at 0 °C for 0.17 h, heated at 130 °C for 20 h, and then cooledto 0 °C and carefully neutralized with NaOH (25 mL of a 10 Maqueous solution). FC-grade silica gel (20 g) was added to the ensuingmixture, and this was then concentrated under reduced pressure. Thefree-flowing solid thus obtained was subjected to flash columnchromatography (silica, 1:19 v/v methanol/dichloromethane elution)to give, after concentration of the appropriate fractions (Rf = 0.6 in 1:1v/v methanol/dichloromethane), a 1:3 mixture of 2-methyl-5-nitropyridin-4-ol (21) and 2-methyl-3-nitropyridin-4-ol (22) (1.88 g,70% combined yield) as a white crystalline solid: mp = 148−150 °C;1H NMR [400 MHz, (CD3)2SO] δ (major product) 12.17 (broad s,1H), 7.72 (d, J = 7.5 Hz, 1H), 6.33 (d, J = 7.5 Hz, 1H), 2.29 (s, 3H);13C NMR [100 MHz, (CD3)2SO] δ (for mixture) 168.2, 151.2, 148.1,143.5, 142.2, 139.4, 137.8, 137.3, 120.7, 118.0, 18.2, 15.3; IR νmax 3037,2796, 1612, 1557, 1502, 1356, 1222, 836, 768 cm−1; MS (ESI, +ve) m/z 331 (42%), 177 [(M + Na)+, 100], 155 [(M + H)+, 10]; HRMS(ESI) m/z (M + Na)+ calcd for C6H6N2NaO3 177.0276, found177.0278.

4-Bromo-2-methyl-3-nitropyridine (24). A magnetically stirred 1:3mixture of 2-methyl-5-nitropyridin-4-ol (21) and 2-methyl-3-nitro-pyridin-4-ol (22) (1.12 g, 7.27 mmol), obtained as describedimmediately above, in toluene (8.0 mL) and maintained under anitrogen atmosphere was treated with POBr3 (2.19 g, 7.63 mmol). Theensuing mixture was heated under reflux for 10 h and then cooled to 0°C before being quenched with NaOH (30 mL of a 1 M aqueoussolution). The ensuing mixture was extracted with ethyl acetate (1 ×150 mL) and washed with H2O (2 × 150 mL). The separated organicphase was then dried (Na2SO4), filtered, and concentrated underreduced pressure. The solid so obtained was subjected to flash columnchromatography (silica, 1:3:20 v/v/v acetone/dichloromethane/40−60 petroleum ether elution) to give, after concentration of theappropriate fractions (Rf = 0.4 in 1:3:6 v/v/v acetone/dichloro-methane/40−60 petroleum ether), a 1:3 mixture of what is presumedto be 4-bromo-2-methyl-5-nitropyridine (23) and 4-bromo-2-methyl-3-nitropyridine (24) (1.46 g, 92% combined) as a white solid. A ca.800 mg portion of this material was subjected to semipreparativeHPLC (silica, normal phase, 17:83 v/v ethyl acetate/n-hexane elution,600 mL/h) to afford, after concentration of the relevant fractions (Rt =0.45 h), a pure sample of 4-bromo-2-methyl-3-nitropyridine (24) (ca.350 mg) as a white, crystalline solid: mp = 78−79 °C; 1H NMR (400MHz, CDCl3) δ 8.40 (d, J = 5.3 Hz, 1H), 7.50 (d, J = 5.3 Hz, 1H),2.60 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 151.8, 150.5, 148.5,126.3, 123.7, 20.9; IR νmax 3072, 1575, 1534, 1365, 1266, 846, 837, 714cm−1; MS (EI, 70 eV) m/z 218 and 216 (M+•, both 90%), 201 and199 (both 70), 172 and 170 (both 95), 93 and 91 (both 83), 62(100%); HRMS m/z M+• calcd for C6H5

79BrN2O2 215.9534, found.215.9533.

2-(2-Methyl-3-nitropyridin-4-yl)cyclohex-2-en-1-one (25). A mag-netically stirred mixture of 2-iodocyclohex-2-en-1-one (6) (205 mg,0.92 mmol), copper powder (117 mg, 1.84 mmol), CuI (132 mg, 0.69mmol), and Pd(dppf)Cl2·CH2Cl2 (38 mg, 0.05 mmol) in degassedDMSO (9 mL) was heated at 50 °C under a nitrogen atmosphere for0.75 h. After this time, a solution of compound 24 (100 mg, 0.46mmol) in degassed DMSO (3 mL) was added to the reaction mixtureover 0.66 h. After a further 6 h the reaction mixture was cooled,quenched with water (3 mL), and then diluted with ethyl acetate (5mL). The ensuing mixture was filtered through a pad comprised of amixture of diatomaceous earth and silica gel, and the solids so retainedwere rinsed with ethyl acetate (2 × 5 mL). The separated organicphase associated with the combined filtrates was washed with water (2× 10 mL) and then brine (2 × 10 mL) before being dried (Na2SO4),filtered, and concentrated under reduced pressure to give a brown oil.Subjection of this material to flash column chromatography (silica,3:9:40 v/v/v acetone/dichloromethane/40−60 petroleum etherelution) gave, after concentration of the appropriate fractions [Rf =0.1(5) in 1:3:6 v/v/v acetone/dichloromethane/40−60 petroleumether], compound 25 (90 mg, 84%) as a light-brown, crystalline solid:mp = 80−81 °C; 1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 5.0 Hz,1H), 7.09−7.05 (complex m, 2H), 2.66 (s, 3H), 2.58−2.54 (complexm, 4H), 2.12 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 195.6, 151.4,150.8, 150.1, 146.6, 139.0, 136.3, 123.4, 38.2, 26.5, 22.5, 22.0; IR νmax2939, 1681, 1594, 1528, 1359, 1229, 860 cm−1; MS (ESI, +ve) m/z255 [(M + Na)+, 100%], 233 [(M + H)+, 10]; HRMS m/z (M + Na)+

calcd for C12H12N2NaO3 255.0746, found 255.0734.1-Methyl-6,7,8,9-tetrahydro-5H-pyrido[3,4-b]indole (26). A mag-

netically stirred mixture of compound 25 (103 mg, 0.44 mmol) and 10wt % Pd/C (42 mg) in degassed methanol (22 mL) was maintainedunder an atmosphere of hydrogen at 22 °C for 16 h and then filtered,and the solids thus retained were washed with methanol (50 mL). Thecombined filtrates were concentrated under reduced pressure, and thewhite solid thus obtained was subjected to flash column chromatog-raphy (silica, 1:4 v/v methanol/dichloromethane elution) to give, afterconcentration of the appropriate fractions (Rf = 0.2 in 1:1 v/vmethanol/dichloromethane), compound 2628 (69 mg, 83%) as awhite, crystalline solid: mp = 187−189 °C (lit.28 mp = 184−188 °C);1H NMR (400 MHz, CD3OD) δ 7.84 (d, J = 5.4 Hz, 1H), 7.19 (d, J =5.4 Hz, 1H), 2.78 (broad s, 2H), 2.63 (broad s, 5H), 1.91−1.84(complex m, 4H) (signal due to N−H group proton not observed);

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00323J. Org. Chem. 2017, 82, 4328−4335

4333

388

Page 411: The Application of Pericyclic, Photolytic, Chemoenzymatic

13C NMR (100 MHz, CD3OD) δ 141.6, 141.2, 136.7, 133.7, 132.9,111.9, 110.6, 24.3, 24.2, 24.1, 21.7, 19.1; IR νmax 3045, 2930, 2846,1563, 1498, 1308, 1226, 809 cm−1; MS (ESI, +ve) m/z 187 [(M +H)+, 100%]; HRMS m/z (M + H)+ calcd for C12H15N2 187.1235,found 187.1232.1-Methyl-9H-pyrido[3,4-b]indole (Harman, 5). A magnetically

stirred mixture of compound 26 (36 mg, 0.19 mmol) and 10 wt %Pd/C (36 mg) in diphenyl ether (15 mL) maintained under a nitrogenatmosphere was heated at 210 °C for 0.66 h. The reaction mixture wasthen cooled to room temperature and filtered (through filter paper),and the solids so retained were washed with ethyl acetate (2 × 7 mL).The combined filtrates were concentrated under reduced pressure, andthe residue thus obtained was subjected to flash column chromatog-raphy (silica, 40−60 petroleum ether elution →1:9 v/v methanol/dichloromethane elution) to give, after concentration of theappropriate fractions (Rf = 0.5 in 1:3 v/v methanol/dichloromethane),compound 529 (32 mg, 91%) as a white, crystalline solid: mp = 233−235 °C (lit.29 mp = 235−238 °C); 1H NMR (400 MHz, CDCl3) δ8.91 (broad s, 1H), 8.38 (d, J = 5.4 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H),7.84 (d, J = 5.4 Hz, 1H), 7.56−7.51 (complex m, 2H), 7.29 (m, 1H),2.84 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 141.9, 140.3, 138.7,134.8, 128.5, 128.4, 122.2, 122.0, 120.2, 113.1, 111.7, 20.5; IR νmax

3135, 3068, 2925, 1626, 1568, 1504, 1450, 1323, 1251, 1237, 742cm−1; MS (ESI, +ve) m/z 183 [(M + H)+, 100%]; HRMS (ESI) m/z(M + H)+ calcd for C12H11N2 183.0922, found 183.0922.X-ray Crystallographic Studies. Crystallographic Data. Com-

pound 1. C11H8N2, M = 168.20, T = 150 K, monoclinic, space groupP21/n, Z = 4, a = 11.1814(2) Å, b = 5.53776(8) Å, c = 13.4546(2) Å, β= 96.2939(15)°, V = 828.09(2) Å3, Dx = 1.349 g cm−3, 1673 uniquereflections (2θmax = 147.6°), R = 0.035 [for 1520 reflections with I >2.0σ(I)], Rw = 0.089 (all data), S = 1.00.Compound 2. C11H8N2, M = 168.20, T = 150 K, orthorhombic,

space group P212121, Z = 4, a = 5.8440(1) Å, b = 9.8140(1) Å, c =14.4195(1) Å, V = 827.00(2) Å3, Dx = 1.351 g cm−3, 1004 uniquereflections (2θmax = 147.8°), R = 0.027 [for 998 reflections with I >2.0σ(I)], Rw = 0.073 (all data), S = 1.00.Compound 3. C11H8N2, M = 168.20, T = 150 K, orthorhombic,

space group Pna21, Z = 4, a = 17.1576(6) Å, b = 12.2955(6) Å, c =3.8213(2) Å, V = 806.15(6) Å3, Dx = 1.386 g cm−3, 944 uniquereflections (2θmax = 147.8°), R = 0.032 [for 906 reflections with I >2.0σ(I)], Rw = 0.062 (all data), S = 1.00.Compound 4. C11H8N2, M = 168.20, T = 150 K, monoclinic, space

group Ia, Z = 4, a = 12.1155(7) Å, b = 3.9036(2) Å, c = 18.1199(13)Å, β = 107.250(7)°, V = 818.42(9) Å3, Dx = 1.365 g cm−3, 820 uniquereflections (2θmax = 146.6°), R = 0.042 [for 807 reflections with I >2.0σ(I)], Rw = 0.107 (all data), S = 1.05.Compound 5. C12H10N2, M = 182.23, T = 150 K, orthorhombic,

space group P212121, Z = 8, a = 9.5865(2) Å, b = 13.2423(4) Å, c =15.1680(4) Å, V = 1925.54(9) Å3, Dx = 1.257 g cm−3, 1994 uniquereflections (2θmax = 52.0°), R = 0.032 [for 1805 reflections with I >2.0σ(I)], Rw = 0.073 (all data), S = 1.00.Structure Determination. Images for compound 5 were collected

on a diffractometer (Mo Kα, graphite monochromator, λ = 0.71073 Å)fitted with an area detector, and the data were extracted using CrysAlisPRO.34 Images for compounds 1, 2, 3, and 4 were measured on adiffractometer (Cu Kα, mirror monochromator, λ = 1.54184 Å) fittedwith an area detector, and the data were extracted using the CrysAlisPRO.34 The structure solutions for all 5 compounds were solved bydirect methods (SIR92)35 and then refined using the CRYSTALSprogram package.36 Atomic coordinates, bond lengths and angles, anddisplacement parameters have been deposited at the CambridgeCrystallographic Data Centre (CCDC nos. 1530002, 1530003,1530004, 1530005, 1530006). These data can be obtained free-of-charge via www.ccdc.cam.ac.uk/data_request/cif, by e-mailing [email protected], or by contacting The Cambridge Crystallo-graphic Data Centre (12 Union Road, Cambridge CB2 1EZ, UK; fax:+ 44 1223 336033).

■ ASSOCIATED CONTENT*S Supporting InformationThe Supporting Information is available free of charge on theACS Publications website at DOI: 10.1021/acs.joc.7b00323.

Crystallographic data for 1 in CIF format (CIF)Crystallographic data for 2 in CIF format (CIF)Crystallographic data for 3 in CIF format (CIF)Crystallographic data for 4 in CIF format (CIF)Crystallographic data for 5 in CIF format (CIF)ORTEPs derived from the single-crystal X-ray analyses ofcompounds 1−5 and 1H and 13C NMR spectra ofcompounds 1−5, 8−12, 14, 15, 17, 18, 20, 21/22, and24−26 (PDF)

■ AUTHOR INFORMATIONCorresponding Author*E-mail: [email protected] G. Banwell: 0000-0002-0582-475XNotesThe authors declare no competing financial interest.Atomic coordinates, bond lengths and angles, and displacementparameters have been deposited at the Cambridge Crystallo-graphic Data Centre (CCDC nos. 1530002, 1530003, 1530004,1530005, 1530006). These data can be obtained free-of-chargevia www.ccdc.cam.ac.uk/data_request/cif, by emailing [email protected], or by contacting The CambridgeCrystallographic Data Centre at 12 Union Road, CambridgeCB2 1EZ, UK (fax: + 44 1223 336033).

■ ACKNOWLEDGMENTSWe thank the Australian Research Council and the Institute ofAdvanced Studies for financial support. Q.Y. is the gratefulrecipient of a PhD Scholarship provided by the ChinaScholarship Council of the People’s Republic of China.

■ REFERENCES(1) For useful points-of-entry into the substantial body of literatureon these compounds, see the following: (a) Smirnova, O. B.; Golovko,T. V.; Granik, V. G. Pharm. Chem. J. 2011, 44, 654. (b) Hung, T. Q.;Dang, T. T.; Janke, J.; Villinger, A.; Langer, P. Org. Biomol. Chem.2015, 13, 1375 and references cited therein.(2) See, for example, the following: Lee, C. W.; Lee, J. Y. Adv. Mater.2013, 25, 5450.(3) Basavaiah, D.; Reddy, D. M. Org. Biomol. Chem. 2012, 10, 8774and references cited therein.(4) (a) Laha, J. K.; Petrou, P.; Cuny, G. D. J. Org. Chem. 2009, 74,3152. (b) Ghahremanzadeh, R.; Ahadi, S.; Bazgir, A. Tetrahedron Lett.2009, 50, 7379. (c) Mineno, M.; Sera, M.; Ueda, T.; Mizuno, M.;Yamano, M.; Mizufune, H.; Zanka, A. Tetrahedron 2014, 70, 5550.(d) Mineno, M.; Sera, M.; Ueda, T.; Mizufune, H.; Zanka, A.; O’Bryan,C.; Brown, J.; Scorah, N. J. Org. Chem. 2015, 80, 1564 and referencescited therein.(5) (a) Zhu, Y.-P.; Liu, M.-C.; Cai, Q.; Jia, F.-C.; Wu, A.-X. Chem. -Eur. J. 2013, 19, 10132. (b) Dhiman, S.; Mishra, U. K.; Ramasastry, S.S. V. Angew. Chem. Int. Ed. 2016, 55, 7737. (c) Dighe, S. U.; Yadav, V.D.; Mahar, R.; Shukla, S. K.; Batra, S. Org. Lett. 2016, 18, 6010 andreferences cited therein.(6) See, for example, the following: (a) Kamlah, A.; Lirk, F.; Bracher,F. Tetrahedron 2016, 72, 837. (b) Du, H.; Gu, H.; Li, N.; Wang, J.MedChemComm 2016, 7, 636.(7) See, for example, the following: (a) Otto, R.; Penzis, R.; Gaube,F.; Winckler, T.; Appenroth, D.; Fleck, C.; Trankle, C.; Lehmann, J.;Enzensperger, C. Eur. J. Med. Chem. 2014, 87, 63. (b) Ran, X.; Zhao,

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00323J. Org. Chem. 2017, 82, 4328−4335

4334

389

Page 412: The Application of Pericyclic, Photolytic, Chemoenzymatic

Y.; Liu, L.; Bai, L.; Yang, C.-Y.; Zhou, B.; Meagher, J. L.;Chinnaswamy, K.; Stuckey, J. A.; Wang, S. J. Med. Chem. 2015, 58,4927.(8) Cao, J.; Xu, Y.; Kong, Y.; Cui, Y.; Hu, Z.; Wang, G.; Deng, Y.; Lai,G. Org. Lett. 2012, 14, 38.(9) For some useful reviews see (a) Wadsworth, A. D.; Naysmith, B.J.; Brimble, M. A. Eur. J. Med. Chem. 2015, 97, 816. (b) Alekseyev, R.S.; Kurkin, A. V.; Yurovskaya, M. A. Chem. Heterocycl. Compd. 2009,45, 889. (c) Alekseyev, R. S.; Kurkin, A. V.; Yurovskaya, M. A. Chem.Heterocycl. Compd. 2010, 46, 777.(10) See also (a) Ishiyama, H.; Ohshita, K.; Abe, T.; Nakata, H.;Kobayashi, J. Bioorg. Med. Chem. 2008, 16, 3825. (b) Butin, A. V.;Pilipenko, A. S.; Milich, A. A.; Finko, A. V. Chem. Heterocycl. Compd.2009, 45, 613. (c) Dagar, A.; Biswas, S.; Samanta, S. RSC Adv. 2015, 5,52497. (d) Li, J.; Tang, Y.; Jin, H.-J.; Cui, Y.-D.; Zhang, L.-J.; Jiang, T.J. Asian Nat. Prod. Res. 2015, 17, 299. (e) Wang, G.; You, X.; Gan, Y.;Liu, Y. Org. Lett. 2017, 19, 110.(11) Peng, H.; Chen, X.; Chen, Y.; He, Q.; Xie, Y.; Yang, C.Tetrahedron 2011, 67, 5725.(12) (a) Zhang, H.; Larock, R. C. J. Org. Chem. 2002, 67, 9318.(b) Hostyn, S.; Van Baelen, G.; Lemiere, G. L. F.; Maes, B. U. W. Adv.Synth. Catal. 2008, 350, 2653. (c) Gupta, S.; Kumar, B.; Kundu, B. J.Org. Chem. 2011, 76, 10154. (d) Dassonneville, B.; Witulski, B.;Detert, H. Eur. J. Org. Chem. 2011, 2011, 2836. (e) Ma, Z.; Ni, F.;Woo, G. H. C.; Lo, S.-M.; Roveto, P. M.; Schaus, S. E.; Snyder, J. K.Beilstein J. Org. Chem. 2012, 8, 829. (f) Markey, S. J.; Lewis, W.;Moody, C. J. Org. Lett. 2013, 15, 6306. (g) Mineno, M.; Sera, M.;Ueda, T.; Mizuno, M.; Yamano, M.; Mizufune, H.; Zanka, A.Tetrahedron 2014, 70, 5550. (h) Pilipenko, A. S.; Uchuskin, M. G.;Trushkov, I. V.; Butin, A. V. Tetrahedron 2015, 71, 8786. (i) Dondas,H. A.; Hempshall, A.; Narramore, S.; Kilner, C.; Fishwick, C. W. G.;Grigg, R. Tetrahedron 2016, 72, 1316. (j) Hingane, D. G.; Parekh, N.P.; Khan, A.; Kusurkar, R. S. Synth. Commun. 2016, 46, 160. (k) He, L.;Allwein, S. P.; Dugan, B. J.; Knouse, K. W.; Ott, G. R.; Zificsak, C. A.Org. Synth. 2016, 93, 272.(13) (a) Clark, V. M.; Cox, A.; Herbert, E. J. J. Chem. Soc. C 1968,831. (b) Rocca, P.; Marsais, F.; Godard, A.; Queguiner, G. Tetrahedron1993, 49, 49. (c) Rocca, P.; Cochennec, C.; Marsais, F.; Thomas-dit-Dumont, L.; Mallet, M.; Godard, A.; Queguiner, G. J. Org. Chem. 1993,58, 7832. (d) Rocca, P.; Marsais, F.; Godard, A.; Queguiner, G.Tetrahedron 1993, 49, 3325. (e) Rocca, P.; Marsais, F.; Godard, A.;Queguiner, G. Tetrahedron Lett. 1993, 34, 7917. (f) Rocca, P.; Marsais,F.; Godard, A.; Queguiner, G.; Adams, L.; Alo, B. J. Heterocycl. Chem.1995, 32, 1171. (g) Iwaki, T.; Yasuhara, A.; Sakamoto, T. J. Chem. Soc.,Perkin Trans. 1 1999, 1505. (h) Laha, J. K.; Barolo, S. M.; Rossi, R. A.;Cuny, G. D. J. Org. Chem. 2011, 76, 6421. (i) Pumphrey, A. L.; Dong,H.; Driver, T. G. Angew. Chem. Int. Ed. 2012, 51, 5920. (j) Dhara, S.;Singha, R.; Ahmed, A.; Mandal, H.; Ghosh, M.; Nuree, Y.; Ray, J. K.RSC Adv. 2014, 4, 45163.(14) (a) Ishida, J.; Wang, H.-K.; Oyama, M.; Cosentino, M. L.; Hu,C.-Q.; Lee, K.-L. J. Nat. Prod. 2001, 64, 958. (b) Aassila, H.; Bourguet-Kondracki, M. L.; Rifai, S.; Fassouane, A.; Guyot, M. Mar. Biotechnol.2003, 5, 163. (c) Kusurkar, R. S.; Goswami, S. K.; Vyas, S. M.Tetrahedron Lett. 2003, 44, 4761.(15) Banwell, M. G.; Jones, M. T.; Reekie, T. A. Chem. New Zealand2011, 75, 122.(16) Pandey, G.; Balakrishnan, M. J. Org. Chem. 2008, 73, 8128.(17) Yan, Q.; Gin, E.; Wasinska-Kalwa, M.; Banwell, M. G.; Carr, P.D. J. Org. Chem. 2017, DOI: 10.1021/acs.joc.7b00044.(18) Okuda, S.; Robison, M. M. J. Am. Chem. Soc. 1959, 81, 740.(19) Various methods are available for the oxidation oftetrahydrocarbolines to their fully aromatic counterparts: (a) Panarese,J. D.; Waters, S. P. Org. Lett. 2010, 12, 4086. (b) Kamal, A.; Tangella,Y.; Manasa, K. L.; Sathish, M.; Srinivasulu, V.; Chetna, J.; Alarifi, A.Org. Biomol. Chem. 2015, 13, 8652. (c) Pakhare, D. S.; Kusurkar, R. S.Tetrahedron Lett. 2015, 56, 6012. (d) Hati, S.; Sen, S. Tetrahedron Lett.2016, 57, 1040.

(20) Burger, M.; Ding, Y.; Han, W.; Lindvall, M.; Nishiguchi, G. A.;Rico, A.; Smith, A.; Tanner, H.; Wan, L. PCT WO 2012/004217 A1,2012.(21) Abramovitch, R. A.; Adams, K. A. H. Can. J. Chem. 1962, 40,864.(22) Snyder, H. R.; Werber, F. X. J. Am. Chem. Soc. 1950, 72, 2962.(23) Mann, F. G.; Prior, A. F.; Willcox, T. J. J. Chem. Soc. 1959, 3830.(24) Smith, P. A. S.; Boyer, J. H. J. Am. Chem. Soc. 1951, 73, 2626.(25) Fontan, R.; Galvez, C.; Viladoms, P. Heterocycles 1981, 16, 1473.(26) Mazu, T. K.; Etukala, J. R.; Jacob, M. R.; Khan, S. I.; Walker, L.A.; Ablordeppey, S. Y. Eur. J. Med. Chem. 2011, 46, 2378.(27) Reich, M. F.; Fabio, P. F.; Lee, V. J.; Kuck, N. A.; Testa, R. T. J.Med. Chem. 1989, 32, 2474.(28) Remers, W. A.; Greenblatt, E. N.; Ellenbogen, L.; Weiss, M. J. J.Med. Chem. 1971, 14, 331.(29) Kusurkar, R. S.; Goswami, S. K. Tetrahedron 2004, 60, 5315.(30) See, for example, the following: (a) Hardegger, L. A.; Habegger,J.; Donohoe, T. J. Org. Lett. 2015, 17, 3222. (b) Sasaki, I. Synthesis2016, 48, 1974.(31) See, for example, the following: (a) Lachance, N.; April, M.;Joly, M.-C. Synthesis 2005, 2571. (b) Spergel, S. H.; Okoro, D. R.;Pitts, W. J. Org. Chem. 2010, 75, 5316.(32) Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.(33) Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.;Timmers, F. J. Organometallics 1996, 15, 1518.(34) CrysAlis PRO Version 1.171.37.35h (released 02/09/2015CrysAlis171.NET); Agilent Technologies: Oxfordshire, UK.(35) SIR92: Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi,A.; Burla, M. C.; Polidori, G.; Camalli, M. J. Appl. Crystallogr. 1994, 27,435.(36) Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.;Watkin, D. J. J. Appl. Crystallogr. 2003, 36, 1487.

The Journal of Organic Chemistry Article

DOI: 10.1021/acs.joc.7b00323J. Org. Chem. 2017, 82, 4328−4335

4335

390

Page 413: The Application of Pericyclic, Photolytic, Chemoenzymatic

S1

SUPP

ORT

ING

INFO

RMAT

ION

FO

R:

A U

nifie

d A

ppro

ach

to th

e Is

omer

ic α

-, β

-, γ-

and

δ-C

arbo

lines

via

thei

r 6,

7,8,

9-T

etra

hydr

o-co

unte

rpar

ts

Qia

o Y

an, E

mm

a G

in, M

artin

G. B

anw

ell*

Ant

hony

C. W

illis

and

Pau

l D. C

arr

Rese

arch

Sch

ool o

f Che

mis

try,

Inst

itute

of A

dvan

ced

Stud

ies,

The

Aust

ralia

n N

atio

nal U

nive

rsity

, Can

berr

a, A

CT

2601

, Aus

tral

ia

Emai

l: M

artin

.Ban

wel

l@an

u.ed

u.au

CO

NT

EN

TS

PA

GE

(i)A

niso

tropi

c D

ispl

acem

ent E

llips

oid

Plot

s fro

m th

e Si

ngle

-cry

stal

X-r

ay

Ana

lyse

s of C

ompo

unds

1-5

S2

(ii)

1 H a

nd 13

C N

MR

Spe

ctra

of C

ompo

unds

1-5

, 8, 9

, 10,

11,

12,

14,

15,

17,

18,

20,

21/2

2 an

d 24

-26

S7

391

Page 414: The Application of Pericyclic, Photolytic, Chemoenzymatic

S2

Figu

re S

1: S

truct

ure

of c

ompo

und

1 (C

CD

C 1

5300

02) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.

392

Page 415: The Application of Pericyclic, Photolytic, Chemoenzymatic

S3

Figu

re S

2: S

truct

ure

of c

ompo

und

2 (C

CD

C 1

1530

003)

with

labe

ling

of se

lect

ed a

tom

s. A

niso

tropi

c di

spla

cem

ent e

llips

oids

show

30%

pr

obab

ility

leve

ls. H

ydro

gen

atom

s are

dra

wn

as c

ircle

s with

smal

l rad

ii.

393

Page 416: The Application of Pericyclic, Photolytic, Chemoenzymatic

S4

Figu

re S

3: S

truct

ure

of c

ompo

und

3 (C

CD

C 1

5300

04) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.

394

Page 417: The Application of Pericyclic, Photolytic, Chemoenzymatic

S5

Figu

re S

4: S

truct

ure

of c

ompo

und

4 (C

CD

C 1

5300

05) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

395

Page 418: The Application of Pericyclic, Photolytic, Chemoenzymatic

S6

Figu

re S

5: S

truct

ure

of c

ompo

und

5 (C

CD

C 1

5300

06) w

ith la

belin

g of

sele

cted

ato

ms.

Ani

sotro

pic

disp

lace

men

t elli

psoi

ds sh

ow 3

0%

prob

abili

ty le

vels

. Hyd

roge

n at

oms a

re d

raw

n as

circ

les w

ith sm

all r

adii.    

396

Page 419: The Application of Pericyclic, Photolytic, Chemoenzymatic

S7

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

10.5

11.0

11.5

f1 (

ppm

)

2.001.001.00

1.001.001.00

3.31 MeOD

397

Page 420: The Application of Pericyclic, Photolytic, Chemoenzymatic

S8

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

48.36 MeOD48.57 MeOD48.79 MeOD49.00 MeOD49.21 MeOD49.43 MeOD49.64 MeOD

112.30116.10118.04121.02121.88122.04128.03129.94

140.57146.13152.90

12

1.8

12

2.0

12

2.2

f1 (

ppm

)

121.88

122.04

398

Page 421: The Application of Pericyclic, Photolytic, Chemoenzymatic

S9

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

1.00

2.00

1.001.001.00

1.00

3.31 MeOD

399

Page 422: The Application of Pericyclic, Photolytic, Chemoenzymatic

S10

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

48.36 MeOD48.57 MeOD48.79 MeOD49.00 MeOD49.21 MeOD49.42 MeOD49.64 MeOD

112.82116.07120.83122.18122.71129.74130.43134.06137.76138.36142.74

400

Page 423: The Application of Pericyclic, Photolytic, Chemoenzymatic

S11

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

10.5

11.0

11.5

12.0

f1 (

ppm

)

1.002.001.00

1.001.00

1.00

3.31 MeOD

401

Page 424: The Application of Pericyclic, Photolytic, Chemoenzymatic

S12

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

48.64 MeOD48.76 MeOD48.88 MeOD49.00 MeOD49.12 MeOD49.24 MeOD49.36 MeOD

107.62

112.42121.53121.60121.64122.42128.17141.50142.71144.40145.82

12

01

21

12

21

23

f1 (

ppm

)121.53121.60121.64

122.42

402

Page 425: The Application of Pericyclic, Photolytic, Chemoenzymatic

S13

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

10.5

11.0

11.5

12.0

12.5

13.0

f1 (

ppm

)

1.012.001.00

1.01

0.83

0.77

0.61

2.50 DMSO

403

Page 426: The Application of Pericyclic, Photolytic, Chemoenzymatic

S14

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

39.16 DMSO39.28 DMSO39.40 DMSO39.52 DMSO39.64 DMSO39.76 DMSO39.88 DMSO

106.37111.43119.43119.93120.56120.70126.54

139.50142.70143.47144.47

11

81

19

12

01

21

12

21

23

f1 (

ppm

)

119.43119.93120.56120.70

404

Page 427: The Application of Pericyclic, Photolytic, Chemoenzymatic

S15

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.5f1

(ppm

)

1.001.002.001.001.001.00

3.31 MeOD

405

Page 428: The Application of Pericyclic, Photolytic, Chemoenzymatic

S16

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

48.36 MeOD48.58 MeOD48.79 MeOD49.00 MeOD49.21 MeOD49.43 MeOD49.64 MeOD

112.58119.86120.83121.28121.43122.35129.04135.07141.46142.28142.37

11

81

19

12

01

21

12

21

23

12

4f1

(ppm

)

119.86120.83121.28121.43122.35

14

2.0

14

2.5 f1

(ppm

)142.28142.37

406

Page 429: The Application of Pericyclic, Photolytic, Chemoenzymatic

S17

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

3.00

1.002.001.001.001.00

1.00

7.26 CDCl3

7.2

7.3

7.4

f1 (

ppm

)

1.00

7.26 CDCl3

407

Page 430: The Application of Pericyclic, Photolytic, Chemoenzymatic

S18

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.48

76.84 CDCl377.16 CDCl377.48 CDCl3

111.73113.08120.24121.97122.18128.36128.49134.79138.72140.33141.93

12

21

24

12

61

28

13

0f1

(ppm

)

121.97122.18

128.36128.49

408

Page 431: The Application of Pericyclic, Photolytic, Chemoenzymatic

S19

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

2.04

4.05

1.00

1.001.00

1.00

7.26 CDCl3

409

Page 432: The Application of Pericyclic, Photolytic, Chemoenzymatic

S20

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

22.5926.50

38.20

76.84 CDCl377.16 CDCl377.48 CDCl3

126.71128.05

137.15141.70147.78148.45

156.95

196.00

410

Page 433: The Application of Pericyclic, Photolytic, Chemoenzymatic

S21

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

4.10

2.062.03

1.00

1.00

1.00

0.98

7.26 CDCl3

411

Page 434: The Application of Pericyclic, Photolytic, Chemoenzymatic

S22

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.8123.1123.2823.34

76.84 CDCl377.16 CDCl377.48 CDCl3

108.38115.09120.83125.73

135.39140.80148.88

23

.02

3.1

23

.22

3.3

23

.42

3.5

f1 (

ppm

)

23.11

23.2823.34

412

Page 435: The Application of Pericyclic, Photolytic, Chemoenzymatic

S23

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

1.00

1.00

1.00

7.26 CDCl3

413

Page 436: The Application of Pericyclic, Photolytic, Chemoenzymatic

S24

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

76.84 CDCl377.16 CDCl377.48 CDCl3

98.48

136.54

145.93149.61152.52

414

Page 437: The Application of Pericyclic, Photolytic, Chemoenzymatic

S25

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

10.5

11.0

11.5

12.0

f1 (

ppm

)

2.08

4.00

0.960.99

0.99

0.97

7.26 CDCl3

415

Page 438: The Application of Pericyclic, Photolytic, Chemoenzymatic

S26

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

22.4926.49

38.17

76.84 CDCl377.16 CDCl377.48 CDCl3

125.61

137.54140.03144.98145.28148.74153.90

195.51

14

41

45

14

61

47

f1 (

ppm

)144.98145.28

416

Page 439: The Application of Pericyclic, Photolytic, Chemoenzymatic

S27

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

4.00

2.002.00

1.00

1.00

1.00

3.31 MeOD

417

Page 440: The Application of Pericyclic, Photolytic, Chemoenzymatic

S28

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

21.5824.0124.2024.22

48.64 MeOD48.76 MeOD48.88 MeOD49.00 MeOD49.12 MeOD49.24 MeOD49.36 MeOD

110.37113.72

132.61134.23134.45136.90142.24

23

.92

4.0

24

.12

4.2

24

.32

4.4

f1 (

ppm

)

24.01

24.2024.22

13

31

34

13

5f1

(ppm

)134.23134.45

418

Page 441: The Application of Pericyclic, Photolytic, Chemoenzymatic

S29

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

2.00

4.00

1.00

1.00

1.00

1.00

7.26 CDCl3

419

Page 442: The Application of Pericyclic, Photolytic, Chemoenzymatic

S30

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

22.5926.54

38.19

76.84 CDCl377.16 CDCl377.48 CDCl3

116.59

125.42

135.97

148.57151.44152.77154.08

196.06

420

Page 443: The Application of Pericyclic, Photolytic, Chemoenzymatic

S31

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10

.0f1

(ppm

)

4.06

4.01

1.00

1.00

0.96

3.31 MeOD

421

Page 444: The Application of Pericyclic, Photolytic, Chemoenzymatic

S32

01

02

03

04

05

06

07

08

09

01

00

11

01

20

13

01

40

15

01

60

17

01

80

19

02

00

21

02

20

23

0f1

(ppm

)

21.6123.8724.0624.20

48.63 MeOD48.76 MeOD48.88 MeOD49.00 MeOD49.12 MeOD49.24 MeOD49.37 MeOD

107.54110.30

126.19

138.08139.08139.88141.57

23

24

25

f1 (

ppm

)23.8724.0624.20

422

Page 445: The Application of Pericyclic, Photolytic, Chemoenzymatic

S33

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

2.082.012.00

2.00

1.00

1.00

7.26 CDCl3

423

Page 446: The Application of Pericyclic, Photolytic, Chemoenzymatic

S34

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

f1 (

ppm

)

22.5026.58

38.25

76.84 CDCl377.16 CDCl377.48 CDCl3

123.36

132.15139.18146.14149.37151.04152.93

196.17

424

Page 447: The Application of Pericyclic, Photolytic, Chemoenzymatic

S35

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

10.5

11.0

11.5

12.0

f1 (

ppm

)

4.00

2.002.00

1.00

1.00

1.00

1.00

7.26 CDCl3

425

Page 448: The Application of Pericyclic, Photolytic, Chemoenzymatic

S36

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.1223.1023.1723.77

76.84 CDCl377.16 CDCl377.48 CDCl3

110.78115.82117.42

129.08

139.19141.91145.59

23

.02

3.5

24

.0f1

(ppm

)

23.1023.17

23.77

426

Page 449: The Application of Pericyclic, Photolytic, Chemoenzymatic

S37

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

10.5

11.0

11.5

12.0

f1 (

ppm

)

3.00

1.99

1.00

3.31 MeOD

427

Page 450: The Application of Pericyclic, Photolytic, Chemoenzymatic

S38

-10

010

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

220

f1 (

ppm

)

19.31

48.36 MeOD48.57 MeOD48.79 MeOD49.00 MeOD49.21 MeOD49.43 MeOD49.64 MeOD

113.04114.71

143.15

156.03

173.35

428

Page 451: The Application of Pericyclic, Photolytic, Chemoenzymatic

S39

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

12

.51

3.0

13

.51

4.0

14

.51

5.0

f1 (

ppm

)

0.92

3.00

1.33

1.00

0.33

1.33

2.50 DMSO

6.0

6.5

7.0

7.5

8.0

8.5

9.0

f1 (

ppm

)

1.33

1.00

0.33

429

Page 452: The Application of Pericyclic, Photolytic, Chemoenzymatic

S40

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

15.3018.20

38.90 DMSO39.10 DMSO39.31 DMSO39.52 DMSO39.73 DMSO39.94 DMSO40.15 DMSO

117.98120.72

137.25137.81139.43142.17143.45148.14151.15

168.15

430

Page 453: The Application of Pericyclic, Photolytic, Chemoenzymatic

S41

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

3.00

1.00

1.00

7.26 CDCl3

431

Page 454: The Application of Pericyclic, Photolytic, Chemoenzymatic

S42

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

20.88

76.84 CDCl377.16 CDCl377.48 CDCl3

123.73126.27

148.47150.48151.77

432

Page 455: The Application of Pericyclic, Photolytic, Chemoenzymatic

S43

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.51

2.0

f1 (

ppm

)

2.004.003.00

2.00

1.00

7.26 CDCl3

433

Page 456: The Application of Pericyclic, Photolytic, Chemoenzymatic

S44

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

f1 (

ppm

)

21.9722.5126.52

38.20

76.84 CDCl377.16 CDCl377.48 CDCl3

123.42

136.34138.95146.61150.09150.82151.38

195.61

434

Page 457: The Application of Pericyclic, Photolytic, Chemoenzymatic

S45

-0

.50

.00

.51

.01

.52

.02

.53

.03

.54

.04

.55

.05

.56

.06

.57

.07

.58

.08

.59

.09

.51

0.0

10

.51

1.0

11

.5f1

(ppm

)

4.00

5.002.00

1.00

1.00

3.31 MeOD

435

Page 458: The Application of Pericyclic, Photolytic, Chemoenzymatic

S46

-1

00

10

20

30

40

50

60

70

80

90

10

01

10

12

01

30

14

01

50

16

01

70

18

01

90

20

02

10

22

0f1

(ppm

)

19.0721.7324.1224.1924.30

48.36 MeOD48.57 MeOD48.79 MeOD49.00 MeOD49.21 MeOD49.43 MeOD49.64 MeOD

110.62111.90

132.91133.67136.67141.18141.56

24

25

f1 (

ppm

)

24.1224.1924.30

436

Page 459: The Application of Pericyclic, Photolytic, Chemoenzymatic

Appendix

Structure of compound 7 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 7 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526109).

OO

O

7

437

Page 460: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 8 in publication 1 with labeling of selected atoms.

Anisotropic displacement ellipsoids show 30% probability levels.

Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 8 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526110).

OH

OOH

8

438

Page 461: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 9 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 9 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526111).

O

HO O

O

H

9

439

Page 462: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 11 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 11 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526112).

OTBS

OH

OH

11

440

Page 463: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 14 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 14 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526113).

OH

OAc

AcO

14

441

Page 464: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 16 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 16 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526114).

OH

AcOOH

16

442

Page 465: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 17 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 17 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526115).

OH

HOOH

17

443

Page 466: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 22 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 22 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526116).

OHOHHOO

22

444

Page 467: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 26 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 26 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526117).

OO

O

PMBOOH

26

445

Page 468: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 30 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 30 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526118).

OO

O

30

O

446

Page 469: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 32 as shown in publication 1 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 32 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1526119).

32

OO

O

OH

O

447

Page 470: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 8 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 8 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545223).

O

H

H

HO

HO

8

448

Page 471: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 9 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 9 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545224).

O

H

H

HO

TBSO

9

449

Page 472: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 10 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 10 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545225).

H

O H

10

OH

OH

450

Page 473: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 13 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 13 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545226).

H

H

13

OH

OTBS

451

Page 474: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 23 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 23 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545227).

OO O

23

452

Page 475: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 27 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 27 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545228).

OO

O

27

453

Page 476: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 30 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 30 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545229).

30

O

H H

OO

454

Page 477: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 32 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 32 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545230).

32

H H

OO

455

Page 478: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 34 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 34 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545231).

O

H

OO

34

456

Page 479: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 35 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 35 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545232).

O

H

OO

35

457

Page 480: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 36 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 36 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545233).

HO

O

O

36

458

Page 481: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 38 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 38 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545234).

HO

O

38

459

Page 482: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 41 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 41 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545235).

41

OO

HO

460

Page 483: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 44 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 44 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545236).

OAcO

OH

44

461

Page 484: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 45 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 45 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545237).

OAcO

OAc

45

462

Page 485: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 47 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 47 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545238).

OAcO

OTBS

47

463

Page 486: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 48 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 48 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545239).

OAcO

OBz

48

464

Page 487: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 53 as shown in publication 2 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 53 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1545240).

H

H

H

OBzO

AcO

53

465

Page 488: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 1 as shown in publication 3 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 1 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1525166).

NH

1

466

Page 489: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 2 as shown in publication 3 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 2 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1525163).

NH

2

467

Page 490: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 3 as shown in publication 3 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 3 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1525164).

NH

3

OMe

468

Page 491: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 4 as shown in publication 3 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 4 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1525162).

NH

4

OMe

469

Page 492: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 5 as shown in publication 3 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 5 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1525167).

NH

5

OHC

OMe

470

Page 493: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 6 as shown in publication 3 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 6 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1525160).

NH

6

CO2Me

OMe

471

Page 494: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 17 as shown in publication 3 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 17 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1525161).

OO2N

17

OMe

472

Page 495: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 25 as shown in publication 3 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 25 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1525165).

N

25

OMe

OOH

473

Page 496: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 1 as shown in publication 4 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 1 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1530002).

1

NNH

474

Page 497: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 2 as shown in publication 4 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 2 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1530003).

2

NNH

475

Page 498: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 3 as shown in publication 4 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 3 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1530004).

3

N

NH

476

Page 499: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 4 as shown in publication 4 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 4 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1530005).

4

N

NH

477

Page 500: The Application of Pericyclic, Photolytic, Chemoenzymatic

Structure of compound 5 as shown in publication 4 with labeling of

selected atoms. Anisotropic displacement ellipsoids show 30% probability

levels. Hydrogen atoms are drawn as circles with small radii. A full X-ray

crystallographic report for compound 5 has been deposited at the

Cambridge Crystallographic Data Centre (CCDC 1530006).

5

NNH

478